2016N289466_02 CONFIDENTIA L
GlaxoSmithKline group of companies 205832
1TITLE PA GE
Protocol Title: A Phase IIb, 24 week, randomized, double -blind, 3 arm parallel group
study , comparing the efficacy , safet y and tolerability  of two doses of umeclidinium 
bromide administered once- daily via a dry  powder inhaler, versus placebo, in participants 
with asthma
Protocol Number :205832 / Amendment 2
Short Title : Short Title : A randomized, double-blind, parallel group study, comparing 
the efficacy , safet y and tolerability of two doses of umeclidinium bromide administered 
once -daily via a dry powder inhaler, versus placebo, in participants with asthma
Compound Number: GW685698+[COMPANY_004]573719
Sponsor Name [CONTACT_29560]: 
GlaxoSmithKline Research & Development Limited
[ADDRESS_845600] Information can be found in the Study 
Reference Manual
.
Regulatory Agency Identifying Number(s): IND No. 104479, EudraCT number 2016 -
002843-40
Approval Date: 06-JUL - 2017
Copy right 2017 the GlaxoSmithKline group of companies. All rights reserved.   
Unauthorised cop ying or use of this information is prohibited. 2018N371775_00
 2018N371775_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2016N289466_02 CONFIDENTIA L
205832
3PROTOCOL AMENDMENT SUM MARYOF CH ANGES TABLE
DOCUMENT HISTORY
Document Date
Amendment 2: 2016N289466_02 06-Jul-2017
Amendment 1: 2016N289466_01 15-Nov-2016
Original Protocol : 2016N289466_00 19-Aug-2016
Amendment 2 06-July-2017
Overall Rationale for the Amendment:
This protocol is being amended to :
broaden the eligibility  criteria of pre -
bronchodilator FEV1 from ≤85% to ≤90% 
reflective of patients with non -obstructed asthma  
Allow re -screening of subjects, with advance approval by [CONTACT_7195]. 
Correct minor t ypographical e rrors and inconsistencies within the Schedule of 
Activities (SOA) and the protocol text. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
4Section # and Name [CONTACT_633406]: 
Section 7.1.3Update S ection 7.1.3 to 
include
albuterol/salbutamol 
medication for Return 
processUpdate to include 
albuterol/salbutamol 
medication and be consistent 
with the body  of the protocol
Section 2: Schedule of 
Activities (SOA)Removed the Screen Run -
in “Window” day  “-7d”Removed the Screen Run -in 
Window day  to avoid 
confusion. 
Secti on 2: Schedule of 
Activities (SOA)Added language to clarify
when ECG is to be 
completed: ECG is to be 
obtained after the vital 
signs assessment but prior 
to performing the pre
-
bronchodilator spi[INVESTIGATOR_1892] (see Section 
9.4.3). At all post 
randomiza tion visits the 
ECG is to be obtained [ADDRESS_845601] the inconsistency  
between the Schedule of 
Activities (SOA) and body  of 
the protocol
Section 6.1 :Inclusion 
Criteria; inclusion criteria 
#5Updating best pre -
bronchodilator morning 
(AM) FEV1 to≤90%To allow the inclusion of 
asthma patients with slightly  
lessrestricted lung function. 
Lung function does not alway s 
correlate with asthma severity
Section 6.2.2 :Inclusion 
Criteria for 
Randomi zation ;inclusion 
criteria #2 Updating Spi[INVESTIGATOR_038] : best 
pre-bronchodilator 
morning (AM) FEV1 to 
≤90%To allow the inclusion of 
asthma patients with slightly  
lessrestricted lung function. 
Lung function does not alway s 
correlate with asthma severity .
Section 6.4 Pre -
Screening/Screening/Run-
In/Randomization 
FailuresUpdate to Includ ere-
screening language : Re-
screening of subjects will 
be permitted; however, 
advance written approval 
to proceed with re -
screening a subject must be 
obtained from the Medical 
MonitorTo allow the re -screening of 
subjects, with advance medical 
monitor approval   2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
5Section # and Name [CONTACT_19523] 7.1.3 :Study  
Treatment, 
albuterol/salbutamol, and 
FF 100 mcg., ReturnUpdate to include 
specificall y the medication 
name, albuterol/salbutamol 
to the return pro cessUpdate to include 
albuterol/salbutamol
medication and be consistent 
with the body  of the protocol
Section 9.1.4 :Asthma 
ExacerbationAdded “moderate” to the 
last sentence in the 
paragraphAdded “moderate” to be 
consistent with other sections 
of the protocol and to clearly  
state that both moderate and 
severe exacerbations are to be 
capture din the eCRF
Section 9.4.3: 
ElectorcardiogramsAdded language (“ but prior 
to performing pre-
bronchodilator spi[INVESTIGATOR_417486] ”) to clarify  
when the ECG is to be 
done.Added (“but prior to 
performing pre-bronchodilator
spi[INVESTIGATOR_1891] ”) to 
clearl y explain that the ECG is 
to be performed after vitals but 
prior to spi[INVESTIGATOR_038] . The 
specific time points for 
performing ECGs are clarified 
in the SOA 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
6TABLE OF CONT ENTS
PAGE
PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE..................................... 3
1.SYNOPSIS ............................................................................................................... 9
2.SCHEDULE OF ACTIVITI ES (SOA) ....................................................................... 13
3.INTRODUCTION .................................................................................................... 19
3.1. Study Rationale .......................................................................................... 19
3.2. Background ................................................................................................ 19
3.3. Benefit/Risk Assessment ............................................................................ 19
3.3.1. Risk Assessmen t......................................................................... 20
3.3.2. Benefit Assessment ..................................................................... 26
3.3.3. Overall Benefit: Risk Conclusion .................................................. 26
4.OBJECTIVES AND ENDPO INTS ........................................................................... 26
5.STUDY DESIGN .................................................................................................... 28
5.1. Overall Design ............................................................................................ 28
5.2. Number of Participants ............................................................................... 30
5.3. Participant and Study Completion ............................................................... 30
5.4. Scientific Rationale for Study Design .......................................................... 30
5.5. Dose Justification ........................................................................................ 31
6.STUDY POPULATION ........................................................................................... 31
6.1. Inclusion Criteria ......................................................................................... 31
6.2. Exclusion Criteria ........................................................................................ 33
6.2.1. Randomization Criteria ................................................................ 35
6.2.2. Inclusion Criteria for Randomization ............................................ 35
6.2.3. Exclusion Criteria for Randomization ........................................... 36
6.3. Lifestyle Restrictions ................................................................................... 36
6.4. Pre-Screening/Screening/Run -in/Randomization Failures .......................... 36
7.TREATMENTS ....................................................................................................... 37
7.1. Treatments Administered ............................................................................ 37
7.1.1. Description of FF 100 mcg and Do uble-Blind Study 
Treatment .................................................................................... 37
7.1.2. Description of Albuterol/Salbutamol ............................................. 39
7.1.3. Study Treatment, albuterol/salbutamol, and FF 100 mcg 
Return .......................................................................................... 39
7.2. Dose Modificat ion....................................................................................... 39
7.3. Method of Treatment Assignment ............................................................... 39
7.4. Blinding ....................................................................................................... 40
7.5. Packaging and Labeling .............................................................................. 41
7.6. Preparation/Handling/Storage/Accounta bility .............................................. 41
7.7. Treatment Compliance................................................................................ 41
7.8. Concomitant Therapy .................................................................................. 42
7.8.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 42
[IP_ADDRESS]. Permi tted Asthma Medications ................................... 42
[IP_ADDRESS]. Permitted Non -Asthma Medications ........................... 43 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
77.9. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ........................................ 44
7.10. Treatment after the End of the Stu dy.......................................................... 45
8.DISCONTINUATION CRIT ERIA ............................................................................. 45
8.1. Discontinuation of Study Treatment ............................................................ 45
8.1.1. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................................ 46
8.1.2. QTc S toppi[INVESTIGATOR_2121] .................................................................. 46
8.1.3. Rechallenge ................................................................................. 47
[IP_ADDRESS]. Study Treatment Restart or Rechallenge .................... [ADDRESS_845602] to Follow Up ........................................................................................ 48
9.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 48
9.1. Efficacy Assessments ................................................................................. 49
9.1.1. Questionnaires ............................................................................ 50
[IP_ADDRESS]. Global Assessment of Severity and Response 
to Treatment ............................................................... 50
[IP_ADDRESS]. Asthma Control Questionnaire (ACQ) ......................... 50
[IP_ADDRESS]. St. George’s Respi[INVESTIGATOR_633329] 
(SGRQ) ...................................................................... 50
[IP_ADDRESS]. Asthma Quality of Life Questionnaire (AQLQ) ............ 51
9.1.2. Daily Diaries ................................................................................ 51
[IP_ADDRESS]. eDiary Questionnaires, Assessments and 
Alerts .......................................................................... 51
[IP_ADDRESS].1. E-RS....................................................... 51
[IP_ADDRESS].2. Supplemental Asthma Items ................... 52
[IP_ADDRESS].3. Night -time Awakening, Asthma 
Symptom and Physical Activity 
Questions ............................................... 52
[IP_ADDRESS].4. Morning and Evening Home 
Spi[INVESTIGATOR_038] .............................................. 52
[IP_ADDRESS].5. Alerts ...................................................... [ADDRESS_845603] ............................................................. 53
[IP_ADDRESS]. Reversibility (Albuterol/Salbutamol) ............................ 54
9.1.4. Asthma Exacerbations ................................................................ .55
[IP_ADDRESS]. Moderate Asthma Exacerbation .................................. 55
[IP_ADDRESS]. Severe Asthma Exacerbation ..................................... [ADDRESS_845604] (AESIs) ................................ .57
9.2.6. Cardiovascular and Death Events ................................................ 58
9.2.7. Pneumonia .................................................................................. 59
9.2.8. Radiography (Chest X -Rays) ....................................................... 59
9.2.9. Pregnancy ................................................................................... 59
9.3. Treatment of Overdose ............................................................................... 60
9.4. Safety Assessments ................................................................................... 60
9.4.1. Physical Examinations ................................................................ .60
9.4.2. Vital Signs .................................................................................... 60 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
89.4.3. Electrocardiograms ...................................................................... 60
9.4.4. Clinical Safety Laboratory Assessments ...................................... 61
9.5. Pharmacokinetics ....................................................................................... 61
9.6. Pharmacodynamics .................................................................................... 62
9.7. Genetics ..................................................................................................... 62
9.8. Biomarkers ................................................................................................ .62
9.9. Health Economics OR Medical Resource Utilization and Health 
Economics .................................................................................................. 62
10.STATISTICAL CONSIDER ATIONS ........................................................................ 62
10.1. Hypotheses ................................................................................................ .62
10.2. Sample Size Determination ........................................................................ 63
10.3. Sample Size Sensitivity ............................................................................... 64
10.4. Samp le site re -estimation or adjustment ..................................................... 65
10.5. Data Analysis .............................................................................................. 65
10.5.1. Analysis population ...................................................................... 65
10.5.2. Treatment Comparisons .............................................................. 66
10.5.3. Multiple Comparisons and Multiplicity .......................................... 66
10.6. Statistical Analysis ...................................................................................... 67
10.6.1. Primary Analyses ......................................................................... 67
10.6.2. Secondary Analyses .................................................................... 67
10.6.3. Other Analyses ............................................................................ 68
10.6.4. Interim Analyses .......................................................................... 68
10.6.5. Exploratory Analyses ................................................................... 68
11.REFERENCES ....................................................................................................... 69
12.APPENDICES ........................................................................................................ 71
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 71
12.2. Appendix 2: Clinical Laboratory Tests ......................................................... 74
12.3. Appendix 3: Study Governance Considerations .......................................... 76
12.4. Appendix 4: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ....................................... 80
12.5. Appendix 5: Contraceptive Guidance and Collection of Pregnancy 
Information .................................................................................................. 85
12.6. Appendix 6: Genetics .................................................................................. 88
12.7. Appendix 7: Liver Safety: Required Actions and Follow -up 
Assessments .............................................................................................. 91
12.8. Appendix 8: Daily Diary Questions .............................................................. 94
12.8.1. Morning Ques tions ....................................................................... 94
12.8.2. Evening Questions ....................................................................... 94
12.9. Appendix 9: Country -specific requirements ................................................. 97
12.10. Appendix 10: Protocol Amendment History ................................................. 98 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
91. SYNOPSIS
Protocol Title: A Phase IIb, 24 week, randomized, double -blind, 3 arm parallel group 
study , comparing the efficacy , safet y and tolerability  of two doses of umeclidinium 
bromide administered once- daily via a dry  powder inhaler, v ersus placebo, in participants
with asthma
Short Title: A randomized, double- blind, parallel group stud y, comparing the efficacy , 
safet y and tolerability of two doses of umeclidinium bromide administered once- daily via 
a dry  powder inhaler, versus placebo, in participan ts with asthma
Rationale:
In the [LOCATION_002] (US) , the long-acting muscarinic antagonist (LAMA) tiotropi[INVESTIGATOR_633330] -term maintenance treatment of asthma in patients 12 y ears of 
age and older.
GlaxoSmithKline ([COMPANY_004]) is currentl y devel opi[INVESTIGATOR_007] a once -daily ‘closed’ triple therap y of a n
inhaled corticosteroid (ICS) /LAMA/ long-acting beta -2-agonist (LABA )combination 
[fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI)] in a single device, with 
the aim of providing a new treatment op tion for the management of asthma in adults. 
Through the evaluation of UMEC 62.5 micrograms ( mcg
)and 31.25 mcg compared to 
placebo, this study  will provide important informa tion regarding the efficacy , safety and 
tolerability of UMEC when administered via a separate inhaler to participants on a 
background of FF without VI .
The primary  objective of this study  is to evaluate the effects of UMEC 62.5 mcg and 
UMEC 31.25 mcg on lung function compared with placebo after 24 weeks of treatment.
Objectives and End points:
Objective Endpoint
Primary
Evaluate the effects of UMEC 62.5 mcg 
and UMEC 31.25 mcg on lung function 
(trough Forced Expi[INVESTIGATOR_1814] 1 
second [FEV 1]) vs placebo after 24 weeks 
of treatment.Mean change from baseline in clinic 
trough FEV 1at W eek 24
Secondary
Evaluate the effects of UMEC 62.5 mcg and 
UMEC 31.25 mcg on lung function (3h ours
post dose FEV 1) vs placebo after 24 weeks 
of treatment.Mean change from baseline in clinic FEV [ADDRESS_845605] dose at Week 24 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
10Objective Endpoint
Safety
To evaluate the s afety and tolerability of UMEC 
62.5 mcg and UMEC 31.25 mcg compared to 
placeboIncidence and type of adverse events
Electrocardiogram (ECG) measurements
Vital signs
Overall Design:
This is a Phase IIb, randomized, double -blind, placebo controlled, 3 -arm parallel group 
study , comparing the efficacy , safet y and tolerability  of UMEC (62.5 mcg and 
31.25 mcg) administered once- dailyin participants with asthma that is not well controlled 
(i.e. participants with an Asthma Control Questionnaire -6 [ACQ -6] total score >0.75 at 
Visit 2 [the Randomization Visit] ) despi[INVESTIGATOR_633331].
Number of Participant s:
The total number of randomized participant s required is approximately  384, with 128
participant s randomized 1:1:1 to each of the 3 double -blind treatment arms
.   2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
11Treatment Groups and Duration:
Eligible participant s will be requested to participa te in the study  for a maximum of 
approximately 31 weeks ( Visit 0to the Follow -up contact , inclusive ) during which time, 
participants will complete the following 4 phases of the study :
Pre-screening: Details about the study  and procedures will be explained 
through the informed consent process. The Pre -screening Visit (Visit 0 ), 
including the informed consent process, must be completed 
within 4 weeks prior
to Visit 1 as well as prior to any  protocol -required changes to a participant’s 
usual asthma treatment and the initiation of any Visit 1 procedures.
Participant s that receive LABA (or LAMA) as a component of their regular (i.e. 
pre-study ) therap y must stop L ABA (or LAMA) treatment from  48 hours prior 
to Visit 1 (Screening) until after they  have completed the study ; therefore, the 
investigator must use their clinical judgment to determine if the participant may 
stop L ABA (or LAMA) prior to study  entry with out incurring undue risk.
Screening / run- in: Participant s who meet all the eligibility  criteria at Visit 1 
(Screening), will enter the run -in period for approximately  2 weeks to continue 
assess ingthe participant ’s eligibility  for the study . On the mornin g of Visit 1, 
participant s will refrain from taking the morning dose of their regular (i.e. pre-
study ) ICS asthma medication. Participant s satisfying all inclusion/exclusion 
criteria and who have successfully  completed all protocol procedures at 
screening will be provided with FF 100 mcg via the ELLIPTA dry -powder 
inhaler (DPI) to take once daily  (QD), in the morning, during the 2- week run -in 
period; the first dose of FF 100 mcg will be self -administered by  [CONTACT_633378]. Participants will refrain from using their own ICS 
asthma medication during the 2 -week run- in and treatment period. Participants 
will also be provided with rescue medication (albuterol/salbutamol) to use on an 
as-needed basis throughout the stud y.
Randomization / treatment: At Visit 2 (the Randomization Visit), participants 
who meet all of the randomization criteria will be randomized 1:1:1 to receive 
oneof the following three double -blind study  treatments via the ELLIPTA DPI  
[CONTACT_78482] 24 -week treatment period:
UMEC 62.5 mcg QD
UMEC 31.25 mcg QD
Placebo QD
Participants will continue to administer FF 100 mcg once dail y (QD), in the 
morning from a separate ELLIPTA DPI [INVESTIGATOR_633332]. On the 
morning of Visits 2, 3, 4, and 5, participant s will perfor m their electronic Diary  
(eDiary ) assessments at home but refrain from taking their morning dose of 
study  treatment and FF 100 mcg (as applicable) until instructed to do so by
[CONTACT_6477]. At Visits 2, 3, [ADDRESS_845606] dose of study  treatment and FF 100 mcg in the clinic on Day  
169 (Visit 5). Participants are expected on non -clinic visit day s to take their  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
12study  treatm ent and FF 100 mcg at home in the morning at approximately  the 
same time each day , as directed b y the clinic. 
Safety f ollow -up: A safety  follow -up telephone contact [CONTACT_417494] 7 day s after the participant completes all of the 
protocol -defined procedures for V isit 5 /End of Study  (EOS )or, if applicable, the 
Early Withdrawal V isit. A participant will be considered to have completed the 
study  when they  have completed all phases of the study  including screening, 
run-in, the randomiz ed treatment phase, and safety  follow -up.
Key Elements of Analysis Plan
The primary  efficacy  analy sis will evaluate the “de facto ” type estimand in the I ntent- to-
Treat population, using a mixed -model repeated measures (MMRM) analysis, including 
all clinic trough FEV 1recorded post randomization. Analy ses will include the fixed, 
categorical effects of treatment, visit, treatment by [CONTACT_23259], sex, aswell as the 
continuous, fixed covariates of age, baseline value, and baseline value by  [CONTACT_633379]. Point estimates and 95% confidence intervals will be calculated for the 
primary  comparisons of interest:
UMEC 62.5 mcg v ersus Placebo
UMEC 31.[ADDRESS_845607] of missing data will be detailed in the reporting and anal ysis plan(RAP ).
The detail s of the statistical anal ysis methods for the secondary  efficacy endpoint will be 
provided in the RAP .  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
132. SCHEDULE OF ACTIVITI ES(SOA)
Protocol Activit yPre-
ScreenScreen
Run-inTreatment Period Follow -up
Visit 0 12
Randomization3 45/End of Study  
(EOS)Early  Withdrawal 
(EW)Safety
Follow -up Contact
[CONTACT_633380]-42to -
14-14 1 29 85 169
Week -6 to -2 -2 0 4 12 241 week after Visit 
5/EOS or EW Visit
Window -5/+2d -5/+2d -5/+2d -1/+4d
Informed consent
(ICF)a X
Genetic I CFbX
Inclusion and 
exclusion criteriaX X
DemographycX X
Medical history X
Asthma historyd
X
Exacerbation
history X
Smoking History 
and status X
Concomitant 
medication reviewX X X X X X X X
Register visit in 
Interactive W eb 
Response System 
(IWRS) (RAMOS 
NG)eX X X X X X X
RandomizationfX
Laboratory  
Assessments
Urinalysis X 
 
 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
14Protocol Activit yPre-
ScreenScreen
Run-inTreatment Period Follow -up
Visit 0 12
Randomization3 45/End of Study  
(EOS)Early  Withdrawal 
(EW)Safety
Follow -up Contact
[CONTACT_633380]-42to -
14-14 1 29 85 169
Week -6 to -2 -2 0 4 12 241 week after Visit 
5/EOS or EW Visit
Window -5/+2d -5/+2d -5/+2d -1/+4d
Hematology and 
clinical chemistryg X
Hepatitis B and C Xm
Genetic sample Xn
Serum pregnancy 
testX oX oX o
Urine pregnancy 
testX oX oX o
Safety  
Assessments
Physical exam 
including height 
and weighthX X X
12-lead 
Electrocardiogram
(ECG)iX X X X
Vital signsjX X X X X X
Adverse Event (AE) 
reviewX X X X X X X
Serious Adverse 
Event (SAE) reviewX X X X X X X X
Stud y Treatment
Dispense
Albuterol/Salbutam
ol, as requiredX X X X
Collect 
Albuterol/Salbutam
ol, as requiredX X X X X 
 
 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
15Protocol Activit yPre-
ScreenScreen
Run-inTreatment Period Follow -up
Visit 0 12
Randomization3 45/End of Study  
(EOS)Early  Withdrawal 
(EW)Safety
Follow -up Contact
[CONTACT_633380]-42to -
14-14 1 29 85 169
Week -6 to -2 -2 0 4 12 241 week after Visit 
5/EOS or EW Visit
Window -5/+2d -5/+2d -5/+2d -1/+4d
Dispense open 
label fluticasone 
furoate (FF) [ADDRESS_845608] double -blind 
study treatmentX X X X
Assess FF 
100mcg run-in 
medication 
complianceX
Assess FF 
100mcg and 
double -blind study 
treatment 
complianceX X X X
Efficacy  
Assessments
Global Assessment 
of Severity k X X X X X 
 
 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
16Protocol Activit yPre-
ScreenScreen
Run-inTreatment Period Follow -up
Visit 0 12
Randomization3 45/End of Study  
(EOS)Early  Withdrawal 
(EW)Safety
Follow -up Contact
[CONTACT_633380]-42to -
14-14 1 29 85 169
Week -6 to -2 -2 0 4 12 241 week after Visit 
5/EOS or EW Visit
Window -5/+2d -5/+2d -5/+2d -1/+4d
Global Assessment 
of Response to 
Treatment kX X X X
Asthma C ontrol 
Questionnaire 
(ACQ -6)kX Xq
Asthma C ontrol 
Questionnaire 
(ACQ -5)kX X X X
St. George’s 
Respi[INVESTIGATOR_6004] 
(SGRQ) kX X X X X
Asthma Quality of 
Life Questionnaire 
(AQLQ) kX X X X X
Evaluating 
Respi[INVESTIGATOR_633333] (E -RS) 
+Asthma symptoms 
+ Peak Expi[INVESTIGATOR_396975] (PEF ) + Home 
Forced Expi[INVESTIGATOR_568928] 1 second
(FEV)1k, lX
eDiary Dispense X
eDiary Collect X X
eDiary Review X X X X X 
 
 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
17Protocol Activit yPre-
ScreenScreen
Run-inTreatment Period Follow -up
Visit 0 12
Randomization3 45/End of Study  
(EOS)Early  Withdrawal 
(EW)Safety
Follow -up Contact
[CONTACT_633380]-42to -
14-14 1 29 85 169
Week -6 to -2 -2 0 4 12 241 week after Visit 
5/EOS or EW Visit
Window -5/+2d -5/+2d -5/+2d -1/+4d
Dispense paper 
Medical 
Problems/Medicatio
ns Taken 
worksheetX X X X X
Review paper 
Medical 
Problems/Medicatio
ns Taken
worksheetX X X X X X
Reversibility Xr
Exacerbation 
assessmentX X X X X
Pre-dose 
spi[INVESTIGATOR_038] (clinic)XsXsXsXsXsXs
Post-dose 
spi[INVESTIGATOR_038] (clinic)XtXtXt 
 
 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
18a)The ICF must be signed before any study procedur es, including medication cessation.
b)Genetics research consent may be obtained at the same time as the study IC and must be obtained prior to obtaining a genetic blood sample.
c)Demography may be captured at either the Pre -screen Visit or Screening Visit (for participants who do not have a Pre-screen Visit).
d)The assessment of asthma history will include: the age of the participant when they were first provided with an inhaler for asthma; completion of an asthma 
medical history questionnaire (a copy of this que stionnaire and instructions for its use can be found in the SRM).
e)The IW RS will be used for randomization, emergency unblinding and study treatment supply management (Please refer to the RAMO S NG IW RS manual and 
SRM for more information).
f)Participants must not be randomized prior to confirming their eligibility to participate in the study.
g)If test otherwise performed within 3 months prior to screening visit , testing at screening is not required.
h)Physical Examination will include height and weight at Visit 1 only. 
i)At the Screening Visit (Visit 1), the ECG is to be obtained after the vital signs assessment but prior to performing the pre- bronchodilator spi[INVESTIGATOR_1891]
(see Section 9.4.3 ). At all post randomization visits th e ECG isto be obtained 15 minutes to 45 minutes after the administration of study treatment.
j)The vital signs assessment will include the measurement of blood pressure, heart rate .
k)Assessment(s) to be completed prior to the administration of study treatmen t.
l)To be completed using the provided combined spi[INVESTIGATOR_14007]/eDiary device. Assessments should be completed in the morning upon wak ening and in the evening 
immediately prior to going to bed.
m)Hepatitis C RNA is optional however a confirmatory negative Hepatiti s C RNA test must be obtained, to be able to enrol participants with positive Hepatitis C 
antibody due to prior resolved disease. Hep B/C: If test otherwise performed within [ADDRESS_845609] dose of study treatment, testing at screening is not 
requi red.
n)Pharmacogenetic sample may be drawn any time from Visit 2 onwards.
o)Assessments only to be conducted in females of reproductive potential.
p)Study treatment should be administered at approximately the same time of day at each applicable clinic visit.
q)Baseline ACQ -5 will be derived from items 1 -5 of the Randomization (Visit 2) ACQ -6.
r)Following completion of the pre -dose spi[INVESTIGATOR_31757], the reversibility test will be conducted between 20 and 60 minutes following 4 inhalations of 
albuterol/salbutamo laerosol. If airway reversibility is not demonstrated at Visit 1 then the assessment may be repeated within 7 days of Visit 1 (see Section 9.1.3 .
for details of the criteria to be met before a repeat of the reversibility asses sment is permitted). If airway reversibility is successfully demonstrated at the second 
attempt and all other eligibility criteria assessed at Visit 1 are met then the participant may enter the 2 -week run -in period.
s)Pre-dose spi[INVESTIGATOR_633334] 6am and 11am after withholding rescue medication for at least 6 hours and prior to taking the morning dose of 
study treatment and FF 10 0mcg. After V2 pre -dose spi[INVESTIGATOR_96610]  1 hour of the V2 spi[INVESTIGATOR_038].
t)Post-dose spi[INVESTIGATOR_417440] 3 hours ( 15 minutes) after taking the morning dose of study treatment. Rescue medication should be withheld for at 
least [ADDRESS_845610] -dose spi[INVESTIGATOR_633335] 1 hour of the V2 spi[INVESTIGATOR_038]. 
 
 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
193. INTRODUCTION
3.1. Stud y Rationale
In the [LOCATION_002] (US) , the long-acting muscarinic antagonist (LAMA) tiotropi[INVESTIGATOR_633330] -term maintenance treatment of asthma in patients 12 y ears of 
age and older.
GlaxoSmithKline ([COMPANY_004]) is currentl y developi[INVESTIGATOR_007] a once -daily ‘closed’ triple therap y of a 
ICS/LAMA/ long-acting beta -2-agonist ( LABA )combination [FF /umeclidinium 
(UMEC) /
vilanterol (VI)] in a single device, with the aim of providing a new treatment 
option for the management of asthma in adults. Through the evaluation of UMEC 
62.[ADDRESS_845611] effective anti- inflammatory  
treatments for all severities of persistent asthma [ National Institutes of Health ( NIH)
2007; Global I nitiative for Asthma (GINA ) 2016].  Treatment with ICS controls asthma 
symptoms, improves quality  of life and lung function, decreases airway hyper-
responsiveness, controls airway  inflammation, and reduces the frequency  and severit y of 
asthma exacerbations, thereb y reducing asthma morbidity .  
Despi[INVESTIGATOR_633336] y of treatments and published guidelines, patients may have asthma 
that is not well controlled.
This trial will, primarily , evaluate trough FEV 1to characterize the efficacy of two doses 
of UMEC (62.5 mcg and 31.25 mcg) in the treatment of asthma when administered as an 
open combination with FF 100 mcg. UMEC is currently
 under development as a closed 
triple therap y in combination with FF and VI in a single inhaler.
3.3. Benefit/Risk A ssessment
More detailed information about the known and expected benefits and risks and 
reaso nably expected adverse events related to FF and UMEC can be found in the 
Investigator ’s Brochure (s) (IB ). The table below provides a summary  of the key  risks in 
association with FF and UMEC. I t is noted that both FF and UMEC have also been 
developed in combi nation with VI , therefore relevant safet y experience is also pr ovided 
by [CONTACT_633381]/VI and UMEC/VI  combinations.    2018N371775_00
2016N289466_02 CONFIDENTI AL
205832
203.3.1. Risk A ssessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) [e.g., GW685698+[COMPANY_004]573719] 
Cardiovascular effects of 
UMEC UMEC
Cardiovascular effects are a potential class effect associated with 
anti-muscarinic therapi[INVESTIGATOR_014]. In the UMEC/VI clinical development 
program in chronic obstructive pulmonary  disease (COPD ) patients, 
UMEC/VI  was generall y well tolerated. Overall, a low numbe r of 
atrial arrh ythmias were reported based on [ADDRESS_845612] with the combination over individual components. Few of 
these findings were reported as SAEs and none were fatal. In a 
narrow* Major Adverse Cardiac Event (MACE) analy sis, the 
incidence of non -fatal my ocardial infarction (Medical Dictionary  for 
Regulatory  Activities (MedDRA) Preferred Terms (PTs) of 
myocardial infarction and acute m yocardial infarction) was low 
(<1%) across all treatment groups, although small imbalances in 
exposure adjusted frequency  were observed between UMEC -and VI 
containing treatment groups when compared with placebo and 
tiotropi[INVESTIGATOR_1890] .  There was no obvious dose relationship or additive effect 
from the combination.  Whether this represents a true effect is 
difficult to determine due to the small numbers. During clinical 
studies in COPD (62.5 and 125mcg daily  dose of UMEC) and in 
Health y Volunteers (in the Thorough QT stud y, UMEC 500mcg dail y 
dose), no effect was observed on heart rate, blood pressure or QT.Mitigation strategy  for UMEC 
-
Exclusion criteria as specified in 
Section 6.2 ofthe protocol
-Collection of cardiovascular risk 
factors and medical history  at 
baseline
-ECGs as per schedule in 
Secti on 2
-Vital sign assessments (heart rate
and blood pressure) as per schedule in 
Section 2
-
Cardiovascular AEs and SAEs will 
be captured on the electronic Case 
Report Form (eCRF) ( see Appendix 
4)
-Protocol defined stoppi[INVESTIGATOR_633337] 8.1
-MACE anal ysis
-Instream review 
ofblinded data 
 
 2018N371775_00
2016N289466_02 CONFIDENTI AL
205832
21Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Health y Volunteers (in the Thorough QT stud y, UMEC 500 mcg 
daily  dose), no effect was observed on heart rate, blood pressure or 
QT.
Data from Thorough QT (TQT) studies with FF, FF/VI and 
UMEC/VI  suggest that, at the doses to be used in phase III studies, 
the closed triple (FF/UMEC/VI ) is unlikel y to cause clinically 
relevant effects on QTc1. No difference in QTcF2was observed 
betwee n UMEC/VI 125/25mcg or UMEC 500 mcg and placebo. 
UMEC/VI  500/100 mcg increased QTcF on average b y 8.2 msec 
(milliseconds) (90% Confidence Intervals (CI): 6.2, 10.2) at 30 
minutes (min) only . A lack of effect was demonstrated for QTcF with 
FF/V I 200/25mcg ( for 7 day s). At a supratherapeutic dose of FF/VI 
(800/100mcg for 7 day s), the largest mean time -matched difference 
from placebo was 9.6 msec (90% CI: 7.2, 12.0) at 30 min only .
1QT interval corrected for heart rate
2QT interval corrected for heart rate by [CONTACT_6550]’s formula
Anticholinergic effects 
(including constipation 
nausea, dry mouth, 
glaucoma, raised 
intraocular pressure and 
blurred vision, urinary  
retention) In clinical studies in COPD, few anticholinergic effects were 
associated with UMEC; those observed included dry  mouth, 
constipation and cough.  Based on post -marketing experience
dysgeusia has been added as an Adverse Drug Reaction (ADR) for 
inhaled UMEC and UMEC/VI .  In addition, UMEC/VI  has had 
urinary  retention, dysuria , vision blurred, glaucoma and increased 
intraocular pressure and paradoxical bronchospasm added as ADRs.  
I
CS has a similar class risk of glaucoma and elevated intraocular -Patients with known narrow -angle 
glaucoma, prostatic h yperplasia or 
bladder outflow obstruction that, in 
the opi[INVESTIGATOR_689], 
contraindicates stud y participation or 
use of an inhaled anticholinergic, will 
be excluded from participating in the 
study .
-Review AEs/SAEs 
 
 2018N371775_00
2016N289466_02 CONFIDENTI AL
205832
22Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
pressure (IOP); however ,these effects occur b y a different 
mechanism that is not expected to be s ynergistic or additive when FF 
is used in combination with UMEC.
Systemic ICS effects 
-Aderenal suppression
-Cataracts & glaucoma
-Reduced bone mineral 
density  and associated 
fracturesNo studies have shown a clinically  relevant effect of FF/VI or FF on 
the hy pothalamic pi[INVESTIGATOR_417483] (HPA). This includes a formal HPA 
study  (HZA106851), which assessed the effects of FF/VI 100/25 and 
200/25 on serum cortisol and 24 hour urinary cortisol excretion, and 
multiple studies with COPD and asthma participant s which 
monitored urinary  cortisol.  
During clinical development of FF & FF/VI no events of Adrenal 
Suppression were reported.  There has been no evidence for adrenal 
suppression based on post- marketing experience to date.  
In stud y HZA106839 (FF/VI, FF and fluticasone propi[INVESTIGATOR_16847] (FP) in 
participant s with asthma), formal O phthalmic assessments were 
conducted (including Lens Opacities Classification Sy stem III 
(LOCS III) evaluations for ocular opacities) throughout the stud y. 
This study  showed no apparent effects on lens opacification, 
compared to baseline assessment.  
During studies in both participant s with asthma and COPD, no 
associated affect on ocular disorders was observed.  Spontaneous 
data received to date does not alter the understanding of this risk.  
A decrease in bone mineral density  and the risk of fractures is a class 
concern for an y ICS-containing product for the treatment of COPD.
In two replicate 12 month studies in the FF/VI clinical program, in a -Review AEs/SAEs
-The occurrence of bone fractures 
will be recorded in the eCRF. 
 
 2018N371775_00
2016N289466_02 CONFIDENTI AL
205832
23Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
total of 3,255 patients with COPD, the incidence of bone fractures 
overall was low in all treatment groups, w ith a higher incidence in all 
FF/V I groups (2%) compared with the VI 25 mcg group (<1%).  
Although there were more fractures in the FF/VI groups compared 
with the VI 25mcg group, fractures t ypi[INVESTIGATOR_1306] y associated with 
corticosteroid use (e.g., spi[INVESTIGATOR_633338]/thoracolumbar vertebral 
fractures, hip and acetabular fractures) occurred in <1% of the FF/VI 
and VI treatment arms.  In an integrated anal ysis of 11 studies in 
asthma with FF/VI (7,034 patients) and 10 studies in asthma with FF 
(6,219), the incidence of fractures with FF/VI and FF was 1%, and 
usually  associated with trauma.   
Pneumonia While I CS use is a recognised risk for pne umonia in patients with 
COPD, a clear causal relationship between inhaled corticosteroid use 
and pneumonia in participant s with asthma has not been established.  
In an 18 study  integration in the FF/VI asthma program, the 
incidence of pneumonia (adjusted for exposure) observed with FF/VI 
100/25 and FF 100 mcg (8.5/1000 patient y ears and 9.6/1000 patient 
years, respectivel y) was similar to that seen with placebo (9.3/1000 
patient y ears). A higher incidence in the FF/VI 200/25 and FF 200 
arms were observed (18.3/1000 patient y ears and 23.6/1000 pa tient 
years, respectivel y). However, the 95% CIs were wide and 
overlapped across all treatment groups, including placebo. Few of the 
pneumonia events led to hospi[INVESTIGATOR_633339], and 
there were no observed differences in the incidence of se rious events 
between the two treatment strengths.  The risk of pneumonia in 
asthma patients is very  low and is consistent with the risk of other 
ICS.  Exclusion criteria:
-Immune suppression (e.g., Human 
Immunodeficiency  Virus [HI V], 
Lupus) or other risk factors for 
pneumonia (e.g.,neurological 
disorders affecting control of the 
upper airway , such as Parkinson’s 
Disease, M yasthenia Gravis).
-Participant s at potentially  high risk 
(e.g., very  low body  mass index 
[BMI ] or severel y malnourished) will
only be included at the discretion of 
the Investigator.
Medical history will also be taken for 
pneumonia in previous 12 months, 
including recording of any  epi[INVESTIGATOR_1841]  
 
 2018N371775_00
2016N289466_02 CONFIDENTI AL
205832
24Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Pneumonia experience with UMEC
In the All Clinical Studies groupi[INVESTIGATOR_007], the incidence of on -treatment 
AEs in the Pneumonia and lower respi[INVESTIGATOR_2826] (LRTI) 
adverse events of special interest (AESI) category  with UMEC 
62.5 mcg (1%; 34.6/1000SY) was similar to placebo (1%; 
34.8/1000SY) and lower than the incidence reported in the UMEC 
125mcg (3%; 72.6/1000SY). A higher incidence of AEs in the 
Pneumonia AESI  category  was reported for UMEC 125 mcg (2%; 
37.4/1000SY) compared with UMEC 62.5 mcg (<1%; 19.8/1000SY) 
and placebo (<1%; 10.7/1000SY). The proportion of participant s 
with SAEs in the Pneumonia A ESI category  was similar between 
both U MEC treatment groups, UMEC 62.5 mcg (<1%; 4.9/1000SY) 
and UMEC 125 mcg (<1%; 17.6/1000SY) and placebo (<1%; 
10.7/1000SY).resulting in hospi[INVESTIGATOR_11956].  
The occurrence of pneumonia will be 
recorded in the eCRF.
Where possible a chest X -ray should 
be performed to confirm a diagnosis, 
whenever a participant has a 
suspected pneumonia.
All reports of pneumonia 
(radiographicall y confirmed and 
unconfirmed) must be reported as an 
AE or SAE, if applicable 
Instream r eview of blinded data.
Review of AESI relevant for 
pneumonia using pre -specified 
MedDRA preferred terms. AE terms 
relating to other Lower Respi[INVESTIGATOR_633340] (excluding 
pneumonia) will also be reviewed.  
Hypersensitivity There have been post- marketing reports of h ypersensitivity  reactions 
with FF/VI and UMEC/VI, including anaph ylaxis, angioedema, rash, 
and urticaria.  The formulation also contains lactose.Participant s with a history  of allergy  
or hy persensitivity  to an y 
corticosteroid, 
anticholi nergic/muscarinic receptor 
antagonist, beta2 -agonist, 
lactose/milk protein or magnesium  
 
 2018N371775_00
2016N289466_02 CONFIDENTI AL
205832
25Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
stearate are excluded from 
participation in this study  (Section 
6.2). 
-Review AEs/SAEs
Paradoxical 
bronchospasmRare reports of paradoxic al bronchospasm (which may  be life 
threatening) with other inhalational products have been reported.  
There have been rare post-marketing reports of paradoxical 
bronchospasm with FF/VI and UMEC/VI.Patients will undergo regular medical 
assessments during c linical studies.  
-Review AEs/SAEs
Pregnancy  and lactation There has been limited pregnancy  exposure to FF and FF/VI in 
humans. Animal studies have shown reproductive toxicity  after 
administration of corticosteroids and beta2 -agonists. 
There is a limite d amount of data from the use of UMEC in pregnant 
women. Animal studies do not indicate direct or indirect harmful 
effects with respect to reproductive toxicity . 
There is limited information on the excretion of FF or VI or their 
metabolites in human milk. However, other corticosteroids and 
beta2 -agonists are detected in human milk. It is unknown whether 
umeclidinium is excreted in human milk. The excretion of 
FF/UMEC/VI in breast milk has not been evaluated. A risk to 
breastfed newborns/infants cannot be e xcluded.Females who are pregnant or breast-
feeding are not eligible for 
participating in the stud y.
Females of child -bearing potential 
will need to follow the contraceptive 
requirements that are specified in 
Appendix 5.  
 
 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
26The risks for FF 100 mcg are recognised pharmacological class effects associated with 
ICS therap y, which are included in the table above. The experience with FF is provided 
in the respective IB.  
3.3.2. Benefit A ssessment
The benefit of UMEC at two dosage strengths 62.5 and 31.25 mcg as compared to 
Placebo in patients with asthma on background therap y of FF 100 mcg is expected to 
improve lung function. The inclusion of two strengths of UMEC will allow comparison 
to placebo for the dose currentl y marketed in COPD, as well as a lower dose. This will 
help show the efficacy  and safet y of UMEC in asthma when administered as an open 
combination on a background of FF. Another LAMA, tiotropi[INVESTIGATOR_1890], is currently  approved 
for the maintenance treatment of asthma. 
3.3.3. Overall Benefit: Risk Conclusion
Taking into account the measures taken to minimize the risk to the participants 
participating in the stud y, the potential risks identified in association with UMEC are 
justified by  [CONTACT_633382].  
The current experience and safet y profile with UMEC in previous Phase II asthma studies 
(alone and in combination with FF) and from clinical trial and marketing experience in 
the COPD population is supportive of evaluating this compound in asthma patients. T he 
potential risks associated with the known pharmacology  of UMEC 
is offset by  [CONTACT_633383] I CS
therap y. Furthermore, t he approval of another LAMA (tiot ropi[INVESTIGATOR_1890]) for the treatment of
asthma demonstrates the suitability  for the use of this class of drug in the asthma 
population.  
4. OBJECTIVES A ND ENDPO INTS
For a definition of baseline for each of the endpoints listed below, please refer to Section 
10.6.
Objectives Endpoints
Primary
Evaluate the effects of UMEC 
62.5 mcg and UMEC 31.25 mcg 
on lung function (trough FEV1) 
versus placebo after 24 weeks of 
treatment.Mean change from baseline in clinic 
trough FEV 1 atWeek 24
Secondary
Evaluate the effects of UMEC 
62.5 mcg and UMEC 31.25 mcg on 
lung function (3hours post dose Mean change from baseline in clinic 
FEV [ADDRESS_845613] dose at Week 24 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
27Objectives Endpoints
FEV1) versu s placebo after 24 
weeks of treatment.
Safety  
To evaluate the safet y and 
tolerability  of UMEC 62.5 mcg and 
UMEC 31.25 mcg compared to 
placeboIncidence and t ype of adverse events
ECG measurements
Vital signs
Other
To evaluate other efficacy  assessments 
of UMEC 62.5 mcg and UMEC 
31.25 mcg compared to placeboMean change from ba seline in morning 
(AM) pre -dose Peak Expi[INVESTIGATOR_105177] 
(PEF) over the 24 week treatment 
period
Mean change from baseline in evening
(PM)PEF over the 24 week treatment 
period
Mean change from baseline in daily  
home trough FEV1 over the 24 week 
treatment peri od
Mean change from baseline in daily  
rescue medication use over the 24 
week treatment period
Mean change from baseline in SGRQ
total score at Week 24
Percent of patients meeting a 
responder threshold of ≥ 4 points 
improvement (decrease) from baseline 
for the SGRQ total score at Week 24
Mean change from baseline in SGRQ 
domain scores at Week 24
Mean change from baseline in the 
AQLQ total score at Week 24
Percent of patients meeting a 
responder threshold of ≥ 0.5 points 
improvement from baseline for the 
AQLQ total score at Week 24
Mean change from base line in E -RS
total score over the 24 week treatment 
period
Mean change from baseline in  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
28Objectives Endpoints
ACQ -5 total score at Week 24
Percent of patients meeting a 
responder threshold of ≥0.5 in change 
from baseline for the ACQ -5 at Week 
24
Annualized rate of moderate/ severe 
asthma exacerbations
5. STUDY DESIGN
5.1. Overall Design
This is a Phase IIb, randomized, double -blind, placebo controlled, 3 -arm parallel group 
study , comparing the efficacy , safet y and tolerability  of UMEC (62.5 mcg and 
31.25 mcg) administered once- dailyin participants with asthma that is not well controlled 
(i.e. participants with an ACQ -6 total score > 0.75 at Visit 2 [the Randomization Visit] ) 
despi[INVESTIGATOR_633331].
Eligible participant s will be requested to participa te in the study  for a maximum of 
approximately 31 weeks ( Visit 0to the Follow -up contact , inclusive ) during which time, 
participants will complete the following 4 phases of the study : 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
29Pre-screening: Details about the study  and pr ocedures will be explained 
through the informed consent process. The Pre -screening Visit (Visit 0 ), 
including the informed consent process, must be completed within 4 weeks prior 
to Visit 1 as well as prior to any  protocol -required changes to a participant ’s 
usual asthma treatment and the initiation of any Visit 1 procedures. Subjects will 
continue treatment with their regular (i.e. pre- study ) asthma medication(s) 
during the pre -screening period; however, medications that are prohibited within 
a specified t ime interval prior to Visit 1 are defined in Section 7.9.
Participant s that 
receive LABA (or LAMA) as a component of their regular (i.e. 
pre-study ) therap y must stop L ABA (or LAMA) treatment from  48 hours prior 
to Visit 1 (Scr eening) until they  have completed the study ; therefore, the 
investigator must use their clinical judgment to determine if the participant may 
stop L ABA (or LAMA) prior to study  entry  without incurring undue risk.
Screening / run- in: Participants who meet a ll the eligibility  criteria at Visit 1 
(Screening), will enter the run -in period for approximately  2 weeks to continue 
assess ingthe participant ’s eligibility  for the study . On the morning of Visit 1, 
participant s will refrain from t aking the morning dose of their regular (i.e. pre -
study ) ICS asthma medication. Participant s satisfying all inclusion/exclusion 
criteria and who have successfully  completed all protocol procedures at 
screening will be provided with FF 100 mcg via the ELLIPTA dry -powder 
inhaler ( DPI) to take once daily  (QD), in the morning, during the 2- week run -in 
period; the first dose of FF 100 mcg will be self -administered by  [CONTACT_633378]. Participants will refrain from using their own ICS 
asthma medication during the 2- week run- in and treatment period. Participants 
will also be provided with rescue medication (albuterol/salbutamol) to use on an 
as-needed basis throughout the stud y.
Randomization / treatment: At Visit 2 (the Randomization Visit), participants 
who me et all of the randomization criteria will be randomized 1:1:1 to receive 
oneof the following three double -blind study  treatments via the ELLIPTA DPI  
[CONTACT_78482] 24 -week treatment period:
UMEC 62.5 mcg QD
UMEC 31.25 mcg QD
Placebo QD
Participants will conti nue to administer FF 100 mcg once dail y (QD), in the 
morning from a separate ELLIPTA DPI [INVESTIGATOR_633332]. On the 
morning of Visits 2, 3, 4, and 5, participant s will perform their electronic Diary  
(eDiary ) assessments at home but refrain from taking their morning dose of 
study  treatment and FF 100 mcg (as applicable) until instructed to do so by
[CONTACT_6477]. At Visits 2, 3, [ADDRESS_845614] at the clinic (see Section 
7.2). Participant s will take their last dose of study  treatment and FF 100 mcg in 
the clinic on Day  169 (Visit 5). Participants are expected on non -clinic visit day
s 
to take their study  treatment and FF 100 mcg at home in the morning at 
approximately  the same time each day , as directed by  [CONTACT_3652]. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
30Safety f ollow -up: A safety  follow -up telephone contact [CONTACT_417494] 7 day s after the participant completes all of the 
protocol -define d procedures for V isit 5 /End of Study  (EOS )or, if applicable, the 
Early Withdrawal V isit. A participant will be considered to have completed the 
study  when they  have completed all phases of the study  including screening, 
run-in, the randomi zed treatment p hase, and safety  follow -up.
To demonstrate the benefit of UMEC the primary  comparisons of interest for the primary  
efficacy  endpoint are:
UMEC 62.5 mcg versus (vs) Placebo
UMEC 31.[ADDRESS_845615] that aim to informally  estimate any  
potential benefit of increasing the UMEC dose are given below for all efficacy  endpoints. 
UMEC 62.[ADDRESS_845616] not withdrawn consent are encouraged to continue in the stu
dy and 
complete all remaining protocol specified clinic visits (see Section 8.1)
5.2. Number of Participants
The total number of randomized participant s required is approximately  384, with 128
participant s randomized 1:1:1 to each o f the 3 double -blind treatment arms (see Section 
10).  
5.3. Participant and Study  Completion
A participant will be considered to have completed the study  when they  have completed 
allphases of the stud y including pre-screening, screening, run
-in, the randomi zed 
treatment phase, and safety  follow -up.
The end of the stud y is defined as the date of the last scheduled procedure shown in the 
Schedule of Activities table (see Section 2) for the last participan t in the trial globall y.
5.4. Scientific Rationale for Study  Design
This study  will use a multicenter, randomized, double -blind, 3 arm 
parallel- group design.  
This is a well -established design to evaluate the efficacy , safety , and tolerability  of the 
UMEC 
drug.   A placebo arm is included. All participants will be placed on open -label FF 
100mcg when they  enter the 2 week run -in period and continue it through the 24 week 
treatment period. The primary  objective of this study  is to evaluate the effects of UMEC 
62.5 mcg and UMEC 31.25 mcg on lung function compared with placebo after 24 weeks 
of treatment. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
31GlaxoSmithKline ([COMPANY_004]) is currentl y developi[INVESTIGATOR_007] a once -daily ‘closed’ triple therap y of a 
ICS/LAMA/LABA combination [FF /UMEC/ VI)] in a single device, with the aim of
providing a new treatment option for the management of asthma in adults. Through the 
evaluation of UMEC 62.5 mcg and 31.25 mcg compared to placebo this study  will 
provide important informa tion regarding the efficacy , safety and tolerability of UMEC in 
asthma when administered via a separate inhaler to participants on a background of FF
without VI .
5.5. Dose Justification
The 200699 (IB, GlaxoSmithKline Document 2011N123107_03, / IB Supplement, 
GlaxoSmithKline Docume nt 2016N284764_00
) data showed UMEC 62.5 mcg to be an 
effective dose; after 4 weeks of treatment in the subset of patients with a primary  
diagnosis of asthma, an average increase in change from baseline trough FEV1 at Day  29 
of 136 mL  was observed in those participants treated with FF/UMEC (100/62.5 mcg) 
compared to those participants treated with FF (100 mcg) alone. However, study  200699 
did not assess the UMEC 31.25 mcg dose, therefore, the efficacy  and safet yprofile of 
both 31.25 and 62.5 mcg doses will be assessed in this study  when administered via a 
separate inhaler to participants treated on a background of FF 100 mcg. No safet y signal 
was identified with an y of the UMEC doses (15.6, 62.5, 125 and 250 mcg) evaluated in 
the 200699 study .
6. STUDY POPULA TION
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
6.1. Inclusion Criteria
Participants are eligible to be include d in the study  only  if all of the following criteria 
apply :
AGE
1.Age: 18 years of age or older at the time of signing the informed consent.
TYPE OF PARTICI PANT AND DISEASE CHARACTERI STICS
2.Diagnosis: Participant s with a diagnosis of asthma as defined b y the National 
Institutes of Health [ NIH2007] at least 6 months prior to Visit 0.
3.Asthma Control :ACQ -6total score of >0.75 at Visit 1 .
4.Current Asthma Maintenance Therapy : Participant s are eligible if they  have 
required daily  ICS thera py 100mcg/day  fluticasone propi[INVESTIGATOR_16847] (FP, or 
equivalent) with or without L ABA or LAMA for at least [ADDRESS_845617] been no changes in maintenance asthma medications d uring the 4 
weeks imm ediatel y prior to Visit 0.
Examples of ac ceptable doses of commonly  prescribed I CS medication will be 
provided in the Study  Reference Manual (SRM) .  Dosing regimen (once or twice 
daily  to equal the total daily  dose) should be restricted to the current local product  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
32labels.
5.Spi[INVESTIGATOR_038]: Both of the following:
a.A best pre -bronchodilator morning (AM) FEV1 ≤90% of the predicted 
normal value. Predicted values will be based upon the ERS Global L ung 
Function Initiative [ Quanjer 2012].
b. A best post- bronchodilator FEV1/ forced vital c apacity (FVC ) ≥0.7 at 
Visit 1.
6.Reversibility of Disease: Airway  reversibility  is defined as ≥12% and ≥200 mL  
increase in FEV1 between 20 and 60 minutes following 4 inhalations of 
albuterol/salbutamol aerosol at Visit 1. 
Note: If the participant does not m eet the above reversibility criteria at Visit 1 
then the reversibility assessment may be repeated once within 7 days of Visit 1 if 
either criteria a) or b) are met:
a) ≥9% increase in FEV1 betwee n 20 and 60 minutes following 4 
inhalations of albuterol/sal butamol aerosol at Visit 1.
b) Documented evidence of a reversibility assessment within [ADDRESS_845618] -bronchodilator increase in FEV1 of 
≥12% and ≥[ADDRESS_845619] reversibil ity (defined as 
≥12% and ≥200 mL increase in FEV1 between 20 and 60 minutes following 4 
inhalations of albuterol/salbutamol aerosol) at the second attempt then, provided 
that all other eligibility criteria assessed at Visit 1 are met, the participant may 
enter the 2-week run -inperiod (seeSection 9.1.3 ).
7.Short -Acting β2 Agonists (SABAs): All subjects must be able to replace their 
current SABA inhaler with albuterol/salbutamol aerosol inhaler at Visit [ADDRESS_845620] be judged capable of 
withholding albuterol/salbutamol for at least 6 hours prior to study  visits.
SEX
8.Gender:
a.Male participants
b.Female participants: 
A female participant is eligible to participate if she is not pregnant (seeAppendix 5),
not breastfeeding, and at least one of the following conditions applies:
Not a woman of childbearing potential (WOCBP) as defined in Appendix 5
OR
A WOCBP who agrees to follow the contraceptive guidance in Appendix [ADDRESS_845621] dose of study   2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
33treatment.
INFORMED CONSENT
9.Informed Consent: Able to give written informed consent prior to participation 
in the study , which will include the ability  to comply  with the requirements and 
restricti ons listed in the consent form and in this protocol.  Participant s must be 
able to read, comprehend, and write at a level sufficient to complete study  related 
materials.
6.2. Exclusion Crite ria
Participant s are excluded from the study  if any  of the following criteria apply :
MEDICAL CONDITIONS
1.Pneumonia :Chest X -ray documented pneumonia in the 12 weeks prior to Visit 1 .
2.Asthma Exacerbation: Any severe asthma exacerbation, defined as deterior ation of 
asthma requiring the use of systemic corticosteroids (oral, parenteral or depot) within 
12 weeks of Visit 1, or an inpatient hospi[INVESTIGATOR_633341] 12 weeks of Visi t 1.
3.Concurrent Respi[INVESTIGATOR_31753]: Current evidence of pneumonia, pneumothorax, 
atelectasis, pulmonary  fibrotic disease, bronchopulmonary  dysplasia, chronic 
bronchitis, emphy sema, chronic obstructive pulmonary  disease, lung cancer, or other 
respi[INVESTIGATOR_633342].
4.Pregnancy: Women who are pregnant or lactating or are planning on becoming 
pregnant during the study.
5.Risk Factors for Pneumonia : Immune suppression (e.g., HIV, Lupus) or other risk 
factors for pneumonia (e.g., neurological disorders affecting control of the upper 
airway , such as Parkinson’s Disease, M yasthenia Gravis) . Patients at potentially  high 
risk (e.g., very low BMI, severel y malnourished, or very  low FEV 1) will only  be 
included at the discretion of the Investigator .
6.Other diseases/abnormalities : Participant s with historical or current evidence of 
clinically  significant cardiovascular, neurological, psy chiatric, renal, hepatic, 
immunological, gastrointestinal, urogenital, nervous sy stem, musculoskeletal, skin, 
sensory , endocrine (including uncontrolled diabetes or thyroid disease) or 
hematological abnormalities that are uncontrolled .  Significant is defined as any  
disease that, in the opi[INVESTIGATOR_689], would put the safet y of the participant
at risk through pa rticipation, or which would affect the efficacy  or safet y analysis if 
the disease/condition exacerbated during the stud y.
7.Unstable liver disease as defined b y the presence of ascites, encephalopathy, 
coagulopath y, hypoalbuminaemia, esophageal or gastric va rices or persistent 
jaundice, cirrhosis, known biliary abnormalities (with the exception of Gilbert’s 
syndrome or as ymptomatic gallstones).  Note: Chronic stable hepatitis B and C are 
acceptable if the participant otherwise meets entry criteria 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
348.Clinically significant ECG abnormality: Evidence of a clinicall y significant 
abnormality  in the 12-lead ECG performed during screening or run- in. The PI  [INVESTIGATOR_633343] ’s medical his
tory and exclude participants who would be at undue risk by  
[CONTACT_19212]. An abnormal and clinically significant finding is defined as a 
12-lead tracing that is interpreted as, but not limited to, any of the following:
AF with r apid ventricul ar rate >120 beats per minute (BPM)
sustained or nonsustained ventricular tach ycardia (VT)
Second degree heart block Mobitz ty pe II and third degree heart block (unless 
pacemaker or defibrillator had been inserted)
QTcF ≥500 msec in patients with QRS <120 msec and QTcF ≥530 msec in 
patients with QRS 
≥120 msec
9.Unstable or life threatening cardiac disease: participant s with any  of the following 
at Screening (Visit 1) would be excluded:
Myocardial infarction or unstable angina in the last 6 months 
Unstable or life threatening cardiac arrh ythmia requiring intervention in the last 
3 months
[LOCATION_001] Heart Association (NYHA) Class IV Heart failure
10.Antimuscarinic effects: Participant s with a medical condition such as narrow -angle 
glaucoma, urinary  retention, prostatic hy pertrophy or bladder neck obstruction should 
only be included if in the opi[INVESTIGATOR_2511] I nvestigator the benefit outweighs the risk 
and that the condition would not contraindicate study  participation.
11.Cancer : Participant s with carcinoma that has not been in complete remission for at 
least [ADDRESS_845622] had carcinoma in situ of the cervix, squamous 
cell carcinoma and basal cell carcinoma of the skin would not be excluded based on 
the 5 year waiting period if the participant has been considered cured b y treatment.
12.Questionable validity of consent : Participant s with a history  of ps ychiatric disease, 
intellectual deficiency , poor motivation or other conditions that will limit the validity  
of informed consent to participate in the study .
PRIOR/CONCOMITANT THERAPY
13.Medication prior to spi[INVESTIGATOR_038] : Participant s who are medically  unable to withhold 
their albuterol/salbutamol for the 6- hour period required prior to spi[INVESTIGATOR_417426] y visit.
PRIOR/CONCURRENT CLI NICAL STUDY EXPERIEN CE/RELEVANT 
HABITS
14.Tobacco Use: Current smoker or a smoking history  of ≥10 pack years (e.g., 
20cigarettes/day  for 10 years).  A participant may not have used inhaled tobacco 
products within the past 12 months (i.e., cigarettes, e-cigarettes/vapi[INVESTIGATOR_007], cigars or pi[INVESTIGATOR_44031]).
15.Drug/alcohol abuse : Participant s with a known or suspected history  of alcohol or  2018N371775_00
2016N289466_02 CONFIDENTIA L
[ADDRESS_845623] 2 y ears. This includes marijuana, which is considered an 
abused drug.
Diagnostic assessments
16.Allergy or Hypersensitivity : A history  of allergy or hy persensitivity  to any  
corticosteroid, anticholinergic/muscarinic receptor antagonist, beta2 -agonist, 
lactose/milk protein or magnesium stearate.
Other Exclusions
17.Non-compliance : Participant s at risk of non- compliance, or unable to comply  with 
the study  procedures. Any infirmit y, disability, or geographic location that would 
limit compliance for scheduled visits.
18.Affiliation with investigator site : Study  investigators, sub- investigators, study  
coordinators, emplo yees of a participating investigator or study  site, or immediate 
family  members of the aforementioned that is involved with this study .
19.Inability to read: In the opi[INVESTIGATOR_2511] I nvestigator, any  participant who is unable to 
read and/or would not be able to complete stud y related materials.
6.2.1. Randomization Criteria
At the end of the run -inperiod (Visit 2) , study  participants must fulfil the following 
additional criteria in order to be randomized into the study  and enter the treatment period :
6.2.2. Inclusion Criteria for Randomization
TYPE OF PARTICI PANT AND DIAGNOSIS INCLUDING DI SEASE SEVERI TY
1.Asthma Control: ACQ -6 total score of >0.75 at Visit 2.
2.Percent -predicted FEV 1: Spi[INVESTIGATOR_038] : A best pre -bronchodilator morning (AM) 
FEV1 ≤90% of the predicted normal value at Visit 2.Predicted values will be based 
upon the ERS Global L ung Function Initiative [ Quanjer 2012].
CONCURRENT CONDITIONS/MEDICAL HISTORY
3. Liver function tests at Visit 1:
alanine aminotransf erase (ALT) ≤2 x upper limit of normal (ULN)
alkaline phosphatase ≤1.[ADDRESS_845624]
bilirubin ≤1.5 x UL N (isolated bilirubin >1.[ADDRESS_845625] bilirubin <35%)
eDIARY
4.Compliance with completion of the Dail y eDiary r eporting defined as completion of 
all questions/assessments on [ADDRESS_845626] 7 day s during the run- in period. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
366.2.3. Exclusion Criteria for Randomization
CONCURRENT CONDITIONS/MEDI CAL  HISTORY
1.Respi[INVESTIGATOR_60623]: Occurrence of a culture -documented or suspected bacterial or 
viral infection of the upper or lower respi[INVESTIGATOR_53121], sinus or middle ear during the 
run-in period that led to a change in asthma management or, in the opi[INVESTIGATOR_684] , is expected to affect the participant ’s asthma status or the participant ’s 
ability  to participate in the study .
2.Asthma exacerbation: Evidence of a moderate asthma exacerbation leading to a 
change in therap y or severe exacerbation during screening or the run-inperiod , 
defined as deterioration of asthma requirin g the use of s ystemic corticosteroids 
(tablets, suspension, or injection) or an in -patient hospi[INVESTIGATOR_633344] s ystemic corticosteroids.
CONCOMITANT MEDICATIONS/TREATMENTS
3.Asthma medication: Changes i n asthma medication (excluding changes after Visit 0 
or run -in medication and albuterol/salbutamol inhalation aerosol provided at Visit 1).
DIAGNOSTIC ASSESSMENTS AND OTHER CRITERIA
4.Laboratory test abnormalities: Evidence of clinically  significant abnorm al 
laboratory  tests during screening or run -in which are still abnormal upon repeat 
analysis and are not believed to be due to disease(s) present.  Each Investigator will 
use his/her own discretion in determining the clinical significance of the abnormalit y.
6.3. Lifest yle Restrictions
No lifesty le restrictions are required for this study .
6.4. Pre-Screening/ Screening/Run -in/Randomization Failures
A participant will be assigned a participant number at the time the informed consent is 
signed at Visit 0.
The study  site will be responsible for reporting pre -screen failures. The following 
information will be collected in the eCRF for participants who are pre -screen failures:
Demographic information including race, age and gender
Participant number
Serious Adverse Event i nformation only for any  SAE considered as related to 
study  participation
Investigator signature [CONTACT_633407] ,pre-screening failures, screening failures , run-in failures
and randomization failures will be defined as follows:
Pre-screening failures: those participant s that sign the informed consent 
document but do not have a Visit 1 (Screening) procedure. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
37Screening failures: those participant s that complete at least one Visit 1 
(Screening) procedure but do not enter the run -in period. 
A participant who completes Visit [ADDRESS_845627] entered the run- in period.
Run-in failures: those participant s that enter the run -in period but do not have 
any Visit 2 (Rand omization) procedures .
Randomization failures: those participants that complete at least one Visit 2 
(Randomization) procedure but do not enter the double- blind study  treatment 
period.
Any participant who completes the run -in period and then meets the 
randomization criteria and is dispensed the double -blind study  treatment at Visit 
[ADDRESS_845628] entered the treatment period.
RAMOS NG will be contact[CONTACT_633384]. 
In order to ensure transparent reporting of screen /run-infailure participant s, meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements, and 
respond to queries from Regulatory  authorities, a minimal set of screen /run-
in/randomization failure information is required including demography , screen/run-
in/randomization failure details, eligibility  criteri a, and an y SAE s(see Section 9.2.4 and 
Appendix 4 ).Further details are provided in the study -specific eCRF completion 
guidelines document .
Re-screening of subjects will be permitted; however, advance written approval to proceed 
with re -screening a subject must be obtained from the Medical Monitor (for contact 
[CONTACT_8972], see the medical monitor/Sponsor I nformation Page at the beginning of this 
protoco
l).
7. TREATMENTS
Study  treatment is defined as any  investigational treatment(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according 
to the study  protocol. The term ‘study  treatment’ within this tri al is used to describe the 
combination of products received by [CONTACT_97246]. Study 
treatment may  also be used to only reference the randomized study  treatment when 
described together with the FF 100 mcg open -label treatment.
7.1. Treatments A dministered
7.1.1. Description of FF 100 mcg and Double -Blind Study Treatment
The ELLIPTA device will be used during the run-in period and the treatment period .  The 
ELLIPTA dry  powder inhaler (DPI)is a molded plastic two- sided device with a dose 
coun ter that can hold two individual blister strips.  The ELLIPTA will deliver, when 
actuated, the contents of a single blister simultaneously  from each of the two strips. The 
ELLIPTA is individually sealed in a foil laminate overwrap that also contains a silica gel 
desiccant packet. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
38A description of the FF (GW685698) 100 mcg inhalation powder administered via the 
ELLIPTA is provided in Table 
1; descriptions of the double -blind study  treatments 
administered via the ELLIPTA are provide d in Table 2.
Table [ADDRESS_845629] Strip Second Strip
GW685698 blended w ith 
lactose monohydrateLactose monohydrate with magnesium 
stearate1
Dosage Form ELLIPTA DPI w ith 30 doses (2 strips w ith 30 blisters)
Unit Dose strengths 100 mcg per blister Not applicable
Physical description White pow der White pow der
Route of 
AdministrationInhaled
1. Magnesium stearate 1.0% w/w of total drug product.
Table 2 Description of Study  Treatment Inhalation Powder in ELLIPTA
 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
397.1.2. Description of Albuterol/Salbutamol
Albuterol/salbutamol via metered -dose inhaler (MDI) will be issued for reversibility  
testing at Visit 1.  An albuterol/salbutamol MDI for as needed (prn) use throughout the 
study  will be provided starting at Visit 1; at the I nvestigator’s discretion, more than one 
MDI  may  be provided at any  one time. Albuterol/salbutamol will be sourced from local 
commercial stock.  If not available loc all
y, [COMPANY_004] will source centrally. The contents of the 
label will be in accordance with all applicable regulatory  requirements.
7.1.3. Study Treatment , albuterol/salbutamol, and FF 100 mcg Return
ELLIPTAs containing FF 100 mcg,and stud y treatment , in addition to 
albuterol/salbutamol, will be dispensed to a participant during their visit to the study  
clinic (as applicable). The participant must return all dispensed ELLIPTAs and 
albuterol/salbutamol at the subsequent clinic visit. The schedule for dispensing and 
collecting FF 100 mcg and study  treatment ELLIPTAs is provided in the Schedule of 
Activities table (Section 2).
All used and unused study  treatment, FF 100 mcg and albuterol/salbutamol 
will be 
returned to [COMPANY_004] at the end of the stud y to be available for disposal.  In some instances ,
for sites outside the US, study  supplies will be disposed of locall y either b y the site, the 
country  medical department or third -party vendor. Detailed instructions for the return of 
the study  drug can be found in the Study  Reference Manual ( SRM ).
If any ELLIPTA fails to function properl y, the participant should return to the clinic as 
soon as possible to obtain a new inhaler.  The site will use the I WRS (RAMOS NG) to 
obtain a new treatment pack number for the participant and dispense a new study  
treatment kit from the site’s study  treatment supply  as instructed by  [CONTACT_941] I WRS.
In addition, any  metered dose inhaler (MDI ) that fails to function properl y must be 
identified and returned to [COMPANY_004] for testing.  Detai ls of the failure will be documented in 
the eCRF.
7.2. Dose Modification
There were no dose modifications planned for this protocol.
7.3. Method of Treatment A ssignment
Participant s will be assigned to study  treatment in accordance with the randomization 
schedule. T he randomization code will be generated by  [CONTACT_417506] a validated 
computerized sy stem . Participant s will be randomized using an interactive web response 
system 
(IWRS) RAMOS NG. The stud y will use central -based randomization to allocate 
treatments. Once a ra ndomization number is assigned to a participant it cannot be 
reassigned to an y other participant in the study .
Following the 2 -week run -inperiod and participant to satisfy ing all eligibility  criteria, 
participant s willbe randomized 1:1:1 to one of the followi ng three double -blind 
treatments for the duration of the treatment period :  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
40UMEC 62.5 mcg QD
UMEC 31.25 mcg QD
Placebo QD
The duration of double -blind treatment for each participant is 24 weeks. O n the morning 
of each scheduled clinic study visit, participant s will refrain from taking their morning 
dose of study  treatment and FF 100 mcg 
until instructed to do so by  [CONTACT_6477]. 
Study  treatment will be taken at the clinic at approximately  the s ame time of day  as taken 
at the Randomization Visit (Visit 2). On the other day s during the treatment period (i.e. 
“non -clinic days”), participants will be instructed to take their study  treatment each 
morning at approximately  the same time. Each Investigator will be provided with 
sufficient supplies to conduc t the trial. Additional treatment packs will be supplied as 
needed to the sites. Details of how to use the I WRS sy stem (RAMOS NG) to randomize 
participant s and manage study  treatment supplies (including dispensing) is prov ided in 
the RAMOS NG I WRS manual a nd SR M.
7.4. Blinding
This will be a double
-blind study  and the following will appl y. 
The Investigator or treating phy sician may  unblind a participant ’s treatment 
assignment onl y in the case of an emergency OR in the event of a serious 
medical condition when knowledge of the stud y treatment is essential for the 
appropriate clinical management or welfare of the participant as judged b y the 
Investigator . 
Investigator s have direct access to the 
participant ’s individual study  treatment. 
It is preferred (but not r equired) that the Investigator first contacts the Medical 
Monitor or appropriate [COMPANY_004] study  personnel to discuss options before 
unblinding the participant ’s treatment assignment. 
If [COMPANY_004] personnel are not contact[CONTACT_222201], the Investigator
must noti fy [COMPANY_004] within 24 hours after unblinding, but without revealing the 
treatment assignment of the unblinded participant , unless that information is 
important for the safety  of participant s currentl y in the study . 
The date and event or condit ion which led to the unblinding (i.e. the primary 
reason) will be recorded in source documentation and in the eCRF. 
Should a participant’s treatment assignment be unblinded then the participant may  
continue the assigned study  treatment and be followed- up as per pro tocol until the 
completion of the Safet y Follow -up assessments .
[COMPANY_004]’s Global Clinical Safet y and Pharmacovigilance (GCSP) staff may unblind the 
treatment assignment for any  participant with an SAE. If the SAE requires that an 
expedited regulatory  report be sent to one or more regulatory  agencies, a copy  of the 
report, identify ing the participant ’s treatment assignment, may  be sent to Investigator s in 
accordance with local regulations and/or [COMPANY_004] policy
.Participants will not be withdrawn 
from the study . 2018N371775_00
2016N289466_02 CONFIDENTIAL
205832
417.5. Packaging and Labeling
The contents of the label will be in accordance with all applicable regulatory 
requirements.
7.6. Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study treatment received and any discrepancies are reported and resolved before use of the study treatment.
2. Only participants enrolled in the study may receive study treatment and only 
authorized site staff may supply or administer study treatment. All study treatments must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff.
3. The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for study treatment accountability, reconciliation, and record maintenance (i.e., receipt, reconciliation, and final disposition records).
4. Further guidance and information for the final disposition of unused study treatment 
are provided in the SRM.
5. Under normal conditions of handling and administration, study treatment is not 
expected to pose significant safety risks to site staff.  Take adequate precautions to avoid direct eye or skin contact [CONTACT_23968]. In the case of unintentional occupational exposure notify the monitor, Medical Monitor and/or [COMPANY_004] study contact.
6. A Material Safety Data Sheet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the investigator, where this is required by [CONTACT_1207], or is available upon request from [COMPANY_004].
7.7. Treatment Compliance
When participants are dosed at the site, they will receive FF 100 mcg and study treatment under medical supervision.  The date and time of each dose administered in the clinic will be recorded in the eCRF.  The dose of study treatment and study participant identification will be confirmed at the time of dosing by a member of the study site staff.  
When participants self-administer study treatment(s) at home, compliance with study 
treatment will be assessed through querying the participant during the site visits and recording the number of doses remaining in the ELLIPTA in the eCRF (see the SRM for details).  A record of the number of ELLIPTAs dispensed to each participant must be maintained and reconciled with study treatment and compliance records. 
Participant compliance with FF 100 mcg and study treatment will be assessed at 
scheduled clinic visits by [CONTACT_633385](s) (see Section 7.1.3).  Participants should be  80% to  120% 
compliant on taking both FF 100 mcg and study treatment between each pair of  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
42compliant on taking both FF 100 mcg and study  treatment between each pair of 
scheduled and consecutive on- treatment clinic visits , as applicable . Participant s who fall 
outside this range should be re -educated on treatment compliance b y their site. This re -
education should be documented in the participant’s source document. If FF 100 mcg 
and/or study  treatment isprematurel y discontinued during the course of the study  or 
compliance repeatedly falls outside of acceptable ranges, the study  sponsor/site monitor 
must be contact[CONTACT_633386] .
7.8. Concomitant Therapy
All asthma medications used within approximately 6 weeks prior to screening and during 
the study  (including the post -treatment period) should be recorded in the eCRF.
All non
-asthma medications taken during the study (after randomization including post -
treatment) and an y changes to concomitant medications will be recorded in the eCRF. 
Note: Study provided FF 100 mcg and albuterol/salbutamol should not be recorded in 
the eCRF; howev er non-study supplied FF 100 mcg and albuterol/salbutamol will be 
recorded in the eCRF.
The minimum requirement is that the drug name, reason for use, dose (including unit e.g. 
mcg) and frequency , route and the dates of administration are to be recorded.
Medications initiated after completion of the assessments at Visit 5/EOS or the Earl y 
Withdrawal Visit will not be recorded in the eCRF unless taken to treat an AE or asthma 
exacerbation. Detailed information of permitted and prohibited medications is incl uded in 
the SRM for y our reference.   Participant s who have completed the Early Withdrawal 
Visit are allowed to use any  medications prescribed by  [CONTACT_633387].
7.8.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014]
[IP_ADDRESS]. Permitted A sthma Medic ations
In addition to FF 100 mcg and stud y treatment, t he following medications are permitted 
during this study :
Study -provided albuterol/salbutamol will be dispensed at Visit [ADDRESS_845630] be judged 
capable of withholding albuterol/salbutamol for at least 6 hours prior to study 
visits.
Temporary  changes in medications are permitted for the treatment of moderate asthma 
exacerbations, at the Investigator’s/treating ph ysician’s discretio n.Asthma exacerbations 
should be treated in line with national and international recommendations and local 
medical standards. Asthma medications permitted on a temporary  basis to treat a 
moderate asthma exacerbation include but are not limited to the foll owing (the Medical 
Monitor may  be contact[CONTACT_245939]; see the SRM for contact [CONTACT_3031]
[refer to S ection [IP_ADDRESS] for guidance on moderate asthma exacerbation] ): 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
43An increase in ICS dose.
Systemi c corticosteroids (tablets, suspension or injection) for no more than 2 
days.
An Investigator -advised change in SABA use (i.e., routinely  scheduled versus 
as needed use).
Leukotriene receptor antagonists (LTRAs) and leukotriene modifiers.
Oral theoph ylline.
[IP_ADDRESS]. Permitted Non-Asthma Medications
The following medications are permitted during this study :
Medications for rhinitis (e.g., intranasal corticosteroids, antihistamines [including 
ocular and intranasal], cromoly n, nedocromil, nasal decongestants)
Note: Us e of these medications should be captured on the concomitant medication 
pages of the eCRF prior to ECG measurements.
Antibiotics for short term treatment of acute infections. L ong term treatment with 
topi[INVESTIGATOR_417436].
Deconge stants: Participants may  take decongestants during the study , but these 
are disallowed for 24 hours prior to ECG measurements.
Immunotherap y: Immunotherap y for the treatment of allergies is allowed during 
the study  provided it was initiated 4 weeks prior t o Visit 1 and participants remain 
in the maintenance phase for the duration of the study .
Topi[INVESTIGATOR_238426].
Systemic and ophthalmic beta -blockers: Administer with caution as s ystemic 
beta-blockers block the pulmonary  effect of beta- agonists and may  produce severe
bronchospasm in patients with reversible obstructive airway s disease. 
Cardioselective beta -blockers should be considered, although they  also should be 
administered with caution.
Localized corticosteroid injections (e.g. intra -articular and epi[INVESTIGATOR_13873]).
Tricy clic antidepressants and monoamine oxidase inhibitors (MAOI s). 
(Administer with extreme caution as they  may  potentiate the effects of beta -
agonists on the cardiovascular s ystem, including QTc prolongation)
Diuretics.  (Caution is advised in the co -administration of beta -agonists with non-
potassium sparing diuretics as this may  result in ECG changes and/or 
hypokalemia )
Cytochrome P450 3A4 ( CYP3A4) inhibitors ( Caution should be exercised when 
considering the coadministration of long- term ketoconazole and other known 
strong CYP3A4 inhibitors (e.g., ritonavir, clarithromy cin, conivaptan, indinavir, 
itraconazole, lopi[INVESTIGATOR_054], nefazodone, nelfinavir, saquinavir, telithromy cin,  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
44troleandomycin, voriconazole) because increased sy stemic cor ticosteroid and 
increased cardiovascular adverse effects may  occur )
Vaccinations (Influenza vaccine, Pneumonia vaccine, Shingles vaccine, etc.) 
(Administration of influenza and pneumonia vaccines should be considered based 
on clinical discretion of the Investigator and local/national guidelines. Current 
influenza vaccines and pneumonia vaccines will be captured on the concomitant 
medication pages of the eCRF )
All medications for other disorders may  be continued throughout the study  provided their
use would not be expected to affect the participant s’ lung function or safety assessments
(e.g., cardiac measurements). However , no sy stemic corti costeroids will be permitted.
7.9. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_417438] 3 isnot permitted during the study .
Table 3 Concomitant Medications
Medication No use during the study and/or within the 
following time interval before Visit 1
Inhaled short -acting anticholinergics 6 hours
Inhaled short -acting anticholinergics+ Short -
acting beta agonist combination6 hours
Inhaled long -acting anticholinergics other than 
study treatment2 days
Immunosuppressive medications
including immunomodulators12 weeks
Inhaled long -acting beta 2-agonis ts (e.g., 
salmeterol, formoterol) or combination products 
containing inhaled long -acting beta 2-agonists 
(e.g., Seretide, Symbicort)
Inhaled very long -acting beta2 -agonists, 
(Indacaterol, Olodaterol)
Oral long -acting beta 2-agonists (e.g., 
bambuterol) [ADDRESS_845631] (rescue 
albuterol/salbutamol will be provided and is 
permitted during the study)6 hours (including all study visits) 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
45Theophyllines, slow -release
bronchodilators, ketotifen, nedocromil sodium,
sodium cromoglycate, roflumilast48 hours Temporary use will be permitted 
during the study to treat moderate asthma 
exacerbations
Anti-leukotrienes 48 hours. Temporary use will be permitted 
during the study to treat moderate asthma 
exacerbations
Any other investigational drug 30 days or within 5 drug half -lives of the 
investigational drug (whichever is longer)
7.10. Treatment after the End of the Study
Participant s will not receive an y additional treatment from G SK after completion of the 
study  because other treatment options are available .
The Investigator is responsible for ensuring that consideration has been given to the post-
study  care of the participant ’s medical condition, whether or not [COMPANY_004] is providing 
specific post -study  treatment.
8. DISCONTINUA TION CRIT ERIA
8.1. Discontinuation of Study  Treatment
Participants that permanently stop study treatment are encouraged to remain in the 
study .  Participant s have the right to discontinue study  treatment before the end of the 
study .  A participant may also be asked to discontinue study  treatment at the 
Investigator’s discretion.
Participant s who withdraw from study  treatment prematurel y (for an y reason) should, 
where possible, continue to be followed -up as per protocol unt il the completion of the 
Safety  Follow -up assessments .If this is not possible, the Investigator must encourage the 
participant to participate in as much of the study  as they  are willing (or able) to.
A participant may be withdrawn from study  treatment at any time. A reason for 
premature discontinuation of study  treatment (e.g., AE, lack of efficacy [including 
moderate or severe asthma exacerbation] , protocol deviation, Investigator discretion, 
consent withdrawn etc.) must be captured in the eCRF.
A partici pant must be withdrawn from study  treatment if any  of the following stoppi[INVESTIGATOR_118048]: 
Liver Chemistry : Meets any  of the protocol- defined liver chemistry  stoppi[INVESTIGATOR_3418] 
QTc: Meets an y of the protocol -defined stoppi[INVESTIGATOR_3418] 
Pregnancy : Posit ive pregnancy  test 2018N371775_00
2016N289466_02 CONFIDENTIA L
[ADDRESS_845632] been designed to 
assure participant safety  and evaluate liver event etiology (in alignment with the FDA 
premarketing clinical liver safety  guidance). These protocol guidelines are in alignment 
with FDA premarketing clinical liver safety  guidance: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf.
Discontinuation of study  treatment for abnormal liver tests should be considered b y the 
investigator when a participant meets one of the conditions outlined in the algorithm or if 
the investigator believes that it is in the best interest of the participant.
Phase II Liver 
Chemistry Stoppi[INVESTIGATOR_633345] d Monitoring Algorithm
Continue  Study  Treatmen t 
Discontinue  Study  Treatmen t Plus
Bilirubin≥2x
ULN (>35% 
direct) 
or plus
INR>1.5 , if 
measur ed*
Possi ble
Hy’s LawALT≥3xULNALT≥5xULNALT≥3xULN
Plus
Sympt oms of 
liver injury
or 
hyper sensitivityALT≥3xULN
but abl
e to 
monitor 
week ly for 
4 week sNo
Yes
YesYes YesNo No No
NoYes
ALT≥3xULN
persist for
4 week s or 
stoppi[INVESTIGATOR_278786]
*INR value not applicable to subjects on  anticoagu lantsYesIf subj ect to be moni tored weekl y must refer to Liver Safety Requi red  Actions and  Follow  up 
Assessme nts  section  in  the  Appendi x
Must refer to Liver Safety Requi red Actions and Follow  up Assess ments section in the Appendi x
Repor t as an SAE if possible Hy’s Law case:  ALT≥3xUL N and  Bilirubin≥2x UL
N (>35% direct)  or 
INR>1.5 , if measured*
Liver Safet y Required Actions a nd Follow up Assessments can be found in Appendix [ADDRESS_845633] be used for each individual participant to 
determine eligibility  for and discontinuation from the study .  This formula may  
not be changed or substituted once the participant has been enrolled. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
47For example, if a participant is eligible for the protocol based on QTcB (QT 
interval corrected for heart rate b y Bazett’s formula ), then QTcB must be used 
for discontinuation of this individual participant as well.
Once the QT correction formula has been chosen for a participant ’s elig ibility , 
the same formula must continue to be used for that participant for all QTc data 
being collected for data analysis . Safety
 ECGs and other non -protocol specified 
ECGs are an exception.  
The QTc should be based on averaged QTc values of triplicate e lectrocardiograms 
obtained over a brief (e.g., 5- 10 minute) recording period.
For this study , the following QTc stoppi[INVESTIGATOR_31764] , lead to withdrawal 
from study  treatment :
QTc>500 msec or uncorrected QT>600 msec
Change from baseline: QTc> 60 msec
For patients with underl ying bundle branch block, follow the discontinuation criteria 
listed below:
Baseline QTc with Bundle Branch Block <450 msec , Discontinuation QTc with 
Bundle Branch Block >500 msec
Baseline QTc with Bundle Branch Block <450 -480 mse c
, Discontinuation QTc 
with Bundle Branch Block ≥530 msec
8.1.3. Rechallenge
[IP_ADDRESS]. Study  Treatment Restart or Rechallenge
Study  treatment restart or rechallenge after liver chemistry  stoppi[INVESTIGATOR_496917].
8.2. Withdrawal from the Study
A participant may  withdraw from the study  at an y time at his/her own request, 
or may  be withdrawn at any  time at the discretion of the investigator for safety , 
behavioral, compliance or administrative reasons.
If the participant withdraws co nsent for disclosure of future information, the 
sponsor may
 retain and continue to use any  data collected before such a 
withdrawal of consent.
If a participant withdraws from the study , he/she may  request destruction of any  
samples taken and not tested, an d the investigator must document this in the site 
study  records.
In the event of earl y withdrawal from the study, every effort should be made to 
have the participant to return to the clinic for an Early  Withdrawal Visit and 
Safety  Follow -up,and to return all study  related materials. Assessments to be 
performed during the Early  Withdrawal Visit and the Safet y Follow -up contact 
[CONTACT_633388] (Section 2). 2018N371775_00
2016N289466_02 CONFIDENTIA L
[ADDRESS_845634] be taken if a participant fails to return to the clinic for a 
required stud y visit:
The s ite must attempt to contact [CONTACT_43207]/or should co ntinue in the study .
Before a participant is deemed lost to follow up, the investigator or designee 
must make every  effort to regain contact [CONTACT_6635] (where possible, 3 
telephone calls and, if necessary , a certified letter to the participant’s last known 
mailing address or local equivalent methods). These contact [CONTACT_19425]’s medical record.
Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study  with a p rimary  reason of lost to follow -
up. 
9. STUDY A SSESSMENTS A ND PROCEDURES
Study  procedures and their timing are summarized in the Schedule of Activities ( SoA) 
(Section 2). There are no protocol waivers or exemptions allowed. Immedi ate safet y 
concerns should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine if the participant should continue or discontinue study  treatment.
Adherence to the stud y design requirements, including those specified in the S oA, is 
essential and required for study conduct.
No study related procedures may be performed until the informed consent form has 
been signed by [CONTACT_2299] .  A Pre- S creening visit (Visit 0) is required in order to 
administer the informed consent befor e any changes are made to the participant ’s current 
medical regimen.  Selection and modification of the participant ’s medications prior to 
study  participation is based on the phy sician’s judgment according to sound medical 
practice, principles, and each participant ’s needs.  A participant ’s treatment must not be 
changed merel y for the purpose of enabling the participant’s participation in the stu dy.
During the P re-Screening visit (V isit 0) the following information will be captured in the 
eCRF for each part icipant: 
Demographic information including race, age and gender
Participant number
Serious Adverse Event information only for any  SAE considered as related to 
study  participation
Investigator signature [CONTACT_3264] 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
49The additional following critical baseline asses sments will be conducted at Screening 
(Visit 1):
Weight and height
A
sthma diagnosis histor y including:
The age of the participant when they  were first provided with an inhaler for 
asthma
Completion of an asthma medical history  questionnaire: a cop y of this
questionnaire and instructions for its use can be found in the SRM
Smoking history and status
Exacerbation history
Asthma and other concurrent medications
Medical History  including previous and/or concurrent medical conditions, 
detailed cardiovascular ris k factor history , pneumonia, and pneumonia vaccine 
status
Reason for screen failure (if applicable)
Vital signs
Questionnaires (ACQ; E-RS)
Pre-and post -albuterol/salbutam ol lung function
Inclusion/Exclusion criteria assessment
Physical examination
12-lead ECG
Child bearing status assessment for all potential female participants
Clinical laboratory
 tests (including hematology , chemistry , urinal ysis and serum 
pregnancy  test)
AE / SAE assessment
Inaddition , the following procedures must be completed at Screen ing (Visit 1):
Electronic device training / dispense eDiary
Review/dispense Medical Problems/Medication Taken worksheet
Dispense F F 100 mcg run-
in medication
9.1. Efficacy  Assessments
The timings of all efficacy  assessments are specified in the Schedule of Activities ( SoA)
(Section 2). 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
509.1.1. Questionnaires
The questionnaires should be completed before any  procedures are performed on the 
participant to avoid influencing the participant ’s response. To avoid biasing responses, 
the participant s should not be told the results of diagnostic tests prior to com pleting the 
questionnaires and i t is recommended that the questionnaires be administered at the same 
time of day  during each visit (as applicable) using the provided electronic device (unless
otherwise specified) .  Adequate time must be allowed to complete all items on the 
questionnaires; the questionnaires must be reviewed for completeness and, if necessary , 
the participant must be encouraged to complete any  missing assessments or items.
Instructions for completing the questionnaires can be found in the SRM.
[IP_ADDRESS]. Global A ssessment of Severity  and Response to Treatment
The participant will be asked to complete the G lobal Assessment of S everity  and 
Response to Treatment at the visits specified in the Schedule of Activities table (Section 
2). The Global Assessment of Severity  is a single item questionnaire; participant s are 
asked to rate their asthma sy mptoms at the study  visit using a five -
point scale (none, 
mild, moderate , severe, very  severe).  The Response to Treatment is a single question of 
the patient’s overall evaluation of response to treatment, using a seven- point rating scale 
with the following definitions: 1 = significantl y improved; 2 = moderatel y improved; 3 = 
mildly  improved; 4 = no change; 5 = mildl y worse; 6 = moderatel y worse; and 7 = 
significantl y worse. Instructions for completing the questionnaires can be found in the 
SRM.
[IP_ADDRESS]. Asthma Control Questionnaire (A CQ)
The ACQ measures attributes of asthma control [ Juniper 1999], measured with questions 
designed to be self -completed by  [CONTACT_2299].  Participants will complete the ACQ at 
specified stud y visits. The ACQ -5 includes five questions (concerning nocturnal 
awakening, waking in the morning, activity  limitation, shortness of breath and wheeze) 
which enquire about the frequency  and/or severit y of sy mptoms over the previous week. 
The ACQ -[ADDRESS_845635] of a zero (no impairment/limitation) to six 
(total impairment/ limitation) scale. The recall period is the past week. A score of <0.75 
indicates well -controlled asthma and a score 1.5 indicates poorl y controlled asthma 
[Juniper 2006].  A change of  0.5 in score suggests a clinically  important change in score 
[Juniper 2005].
[IP_ADDRESS]. St. George’s Respi[INVESTIGATOR_633346] (SGRQ)
The SGRQ is a well established instrument, comprising [ADDRESS_845636], and activity . The questions are designed to be self -completed by  [CONTACT_2299]
[Jones 1992] with a recall over the past 3 months .  A change of 4 points is considered a 
clinically  relevant change [ Jones 2005]. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
[IP_ADDRESS]. Asthma Quality  of Life Questionnaire (A QLQ)
The AQLQ was developed to measure the functional impairments related to asthma 
experienced b y adults 17+ y ears old.  The AQLQ (+12), is a modified version of the 
original AQLQ and validated for use in asthma patients between the ages of 12 and 70 
[Junipe r2005]. The response scale ranges from 1 (totally  impaired) to 7 (not at all 
impaired).  The questions are designed to be self -completed by  [CONTACT_477022] a 
recall over the past 2 weeks.  A change of 0.5 is considered clinicall y important [ Juniper
1994].
9.1.2. Daily  Diaries
Participant s will be issued with a combination spi[INVESTIGATOR_417458] 1 for 
twice dail y use (in the morning upon waking and in the evening just before going to bed)
throughout the stud y. The eDiary  device will be provided by a third- party vendor . 
Information on the dev ice and its use are documented in the SRM and the third- party 
vendor manual . Participants will be instructed on how to use the device in order to record 
results for the following in the eDiary  each day from Visit 1 onwards :
Daily symptom assessment (E -RS a nd supplemental asthma items; night -time 
awakening, asthma sy mptom and phy sical activity questions)
The number of inhalations of rescue albuterol/salbutamol used during the day and 
night.
Morning and evening FEV 1
Morning and Evening PEF
Morning FF 100 mcg medication use
Morning double -blind study  medication use (during the treatment period only )
Section 9.1.2 describes the assessments and questionnaires recorded on the eDiary  
device, as well as the alerts that can be triggered based on recorded results. The data from 
the eDiary  device will be automatically  transmitted to a centralised server. 
Participants will also be
issued with a paper Medical Problems/Medications Taken
worksheet to record medical problems experienced and medications used during the 
study (please refer to the SRM for further details) .Participants must also use this paper 
worksheet to record all healthcare contacts that occur during their participation in the 
study . This paper worksheet will be used to assist participant recall in discussions with 
the Investigator , for site staff to then enter as appropriate in the eCRF.
[IP_ADDRESS]. eDiary  Questionnaires, Assessments and A lerts
For information on the eDiary  questions, please refer to Appendix 8 .
[IP_ADDRESS].1. E-RS
The Evaluating Respi[INVESTIGATOR_244774] (E -RS) in COPD consists of 11 items from the 14 
item Exacerbations of COPD ( EXACT -PRO )instrument.  E -RS is intended to cap ture 
information related to respi[INVESTIGATOR_23908], i.e. breathlessness, cough, sputum  2018N371775_00
2016N289466_02 CONFIDENTIA L
[ADDRESS_845637] tightness. The E -RS was developed for use in 
patients with COPD but symptom experience of patients with asthma may  be 
appropriatel y measured with the E -RS. The daily recording of information allows an 
assessment of the underlyi ng day  to day  variability  of a patient's s ymptoms. The 
instrument is to be completed dail y each night prior to going to bed .  The 11 -items are 
scored on a 5 -point scale of “not at all” to “extreme”.  The E -RS has a scoring range of 0 -
40.
[IP_ADDRESS].2. Supplemental Asthm a Items
To ensure that asthma s ymptoms are completel y evaluated, two additional questions will 
be asked.  A question on wheeze, a symptom of importance in asthma will also be asked 
within the context of the daily  diary . An item on breathlessness activities will evaluate 
shortness of breath associated with strenuous activities.  Subject s will be asked to respond 
to the question ‘Did y ou wheeze today ?’ with response options of: Not at all, Rarely , 
Occasionall y, Frequently, Almost constantly.  Subjects will be asked to respond to the 
question “Were you short of breath today when performing strenuous activities such 
climbing stairs, running, or participating in sports activity  with a response scale of not at 
all, slightly , moderatel y, severel y, extremely  or too breathless to do these.
[IP_ADDRESS].3. Night -time Awakening, Asthma Symptom and Physical Activity 
Questions
Every  morning upon waking (from the morning after Visit 1 onwards ), participant s will 
answer a question on the occurrence of night- time awakenings due to asthma sy mptoms. 
The participant ’s response to the question on the occurrence of night- time awakenings 
will be either ‘Yes’ (i.e. Did y ou wake up due to asthma sy mptoms ( i.e. wheezing, 
coughing, shortness of breath, or chest tightness ) or ‘No’ (i.e. they did not ex perience at 
least one night -time awakening due to asthma s ymptoms ). If ‘Yes’ ,participants will be 
asked to respond either ‘Yes’ or ‘No’ to the question on rescue medication (i.e. when you 
woke up due to your asthma symptoms did you use an y rescue bronchodilator?) .
On the evening of Visit 1 (just before going to bed) and every  evening there- after, 
participant s will answer a question on day time asthma sy mptoms and day time phy sical 
activity  limitation. These questions will be answered on a 5- point scale (0 to 4) with ‘0’ 
representing no daytime asthma s ymptoms/phy sical activity  limitations and ‘4’ 
representing very  severe day time asthma sy mptoms or total day time activity  limitation.
(Please describe the severity  of your asthma s ymptoms (i.e. cough, wheeze, che st 
tightness, shortness of breath) today  [0=no asthma sy mptoms, 1=mild asthma sy mptoms, 
2= moderate asthma s ymptoms, 3=severe asthma sy mptoms, 4= very  severe asthma 
symptoms ]. How limited were you in your a ctivities today  because of your asthma [ 0=not 
at all limited, 1=a little limited, 2=moderatel y limited, 3=severely limited, 4=totally 
limited ].
[IP_ADDRESS].4. Morning and Evening Home Spi[INVESTIGATOR_417459]/eDiary  device will be issued to participant s at Visit [ADDRESS_845638] ion(i.e. FEV 1and PEF) . The home Spi[INVESTIGATOR_14007]/eDiary  
device will be provided by a third -party vendor . Information on the device and its use 
are  2018N371775_00
2016N289466_02 CONFIDENTIA L
[ADDRESS_845639] 
spi[INVESTIGATOR_417460] , prior to study  treatment and FF 100 mcg dosing ,
and each evening. Three measurements for each session will be recorded by  [CONTACT_2416] s in the eDiary. Assessments will be performed:
After completing all other eDiary  assessments
Prior to albuterol/salbutamol use
Prior to study  treatment and FF [ADDRESS_845640] of the assigned double
-blind study  treatment.
[IP_ADDRESS].5. Alerts
For safet y the following alerts, indicative of worsen ing asthma, will be programmed into 
the eDiary with instructions for the participant to contact [CONTACT_093] (either by  
[CONTACT_18623]/or b y visiting the stud y clinic) if any  of the alert criteria are met:
Nocturnal awakening(s) due to asthma requiring albuterol/salbutamol use for 2 
consecutive nights.
An increase from baseline of ≥ 4 puffs /day  of albuterol/salbutamol use on 2 
consecutive day s.
A ≥30% decrease in AM PEF from baseline on 2 consecutive mornings.
A ≥30% decrease in PM PEF from baseline on 2 consecutive evenings
A ≥30% decrease in AM FEV1 from baseline on 2 consecutive mornings.
A ≥30% decrease in PM FEV1 from baseline on [ADDRESS_845641] 3 
acceptable spi[INVESTIGATOR_417445] (from a maximum of 8 attempts) should be achieved 
on each occasion that spi[INVESTIGATOR_417446], in accordance with the 
American Thoracic S ociety / European Respi[INVESTIGATOR_21584] y (ATS/ERS )standards [ Miller
2005]. The highest of 3 technicall y acceptable measurements will be recorded at each 
visit:
Pre-dose Spi[INVESTIGATOR_038]: At Visits 1through 5/EOS (and the Early  Withdrawal 
Visit, if applicable), participant s should w ithhold short -acting beta -2-agonists 
(SABAs) for [ADDRESS_845642] be performed:
oBetween 6am and 11am on the day  of the visit.
oAt the same time of day  (1 hour) as the assessment performed at Vis it 2
(the baseline assessment).
oAt least 24 hours after the participant ’s last morning dose of study  
treatment on the day  prior to the visit. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
54oBefore the participant ’s morning dose of study  treatment on the day  of the 
visit.
Post-dose Spi[INVESTIGATOR_038]: At Visits 2 and 5/EOS (and the Earl y Withdrawal Visit, if 
applicable), spi[INVESTIGATOR_417447] 3 hours after the 
participant ’s morning dose of study  treatment; the assessment performed at Visit 
5/EOS should be performed at the same time of day  (1 hour) as the assessment 
performed at Visit 
2 (the baseline assessment). At each visit, participant s should 
withhold short -acting beta -2-agonists (SABAs) between receiving their morning 
dose of study  treatment and completing the spi[INVESTIGATOR_44022], if p
ossible.
Spi[INVESTIGATOR_417448]  a third -party vendor; the same 
third- party vendor will also centrall y analyse the spi[INVESTIGATOR_417449] . Details 
on performing the spi[INVESTIGATOR_44022], including information on the equipment 
provided and its use as well as specific instructions on performing the spi[INVESTIGATOR_417450], are documented in the SRM and the third- party vendor manual.
[IP_ADDRESS]. Reversibility  (Albuterol/Salbutamol)
All reversibility evaluations should follow the recommendations of the AT S/ERS Task 
force: Standardization of Lung Function Testing [ Miller 2005]. A pre-bronchodilator
spi[INVESTIGATOR_417451] a washout period of at least [ADDRESS_845643] s.
To perform the reversibility  assessment, 4 puffs of the provided albuterol /salbutamol is 
administered (aspace r device may  be used, if required
). Following completion of the pre-
bronchodilator assessment, a second spi[INVESTIGATOR_633347] 20 to 60
minutes after a dministration of the albuterol /salbutamol.
Percent reversibility  will be calculated as follows:
(Post -bronchodilator FEV 1–Pre-bronchodilator FEV 1) x [ADDRESS_845644] 
demonstrate a  12% and 200 mL  increase in FEV 1to be eligible for the study .If these 
reversibility  criteria are not met at Visit 1 then the participant may  not enter the 2- week 
run-in period; however, the reversibility  assessment may  be repeated once within 7 day s 
of Visit 1 if either criteria a) or b) are met:
a)≥9% increase in FEV 1between 20 and 60 minutes following 4 inhalations of 
albuterol/salbutamol aerosol at Visit 1.
b)Documented evidence of a reve rsibility  assessment within [ADDRESS_845645] -bronchodilator increase in FEV 1 of ≥12% and ≥[ADDRESS_845646]  reversibility  (defined as ≥12% 
and ≥200 mL  increase in FEV 1between 20 and 60 minutes following 4 inhalations of 
albuterol/salbutamol aerosol) at the second attempt then, provided that a ll other eligibility  
criteria assessed at Visit 1 are met, the participant may  enter the 2- week run -in period. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
559.1.4. Asthma Exacerbations
Moderate and s evere asthma exacerbation data will be collected from the start of 
randomized double blinded treatment until Visit 5/EOS Visit or the Early  Withdrawal 
Visit for those participants that withdraw from participation in the study  (see Section 
8.2). For consistency ,exacerbations separated b y less than 7 day s will be treated as a 
continuation of the same exacerbation.
Participants will
complete a paper Medical Problems/Medications Taken worksheet to
record medical problems expe rienced and medications used during the study, as well as 
all emergency  department visits and/or hospi[INVESTIGATOR_633348] . This paper worksheet must be reviewed by  [CONTACT_737] (or
designee) at each visit to t he study  site to assist the I nvestigator in the identification of
new asthma exacerbations.
All moderate/ severe asthma exacerbations will be recorded in the eCRF b y the
Invest igator (or designee).
[IP_ADDRESS]. Moderate A sthma Exacerbation
Guidance for identify ing moder ate exacerbations includes the following [ Reddel 2009;
Virchow 2015]
A moderate asthma exacerbation is considered to be a deterioration in asthma 
symptoms, deterioration in lung function, or increased rescue bronchodilator use 
lasting for at least 2 day s or more, but will not be severe enough to warrant 
systemic corticosteroid use for 3 day s or more and/ or hospi[INVESTIGATOR_059]. 
A moderate asthma exacerbation is an event that, when recognized, should result 
in a temporary  change in treatment, in an effort to prevent the exacerbation from 
becoming severe.
At the I nvestigator’s discretion, a temporary  change in background asthma medication 
will be permitted in order to treat the s ymptoms of a moderate asthma exacerbation 
(Refer to S ection 7.8.1 above)
The Medical Monitor may be contact[CONTACT_245939], see the medical 
monitor/Sponsor I nformation Page .
[IP_ADDRESS]. Severe A sthma Exacerbation
A severe asthma exacer bation is defined as: 
The deterioration of asthma requiring the use of systemic corticosteroids (tablets,
suspens ion or injection) for at least 3 days.
OR
An inpatient hospi[INVESTIGATOR_633349], requiring
systemic c orticosteroids.
9.2. Adverse Events
The definitions of an AE or SAE can be found in Appendix 4 . 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
56The investigator and an y designees are responsible for detecting, documenting, and 
reporting events that meet the definition of an AE or SAE an d remain responsible for 
following up AEs that are serious, considered related to the study  treatment or the study , 
or that caused the participant to discontinue the study  treatment or withdraw from the 
study  (see Section 8).
9.2.1. Time Period and Frequency  for Collecting A E and SA E 
Information
Any SAEs assessed as related to study  participation (e.g., protocol
-mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] 
product will be recorded from the time a participant consents to participate in the 
study  up to and including any  follow -up contact. 
AEs will be collected from the start of Study  Screening until the follow -up contact 
(see Section 9.2.3) at the tim epoints specified in the Schedule of Activities (SoA) 
table (Section 2).
Medical occurrences that begin prior to the start of study
 treatment but after 
obtaining informed consent may  be recorded on the Medical H istory /Current 
Medical Conditions section of the eCRF.
All SAEs will be recorded and reported to [COMPANY_004] within 24 hours, as indicated in
Appendix 4 .The investigator will submit any  updated SAE data to the sponsor 
within 24hours of it being available.
Investigator s are not obligated to activel y seek AEs or SAEs in former study 
participant s. However, if the Investigator learns of any  SAE, including a death, at 
any time after a participant has been discharged from the study , and he/she 
considers the event reasonably  related to the study treatment or study  
participation, the Investigator must promptl y notify [COMPANY_004].
NOTE: The method of recording, evaluating and assessing causality  of AEs and SAEs 
plus procedures for completing a nd transmitting SAE reports to [COMPANY_004] are provided i n 
Appendix 4
9.2.2. Method of Detecting A Es and SA Es
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended 
and non- leading verbal questioning of the participant is the preferred method to inquire 
about AE occurrence.  Appropriate questions include:
“How are you feeling?” 
“Have you had an y (other) medical problems since y our last visit/contact?” 
“Have you taken an y new medicines, other than those provided in this study , since 
your last visit/contact?” 
Participant s will be issued with a paper Medical Problems/Medications Taken worksheet
to record an y medical problems experienced and medications used during the study .This  2018N371775_00
2016N289466_02 CONFIDENTIA L
[ADDRESS_845647] par ticipant recall in discussions with the 
Investigator (or designee) , for site staff to then enter as appropriate in the eCRF.
9.2.3. Follow -up of A Es and SA Es
After the initial AE/SAE report, the Investigator is required to proactivel y follow each 
participant at subsequent visits/contacts.  All SAEs, and non- serious AEs of special 
interest (as defined in Section 9.2.5), will be followed until the event is resolved, 
stabilized, otherwise explained, or the participant is lost to 
follow-up (as defined in 
Section 8.3). Further information on follow -up procedures is given in Appendix 4
9.2.4. Regulatory  Reporting Requirements for SA Es
Prompt notification by  [CONTACT_11012] a SAE is essential so 
that legal obligations and ethical responsibilities towards the safet y of 
participants and the safety  of a study  treatment under clinical investigation are 
met. 
The sponsor has a legal responsibility  to notify  both the local regulatory  
authority  and other regulatory  agencies about the safet y of a stud y treatment 
under clinical investigation. The sponsor will comply  with country -specific 
regulatory  requirements relating to safet y reporting to the regulatory authority, 
Institutional Review Bo ards (IRB)/Independent Ethics Committees (I EC), and 
investigators.
Investigator safety
 reports must be prepared for suspected unexpected serious 
adverse reactions (S[LOCATION_003]R) according to local regulatory  requirements and 
sponsor policy  and forwarded to invest igators as necessary .
An investigator who receives an investigator safety report describing a SAE or 
other specific safet y information eg, summary  or listing of SAE) from the 
sponsor will review and then file it along with the Investigator’s Brochure and 
will notify  the IRB/IEC, if appropriate according to local requirements.
9.2.5. Adverse Events of Special Interest (A ESIs)
AE groups of special interest have been defined as AEs which have specified areas of 
interest for one or more of class of drugs (ICS, L AMA). Some AE groups may  have 
subgroups defined.
The following table presents the current special interest AE groups and subgroups. These 
may be updated prior to conclusion of the study  reporting. The final list, including the 
preferred terms which contribute to each of the groups will be documented a priori in the 
study  Reporting and Analy sis Plan (RAP).
Special interest AE group Special interest AE subgroup
Cardiovascular effects Cardiac arrh ythmia
Cardiac failure 2018N371775_00
2016N289466_02 CONFIDENTIA L
[ADDRESS_845648] AE subgroup
Cardiac ischemia
Stroke
Anticholinergic syndrome -
Urinary  retention -
Dry mouth / dry ing of 
airway  secretions-
Gastrointestinal obstruction -
Antimuscarinic ocular 
effects / Corticosteroids 
associated ey e disordersGlaucoma (antimuscarinic/corticosteroid)
Cataracts (corticosteroid)
Pneumonia and L RTI Pneumonia 
LRTI excluding pneumonia
Adrenal suppression -
Decreased bone mineral 
density  and associated 
fractures-
Effects on glucose -
Hypersensitivity -
Local steroid effects -
9.2.6. Cardiovascular and Death Events
For an y cardio vascul ar events detailed in Appendix 4 and all deaths, whether or not they 
are considered SAEs, specific Cardiovascular (CV) and Death sections of the eCRF will 
be required to be completed. These sections include questions regarding cardio vascular 
(including sudden cardiac death) and non- cardiovascular death. 
The CV e CRFs are presented as queries in response to reporting of certain CV MedDRA 
terms. The CV information should be recorded in the specific cardiovascular section of 
the e CRF wi thin one week of receipt of a CV Event data query prompting its completion. 
The Death eCRF is provided immediately  after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed within one 
week of whe n the death is reported. 2018N371775_00
2016N289466_02 CONFIDENTIA L
[ADDRESS_845649] X- ray 
should be performed to confirm a diagnosis, whenever a participant has a suspected 
pneumonia.   Suspected pneumonias will require confirmation as defined by [CONTACT_417515](s) on chest x- ray AND at least 2 of the following signs and sy mptoms: 
Increased cough 
Increased sputum purulence (color) or production 
Auscultatory  findings of adventitious sounds ( e.g., egophon y, bronchial breath sounds, 
rales, etc.)
Dyspnea or tachy pnea
Fever (oral temperature >37.5 degrees centigrade [ °C])
Elevated white blood cells ( WBC )(>10,000/ millimetres cubed [ mm3]or >15% immature 
forms)
Hypoxemia ( Oxyhemoglobin ( HbO2 ) saturation <88% or at least 2% lower than baseline 
value)
All pneumonias must be captured on the AE/SAE page of the eCRF and on the 
pneumonia page of the eCRF. 
For all suspected cases of pneumonia, investigator s are strongl y encouraged to confirm 
the diagnosis (this includes obtaining a chest x -ray) and to initiate appropriate therap y as 
promptly  as possible. All diagnoses of pneumonia (radiographicall y confirmed or 
unconfirmed) must be reported as an AE or SAE (if applicable).
9.2.8. Radiography  (Chest X -Rays)
Confirmation by  [CONTACT_13190] x -ray (posteroanterior and lateral) should be performed as soon as 
possible and preferabl y within [ADDRESS_845650]/v isit.
If a pregnancy  is reported then the Investigator should inform [COMPANY_004] within 2 weeks of 
learning of the pregnancy  and should follow the procedures outlined in Appendix 5.
Abnormal pregn ancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAE. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
609.3. Treatment of Overdose
An overdose is defined as a dose greater than the total doses described above which 
results in clinical sig ns and sy mptoms.  These should be recorded by  [CONTACT_417509]/SAE eCRF pages.  I n the event of an overdose of study  treatment, the Investigator 
should use clinical judgment in treating the overdose and contact [CONTACT_417510].
[COMPANY_004] is not recommending specific treatment guidelines for overdose and toxicity  
management. The Investigator is advised to refer to the relevant document(s) for detailed 
information regarding warnings, precautions, contraindications, adverse events, and other 
signif icant data pertaining to the study  drug being used in this study . Such documents 
may include, but not be limited to, the IB or equivalent document provided by  [CONTACT_23983].
9.4. Safet y Assessments
Planned time points for all safety  assessments are provided in the Schedule of Activities 
(SoA).
9.4.1. Physical Examinations
Physical exams will be performed at the time points specified in the Schedule of 
Activities (SoA) table ( Section 2).
A complete ph ysical examination will include, at a minimum, asse ssment of the 
Cardiovascular, Respi[INVESTIGATOR_696] , Gastrointes tinal and Neurological s ystems.
Height and weight wi ll be measured at Visit 1.
Investigators should pay  special attention to clinical signs related to previous 
serious illnesses.
9.4.2. Vital Signs
Vital signs will be performed at the time points specified in the Schedule 
of Activities 
(SoA) table ( Section 2) prior to conducting spi[INVESTIGATOR_633350] 100 mcg. Blood pressure (s ystolic and diastolic) and 
pulse rate will be measured in the sitting position after approximately  [ADDRESS_845651]. A 
single set of values will be collected and recorded in the source documentation and 
eCRF.
9.4.3. Electrocardiograms
All sites will use standardised ECG equipment provided by  a centralized external vendor. 
A single 12 -lead ECG and rhy thm strip will be recorded after measurement of vital signs
assessment but prior to performing the pre -bronchodilator 
spi[INVESTIGATOR_1891] . 
Recordings will be made at the ti me-points defined in the Schedule of Activities (SoA)  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
61table ( Section 2). All ECG measurements will be made with the participant in a supi[INVESTIGATOR_633351]  5 minutes before each reading .
For participant s who meet the QTc, protocol defined stoppi[INVESTIGATOR_3418], triplic
ate ECGs 
(over a brief period of time) should be performed ( Section 8.1.2).
The Investigator, a designated sub
-Investigator or other appropriatel y trained site 
personnel will be responsible for performing each 12- lead ECG. The Investigator must 
provide his/her dated signature [CONTACT_238540], attesting to the authenticit y 
of the ECG machine interpretation.
All ECGs will be electronicall y transmitted to an independent cardiologist and evaluated. 
The independent cardiologist, blinded to treatment assignment, will be responsible for 
providing measurements of heart rate, QT intervals and an interpretation of all ECGs 
collected in this study .A hard cop y of these results will be sent to the I nvestigator. The 
Investigator must provide his/her dated signature [CONTACT_417535], attesting to 
his/her review of the independent cardiologist’s assessment.
Details of the cardiac monitoring proce dures will be provided by
 [CONTACT_633389].
9.4.4. Clinical Safety  Laboratory  Assessments
Refer to Appendix 2for the list of clinical laboratory  tests to be performed and 
to the Schedule of Activities ( SoA)for the timing and frequency . 
The investigator must review the laboratory  report, document this review, and 
record an y clinicall y relevant changes occurring during the stud y in the AE 
section of the CRF. The laboratory  reports must be filed with the source 
docu ments. Clinically  significant abnormal laboratory  findings are those which 
are not associated with the underl ying disease, unless judged b y the investigator 
to be more severe than expected for the participant's condition.
All laboratory  tests with values c onsidered clinically  significantl y abnormal 
during participation in the study  or within [ADDRESS_845652] dose of study  
treatment should be repeated until the values return to normal or baseline or are 
no longer considered significantly  abnormal by  [CONTACT_633390]. 
If such values do not return to normal/baseline within a period of time judged 
reasonable b y the investigator, the etiology should be identified and the sponsor 
notified.
All protocol -required laboratory  assessments, as d efined in 
Appendix 2, must be 
conducted in accordance with the laboratory  manual and the Schedule of 
Activities ( SoA)
.
9.5. Pharmacokinetics
Pharmacokinetics is not relevant for this protocol. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
629.6. Pharmacody namics
Pharmacod ynamic parameters a re not evaluated in this study .
9.7. Genetics
Information regarding genetic/ pharmacogenetic (PGx) research is included in Appendix 
6.The IEC/I RB and, where required, the applicable regulatory  agency  must approve the 
PGx and genetic asses
sments before these can be conducted at the site.  The approval(s) 
must be in writing and will clearly  specify  approval of the PGx and genetic assessments 
(i.e., approval of Appendix 6).
In some cases, approval of the PGx and genetic assessments can occur after approval is 
obtained for the rest of the study .  If so, then the written approval will clearly  indicate 
approval of the PGx and genetic assessments is being deferred and the study, except for 
PGx and genetic assessments, can be initiated.  When PGx and genetic assessments will 
not be approved, then the approval for the rest of the study  will clearl y indicate this and 
therefore, PGx and genetic assessments will not be conducted.
9.8. Biomarkers
Biomarkers are not evaluated in this stud y.
9.9. Health Economics OR Medical Resource Utilization and 
Health Economics
Health Economics/Medical Resource Utilization and Health Economics parameters are 
not evaluated in this study
.
10. STATISTICA L CONSIDER ATIONS
10.1. Hypotheses
The primary  objective of this stud y is to evaluate the efficacy  of UMEC 62.[ADDRESS_845653] for the primary  efficacy  endpoint is such that the null hy pothesis is that there is 
no difference between treatment groups. 
H0: T1 –
T2 = 0
Thealternative hy pothesis is that there is a difference between treatment groups.
H1: T1 – T 2 ≠ 0 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
63For the primary  endpoint (and other lung function related efficacy endpoints), the 
primary  treatment comparisons of interest are:  
UMEC 62.5mcg vs Placebo
UMEC 31.25mcg vs Placebo
For each comparison test on the primary  endpoint, the null hy pothesis is there is no 
difference between treatment groups.  The alternative hy pothesis is there is a difference 
between treatment groups.
Therefore T 1and T 2for these endpoints are the mean changes from baseline for the 
UMEC therap y and placebo , respectivel y, as listed above. 
Details on all pairwise treatment comparisons of interest are provided in S ection 10.5.2.
10.2. Sample Size Determination
Sample size calculation is based on the primary  efficacy  endpoint of mean change from 
baseline 
in trough FEV1 at the end of the 24 -week treatment period.
A total of 3 84 randomized participant s are required for this study , with 128 participant s 
in each of the three double- blind treatment groups: UMEC 62.5mcg, UMEC 31.25mcg or 
Placebo. Assuming 10% mi ssing data on spi[INVESTIGATOR_417468] 24- week treatment 
period, due to earl y withdrawal from study, approximately  [ADDRESS_845654] deviations in change from baseline trough FEV1 at Week 24 
ranged from 325 to 354m L;from this a SD estimate of 350 mL was chosen. This was 
estimated from a wide selection of studies , critically to minimise the risk of reduced 
power for the primary  endpoint. The range of observed treatment differences across the 
Tiotropi[INVESTIGATOR_633352] 133 – 185mL , which supports the expectation that the 
treatment effect seen in a moderate asthma population islarger than in the more severe 
asthma population in study  205715 treated on a background of FF/VI . This is in line with 
data from 
[COMPANY_004] study 200699 which showed UMEC 62.5 mcg to be an effective dose. An 
average increase in change from baseline trough FEV1 at Day  29 of 136 mL  was 
observed in an asthma subset of patients treated with FF/UMEC (100/62.5) compared 
with FF (100 mcg) alone. The [COMPANY_004] phase III closed triple asthma study  205715, which 
this study  supports, is in a more severe asthma population and conservatively  assumes a 
SD estimate of 400 mL.
Based on a true population difference of 130 mL, a sample size of 115 patients per 
treatment gro
up has an estimated 80% power to observe statistical significance at the two 
sided 5% level, for each of the two primary  comparisons of interest for each UMEC dose . 
Using the above assumptions the smallest observed effect predicted to result in a  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
64statistic ally significant difference between treatment groups is 90.5 mL (minimum 
detectable difference) .
No interim anal ysis is planned for this study .
10.3. Sample Size Sensitivity
To demonstrate the sensitivity  of the sample size calculation for this study , the follow ing 
table and graph show the power function for a fixed sample size of n= 115per arm in the 
intent to t reat(ITT)population for the primary  efficacy  anal ysis, vary ing the true
treatment difference and estimated standard deviation on the change from baseli ne in 
trough FEV 1at the end of the 24 -week treatment period.
Treatment difference (mL)
Standard Deviation100 115 130 145 160
300 0.71 0.82 0.91 0.95 0.98
350 0.58 0.70 0.80 0.88 0.93
400 0.47 0.58 0.69 0.78 0.86 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
65
10.4. Sample site re -estimation or adjustment
No sample size re -estimation is planned.
10.5. Data Analysis
10.5.1. Analysis population
The following participant populations will be identified:
All Participants Enrolled Population: This population will comprise all participants for 
whom a record exists on the study  database, including pre- screened participant s that sign 
the informed consent document but do not complete a Visit 1 (screening) procedure (i.e., 
pre-screening failures), or participant s that complete at least one Visit 1 procedure but do 
not ente r the run- in period (i.e., screening failures). This population will be used for the 
summary  of participant disposition . 
All Participant s Screened Population: This population contains all participants that 
complete at least one Visit 1 (Screening) procedu re. This population will be used for the 
summary  of participant disposition (including reasons for screening failures and run-in 
failures) and for the listing of AEs and SAEs for non -randomized participant s. 
ITT Population: This population will comprise a ll randomized participants, excluding 
those who were randomized in error. A participant who is recorded as a screen failure or  2018N371775_00
2016N289466_02 CONFIDENTIA L
[ADDRESS_845655] for the primary  
efficacy  endpoint are :
UMEC 62.5 mcg vs Placebo
UMEC 31.[ADDRESS_845656] that aim to informally  estimate any  
potential benefit of increasing the UMEC dose are given below f or all efficacy  endpoints. 
UMEC 62.[ADDRESS_845657] in the 
hierarch y. 
A step
-down procedure with the following hierarchy  will be used for the primary  
comparisons in the primary  endpoint.  
The contrast between UMEC 62.5 mcg vs Placebo 
(two-sided, alpha = 0.05.  Null hy pothesis of no treatment difference)
The contrast between UMEC 31.[ADDRESS_845658] acebo 
(two-sided, alpha = 0.05.  Null hy pothesis of no treatment difference)
The second h ypothesis will be formally tested only if the first hypothesis has been 
rejected, thus maintaining the overall significance level at 5%.   
Specificall y, if t he defined treatment comparison for the primary  efficacy  endpoint at the 
highestdose of UMEC 62.[ADDRESS_845659] hypothesis is not rejected a nominal p -value for the 
second h ypothesis may be provided in the displays for descriptive purposes only  and will 
not alter the conclusion of the step -down procedure. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
67No multiplicity  adjustment will be made on these two treatment comparisons on the 
secondar y endpoint .
For all efficacy  endpoints (primary , secondary  and other), treatment comparisons 
between UMEC 62.5 vs UMEC 31.25 mcg informally  investigating the benefit of 
increasing UMEC dose will be made without adjusting for multiplicity .  Any  p -values ≤ 
0.[ADDRESS_845660] acceptable/borderline acceptable (pre -dose) FEV1 value obtained prior to 
randomization (either from Visit 2pre-dose or from Visit 1pre-bronchodilator ).
The primary  efficacy  analy sis will evaluate the “de facto” ty pe estimand in the I ntent- to-
Treat population, using a mixed -model repeated measures (MMRM) analysis, including 
all trough FEV 1recorded post randomization.  Analy ses will include the fixed, 
categorical effects of treatment, visit, treatment by [CONTACT_23259], sex,as well as the 
continuous, fixed covariates of age, baseline value, and baseline value by  [CONTACT_150133].  Point estimates and 95% confidence intervals will be calculated for the 
following primary  comparisons of interest. 
UMEC 62.5 mcg vs Placebo
UMEC 31.[ADDRESS_845661] as outlined in Section 10.5.2 will also 
be provided for t he primary  efficacy  endpoint.
10.6.2. Secondary Analyses
Full details of the analy ses to be performed on the secondary  efficacy  endpoint will be 
given in the RAP. 2018N371775_00
2016N289466_02 CONFIDENTIA L
[PHONE_13165].6.3. Other A nalyses
Full details of the analy ses to be performed on all efficacy  endpoints, as well as det ails of 
time points to be analy zed, will be given in the RAP.
10.6.4. Interim A nalyses
No interim anal ysis is planned for this study .
10.6.5. Exploratory  Analyses
The psy chometric properties of the E -RS and Supplemental asthma items will be 
evaluated to characterize the E- RS as an endpoint for asthma.  These exploratory  anal yses 
may be provided in a separate RAP. 2018N371775_00
2016N289466_02 CONFIDENTIA L
[PHONE_13166]. REFERENCES
Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 
National Asthma Education and Prevention Programme, National Heart, Lung and Blood 
Institute, National Institutes of Health (NIH) 2007. Available from: 
http://www.nhlbi.nih.gov/health- pro/guidelines/current/asthma -guidelines
GlaxoSmithKline Document Number: 2011N123107_03 GW685698+[COMPANY_004]573719 
Investigator’s Brochure, Version 03, dated 19 Jun 2014 
GlaxoSmithKline Document Number: 2016N284764_00 GW685698+[COMPANY_004]573719 
Investigator’s Brochure , Version 03, Supplement 01, dated 27 May 2016
Global Strategy for Asthma Management and Prevention , Global Initiative for Asthma 
(GINA ) 2016. Ava ilable from: http://www.ginasthma.org/
Jones PW, Quirk FH, Bavey stock CM, Littlejohns P. A self -complete measure of health 
status for chronic airflow limitation. The St. George's Respi[INVESTIGATOR_21606] .Am Rev 
Respir Dis 1992;145:[ADDRESS_845662]. George’s Respi[INVESTIGATOR_6015]: MCI D. Journal of Chronic 
Obstructive Pulmonary Disease 2005;2:75 -79.
Juniper EF, Bousquet J, Abetz L , Bateman ED; GOAL Committee. I dentify ing 'well-
controlled' and 'not well -controlled' asthma using the Asthma Control Questionnaire.
Respir Med 2006;100 :616- 621.
Juniper EF, Guy att GH, Willan A, Griffith L E. Determining a minimal important change 
in a disease -specific quality  of life instrument . J Clin Epi[INVESTIGATOR_5541] 1994;47: 81 -87.
Juniper EF, O'By [CONTACT_21143], Guy att GH, Ferrie PJ, King DR. Development and validation of 
a questionnaire to measure asthma control. Eur Respir J 1999;14:902 -
907.
Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of 
three shortened versions of t he asthma control questionn aire. Respir Med 2005;99: 553-
558.
Junipe r EF, Svensson K, Mörk AC, Ståhl E. Modification of the Asthma Quality  of Life 
Questionnaire (standardised) in patients 12 y ears and older. 
Health and Quality of Life 
Outcomes 2005; 3:58.
Miller MR et al. Standardizat ion of L ung Function Testing. Eur Resp J 2005; 26:153 -161.
Quanjer P, Stanojevic S, Cole T, Baur X., Hall G, Enright P, et al. on behalf of the ERS 
Global L ung Function Initiative. Multi- ethnic reference values for spi[INVESTIGATOR_105221] 3 -95 
year age range: th e global lung function 2012 equations. Eur Respir J 2012;40:1324-
1343. 2018N371775_00
2016N289466_02 CONFIDENTIA L
[ADDRESS_845663], Bateman ED, Boulet L -P, Boushey  HA, Busse WW, et al. On
behalf of the American Thoracic Societ y/European Respi[INVESTIGATOR_21584] y task force on 
asthma control and exace rbations. An official American Thoracic Societ y/European 
Respi[INVESTIGATOR_21584] y statement: asthma control and exacerbations; standardizing endpoints 
for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59 -
99. 
US Department ofHealth and Human Sciences; Food and Drug Administration (FDA).
Guidance for Industry ; Drug -Induced Liver Injury: Premarketing Clinical Evaluation 
(July  2009). 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf (Accessed 16 July 2014).
Virchow JC, Backer V, de Blay  F, Kuna P, L jorring C, Prieto J L, et al. Defining 
moderate asthma exacerbations in clinical trials based on ATS/ERS joint statement. 
Respi[INVESTIGATOR_33593] 2015;109:547 -556
Wyrwich KW, Khan SA, Navara tnam P, Nolte H, Gates Jr DF. Validation and agreement 
across four versions of the asthma control questionnaire in patients with persistent 
asthma. Resp Med 2011;105:698 -712. 2018N371775_00
2016N289466_02 CONFIDENTIA L
[PHONE_13167]. APPENDICES
12.1. Appendix 1: A bbreviations and Trademarks
Abbrev iations
ACQ Asthma Cont rol Questionnaire
ADR Adverse Drug Reaction
AE Adverse Event
AESI Adverse Event of Special Interest
ALT Alanine Transaminase
AM Morning
AQLQ Asthma Quality  of Life Questionnaire
AST Aspartate Transaminase
ATS American Thoracic Society
BMI Body Mas s Index
BPM Beats Per Minute
BST Bioanal ytical Science and Toxicokinetics
BUN Blood Urea Nitrogen
CI Confidence Interval
CONSORT Consolidated Standards of Reporting Trials
COPD Chronic Obstructive Pulmonary  Disease
DNA Deox yribonucleic acid
DPI [INVESTIGATOR_633353]
(e)CRF (Electronic) Case Report Form
eDiary Electronic Diary
EOS End of study
E-RS Evaluating Respi[INVESTIGATOR_633354]1 Forced expi[INVESTIGATOR_4034] [ADDRESS_845664] hma
[COMPANY_004] GlaxoSmithKline
hCG Human Chorionic Gonadotropin
HIV Human Immunodeficiency  Virus
HPA Hypothalamic Pi[INVESTIGATOR_633355] y
IB Investigator ’s Brochure 2018N371775_00
2016N289466_02 CONFIDENTIA L
[ADDRESS_845665] Infection
MACE Major Adverse Cardiac Event
MAOI Monoamine Oxidase I nhibitors
MedDRA Medicinal Dictionary for Regulatory  Activities
mcg ( g) Microgram
MDI Metered Dose Inhaler
mg Milligram
min Minute
mL Milliliter
MMRM Mixed -Model Repeated Measures
MSDS Material Safet y Data Sheet
msec Millisecond
NIH National Institutes of Health
NYHA [LOCATION_001] Heart Association
PEF Peak Expi[INVESTIGATOR_633356] y
QTc QT interval corrected for heart rate
QTcB QT interval corrected for heart rate b y Bazett’s formula
QTcF QT interval corrected for heart rate b y Frid ericia’s formula
RAP Reporting and Anal ysis Plan
RBC Red Blood Cell
RNA Ribonucleic acid
SABA Short -Acting Beta -2-Agonists
SAE Serious Adverse Event
SGRQ St. George’s Respi[INVESTIGATOR_633357] 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
73US [LOCATION_002]
VI Vilanterol
VT Ventricular Tach ycardia
WBC White Blood Cell
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_633391] 2018N371775_00
2016N289466_02 CONFIDENTIA L
[PHONE_13168].2. Appendix 2: Clinical Laboratory  Tests
All protocol required laboratory  assessments (haematology , clinical chemistry  
and urinal ysis) must be conducted in accordance with the L aboratory  Manua l, 
and Protocol Schedule of Activities (Section 2)Laboratory  requisition forms 
must be completed and samples must be clearl ylabelled with the participant
number, protocol number, site/centre number, and visit date. Details fo r the 
preparation and shipment of samples will be provided by  [CONTACT_633392]. Reference for all safet y parameters will be 
provided to the site by  [CONTACT_90633].
All blood samples which will be taken pre -dose, will be sent to a central 
laboratory  for anal ysis (details provided in the Laboratory  Manual). Standard 
reference ranges will be used. 
If additional non -protocol specified laboratory  assessments are performed at the 
institution ’s local laboratory and result in a change in participant management or 
are considered clinically  significant b y the Investigator (e.g., SAE or AE or dose 
modification) the results must be recorded in the eCRF. 
Refer to the Laboratory  Manual for appropria te processing and handling of 
samples to avoid duplicate and/or additional blood draws.
Protocol -specific requirements for inclusion or exclusion of participants are 
detailed in Section 6 of the protocol.
Additional tests may  beperformed at any  time during the study  as determined 
necessary  by [CONTACT_43215]. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
75Protocol -Required Safety Laboratory Assessments
Laboratory 
AssessmentsParameters
HaematologyPlatelet Count RBC Indices: WBC count wit h Differential:
Red Blood Cell (RBC) 
CountMCV Neutrophils
Hemoglobin MCH Lymphocytes
Hematocrit Monocytes
Eosinophils
Basophils
Clinical 
Chemistry 1Blood Urea 
Nitrogen 
(BUN)Potassium AST (SGOT) Total and direct 
bilirubin
Creatinine Sodium ALT (SGPT) Total Protein
Glucose Calcium Alkaline phosphatise Albumin
Routine 
UrinalysisSpecific gravity
pH, glucose, protein, blood and ketones by [CONTACT_5230]
Microscopic examination (if blood or protein is abnormal)
Other 
Screening 
TestsFollic le stimulating hormone (FSH) and estradiol (as needed in females 
of non -reproductive potential only)
Serum/urine hCG Pregnancy test (as specif ied in the Schedule of 
Activities table [Section 2])
NOTES:
1.Details of L iver Chemistry  Stoppi[INVESTIGATOR_131963] -Up 
Assessments after liver stoppi[INVESTIGATOR_31777] 8.1.1 and 
Appendix 7 2018N371775_00
2016N289466_02 CONFIDENTIA L
[PHONE_13169].3. Appendix 3: Study  Governance Considerations
Regulatory  and Ethical Considerations
This study  will be conducted in accordance with the protocol and with:
Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki a nd Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Brochure, and other 
relevant documents (eg, advertisements) must be submitted to an I RB/IEC by  
[CONTACT_20003] b y the I RB/IEC before the study  is 
initiated. 
Any amendments to the protocol will require IEC/I RB approval before 
implementation of changes made to the stud y design, except for changes 
necessary  to eliminate an immediate hazard to study participants. 
The investigator will be responsible for the following:
Providing written summaries of the status of the study to the IRB/IEC 
annuall y or more frequently  in accordance with the requirements, policies, 
and procedures established by  [CONTACT_1201]/EC
Notify ing the IRB/IEC of SAE or other significant safet y findings as 
required b y IRB/IEC procedures
Providing oversight of the conduct of the stud yat the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European 
regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations
Financial Disclosure
Investigators and sub -investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible f or providing information on financial interests during the 
course of the stud y and for 1 y earafter completion of the study .
Informed Consent Process
The investigator or his/her representative will explain the nature of the study to 
the participant or his/ her legally  authorized representative and answer all 
questions regarding the study .  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
77Participants must be informed that their participation is voluntary . Participants 
or their legall y authorized representative will be required to sign a statement of 
inform ed consent that meets the requirements of [ADDRESS_845666] (HI PAA) 
requirements, where applicable, and the IRB/IEC or study  center. 
The medical record must include a statemen t that written informed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent 
must also sign the I CF.
Participants must be re -consented to t he most current version of the ICF(s) 
during their participation in the study . 
A cop y of the ICF(s) must be provided to the participant or the participant’s 
legally  authorized representative. 
Participants who are rescreened are required to sign a new ICF .
Data Protection
Participants will be assigned a unique identifier by  [CONTACT_456]. Any  participant 
records or datasets that are transferred to the sponsor will contain the identifier 
only; participant names or any  information which would make the particip ant 
identifiable will not be transferred. 
The participant must be informed that his/her personal study -related data will be 
used by  [CONTACT_10999]. The level of 
disclosure must also be explained to the participant. 
The participant must be informed that his/her medical records may  be examined 
by [CONTACT_17080] y Assurance auditors or other authorized personnel appointed 
by [CONTACT_456], b y appropriate IRB/IEC members, and by  [CONTACT_43216].
Publication Policy
The results of this study  may  be published or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to 
the sponsor before submission. This allows the sponsor to protect propr ietary  
information and to provide comments.
The sponsor will comply  with the requirements for publication of study  results. 
In accordance with standard editorial and ethical practice, the sponsor will 
generall y support publication of multicenter studies o nly in their entiret y and not 
as individual site data. In this case, a coordinating investigator [INVESTIGATOR_43192] b y mutual agreement.
Authorship will be determined by  [CONTACT_633393] a uthorship requirements. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
78Dissemination of Clinical Study  Data
For this study  participant data will be entered into [COMPANY_004] defined eCRFs, 
transmitted electronically to [COMPANY_004] or designee and combined with data provided 
from other sources in a validated data s ystem.  
Data Quality  Assurance
Management of clinical data will be performed in accordance with applicable 
[COMPANY_004] standards and data cleaning procedures to ensure the integrit y of the data, 
e.g., removing errors and inconsistencies in the data.
Adverse events and concomitant medications terms will be coded using 
MedDRA (Medical Dictionary  for Regulatory  Activities) and an internal 
validated medication dictionary , [COMPANY_004]Drug.  
eCRFs (including queries and audit trails) will be retained b y [COMPANY_004], and copi[INVESTIGATOR_633358] I nvestigator to maintain as the Investigator copy.  Participant 
initials will not be collected or transmitted to [COMPANY_004] according to [COMPANY_004] policy.
All participant data relating to the stud y will be recorded on printed or electronic 
CRF unless transmitte d to the sponsor or designee electronically  (eg, laboratory  
data). The investigator is responsible for verify ing that data entries are accurate 
and correct b y physically or electronically signing the CRF. 
The investigator must maintain accurate documentat ion (source data) that 
supports the information entered in the CRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory  agency  inspections and provide direct access to source data 
documents. 
The sponsor or designee is responsible for the data management of this study  
including qualit y checking of the data. 
Study  monitors will perform ongoing source data verification to confirm that 
data entered into the CRF b y authorized site personnel are accurate, complete, 
andverifiable from source documents; that the safety  and rights of participants 
are being protected; and that the study is being conducted in accordance with the 
currentl y approved protocol and an y other stud y agreements, ICH GCP, and all 
applicable regulato ry requirements. 
Records and documents, including signed ICF, pertaining to the conduct of this 
study  must be retained by [CONTACT_1732] 25years after study  completion 
unless local regulations or institutional policies require a longer retention pe riod. 
No records may  be destroy ed during the retention period without the written 
approval of the sponsor. No records may  be transferred to another location or 
party  without written notification to the sponsor.  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
79Source Documents
Source documents provide ev idence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from 
source documents must be consistent with the source documents or the 
discrepancies must be explained. The investigator may  need to request previous 
medical records or transfer records, depending on the study . Also, current 
medical records must be available.
Study and Site Closure
[COMPANY_004] or its designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of [COMPANY_004]. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include 
but are not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, o r GCP guidelines
Inadequate recruitment of participants by [CONTACT_093]
Discontinuation of further study  treatment development 2018N371775_00
2016N289466_02 CONFIDENTIA L
[PHONE_13170].4. Appendix 4: A dverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
Definition of A E
AE Definition
An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of a study  treatment, whether or not considered related to the 
study  treatment.
NOTE: An AE can therefore be an y unfavorable and unin tended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study  treatment.
Events Meeting the AE Definition 
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator (ie, not relate d to progression of 
underly ing disease).
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.
"Lack of efficacy " or "failure of expected phar macological action" per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy  
assessments. However, the signs, s ymptoms, and/or clinical sequelae resulting from 
lack of efficacy  will be reported as AE or SAE if they  fulfi ll the definition of an AE 
or SAE. 
The signs, s ymptoms, and/or clinical sequelae resulting from lack of efficacy  will be 
reported as AE or SAE if they  fulfill the definition of an AE or SAE. Also, "lack of 
efficacy " or "failure of expected pharmacological action" constitutes an AE or SAE. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
81Events NOT Meeting the AE Definition 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscopy , appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuation s of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
Definition of SA E
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, 
death due to progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_42244]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the AE 
should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
82significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) which may  interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or hospi[INVESTIGATOR_217611]. These events should usually  
be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse.
Recording A E and SA E
AE and SAE Recording
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_171087]’s 
medical records to [COMPANY_004] in lieu of completion of the [COMPANY_004] /AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004]. 
In this case, all participant identifiers, with the exception of the 
participant n umber, will be redacted on the copi[INVESTIGATOR_31785].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event tha t is easily  tolerated by  [CONTACT_2299], causing minimal discomfort 
and not interfering with every day activities.
Moderate: An event that causes sufficiently  discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities. An AE that is assessed as  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
83severe should not be confused with an SAE. Severe is a category  utilized for rating 
the intensity  of an event; and both AE and SAE can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment and 
each occurrence of each AE/SAE.
A "reasonable possibility " of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  treatment 
administration will be considered and investigated.
The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to [COMPANY_004]. However, it is very 
important that the investigator always make an assessment of causality for 
every event before the in itial transmission of the SAE data to [COMPANY_004] .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up report with the updated causality  
assessment.
The causality  assessment is one of the criteria us ed when determining regulatory  
reporting requirements.
Follow -up of AE and SAE
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_31859]/or causalit y of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathological examinations, 
or consultation with other health care professionals.
If a participant dies during participa tion in the study  or during a recognized follow -
up period, the investigator will provide [COMPANY_004] with a cop y of an y post-mortem 
findings including histopathology .  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
84New or updated information will be recorded in the originally  completed CRF.
The investigator wi ll submit any  updated SAE data to [COMPANY_004] within 24 hours of 
receipt of the information.
Reporting of SA E to [COMPANY_004]
SAE Reporting to [COMPANY_004] via Electronic Data Collection Tool
The primary  mechanism for reporting SAE to [COMPANY_004] will be the electronic data 
collection t ool.
If the electronic s ystem is unavailable for more than 24 hours, then the site will use 
the paper SAE data collection tool (see next section).
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
After the stud y is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form or to the 
assigned SAE contact [CONTACT_107461].
Contacts for SAE reporting can be found at the beginning of this pr otocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774].
SAE Reporting to [COMPANY_004] via Paper CRF
Facsimile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the assigned SAE contact [CONTACT_107461].
In rare circums tances and in the absence of facsimile equipment, notification by  
[CONTACT_9337] a cop y of the SAE data collection tool sent by [CONTACT_19515].
Initial notification via telephone does not replace the need for the investigat or to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774]. 2018N371775_00
2016N289466_02 CONFIDENTIA L
[PHONE_13171].5. Appendix 5: Contraceptive Guidance a nd Collection of 
Pregnancy  Information
Definitions
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanentl y sterile (see below)
Women in the following categories are not considered WOCBP
1.Premenarchal
2.Premenopausal female with ONE of the following:
Documented h ysterectomy
Documented bilateral salpi[INVESTIGATOR_1656]
Documented bilateral oophorectom y
Note:  Documentation can come from the site personnel’s: review of participant’s 
medi cal records, medical examination, or medical history  interview.
3.Postmenopausal female
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimulating hormone (FSH) level in 
the postmenopausal r ange may  be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormonal replacement therapy  
(HRT). However, in the absence of 12 months of amenorrhea, a single FSH 
measurement is insufficient. 
Females on HRT and whose meno pausal status is in doubt will be required to 
use one of the non -hormonal highl y effective contraception methods if they wish 
to continue their HRT during the stud y. Otherwise, they must discontinue HRT 
to allow confirmation of postmenopausal status before study  enrollment.
Contraception Guidance
Female participants
Female participants of childbearing potential are eligible to participate if they  agree to 
use a highly effective method of contraception consistently  and correctly  as described in 
Table 4. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
86Table 4 Highly  Effective Contraceptive Methods
Highly Effective Contraceptive Methods That Are User Dependent a
Failure rate of <1%  per year when used consistently and correctly. 
Combined (estrogen -and prog estogen -containing) hormonal contraception associated with 
inhibition of ovulation 
oral
intravaginal 
transdermal 
Progestogen -only hormonal contraception associated with inhibition of ovulationb
injectable 
Highly Effective Methods That Are User Indep endent 
Implantable progestogen -only hormonal contraception associated with inhibition of 
ovulationb
Intrauterine device (IUD)
Intrauterine hormone -releasing system (IUS)
bilateral tubal occlusion
Vasectomized partner 
(A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, an additional highly effective method of contraception should be used.) 
Sexual abstinence 
(Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the d uration of the study and 
the preferred and usual lifestyle of the participant.)
NOTES: 
a. Typi[INVESTIGATOR_35818]. Use should be consistent 
with local regulations regarding the use of contracepti ve methods for participants in clinical studies.
Pregnancy  Testing
WOCBP should only  be included after a confirmed menstrual period and a negative 
highl y sensitive urine or serum pregnancy test 
Pregnancy  testing will be performed whenever a menstrual cycle is missed or when 
pregnancy  is otherwise suspected 
Pregnancy testing, with a sensitivity  of [5, 10, 25] mI U/mL will be performed [and 
assay ed in a certified laboratory  OR and assay ed in the central laboratory  OR using  2018N371775_00
2016N289466_02 CONFIDENTIA L
[ADDRESS_845667] kit provided by  [CONTACT_190906]  / provided by  [CONTACT_456] /approved by  
[CONTACT_633394]]  
Collection of Pregnancy  Information
Female Participants who become pregnant
Investigator will collect pregnancy  inform ation on any  female participant, who 
becomes pregnant while participating in this study. 
Information will be recorded on the appropriate form and submitted to [COMPANY_004] within 
24 hours of learning of a participant's pregnancy . 
Participant will be followed to d etermine the outcome of the pregnancy . The 
investigator will collect follow up information on participant and neonate, which will 
be forwarded to [COMPANY_004] Generall y, follow- up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date.
  
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure. 
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy  will be reported as an AE or 
SAE. 
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post -study  pregnancy  which is considered 
reasonabl y related to the study  treatment b y the investigator, will be reported to [COMPANY_004]
as described in Appendix 4 . While the investigator is not obligated to actively  seek 
this information in former study  participants, he or she may  learn of an SAE through 
spontaneous reporting. 
Any female participant who becomes pregnant while participating in the study will 
immediately discontinue study medication. 2018N371775_00
2016N289466_02 CONFIDENTIA L
[PHONE_13172].6. Appendix 6: Genetics
Genetics –Background
Naturall y occurring genetic variation may  contribute to inter -individ ual variability  in 
response to medicines, as well as an individual's risk of developi[INVESTIGATOR_42259]. 
Genetic factors associated with disease characteristics may  also be associated with 
response to therap y, and could help to explain some clinical stud y outcomes. For 
example, genetic variants associated with age- related macular degeneration (AMD) are 
reported to account for much of th e risk for the condition [ Gorin 2012] with certain 
variants reported to inf luence treatment respons e [Chen 2012]. Thus, knowledge of the 
genetic etiology  of disease may  better inform understanding of disease and the 
development of medicines. Additionally , genetic variability  may  impact the 
pharmacokinetics (absorption, distribution, metabolism, and elimination), or 
pharmacod ynamics (relationship between concentration and pharmacologic effects or the 
time course of pharmacologic effects) of a specific medicine and/or clinical outcomes 
(efficacy  and/or safet y) observed in a clinical study.
Genetic Research Objectives and A nalyses
The objectives of the genetic research are to investigate the relationship between genetic 
variants and: 
Response to medicine or any  concomitant medicines;
Asthma susceptibility , severity , and progression and related conditions
Genetic data may  be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include focused candidate gene approaches and/or 
examination of a large number of genetic variants throughout the g enome (whole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives highlighted above.  Analy ses may  be performed using data 
from multiple clinical studies to investigate these resear ch objectives.
Appropriate descriptive and/or statistical analy sis methods will be used. A detailed 
description of an y planned anal yses will be documented in a Reporting and Analy sis Plan 
(RAP) prior to initiation of the anal ysis. Planned analy ses and results of genetic 
investigations will be reported either as part of the clinical RAP and study  report, or in a 
separate genetics RAP and report, as appropriate.
Study Population
Any participant who is enrolled in the study  can participate in genetic research.   Any 
participant who has received an allogeneic bone marrow transplant must be excluded 
from the genetic research.
Study Assessments and Procedures
A key  component of successful genetic research is the collection of samples during 
clinical studies. Collec tion of samples, even when no 
a priori hypothesis has been  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
89identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in disease and medicine response.  
A 6ml blood sample will be taken for Deox yribonucleic acid (DNA) ex traction. A 
blood sample is collected at the baseline visit, after the participant has been 
randomized and provided informed consent for genetic research. Instructions for 
collection and shippi[INVESTIGATOR_278799] . 
The DNA from the blood sample may  undergo quality  control anal yses to confirm 
the integrit y of the sample. If there are concerns regarding the quality of the sample, 
then the sample may  be destroy ed. The blood sample is taken on a single occasion 
unless a duplicate sample is required due to an inability  to utilize the original sample.  
The genetic sample is labelled (or “coded”) with the same stud y specific number used to 
label other samples and data in the study .   This number can be traced or linked ba ck to 
the 
participant by [CONTACT_42393]. Coded samples do not carry personal 
identifiers (such as name [CONTACT_42405]). 
Samples will be stored securel y and may be kept for up to [ADDRESS_845668] 
participant completes the study , or [COMPANY_004] may  destroy  the samples sooner.  [COMPANY_004] or those 
working with [COMPANY_004] (for example, other researchers) will only  use samples collected from 
the study  for the purpose stated in this protocol and in the informed consent form.  
Samples may  be used as p art of the development of a companion diagnostic to support 
the [COMPANY_004] medicinal product.
Participant s can request their sample to be destro yed at an y time.
Informed Consent
Participant s who do not wish to participate in the genetic research may still partici pate in 
the study .  Genetic informed consent must be obtained prior to an y blood being taken.
Participant Withdrawal from Study
If a participant who has consented to participate in genetic research withdraws from the 
clinical study  for any  reason other tha n being lost to follow -up, the participant will be 
given a choice of one of the following options concerning the genetic sample, if alread y 
collected:
Continue to participate in the genetic research in which case the genetic DNA 
sample is retained
Disconti nue participation in the genetic research and destroy  the genetic DNA 
sample 
If a participant withdraws consent for genetic research or requests sample destruction for 
any reason, the Investigator must complete the appropriate documentation to request 
sample destruction within the timeframe specified by [CONTACT_420264] .  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
90Genoty pe data may  be generated during the study  or after completion of the study  and 
may be anal yzed during the study  or stored for future anal ysis. 
If a participant withdraws consent for genetic research and genot ype data has not 
been analy zed, it will not be anal yzed or used for future research.  
Genetic data that has been anal yzed at the time of withdrawn consent will 
continue to be stored a nd used, as appropriate.
Screen and Baseline Failures
If a sample for genetic research has been collected and it is determined that the 
participant does not meet the entry  criteria for participation in the study , then the 
Investigator should instruct the participant that their genetic sample will be destroy ed. No 
forms are required to complete this process as it will be completed as part of the consent 
and sample reconciliation process.  In this instance a sample destruction form will not be 
available to include in the site files.
Provision of Study Results and Confidentiality  of Participant ’s Genetic Data
[COMPANY_004] may  summarize the genetic research results in the clinical study  report, or 
separately  and may  publish the results in scientific journals. 
[COMPANY_004] may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. [COMPANY_004] does not inform the 
participant , famil y members, insurers, or emplo yers of individual genot ypi[INVESTIGATOR_42261] ’s medical care at the time of the study , 
unless required b y law. This is due to the fact that the information generated from genetic 
studies is generall y preliminary in nature, and therefore the significance and scientific 
validity  of the results are undetermined.  Further, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care.
References
Chen H, Yu KD, Xu GZ. Association between Variant Y402H in Age
-Related Macular 
Degene ration (AMD) Susceptibility  Gene CFH and Treatment Response of AMD: A 
Meta -Anal ysis. PloS ONE 2012; 7: e42464
Gorin MB. Genetic insights into age-related macular degeneration: Controversies 
addressing risk, causality, and therapeutics. Mol. Asp. Med. 2012; 33: 467-486. 2018N371775_00
2016N289466_02 CONFIDENTIA L
[PHONE_13173].7. Appendix 7: Liver Safety : Required A ctions and Follow -up 
Assessments
Phase II l iver chemistry stoppi[INVESTIGATOR_633359]  (in alignment with the FDA 
premark eting clinical liver safety  guidance [ Food and Drug Administration 2009]).
Phase II liver chemistry stoppi[INVESTIGATOR_90566] –Liver St oppi[INVESTIGATOR_53053]- absolute ALT  5xULN
ALT Increase ALT 3xULN persists for 4 weeks
Bilirubin1, 2ALT  3xULN andbilirubin 2xULN (>35% direct bilirubin)
INR2ALT  3xULN andINR>1.5, if INR measured
Cannot Monitor ALT 3xULN and cannot be monitor ed weekly for 4 weeks
Symptomatic3ALT   3xULN associated with symptoms (new or worsening) believed to be 
related to liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stoppi[INVESTIGATOR_633360]
Immediately discontinue study treatment 
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF and complete an 
SAE data collection tool if the event also meets 
the criteria for an SAE2
Perform liver event follow up assessments 
Monito r the participant until liver chemistries
resolve, stabilize, or return to within baseline 
(see MONITORING below)
Do not restart/rechallenge participant with 
study treatment unless allowed per protocol and 
[COMPANY_004] Medical Governance approval is granted 
(refer to Section 8.1.3 )
If restart/rechallenge not allowed per protocol or 
not granted , permanently discontinue study 
treatment and may continue participant in the study 
for any protocol specified follow up assessments Viral hepatitis serology4
Blood sample for pharmacokinetic (PK) 
analysis, obtained [ADDRESS_845669] 
dose5
Serum creatine phosphokinase (CPK) 
and lactate dehydrogenase ( LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form
Record use of con comitant medications 
on the concomitant medications report 
form including acetaminophen, herbal 
remedies, other over the counter  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
92MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin ) and perform 
liver event follow up assessments within 24 hrs
Monitor participants twice weekly until liver 
chemistries resolve, stabilize or return to within 
baseline 
A specialist or hepatology consultation is 
recommended
For All other criteria: 
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within 24-72 
hrs 
Monitor participants weekly until liver 
chemistries resolve, stabilize or return to within 
baselinemedications .
Record alcohol use on the liver event 
alcohol intake case report form
For bilirubin or INR criteria:
Anti-nuclea r antibody, anti- smooth 
muscle antibody, Type 1 anti- liver 
kidney microsomal antibodies, and 
quantitative total immunoglobulin G 
(IgG or gamma globulins).
Serum acetaminophen adduct HPLC 
assay (quantifies potential 
acetaminophen contribution to liver 
injury in participants with definite or 
likely acetaminophen use in the 
preceding week ( James 2009) Not 
Required in China
Liver imaging (ultrasound, magnetic 
resonance, or computerised 
tomography) and /or liver biopsy to 
evaluate liver di sease; complete Liver 
Imaging and/or Liver Biopsy CRF 
forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that participant if ALT 3xULN andbilirubin 2xULN.. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2. Alleven ts of ALT 3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT  3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to participants receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness , or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody; Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing); Hepatitis E IgM antibody 
5. PK sample may not be required for participant s known to be receiving placebo or non -[COMPANY_004] comparator 
treatments.)  Record th e date/time of the PK blood sample draw and the date/time of the last dose of study 
treatment prior to blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the 
participant ’s best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot 
be collected in the time period indicated above, do not obtain a PK sample. Instructions for sample handling and 
shippi[INVESTIGATOR_42253].    2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
93Phase II liver chemistry increased monitoring criteria with conti nued therapy
Liver Chemistry Increased Monitoring Criteria – Liver Monitoring Event
Criteria Actions
ALT  3xULN and <5xULN andbilirubin 
<2xULN , without symptoms believed to 
be related to liver injury or 
hypersensitivity, andwho can be 
monitored weekly for 4 weeksNotify the [COMPANY_004] medical monitor within 24 hours of 
learning of the abnormality to discuss participant 
safety. 
Participant can continue study treatment   
Participant must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphata se, 
bilirubin) until they resolve, stabilise or return to 
within baseline 
If at any time participant meets the liver chemistry 
stoppi[INVESTIGATOR_3418], proceed as described above
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor particip ants twice monthly 
until liver chemistries normalize or return to within 
baseline.
References
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784. 2018N371775_00
2016N289466_02 CONFIDENTIA L
[PHONE_13174].8. Appendix 8: Daily Diary  Questions
12.8.1. Morning Questions
The participant should complete the morning eDiary  questions upon wakening and prior 
to the administration of study  treatment.
Night -time Awakening
1. Did y ou wake up due to asthma 
symptoms (i.e. wheezing, coughing, 
shortness of breath, or chest 
tightness).No
Yes
2.If Yes; when you woke up due to 
your asthma sy mptoms did you use 
any rescue inhaler?No
Yes
12.8.2. Evening Questi ons
The participant should complete the evening eDiary questions just before going to bed.
E-RS
1.Did your chest feel congested 
today?Not at all
Slightly
Moderately
Severely
Extremely
2.How often did you cough today? Not at all 
Rarely 
Occasionally 
Frequently 
Almost constantly 
3.How much mucus (phlegm) did 
you bring up when coughing 
today?None at all 
A little 
Some 
A great deal 
A very great deal 
4.How difficult was it to bring up 
mucus (phlegm) tod ay?Not at all 
Slightly 
Moderately 
Quite a bit 
Extremely  2018N371775_00
2016N289466_02 CONFIDENTIA L
[ADDRESS_845670] discomfort 
today?Not at all 
Slight 
Moderate 
Severe 
Extreme 
6. Did your chest feel tight today? Not at all
Slightly
Moderately
Severely
Extremely
7.    Were you breathless today? Not at all
Slightly
Moderately
Severely
Extremely
8. Describe how breathless you were 
today:Unaware of breathlessness
Breathless during strenuous activity
Breathless during light activity
Breathless when washing or dressing
Present when resting 
9. Were you short of breath today 
when performing your usual 
personal care activities like 
washing or dressing?Not at all 
Slightly 
Moderately 
Severely 
Extremely 
Too breathless to do these 
10. W ere y ou short of breath today 
when performing your usual indoor 
activities like cleaning or 
household work?Not at all 
Slightly 
Moderately 
Severely 
Extremely 
Too breathless to do these 
11. W ere y ou short of breath today 
when performing your usual 
activities outside the home such 
as yard work or errands?Not at all 
Slightly 
Moderately 
Severely 
Extremely 
Too breathless to do these  2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
96Supplemental Asthma Items
1. Did you wheeze today?’ Not at all 
Rarely
Occasionally 
Frequently
Almost constantly
2. Were you short of breath today 
when performing strenuous activities 
such climbing stairs, running, or 
participating in sports activity.  Not at all 
Slightly 
Moderately 
Severely 
Extremely
Asthma Symptom and Physical Activity Questions
1.Please describe the severity of 
your asthma sy mptoms today (i.e. 
cough, wheeze, chest tightness, 
shortness of breathNo asthma sy mptoms
Mild asthma sy mptoms
Moderate asthma sy mptoms
Sever e asthma sy mptoms
Very severe asthma sy mptoms
2.How limited were you in your 
activities today because of your 
asthmaNot at all limited
A little limited
Moderately limited
Severely limited
Totally limited 2018N371775_00
2016N289466_02 CONFIDENTIA L
[PHONE_13175].9. Appendix 9: Country -specific requireme nts
There are currently  no country  specific requirements.  2018N371775_00
2016N289466_02 CONFIDENTIA L
[PHONE_13176].10. Appendix 10: Protocol A mendment History
The Protocol Amendment Summary  of Changes Table for the current amendment is 
located directly  before the Table of Contents (TOC).
Amendment 1 15-November - 2016
Overall Rationale for the Amendment:
To address t ypographical errors and inconsistencies between the Schedule of Activities 
(SOA) and the protocol text. I n addition, language has been added to Exclusion criteria 
#14 to clearl y explain examples of inhaled products (e -cigarettes/vapi[INVESTIGATOR_007]) as well as 
provide an example of a drug; in Exclusion #15. (marijuana is considered an abused 
drug).
Section # and Name [CONTACT_19523] 2: Schedule 
of Activities (SOA)Included Line item “X” i n the box for 
inclusion/exclusion criteria at Visit 2 
(randomization) To correct the 
inconsistency  
between the 
Schedule of 
Activities (SOA) 
and the protocol 
text.
Section 2: Schedule 
of Activities (SOA)Included row for “Exacerbation history” and 
Line it em “X” at “screening”To correct the 
inconsistency  
between the 
Schedule of 
Activities (SOA) 
and the protocol 
text.
Section 2: Schedule 
of Activit ies (SOA)Included row for Exacerbation assessment 
and line item “X” in the boxes from Visit 2 
(randomization) to “EOS/EW”. To correct the 
inconsistency  
between the 
Schedule of 
Activities (SOA) 
and the protocol 
text. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
99Section # and Name [CONTACT_19523] 2: Schedule 
of Activities (SOA)
[Study  Treatment]Included row for dispensing 
Albuterol/Salbutamol and line item “X” at 
Visit 1 ( screening )until Visit 4. To correct the 
inconsistency  
between the 
Schedule of 
Activities (SOA) 
and the protocol 
text.
Section 2: Schedule 
of Activities (SOA) 
[Study  Treatment]Included row for collection of 
Albuterol/Salbutamol and line item at Visit 2 
until Visi t EOS/EW for collection of 
Albuterol/Salbutamol.To correct the 
inconsistency  
between the 
Schedule of 
Activities (SOA) 
and the protocol 
text.
Section 3.3.1 Risk 
Assessments
(Potential Risk of 
Clinical Significance 
Systemic ICS effects 
Adrenal suppression)Updated the information of HPA study  
(Mentioned 24 hour urinary  cortisol 
excretion [Previously  mentioned as 24 hour 
serum cortisol excretion]) Corrected the 
information of 
HPA study
Section 6.2 Exclusion 
CriteriaExample of tobacco products has been ad ded 
to Exclusion criteria #14 Tobacco Use (e -
cigarettes/vapi[INVESTIGATOR_007])To clearl y 
explain examples 
of inhaled 
tobacco 
products.
Section 6.2 Exclusion 
CriteriaExample of a drug has been added to 
Exclusion criteria 15 Drug/alcohol abuse 
(marijuana is considered a n abused drug).Updated 
example of a 
drug/alcohol 
abuse.
Section 9, Study  
Assessments and 
Procedures Removed: Healthcare Resource Utilization 
(HRU) from the additional critical baseline 
assessments (Screening [Visit 1])To correct the 
inconsistency  
between the 
Schedule of 
Activities (SOA) 
and the protocol 
text. 2018N371775_00
2016N289466_02 CONFIDENTIA L
205832
100Section # and Name [CONTACT_19523] 9, Study  
Assessments and 
Procedures Removed: Questionnaires (SGRQ; AQLQ) 
from the additional critical baseline 
assessments (Screening [Visit 1])To correct the 
inconsistency  
between the 
Schedule of 
Activities (SOA) 
and the protocol 
text.
Section 9, Study  
Assessments and 
Procedures Added : Letters “AE” to the additional critical 
baseline assessments (Screening [Visit 1])To correct the 
inconsistency  
between the 
Schedule of 
Activities (SOA)
and the protocol 
text.
Section 9 .2.1,Time 
Period and Frequency  
for collecting AE and 
SAE I nformationUpdated the information in the second bullet; 
(Stated AEs will be collected from the start 
of Study  Screening [Previously  mentioned 
AEs will be collect ed from the start of Study  
Treatment])To correct the 
inconsistency  
between the 
Schedule of 
Activities (SOA) 
and the protocol 
text. 2018N371775_00
2016N289466_01 CONFIDENTIA L
GlaxoSmithKline group of companies 205832
1TITLE PA GE
Protocol Title: A Phase IIb, 24 week, randomized, double -blind, 3 arm parallel group 
study , comparing the efficacy , safet y and tolerability  of two doses of umeclidinium 
bromide administered once- daily via a dry  powder inhaler, versus placebo, in participants 
with asthma
Protocol Number : 205832/ Amendment 1
Short Title : A randomized, double- blind, parallel group stud y, comparing the efficacy , 
safet y and tolerability of two doses of umeclidinium bromide administered once -daily via 
a dry  powder inha ler, versus placebo, in participants with asthma
Compound Number: GW685698+[COMPANY_004]573719
Sponsor Name [CONTACT_29560]: 
GlaxoSmithKline Research & Development Limited
[ADDRESS_845671] Information can be found in the Study 
Reference Manual
Regulatory Agency Identifying Number(s): IND No. 104479, EudraCT number 2016 -
002843-40
Approval Date: 15-NOV - 2016
Copy right 2016 the GlaxoSmithKline group of companies.  All rights reser ved.  
Unauthorised cop ying or use of this information is prohibited. 2018N371775_00
 2018N371775_00
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
2016N289466_01 CONFI DENTIA L
205832
3PROTOCOL A MENDMENT SUMMA RY OF CHA NGES TA BLE
DOCUMENT HISTORY
Document Date of Issue
Amendment 1 15-Nov-2016
Original Protocol 19-Aug-2016
Overall Rationale for the Amendment:
To address t ypographical errors and inconsistencies between the Schedule of Activities 
(SOA) and the protocol text. I n addition, language has been added to Exclusion criteria 
#14 to clearl y explain examples of inhaled products (e- cigarettes/vapi[INVESTIGATOR_007]) as well as 
provide an example of a drug ;in Exclusion #15. (marijuana is considered an abused 
drug).
Amendment 1 15-November - 2016
Section # and Name [CONTACT_19523] 2: Schedule 
of Activities (SOA)Included Line item “X”  in the box for 
inclusion/exclusion criteria at Visit 2 
(randomization) To correct the 
inconsistency  
between the 
Schedule of 
Activi ties (SOA) 
and the protocol 
text.
Section 2: Schedule 
of Activities (SOA)Included row for “Exacerbation history” and 
Line item “X” at “screening”To correct the 
inconsistency  
between the 
Schedule of 
Activities (SOA) 
and the protocol 
text. 2018N371775_00
2016N289466_01 CONFI DENTIA L
205832
4Section # and Name [CONTACT_19523] 2: Schedule 
of Activit ies (SOA)Included row for Exacerbation assessment 
and line item “X” in the boxes from Visit 2 
(randomization) to “EOS/EW”. To correct the 
inconsistency  
between the 
Schedule of 
Activities (SOA) 
and the protocol 
text.
Section 2: Schedule 
of Activities (SOA)
[Study  Treatment]Included row for dispensing 
Albuterol/Salbutamol and line item “X” at 
Visit 1 ( screening )until Visit 4. To correct the 
inconsistency  
between the 
Schedule of 
Activities (SOA) 
and the protocol 
text.
Section 2: Schedule
of Activities (SOA) 
[Study  Treatment]Included row for collection of 
Albuterol/Salbutamol and line item at Visit 2 
until Visit EOS/EW for collection of 
Albuterol/Salbutamol.To correct the 
inconsistency  
between the 
Schedule of 
Activities (SOA) 
and the protocol 
text.
Section 3.3 .1Risk 
Assessments
(Potential Risk of 
Clinical Significance 
Systemic ICS effects 
Adrenal suppression)Updated the information of HPA study  
(Mentioned 24 hour urinary  cortisol 
excretion [Previously  mentioned as 24 hour 
serum cortis ol excretion]) Corrected the 
information of 
HPA study
Section 6.2 Exclusion 
CriteriaExample of tobacco products has been added 
to Exclusion criteria #14 Tobacco Use (e -
cigarettes/vapi[INVESTIGATOR_007])To clearl y 
explain examples 
of inhaled 
tobacco 
products.
Section 6.2 Exclusion 
CriteriaExample of a drug has been added to 
Exclusion criteria 15 Drug/alcohol abuse 
(marijuana is considered an abused drug).Updated 
example of a 
drug/alcohol 
abuse. 2018N371775_00
2016N289466_01 CONFI DENTIA L
205832
5Section # and Name [CONTACT_19523] 9, Study  
Assessments and 
Procedures Removed: Healthcare Resourc e Utilization 
(HRU) from the additional critical baseline 
assessments (Screening [Visit 1])To correct the 
inconsistency  
between the 
Schedule of 
Activities (SOA) 
and the protocol 
text.
Section 9, Study  
Assessments and 
Procedures Removed: Questionnaires ( SGRQ; AQLQ) 
from the additional critical baseline 
assessments (Screening [Visit 1])To correct the 
inconsistency  
between the 
Schedule of 
Activities (SOA) 
and the protocol 
text.
Section 9, Study  
Assessments and 
Procedures Added : Letters “AE” to the additi onal critical 
baseline assessments (Screening [Visit 1])To correct the 
inconsistency  
between the 
Schedule of 
Activities (SOA) 
and the protocol 
text.
Section 9 .2.1,Time 
Period and Frequency  
for collecting AE and 
SAE I nformationUpdated the information i n the second bullet; 
(Stated AEs will be collected from the start 
of Study  Screening [Previously  mentioned 
AEs will be collected from the start of Study  
Treatment])To correct the 
inconsistency  
between the 
Schedule of 
Activities (SOA) 
and the protocol 
text. 2018N371775_00
2016N289466_01 CONFI DENTIA L
205832
6TABLE OF CONTENTS
PAGE
PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE..................................... 3
1.SYNOPSIS .............................................................................................................
..9
2.SCHEDULE OF ACTIVITI ES (SOA) ....................................................................... 13
3.INTRODUCTION .................................................................................................... 19
3.1. Study Rationale .......................................................................................... 19
3.2. Background ................................................................................................ 19
3.3. Benefit/Risk Assessment ............................................................................ 19
3.3.1. Risk Assessment ......................................................................... 20
3.3.2. Benefit Assessment ..................................................................... 26
3.3.3. Overall Benefit: Risk Conclusion .................................................. [ADDRESS_845672] udy Design .......................................................... 30
5.5. Dose Justification ........................................................................................ 31
6.STUDY POPULATION ........................................................................................... 31
6.1. Inclusion Criteria ......................................................................................... 31
6.2. Exclusion Criteria ........................................................................................ 33
6.2.1. Randomization Criteria ................................................................ 35
6.2.2. Inclusion Criteria for Randomization ............................................ 35
6.2.3. Exclusion Criteria for Randomization ........................................... 36
6.3. Lifestyle Restrictions ................................................................................... 36
6.4. Pre-Screening/Screening/Run -in/Randomization Failures .......................... 36
7.TREATMENTS ....................................................................................................... 37
7.1. Treatments Administered ............................................................................ 37
7.1.1. Description of FF 100 mcg and Double- Blind Study 
Treatment .................................................................................... 37
7.1.2. Description of Albuterol/Salbutamol ............................................. 38
7.1.3. Study Treatment and FF 100 mcg Return .................................... 39
7.2. Dose Modification ....................................................................................... 39
7.3. Method of Treatment Assignment ............................................................... 39
7.4. Blinding ....................................................................................................... 40
7.5. Packaging and Labeling .............................................................................. 40
7.6. Preparation/Handling/Storage/Accountabilit y.............................................. 41
7.7. Treatment Compliance................................................................................ 41
7.8. Concomitant Therapy .................................................................................. 42
7.8.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 42
[IP_ADDRESS]. Permitted Asthma Medications ................................... 42
[IP_ADDRESS]. Permitted Non -Asthma Medications ........................... 43
7.9. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ........................................ 44 2018N371775_00
2016N289466_01 CONFI DENTIA L
205832
77.10. Treatment after the End of the Study .......................................................... 44
8.DISCONTINUATION CRIT ERIA ............................................................................. 45
8.1. Discontinuation of Study Treatment ............................................................ 45
8.1.1. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................................ 45
8.1.2. QTc Stoppi [INVESTIGATOR_2121] .................................................................. 46
8.1.3. Rechallenge ................................................................................. 47
[IP_ADDRESS]. Study Treatment Restart or Rechallenge .................... [ADDRESS_845673] to F ollow Up ........................................................................................ 47
9.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 48
9.1. Efficacy Assessments ................................................................................. 49
9.1.1. Questionnaires ............................................................................ 49
[IP_ADDRESS]. Global Assessment of S everity and Response 
to Treatment ............................................................... 49
[IP_ADDRESS]. Asthma Control Questionnaire (ACQ) ......................... 50
[IP_ADDRESS]. St. George’s Respi[INVESTIGATOR_633329] 
(SGRQ) ...................................................................... 50
[IP_ADDRESS]. Asthma Quality of Life Questionnaire (AQLQ) ............ 50
9.1.2. Daily Diaries ................................................................................ 50
[IP_ADDRESS]. eDiary Questionnaires, Assessments and 
Alerts .......................................................................... 51
[IP_ADDRESS].1. E-RS....................................................... 51
[IP_ADDRESS].2. Supplemental Asthma Items ................... 51
[IP_ADDRESS].3. Night -time Awakening, Asthma 
Symptom and Physical Activity 
Questions ............................................... 52
[IP_ADDRESS].4. Morning and Evening Home 
Spi[INVESTIGATOR_038] .............................................. 52
[IP_ADDRESS].5. Alerts ...................................................... [ADDRESS_845674] ............................................................. 53
[IP_ADDRESS]. Reversibility (Albuterol/Salbutamol) ............................ 54
9.1.4. Asthma Exacerbations ................................................................ .54
[IP_ADDRESS]. Moderate Asthma Exacerbation .................................. 55
[IP_ADDRESS]. Severe Asthma Exacerbation ..................................... [ADDRESS_845675] (AESIs) ................................ .57
9.2.6. Cardiovascular and Death Events ................................................ 58
9.2.7. Pneumonia .................................................................................. 58
9.2.8. Radiography (Chest X -Rays) ....................................................... 59
9.2.9. Pregnancy ................................................................................... 59
9.3. Treatment of Overdose ............................................................................... 59
9.4. Safety Assessments ................................................................................... 60
9.4.1. Physical Examinations ................................................................ .60
9.4.2. Vital Signs .................................................................................... 60
9.4.3. Electrocardiograms ...................................................................... 60 2018N371775_00
2016N289466_01 CONFI DENTIA L
205832
89.4.4. Clinical Safety Laboratory Assessments ...................................... 61
9.5. Pharmacokinetics ....................................................................................... 61
9.6. Pharmacodynamics .................................................................................... 61
9.7. Genetics ..................................................................................................... 61
9.8. Biomarkers ................................................................................................ .62
9.9. Health Economics OR Medical Resource Utilization and Health 
Economics .................................................................................................. 62
10.STATISTICAL CONSIDER ATIONS ........................................................................ 62
10.1. Hypotheses ................................................................................................ .62
10.2. Sample Size Determination ........................................................................ 63
10.3. Sample Size Sensitivity ............................................................................... 63
10.4. Sample si te re-estimation or adjustment ..................................................... 64
10.5. Data Analysis .............................................................................................. 64
10.5.1. Analysis population ...................................................................... 64
10.5.2. Treatment Comparisons .............................................................. 65
10.5.3. Multiple Comparisons and Multiplicity .......................................... 65
10.6. Statistical Analysis ...................................................................................... 66
10.6.1. Primary Analyses ......................................................................... 66
10.6.2. Secondary Analyses .................................................................... 67
10.6.3. Other Analyses ............................................................................ 67
10.6.4. Interim Analyses .......................................................................... 67
10.6.5. Exploratory Analyses ................................................................... 67
11.REFERENCES ....................................................................................................... 68
12.APPENDICES ........................................................................................................ 70
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 70
12.2. Appendix 2: Clinical Laboratory Tests ......................................................... 73
12.3. Appendix 3: Study Governance Considerations .......................................... 75
12.4. Appendix 4: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ....................................... 79
12.5. Appendix 5: Contraceptive Guidance and Collection of Pregnancy 
Information .................................................................................................. 84
12.6. Appe ndix 6: Genetics .................................................................................. 87
12.7. Appendix 7: Liver Safety: Required Actions and Follow -up 
Assessments .............................................................................................. 90
12.8. Appendix 8: Daily Diary Questions .............................................................. 93
12.8.1. Morning Questions ....................................................................... 93
12.8.2. Evening Questions ....................................................................... 93
12.9. Appendix 9: Country -specific requirements ................................................. 96
12.10. Appendix 10: Protocol Amendment History ................................................. 97 2018N371775_00
2016N289466_01 CONFI DENTIA L
205832
91. SYNOPSIS
Protocol Title: A Phase IIb, 24 week, randomized, double -blind, 3 arm parallel group 
study , comparing the efficacy , safet y and tolerability  of two doses of umeclidinium 
bromide administered once- daily via a dry  powder inhaler, v ersus placebo, in p articipants
with asthma
Short Title: A randomized, double- blind, parallel group stud y, comparing the efficacy , 
safet y and tolerability of two doses of umeclidinium bromide administered once- daily via 
a dry  powder inhaler, versus placebo, in participants wi th asthma
Rationale:
In the [LOCATION_002] (US) , the long-acting muscarinic antagonist (LAMA) tiotropi[INVESTIGATOR_633330] -term maintenance treatment of asthma in patients 12 y ears of 
age and older.
GlaxoSmithKline ([COMPANY_004]) is currentl y developi[INVESTIGATOR_007] a once -daily ‘closed’ triple therap y of a n
inhaled corticosteroid (ICS) /LAMA/ long-acting beta -2-agonist (LABA )combination 
[fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI)] in a single device, with 
the aim of providing a new treatment option for the management of asthma in adults. 
Through the evaluation of UMEC 62.5 micrograms ( mcg
)and 31.25 mcg compared to 
placebo, this study  will provide important informa tion regarding the efficacy , safety and 
tolerability of UMEC when administered via a se parate inhaler to participants on a 
background of FF without VI .
The primary  objective of this study  is to evaluate the effects of UMEC 62.5 mcg and 
UMEC 31.25 mcg on lung function compared with placebo after 24 weeks of treatment.
Objectives and Endpoint s:
Objective Endpoint
Primary
Evaluate the effects of UMEC 62.5 mcg 
and UMEC 31.25 mcg on lung function 
(trough Forced Expi[INVESTIGATOR_1814] 1 
second [FEV 1]) vs placebo after 24 
weeks of treatment.Mean change from baseline in clinic 
trough FEV 1at Week 2 4
Secondary
Evaluate the effects of UMEC 62.5 mcg 
and UMEC 31.25 mcg on lung function 
(3hours post dose FEV 1) vs placebo after 
24 weeks of treatment.Mean change from baseline in clinic FEV [ADDRESS_845676] dose at Week 24 2018N371775_00
2016N289466_01 CONFI DENTIA L
205832
10Objective Endpoint
Safety
 To evaluate the  safet y and tolerability of 
UMEC 62.5 mcg and UMEC 31.25 mcg 
compared to placebo Incidence and type of adverse events
 Electrocardiogram (ECG) 
measurements
 Vital signs
Overall Design:
This is a Phase IIb, randomized, double -blind, placebo controlled, 3 -arm para llel group 
study , comparing the efficacy , safet y and tolerability  of UMEC (62.5 mcg and 
31.25 mcg) administered once- dailyin participants with asthma that is not well controlled 
(i.e. participants with an Asthma Control Questionnaire -6 [ACQ -6] total score >0.75 at 
Visit 2 [the Randomization Visit] ) despi[INVESTIGATOR_633331].
Number of Participant s:
The total number of randomized participant s required is approximately  384, with 128
participant s randomized 1:1:1 to each of the 3 double -blind t reatment arms.   2018N371775_00
2016N289466_01 CONFI DENTIA L
205832
11Treatment Groups and Duration:
Eligible participant s will be requested to participa te in the study  for a maximum of 
approximately 31 weeks ( Visit 0to the Follow -up contact , inclusive ) during which time, 
participants will complete the foll
owing 4 phases of the study :
Pre-screening: Details about the study  and procedures will be explained 
through the informed consent process. The Pre -screening Visit (Visit 0 ), 
including the informed consent process, must be completed within 4 weeks prior 
to Visit 1 as well as prior to any  protocol -required changes to a participant’s 
usual asthma treatment and the initiation of any Visit 1 procedures.
Participant s that receive LABA (or LAMA) as a component of their regular (i.e. 
pre-study ) therap y must stop L ABA (or LAMA) treatment from 48 hours prior 
to Visit 1 (Screening) until after they  have completed the study ; therefore, the 
investigator must use their clinical judgment to determine if the participant may 
stop L ABA (or LAMA) prior to study  entry  without incurring undue risk.
Screening / run- in: Participant s who meet all the eligibility  criteria at Visit 1 
(Screening), will enter the run -in period for approximately  2 weeks to continue 
assess ingthe participant ’s eligibility  for the study . On the morning of Visit 1, 
participant s will refrain from taking the morning dose of their regular (i.e. pre-
study ) ICS asthma medication. Participant s satisfying all inclusion/exclusion 
criteria and who have successfully  completed all protocol procedures at 
screening will be provided with FF 100 mcg via the ELLIPTA dry -powder 
inhaler (DPI) to take once daily  (QD), in the morning, during the 2- week run -in 
period; the first dose of FF 100 mcg will be self -administered by  [CONTACT_633378]. Participants will refrain from using their own ICS 
asthma medication during the 2 -week run- in and treatment period. Participants 
will also be provided with rescue medication (albuterol/salbutamol) to use on an 
as-needed basis throughout the stud y.
Randomization / tre atment: At Visit 2 (the Randomization Visit), participants 
who meet all of the randomization criteria will be randomized 1:1:1 to receive 
oneof the following three double -blind study  treatments via the ELLIPTA DPI  
[CONTACT_78482] 24 -week treatment period:
UMEC 62.5 mcg QD
UMEC 31.25 mcg QD
Placebo QD
Participants will continue to administer FF 100 mcg once dail y (QD), in the 
morning from a separate ELLIPTA DPI [INVESTIGATOR_633332]. On the 
morning of Visits 2, 3, 4, and 5, participant s will perform their electronic Diary  
(eDiary ) assessments at home but refrain from taking their morning dose of 
study  treatment and FF 100 mcg (as applicable) until instructed to do so by
[CONTACT_6477]. At Visits 2, 3, [ADDRESS_845677] dose of study  treatment and FF 100 mcg in the clinic on Day  
169 (Visit 5). Participants are expected on non -clinic visit day s to take their  2018N371775_00
2016N289466_01 CONFI DENTIA L
205832
12study  treatment and FF 100 mcg at home in the morning at approximately  the 
same time each day , as directed b y the clinic. 
Safety f ollow -up: A safety  follow -up telephone contact [CONTACT_417494] 7 day s after the participant completes all of the 
protocol -defined procedures for V isit 5 /End of Study  (EOS )or, if applicable, the 
Early Withdrawal V isit. A participant will be considered to have completed the 
study  when they  have completed all phases of the study  including screening, 
run-in, the ran domiz ed treatment phase, and safety  follow -up.
Key Elements of Analysis Plan
The primary  efficacy  analy sis will evaluate the “de facto ” type estimand in the I ntent- to-
Treat population, using a mixed -model repeated measures (MMRM) analysis, including 
all cl inic trough FEV 1recorded post randomization. Analy ses will include the fixed, 
categorical effects of treatment, visit, treatment by [CONTACT_23259], sex, aswell as the 
continuous, fixed covariates of age, baseline value, and baseline value by  [CONTACT_150133]. Point estimates and 95% confidence intervals will be calculated for the 
primary  comparisons of interest:
UMEC 62.5 mcg v ersus Placebo
UMEC 31.[ADDRESS_845678] of missing data will be detailed in the reporting and anal ysis plan(RAP ).
The detail s of the statistical anal ysis methods for the secondary  efficacy endpoint will be 
provided in the RAP .  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
132. SCHEDULE OF ACTIVITI ES(SOA)
Protocol Activit yPre-
ScreenScreen
Run-inTreatment Period Follow -up
Visit 0 12
Randomization3 45/End of Study  
(EOS)Early  Withdrawal 
(EW)Safety
Follow -up Contact
[CONTACT_633380]-42to -
14-14 1 29 85 169
Week -6 to -2 -2 0 4 12 241 week after Visit 
5/EOS or EW Visit
Window -7d -5/+2d -5/+2d -5/+2d -1/+4d
Informed consent
(ICF)a X
Genetic I CFbX
Inclusion and 
exclusion criteriaX X
DemographycX X
Medical history X
Asthma historyd
X
Exacerbation
history X
Smoking History 
and status X
Concomitant 
medication reviewX X X X X X X X
Register visit in 
Interactive W eb 
Response System 
(IWRS) (RAMOS 
NG)eX X X X X X X
RandomizationfX
Laboratory  
Assessments
Urinalysis X 
 
 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
14Protocol Activit yPre-
ScreenScreen
Run-inTreatment Period Follow -up
Visit 0 12
Randomization3 45/End of Study  
(EOS)Early  Withdrawal 
(EW)Safety
Follow -up Contact
[CONTACT_633380]-42to -
14-14 1 29 85 169
Week -6 to -2 -2 0 4 12 241 week after Visit 
5/EOS or EW Visit
Window -7d -5/+2d -5/+2d -5/+2d -1/+4d
Hematology and 
clinical chemistryg X
Hepatitis B and C Xm
Genetic sample Xn1.
Serum pregnancy 
testX oX oX o
Urine pregnancy 
testX oX oX o
Safety  
Assessments
Physical exam 
including height 
and weighthX X X
12-lead 
Electrocardiogram
(ECG)iX X X X
Vital signsjX X X X X X
Adverse Event (AE) 
reviewX X X X X X X
Serious Adverse 
Event (SAE)  
reviewX X X X X X X X
Study Treatment
Dispense
Albuterol/Salbutam
ol, as requiredX X X X
Collect 
Albuterol/Salbutam
ol, as requiredX X X X X 
 
 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
15Protocol Activit yPre-
ScreenScreen
Run-inTreatment Period Follow -up
Visit 0 12
Randomization3 45/End of Study  
(EOS)Early  Withdrawal 
(EW)Safety
Follow -up Contact
[CONTACT_633380]-42to -
14-14 1 29 85 169
Week -6 to -2 -2 0 4 12 241 week after Visit 
5/EOS or EW Visit
Window -7d -5/+2d -5/+2d -5/+2d -1/+4d
Dispense open 
label fluticasone 
furoate (FF) [ADDRESS_845679] double -blind 
study treatmentX X X X
Assess FF 
100mcg run-in 
medication 
complianceX
Assess FF 
100mcg and 
double -blind study 
treatment 
complianceX X X X
Efficacy  
Assessments
Global Assessment 
of Severity k X X X X X 
 
 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
16Protocol Activit yPre-
ScreenScreen
Run-inTreatment Period Follow -up
Visit 0 12
Randomization3 45/End of Study  
(EOS)Early  Withdrawal 
(EW)Safety
Follow -up Contact
[CONTACT_633380]-42to -
14-14 1 29 85 169
Week -6 to -2 -2 0 4 12 241 week after Visit 
5/EOS or EW Visit
Window -7d -5/+2d -5/+2d -5/+2d -1/+4d
Global Assessment 
of Response to 
Treatment kX X X X
Asthma C ontrol 
Questionnaire 
(ACQ -6)kX Xq
Asthma Control 
Questionnaire 
(ACQ -5)kX X X X
St. George’s 
Respi[INVESTIGATOR_6004] 
(SGRQ) kX X X X X
Asthma Quality of 
Life Questionnaire 
(AQLQ) kX X X X X
Evaluating 
Respi[INVESTIGATOR_633333] (E -RS) 
+Asthma symptoms 
+ Peak Expi[INVESTIGATOR_396975] (PEF) + Home 
Forced Expi[INVESTIGATOR_568928] 1 second
(FEV)1k, lX
eDiary Dispense X
eDiary Collect X X
eDiary Review X X X X X 
 
 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
17Protocol Activit yPre-
ScreenScreen
Run-inTreatment Period Follow -up
Visit 0 12
Randomization3 45/End of Study  
(EOS)Early  Withdrawal 
(EW)Safety
Follow -up Contact
[CONTACT_633380]-42to -
14-14 1 29 85 169
Week -6 to -2 -2 0 4 12 241 week after Visit 
5/EOS or EW Visit
Window -7d -5/+2d -5/+2d -5/+2d -1/+4d
Dispense paper 
Medical 
Problems/Medicatio
ns Taken 
worksheetX X X X X
Review paper 
Medical 
Problems/Medicatio
ns Taken
worksheetX X X X X X
Reversibility Xr
Exacerbation 
assessmentX X X X X
Pre-dose 
spi[INVESTIGATOR_038] (clinic)XsXsXsXsXsXs
Post-dose 
spi[INVESTIGATOR_038] (clinic)XtXtXt 
 
 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
181.Notes:
a)The ICF must be signed before any study pro cedures, including medication cessation.
b)Genetics research consent may be obtained at the same time as the study IC and must be obtained prior to obtaining a genetic blood sample.
c)Demography may be captured at either the Pre -screen Visit or Screening Visit (for participants who do not have a Pre -screen Visit).
d)The assessment of asthma history will include: the age of the participant when they were first provided with an inhaler for asthma; completion of an asthma 
medical history questionnaire (a copy of thi s questionnaire and instructions for its use can be found in the SRM).
e)The IW RS will be used for randomization, emergency unblinding and study treatment supply management (Please refer to the RAMO S NG IW RS manual and 
SRM for more information).
f)Participants must not be randomized prior to confirming their eligibility to participate in the study.
g)If test otherwise performed within [ADDRESS_845680] dose of study treatment, testing at screening is not required.
h)Physical Examination will include height an d weight at Visit 1 only. 
i)ECG to be obtained 15 minutes to 45 minutes after the administration of study treatment.
j)The vital signs assessment will include the measurement of blood pressure, heart rate .
k)Assessment(s) to be completed prior to the administra tion of study treatment.
l)To be completed using the provided combined spi[INVESTIGATOR_14007]/eDiary device. Assessments should be completed in the morning upon wak ening and in the evening 
immediately prior to going to bed.
m)Hepatitis C RNA is optional however a confirma tory negative Hepatitis C RNA test must be obtained, to be able to enrol participants with positive Hepatitis C 
antibody due to prior resolved disease. Hep B/C: If test otherwise performed within [ADDRESS_845681] dose of study treatment, testing at screening is not 
required.
n)Pharmacogenetic sample may be drawn any time from Visit 2 onwards.
o)Assessments only to be conducted in females of reproductive potential.
p)Study treatment should be administered at approximately the same time of day at each appli cable clinic visit.
q)Baseline ACQ -5 will be derived from items 1 -5 of the Randomization (Visit 2) ACQ -6.
r)Following completion of the pre -dose spi[INVESTIGATOR_31757], the reversibility test will be conducted between 20 and 60 minutes following 4 inhalations of 
albuterol/salbutamol aerosol. If airway reversibility is not demonstrated at Visit 1 then the assessment may be repeated with in 7 days of Visit 1 (see Section 9.1.3 .
for details of the criteria to be met before a repeat of the reversibility assessment is permitted). If airway reversibility is successfully demonstrated at the second 
attempt and all other eligibility criteria assessed at Visit 1 are met then the participant may enter the 2 -week run -in period.
s)Pre-dose spi[INVESTIGATOR_23943] y should be performed between 6am and 11am after withholding rescue medication for at least 6 hours and prior to taking the m orning dose of 
study treatment and FF 10 0mcg. After V2 pre -dose spi[INVESTIGATOR_96610]  1 hour of the V2 spi[INVESTIGATOR_038].
t)Post-dose spi[INVESTIGATOR_417440] 3 hours ( 15 minutes) after taking the morning dose of study treatment. Rescue medication should be withheld for at 
least [ADDRESS_845682] -dose spi[INVESTIGATOR_633335] 1 hour of the V2 spi[INVESTIGATOR_038].
1. 
 
 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
193. INTRODUCTION
3.1. Stud y Rationale
In the [LOCATION_002] (US) , the long-acting muscarinic antagonist (LAMA) tiotropi[INVESTIGATOR_633330] -term maintenance treatment of asthma in patients 12 y ears of 
age and older.
GlaxoSmithKline ([COMPANY_004]) is currentl y developi[INVESTIGATOR_007] a once -daily ‘closed’ triple therap y of a 
ICS/LAMA/ long-acting beta -
2-agonist ( LABA )combination [ FF /umeclidinium 
(UMEC)/ vilanterol (VI)] in a single device, with the aim of providing a new treatment 
option for the management of asthma in adults. Through the evaluation of UMEC 
62.[ADDRESS_845683] effective anti- inflammatory  
treatments for all sev erities of persistent asthma [ National Institutes of Health ( NIH)
2007; Global I nitiative for Asthma (GINA ) 2016].  Treatment with ICS controls asthma 
symptoms, improves quality  of life and lung func tion, decreases airway  hyper -
responsiveness, controls airway  inflammation, and reduces the frequency  and severit y of 
asthma exacerbations, thereb y reducing asthma morbidity .  
Despi[INVESTIGATOR_633336] y of treatments and published guidelines, patients may ha ve asthma 
that is not well controlled.
This trial will, primarily , evaluate trough FEV 1to characterize the efficacy of two doses 
of UMEC (62.5 mcg and 31.25 mcg) in the treatment of asthma when administered as an 
open combination with FF 100 mcg. UMEC is currently  under development as a closed 
triple therap y in combination with FF and VI in a single inhaler.
3.3. Benefit/Risk A ssessment
More detailed information about the known and expected benefits and risks and 
reaso nably expected adverse events related to FFand UMEC can be found in the 
Investigator ’s Brochure (s) (IB ). The table below provides a summary  of the key  risks in 
association with FF and UMEC. I t is noted that both FF and UMEC have also been 
developed in combi nation with VI , therefore relevant safety experience is also provided 
by [CONTACT_633381]/VI and UMEC/VI  combinations.    2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
203.3.1. Risk A ssessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Investigational Product (IP) [e.g., GW685698+[COMPANY_004]573719 ] 
Cardiovascular effects of 
UMEC UMEC
Cardiovascular effects are a potential class effect associated with 
anti-muscarinic therapi[INVESTIGATOR_014]. In the UMEC/VI clinical development 
program in chronic obstructive pulmonary  disease (COPD ) patients, 
UMEC/VI  was generall y well tolerated . Overall, a low number of 
atrial arrh ythmias were reported based on [ADDRESS_845684] with the combination over individual components.  Few of 
these findings were reported as SAEs and none were fatal. In a 
narrow* Major Adverse Cardiac Event (MACE) analysis , the 
incidence of non -fatal my ocardial infarction (Medical Dictionary  for 
Regulatory  Activities (MedDRA) Prefe rred Terms (PTs) of 
myocardial infarction and acute m yocardial infarction) was low 
(<1%) across all treatment groups, although small imbalances in 
exposure adjusted frequency  were observed between UMEC -and VI 
containing treatment groups when compared with placebo and 
tiotropi[INVESTIGATOR_1890].  There was no obvious dose relationship or additive effect 
from the combination.  Whether this represents a true effect is 
difficult to determine due to the small numbers. During clinical 
studies in COPD (62.5 and 125mcg daily dose of UMEC) and in 
Health y Volunteers (in the Thorough QT stud y, UMEC 500mcg dail y 
dose), no effect was observed on heart rate, blood pressure or QT.Mitigation strategy  for UMEC 
- Exclusion criteria as specified in 
Section 6.2 ofthe protocol
-Collection of cardiovascular risk 
factors and medical history  at 
baseline
-ECGs a s per schedule in Section 2
-Vital sign assessments (heart rate
and blood pressure) as per schedule in 
Section 2
- Cardiovascular AEs and SAEs will 
be captured on the electronic Case 
Report Form (e CRF) ( seeAppendix 4 )
-Protocol defined stoppi[INVESTIGATOR_633337] 8.1
-MACE anal ysis
-Instream review of blinded data 
 
 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
21Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Health y Volunteers (in the Thorough QT stud y, UMEC 500 mcg 
daily  dose), no effect was observed on heart rate , blood pressure or 
QT.
Data from Thorough QT (TQT) studies with FF, FF/VI and 
UMEC/VI  suggest that, at the doses to be used in phase III studies, 
the closed triple (FF/UMEC/VI ) is unlikel y to cause clinically 
relevant effects on QTc1. No difference in QT cF2was observed 
between UMEC/VI 125/25mcg or UMEC 500 mcg and placebo. 
UMEC/VI  500/100 mcg increased QTcF on average b y 8.2 msec 
(milliseconds) (90% Confidence Intervals (CI): 6.2, 10.2) at 30 
minutes (min) only . A lack of effect was demonstrated for QTcF with 
FF/V I 200/25mcg (for 7 days). At a supratherapeutic dose of FF/VI 
(800/100mcg for 7 day s), the largest mean time -matched difference 
from placebo was 9.6 msec (90% CI: 7.2, 12.0) at 30 min only .
1QT interval corrected for heart rate
2QT interval co rrected for heart rate by [CONTACT_6550]’s formula
Anticholinergic effects 
(including constipation 
nausea, dry mouth, 
glaucoma, raised 
intraocular pressure and 
blurred vision, urinary  
retention) In clinical studies in COPD, few anticholinergic effects were 
associated with UMEC; those observed included dry  mouth, 
constipation and cough.  Based on post -marketing ex perience 
dysgeusia has been added as an Adverse Drug Reaction (ADR) for 
inhaled UMEC and UMEC/VI .  In addition, UMEC/VI  has had 
urinary  retention, dysuria , vision blurred, glaucoma and increased 
intraocular pressure and paradoxical bronchospasm added as AD Rs.  
ICS has a similar class risk of glaucoma and elevated intraocular -Patients with known narrow -angle 
glaucoma, prostatic h yperplasia or 
bladder outflow obstruction that, in 
the opi[INVESTIGATOR_689], 
contraindicates stud y participation or 
use of an inhaled anticholinergic, will 
be excluded from participating in the 
study .
-Review AEs/ SAEs 
 
 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
22Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
pressure (IOP); however these effects occur b y a different mechanism 
that is not expected to be sy nergistic or additive when FF is used in
combination with UMEC.
Systemic ICS effects 
-Aderenal suppression
-Cataracts & glaucoma
-Reduced bone mineral 
density  and associated 
fracturesNo studies have shown a clinically  relevant effect of FF/VI or FF on 
the hy pothalamic pi[INVESTIGATOR_417483] (HPA). This includes a form al HPA 
study  (HZA106851), which assessed the effects of FF/VI 100/25 and 
200/25 on serum cortisol and 24 hour urinary cortisol excretion, and 
multiple studies with COPD and asthma participant s which 
monitored urinary  cortisol.  
During clinical development of FF & FF/VI no events of Adrenal 
Suppression were reported.  There has been no evidence for adrenal 
suppression based on post- marketing experience to date.  
In stud y HZA106839 (FF/VI, FF and fluticasone propi[INVESTIGATOR_16847] (FP) in 
participant s with asthma), f ormal Ophthalmic assessments were 
conducted (including Lens Opacities Classification Sy stem III 
(LOCS III) evaluations for ocular opacities) throughout the stud y. 
This study  showed no apparent effects on lens opacification, 
compared to baseline assessment.  
During studies in both participant s with asthma and COPD, no 
associated affect on ocular disorders was observed.  Spontaneous 
data received to date does not alter the understanding of this risk.  
A decrease in bone mineral density  and the risk of fra ctures is a class 
concern for an y ICS-containing product for the treatment of COPD.
In two replicate 12 month studies in the FF/VI clinical program, in a -Review AEs/SAEs
-The occurrence of bone fractures 
will be recorded in the eCRF. 
 
 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
23Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
total of 3,255 patients with COPD, the incidence of bone fractures 
overall was low in all treatment gr oups, with a higher incidence in all 
FF/V I groups (2%) compared with the VI 25 mcg group (<1%).  
Although there were more fractures in the FF/VI groups compared 
with the VI 25mcg group, fractures t ypi[INVESTIGATOR_1306] y associated with 
corticosteroid use (e.g., spi[INVESTIGATOR_629921]/thoracolumbar vertebral 
fractures, hip and acetabular fractures) occurred in <1% of the FF/VI 
and VI treatment arms.  In an integrated anal ysis of 11 studies in 
asthma with FF/VI (7,034 patients) and 10 studies in asthma with FF 
(6,219), the in cidence of fractures with FF/VI and FF was 1%, and 
usually  associated with trauma.   
Pneumonia While I CS use is a recognised risk for pne umonia in patients with 
COPD, a clear causal relationship between inhaled corticosteroid use 
and pneumonia in participant s with asthma has not been established.  
In an 18 study  integration in the FF/VI asthma program, the 
incidence of pneumonia (adjusted for exposure) observed with FF/VI
100/25 and FF 100 mcg (8.5/1000 patient y ears and 9.6/1000 patient 
years, respectivel y) was similar to that seen with placebo (9.3/1000 
patient y ears). A higher incidence in the FF/VI 200/25 and FF 200 
arms were observed (18.3/1000 patient y ears and 23.6/ 1000 patient 
years, respectivel y). However, the 95% CIs were wide and 
overlapped across all treatment groups, including placebo. Few of the 
pneumonia events led to hospi[INVESTIGATOR_633339], and 
there were no observed differences in the incidenc e of serious events 
between the two treatment strengths.  The risk of pneumonia in 
asthma patients is very  low and is consistent with the risk of other 
ICS.  Exclusion criteria:
-Immune suppression (e.g., Human 
Immunodeficiency  Virus [HI V], 
Lupu s) or other risk factors for 
pneumonia (e.g.,neurological 
disorders affecting control of the 
upper airway , such as Parkinson’s 
Disease, M yasthenia Gravis).
-Participant s at potentially  high risk 
(e.g., very  low body  mass index 
[BMI ] or severel y malnourishe d) will 
only be included at the discretion of 
the Investigator.
Medical history will also be taken for 
pneumonia in previous 12 months, 
including recording of any  epi[INVESTIGATOR_1841]  
 
 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
24Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
Pneumonia experience with UMEC
In the All Clinical Studies groupi[INVESTIGATOR_007], the incidence of on -treatm ent 
AEs in the Pneumonia and lower respi[INVESTIGATOR_2826] (LRTI) 
adverse events of special interest (AESI) category  with UMEC 
62.5 mcg (1%; 34.6/1000SY) was similar to placebo (1%; 
34.8/1000SY) and lower than the incidence reported in the UMEC 
125mcg (3%; 72.6/1000SY). A higher incidence of AEs in the 
Pneumonia AESI  category  was reported for UMEC 125 mcg (2%; 
37.4/1000SY) compared with UMEC 62.5 mcg (<1%; 19.8/1000SY) 
and placebo (<1%; 10.7/1000SY). The proportion of participant s 
with SAEs in the Pneumonia AESI  category  was similar between 
both U MEC treatment groups, UMEC 62.5 mcg (<1%; 4.9/1000SY) 
and UMEC 125 mcg (<1%; 17.6/1000SY) and placebo (<1%; 
10.7/1000SY).resulting in hospi[INVESTIGATOR_11956].  
The occurrence of pneumonia will be 
recorded in the eCRF.
Where possible a chest X -ray should 
be performed to confirm a diagnosis, 
whenever a participant has a 
suspected pneumonia.
All reports of pneumonia 
(radiographicall y confirmed and 
unconfirmed) must be reported as an 
AE or SAE, if applicable 
Instream review of blinded data.
Review of AESI relevant for 
pneumonia using pre -specified 
MedDRA preferred terms. AE terms 
relating to other Lower Respi[INVESTIGATOR_633340] (excluding 
pneumonia) will also be reviewed.  
Hypersensitivity There have been p ost-marketing reports of h ypersensitivity  reactions 
with FF/VI and UMEC/VI, including anaph ylaxis, angioedema, rash, 
and urticaria.  The formulation also contains lactose.Participant s with a history  of allergy  
or hy persensitivity  to an y 
corticosteroid, 
anticholinergic/muscarinic receptor 
antagonist, beta2 -agonist, 
lactose/milk protein or magnesium  
 
 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
25Potential Risk of Clinical 
SignificanceSummary of Data/Rationale for Risk Mitigation Strategy
stearate are excluded from 
participation in this study  (Section 
6.2). 
-Review AEs/SAEs
Paradoxical 
bronchospasmRare reports of pa radoxical bronchospasm (which may be life 
threatening) with other inhalational products have been reported.  
There have been rare post-marketing reports of paradoxical 
bronchospasm with FF/VI and UMEC/VI.Patients will undergo regular medical 
assessments during clinical studies.  
-Review AEs/SAEs
Pregnancy  and lactation There has been limited pregnancy  exposure to FF and FF/VI in 
humans. Animal studies have shown reproductive toxicity  after 
administration of corticosteroids and beta2 -agonists. 
There is a limited amount of data from the use of UMEC in pregnant 
women. Animal studies do not indicate direct or indirect harmful 
effects with respect to reproductive toxicity . 
There is limited information on the excretion of FF or VI or their 
metabolites in huma n milk. However, other corticosteroids and 
beta2 -agonists are detected in human milk.I t is unknown whether 
umeclidinium is excreted in human milk. The excretion of 
FF/UMEC/VI in breast milk has not been evaluated. A risk to 
breastfed newborns/infants canno t be excluded.Females who are pregnant or breast-
feeding are not eligible for 
participating in the stud y.
Females of child -bearing potential 
will need to follow the contraceptive 
requirements that are specified in 
Appendix 5.  
 
 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
26Therisks for FF 100 mcg are recognised pharmacological class effects associated with 
ICS therap y, which are included in the table above. The experience with FF is provided 
in the respective IB.  
3.3.2. Benefit A ssessment
The benefit of UMEC at two dosage strengths 62.5 and 31.25 mcg as compared to 
Placebo in patients with asthma on background therap y of FF 100 mcg is expected to 
improve lung function. The inclusion of two strengths of UMEC will allow comparison 
to placebo for the dose currentl y marketed in COPD, as well as a lower dose. This will 
help show the efficacy  and safet y of UMEC in asthma when administered as an open 
combination on a background of FF. Another LAMA, tiotropi[INVESTIGATOR_1890], is currently  approved 
for the maintenance treatment of asthma. 
3.3.3. Overall Benefit: Risk Conclusion
Taking into account the measures taken to minimize the risk to the participants 
participating in the stud y, the potential risks identified in association with UMEC are 
justified by  [CONTACT_633395].  
The current experience and safet y profile with UMEC in previous Phase II asthma studies 
(alone and in combination with FF) and from clinical trial and marketing experience in 
the COPD population is supportive of evaluating this compound in asthma patients . The 
potential risks associated with the known pharmacology  of UMEC is offset by  [CONTACT_633383] I CS
therap y. Furthermore, t he approval of another LAMA (tiotropi[INVESTIGATOR_1890]) for the treatment of
asthma demonstrates the suitability  for the use of this class of drug in the asthma 
population.  
4. OBJECTIVES A ND ENDPO INTS
For a definition of baseline for each of the endpoints listed below, please refer to Section 
10.6.
Objectives Endpoints
Primary
Evaluate the effects of UMEC 
62.5 mcg and UMEC 31.25 mcg 
on lung function (trough FEV1) 
versus placebo after 24 weeks of 
treatment.Mean change from baseline in clinic 
trough FEV 1atWeek 24
Secondary
Evaluate the effects of UMEC 
62.5 mcg and UMEC 31.25 mcg on 
lung function (3hours post dose Mean change from baseline in clinic 
FEV 1at [ADDRESS_845685] dose at Week 24 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
27Objectives Endpoints
FEV1) versu s placebo after 24 
weeks of treatment.
Safety  
To evaluate the  safet y and 
tolerabili ty of UMEC 62.5 mcg and 
UMEC 31.25 mcg compared to 
placeboIncidence and t ype of adverse events
ECG measurements
Vital signs
Other
To evaluate other efficacy  assessments 
of UMEC 62.5 mcg and UMEC 
31.25 mcg compared to placeboMean change from baseline i n morning 
(AM) pre -dose Peak Expi[INVESTIGATOR_105177] 
(PEF) over the 24 week treatment 
period
Mean change from baseline in evening
(PM)PEF over the 24 week treatment 
period
Mean change from baseline in daily  
home trough FEV1 over the 24 week 
treatment period
Mean change from baseline in daily  
rescue medication use over the 24 
week treatment period
Mean change from baseline in SGRQ
total score at Week 24
Percent of patients meeting a 
responder threshold of ≥ 4 points 
improvement (decrease) from baseline 
for the SGRQ total score at Week 24
Mean change from baseline in SGRQ 
domain scores at Week 24
Mean change from baseline in the 
AQLQ total score at Week 24
Percent of patients meeting a
responder threshold of ≥ 0.5 points 
improvement from baseline for the 
AQLQ total score at Week 24
Mean change from base line in E -RS
total score over the 24 week treatment 
period
Mean change from baseline in  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
28Objectives Endpoints
ACQ -5 total score at Week 24
Percent of patient s meeting a 
responder threshold of ≥0.5 in change 
from baseline for the ACQ -5 at Week 
24
Annualized rate of moderate/ severe 
asthma exacerbations
5. STUDY DESIGN
5.1. Overall Design
This is a Phase IIb, randomized, double -blind, placebo controlled, 3 -arm parallel group 
study , comparing the efficacy , safet y and tolerability  of UMEC (62.5 mcg and 
31.25 mcg) administered once- dailyin participants with asthma that is not well controlled 
(i.e. participants with an ACQ -6 total score > 0.75 at Visit 2[the Randomization V isit]) 
despi[INVESTIGATOR_633331].
Eligible participant s will be requested to participa te in the study  for a maximum of 
approximately 31 weeks ( Visit 0to the Follow -up contact , inclusive ) during which time, 
participants will complete the fol lowing 4 phases of the study : 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
29Pre-screening: Details about the study  and procedures will be explained 
through the informed consent process. The Pre -screening Visit (Visit 0 ), 
including the informed consent process, must be completed within 4 weeks prior 
toVisit 1 as well as prior to any  protocol -required changes to a participant’s 
usual asthma treatment and the initiation of any Visit 1 procedures. Subjects will 
continue treatment with their regular (i.e. pre- study ) asthma medication(s) 
during the pre -screening period; however, medications that are prohibited within 
a specified time interval prior to Visit 1 are defined in Section 7.9.
Participant s that receive LABA (or LAMA) as a component of their regular (i.e. 
pre-study ) ther apy must stop L ABA (or LAMA) treatment from  48 hours prior 
to Visit 1 (Screening) until they  have completed the study ; therefore, the 
investigator must use their clinical judgment to determine if the participant may 
stop L ABA (or LAMA) prior to study  entry without incurring undue risk.
Screening / run- in: Participant s who meet all the eligibility  criteria at Visit 1 
(Screening), will enter the run -in period for approximately  2 weeks to continue 
assess ingthe participant ’s eligibility  for the study . On the morning of Visit 1, 
participant s will refrain from taking the morning dose of their regular (i.e. pre-
study ) ICS asthma medication. Participant s satisfying all inclusion/exclusion 
criteria and who have successfully  completed all protocol procedures at 
screening will be provided with FF 100 mcg via the ELLIPTA dry -powder 
inhaler (DPI) to take once daily  (QD), in the morning, during the 2- week run -in 
period; the first dose of FF 100 mcg will be self -administered by  [CONTACT_633378]. Participants will refrain from using their own ICS 
asthma medication during the 2 -week run- in and treatment period. Participants 
will also be provided with rescue medication (albuterol/salbutamol) to use on an 
as-needed basis throughout the stud y.
Randomiza tion / treatment: At Visit 2 (the Randomization Visit), participants 
who meet all of the randomization criteria will be randomized 1:1:1 to receive 
oneof the following three double -blind study  treatments via the ELLIPTA DPI  
[CONTACT_78482] 24 -week treatment pe riod:
UMEC 62.5 mcg QD
UMEC 31.25 mcg QD
Placebo QD
Participants will continue to administer FF 100 mcg once dail y (QD), in the 
morning from a separate ELLIPTA DPI [INVESTIGATOR_633332]. On the 
morning of Visits 2, 3, 4, and 5, participant s will perform their electronic Diary  
(eDiary ) assessments at home but refrain from taking their morning dose of 
study  treatment and FF 100 mcg (as applicable) until instructed to do so by
[CONTACT_6477]. At Visits 2, 3, [ADDRESS_845686] at the clinic (see Section 
7.2). Participant s will take their last dose of study  treatment and FF 100 mcg in 
the clinic on Day  169 (Visit 5). Participants are expecte
d on non -clinic visit days 
to take their study  treatment and FF 100 mcg at home in the morning at 
approximately  the same time each day , as directed by  [CONTACT_3652]. 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
30Safety f ollow -up: A safety  follow -up telephone contact [CONTACT_633396] 7 day s after the participant completes all of the 
protocol -defined procedures for V isit 5 /End of Study  (EOS )or, if applicable, the 
Early Withdrawal V isit. A participant will be considered to have completed the 
study  when they  have completed all phases of the study  including screening, 
run-in, the randomi zed treatment phase, and safety  follow -up.
To demonstrate the benefit of UMEC the primary  comparisons of interest for the primary  
efficacy  endpoint are:
UMEC 62.5 mcg versus (vs) Placebo
UMEC 31.[ADDRESS_845687] that aim to informally  estimate any  
potential benefit of increasing the UMEC dose are given below for all efficacy  endpoints. 
UMEC 62.[ADDRESS_845688] not withdrawn consent are encouraged to continue in the study  and 
complete all remaining protocol specified clinic visits (see Section 
8.1)
5.2. Number of Participants
The total number of randomized participant s requ ired is approximately  384, with 128
participant s randomized 1:1:1 to each of the 3 double -blind treatment arms (see Section 
10).  
5.3. Participant and Study  Completion
A participant will be considered to have completed the study  when they  have completed 
allphases of the stud y including pre-screening, screening, run
-in, the randomi zed 
treatment phase, and safety  follow -up.
The end of the stud y is defined as the date of the last scheduled procedure shown in the 
Schedule of Activities table (see Section 2) for the last participant in the trial globall y.
5.4. Scientific Rationale for Study  Design
This study  will use a multicenter, randomized, double -blind, 3 arm parallel- group design.  
This is a well -established design to evaluate the efficacy , safety , and tolerability  of the 
UMEC 
drug.  A placebo arm is included . All participants will be placed on open -label FF 
100mcg when they  enter the 2 week run -in period and continue it through the 24 week 
treatment period. The primary  objective of this study  is to evaluate the effects of UMEC 
62.5 mcg and UMEC 31.25 mcg on lung function compared with placebo after 24 weeks 
of treatment. 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
31GlaxoSmithKline ([COMPANY_004]) is currentl y developi[INVESTIGATOR_007] a once -daily ‘closed’ triple therap y of a 
ICS/LAMA/LABA combination [FF /UMEC/ VI)] in a single device, with the aim of 
providing a new treatment option for the management of asthma in adults. Through the 
evaluation of UMEC 62.5 mcg and 31.25 mcg compared to placebo this study  will 
provide important informa tion regarding the efficacy , safety and tolerability of UMEC in 
asthma when administered via a separate inhaler to participants on a background of FF
without VI .
5.5. Dose Justification
The 200699 (IB Supplement, GlaxoSmithKline Document 2011N123107_03) data 
showed UMEC 62.5 mcg to be an effective dose; after 4 weeks of treatment in the 
subset of patients with a primary  diagnosis of asthma, an average increase in change 
from baseline trough FEV 1at Day  29 of 136 m L was obser ved in those participant s
treated with FF/UMEC (100/62.5 mcg) compared to those participant s treated with 
FF(100 mcg) alone. However, stud y 200699 did not assess the UMEC 31.25 mcg 
dose, therefore, the efficacy  and safet y profile of both 31.25 and 62.5 mcg doseswill 
be assessed in this study when administered via a separate inhaler to participants 
treated on a background of FF 100 mcg. No safety signal was identified with any  of 
the UMEC doses (15.6, 62.5, 125 and 250 mcg) evaluated in the 200699 study .
6. STUDY POPULA TION
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
6.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria 
apply :
AGE
1.Age: 18 years of age or older at the time of signing the informed consent.
TYPE OF PARTICI PANT AND DISEASE CHARACTERI STICS
2.Diagnosis: Participant s with a diagnosis of asthma as defined b y the National 
Institutes of Health [NIH, 2007] at least 6 months prior to Visit 0.
3.Asthma Control :ACQ -6total score of >0.75 at Visit 1 .
4.Current Asthma Maintenance Therapy : Participant s are eligible if they  have 
required daily  ICS therapy  100 mc g/day  fluticasone prop ionate (FP, or 
equivalent) with or without L ABA or LAMA for at least [ADDRESS_845689] been no changes in maintenance asthma medications d uring the 4 
weeks imm ediatel y prior to Visit 0.
Examples of acceptable doses of commonly  prescr ibed I CS medication will be 
provided in the Study  Reference Manual (SRM) .  Dosing regimen (once or twice 
daily  to equal the total daily  dose) should be restricted to the current local product  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
32labels.
5.Spi[INVESTIGATOR_038]: Both of the following:
a.A best pre -bronchodi lator morning (AM) FEV1 ≤85 % of the predicted 
normal value. Predicted values will be based upon the ERS Global L ung 
Function Initiative [ Quanjer , 2012].
b. A best post- bronchodilator FEV1/ forced vital c apacity (FVC ) ≥0.7 at 
Visit 1.
6.Reversibility of Disease: Airway  reversibility  is defined as ≥12% and ≥200 mL  
increase in FEV1 between 20 and 60 minutes following 4 inhalations of 
albuterol/salbutamol aerosol at Visit 1. 
Note: If the participant does not meet the above reversibility criteria at Visit 1 
then the reversibility assessment may be repeated once within 7 days of Visit 1 if 
either criteria a) or b) are met:
a) ≥9% increase in FEV1 betwee n 20 and 60 minutes following 4 
inhalations of albuterol/salbutamol aerosol at Visit 1.
b) Documented evidence of a reversibility assessment within [ADDRESS_845690] -
bronchodilator increase in FEV1 of 
≥12% and ≥[ADDRESS_845691] reversibility (defined as 
≥12% and ≥200 mL increase in FEV1 betwee n 20 and 60 minutes following 4 
inhalations of albuterol/salbutamol aerosol) at the second attempt then, provided 
that all other eligibility criteria assessed at Visit 1 are met, the participant may 
enter the 2- week run- inperiod (seeSection 9.1.3 ).
7.Short -Acting β2 Agonists (SABAs): All subjects must be able to replace their 
current SABA inhaler with albuterol/salbutamol aerosol inhaler at Visit [ADDRESS_845692] be judged capable of 
withholding albuterol/salbuta mol for at least 6 hours prior to study  visits.
SEX
8.Gender:
a.Male participants
b.Female participants: 
A female participant is eligible to participate if she is not pregnant (see Appendix 5),
not breastfeeding, and at least one of t he following conditions applies:
Not a woman of childbearing potential (WOCBP) as defined in Appendix 5
OR
A WOCBP who agrees to follow the contraceptive guidance in Appendix [ADDRESS_845693] dose of study   2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
33treatment.
INFORMED CONSENT
9.Informed Consent: Able to give written informed consent prior to participation 
in the study , which will include the ability  to comply  with the requirements and 
restricti ons list ed in the consent form and in this protocol.  Participant s must be 
able to read, comprehend, and write at a level sufficient to complete study  related 
materials.
6.2. Exclusion Criteria
Participant s are excluded from the study  if any  of the following criteria apply :
MEDICAL CONDITIONS
1.Pneumonia :Chest X -ray documented pneumonia in the 12 weeks prior to Visit 1 .
2.Asthma Exacerbation: Any severe asthma exacerbation, defined as deterioration of 
asthma requiring the use of systemic corticosteroids (oral, parentera l or depot) within 
12 weeks of Visit 1, or an inpatient hospi[INVESTIGATOR_633341] 12 weeks of Visit 1.
3.Concurrent Respi[INVESTIGATOR_31753]: Current evidence of pneumonia, pneumothor ax, 
atelectasis, pulmonary  fibrotic disease, bronchopulmonary  dysplasia, chronic 
bronchitis, emphy sema, chronic obstructive pulmonary  disease, lung cancer, or other 
respi[INVESTIGATOR_633342].
4.Pregnancy: Women who are pregnant or lactating or are planning on becoming 
pregnant during the study.
5. Risk Factors for Pneumonia : Immune suppression (e.g., HIV, Lupus) or other 
risk factors for pneumonia (e.g., neurological disorders affecting control of the upper 
airway , such as Parkinson’s Disease, Myasthenia Gravis) . Patients at potentially  high 
risk (e.g., very low BMI, severel y malnourished, or very  low FEV 1) will only  be 
included at the discretion of the Investigator .
6.Other diseases/abnormalities : Participant s with historical or current evidence of 
clinically  significant cardiovascular, neurological, psy chiatric, renal, hepatic, 
immunological, gastrointestinal, urogenital, nervous sy stem, musculoskeletal, skin, 
sensory , endocrine (including uncontrolled diabetes or thy
roid disease) or 
hematologica l abnormalities that are uncontrolled .  Significant is defined as any  
disease that, in the opi[INVESTIGATOR_689], would put the safet y of the participant
at risk through participation, or which would affect the efficacy  or safet y analysis if 
the dise ase/condition exacerbated during the stud y.
7.Unstable liver disease as defined b y the presence of ascites, encephalopathy, 
coagulopath y, hypoalbuminaemia, esophageal or gastric varices or persistent 
jaundice, cirrhosis, known biliary  abnormalities (with the exception of Gilbert’s 
syndrome or as ymptomatic gallstones).  Note: Chronic stable hepatitis B and C are 
acceptable if the participant otherwise meets entry criteria 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
348.Clinically significant ECG abnormality: Evidence of a clinicall y significant 
abnormality  in the 12-lead ECG performed during screening or run- in. The PI  [INVESTIGATOR_633343] ’s medical history  and exclude participant
s who would be at undue risk by  
[CONTACT_7624] t he trial. An abnormal and clinically  significant finding is defined as a 
12-lead tracing that is interpreted as, but not limited to, any of the following:
AF with r apid ventricular rate >120 beats per minute (BPM)
sustained or nonsustained ventricular tach ycardia (VT)
Second degree heart block Mobitz ty pe II and third degree heart block (unless 
pacemaker or defibrillator had been inserted)
QTcF ≥500 msec in patients with QRS <120 msec and QTcF ≥530 msec in 
patients with QRS 
≥120 msec
9.Unstable or life threatening cardiac disease: participant s with any  of the following 
at Screening (Visit 1) would be excluded:
Myocardial infarction or unstable angina in the last 6 months 
Unstable or life threatening cardiac arrh ythmia requiring intervention in the last 
3 months
[LOCATION_001] Heart Association (NYHA) Class IV Heart failure
10.Antimuscarinic effects: Participant s with a medical condition such as narrow -angle 
glaucoma, urinary  retention, prostatic hy pertrophy or bladder neck obstruction should 
only be included if in the opi[INVESTIGATOR_2511] I nvestigator the benefit outweighs the risk 
and that the condition would not contraindicate study  participation.
11.Cancer : Participant s with carcinoma that has not been in complete remission for at 
least [ADDRESS_845694] had carcinoma in situ of the cervix, squamous 
cell carcinoma and basal cell carcinoma of the skin would not be excluded based on 
the 5 year waiting period if the participant has been considered cured b y treatment.
12.Questionable validity of consent : Participant s with a history  of ps ychiatric disease, 
intellectual deficiency , poor motivation or other conditions that will limit the validity  
of informed consent to participate in the study .
PRIOR/CONCOMITANT THERAPY
13.Medication prior to spi[INVESTIGATOR_038] : Participant s who are medically  unable to withhold 
their albuterol/salbutamol for the 6- hour period required prior to spi[INVESTIGATOR_417426] y visit.
PRIOR/CONCURRENT CLI NICAL STUDY EXPERIEN CE/RELEVANT 
HABITS
14.Tobacco Use: Current smoker or a smoking history  of ≥10 pack years (e.g., 
20cigarettes/day  for 10 years).  A participant may not have used inhaled tobacco 
products within the past 12 months (i.e., cigarettes, e-cigarettes/vapi[INVESTIGATOR_007], cigars or pi[INVESTIGATOR_5836]  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
35tobacco).
15.Drug/alcohol abuse : Participant s with a known or suspected history  of alcohol or 
drug abuse within the last 2 y ears. This includes marijuana, which is considered an 
abused drug.
Diagnostic assessments
16.Allergy or Hypersensitivity : A history  of allergy or hy persensiti vity to any  
corticosteroid, anticholinergic/muscarinic receptor antagonist, beta2 -agonist, 
lactose/milk protein or magnesium stearate.
Other Exclusions
17.Non-compliance : Participant s at risk of non- compliance, or unable to comply  with 
the study  procedures.  Any  infirmit y, disability, or geographic location that would 
limit compliance for scheduled visits.
18.Affiliation with investigator site : Study  investigators, sub- investigators, study  
coordinators, emplo yees of a participating investigator or study  site, or immediate 
family  members of the aforementioned that is involved with this study .
19. Inability to read: In the opi[INVESTIGATOR_2511] I nvestigator, any  participant who is unable to 
read and/or would not be able to complete stud y related materials.
6.2.1. Randomization Criteria
At the end of the run -inperiod (Visit 2) , study  participants must fulfil the following 
additional criteria in order to be randomized into the study  and enter the treatment period :
6.2.2. Inclusion Criteria for Randomization
TYPE OF PARTICI PANT AND DIAGNOSI S INCL UDING DI SEASE SEVERI TY
1.Asthma Control : ACQ -6 total score of >0.75 at Visit 2.
2.Percent -predicted FEV 1: Spi[INVESTIGATOR_038] : A best pre -bronchodilator morning (AM) 
FEV1 ≤85% of the predicted normal value at Visit 2.Predicted values will be based 
upon the ERS Global L ung Function Initiative [ Quanjer 2012].
CONCURRENT CONDITIONS/MEDICAL HISTORY
3. Liver function tests at Visit 1:
alanine aminotransf erase (ALT) ≤2 x upper limit of normal (ULN)
alkaline phosphatase  ≤1.[ADDRESS_845695]
bilirubin ≤1.5 x UL N (isolated bilirubin >1.[ADDRESS_845696] bilirubin <35%)
eDIARY
4.Compliance with completion of the Dail y eDiary reporting defined as completion of 
all questions/assessments on [ADDRESS_845697] 7 day s during the run- in period. 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
366.2.3. Exclusion Criteria for Randomization
CONCURRENT CONDITIONS/MEDI CAL  HISTORY
1.Respi[INVESTIGATOR_60623]: Occurrence of a culture -documented or suspec ted bacterial or 
viral infection of the upper or lower respi[INVESTIGATOR_53121], sinus or middle ear during the 
run-in period that led to a change in asthma management or, in the opi[INVESTIGATOR_684] , is expected to affect the participant ’s asthma status o r the participant ’s 
ability  to participate in the study .
2.Asthma exacerbation: Evidence of a moderate asthma exacerbation leading to a 
change in therap y or severe exacerbation during screening or the run-inperiod , 
defined as deterioration of asthma requiring the use of s ystemic corticosteroids 
(tablets, suspension, or injection) or an in -patient hospi[INVESTIGATOR_633344] s ystemic corticosteroids.
CONCOMITANT MEDICATIONS/TREATMENTS
3.Asthma medication: Changes in asthma medication (excluding changes after Visit 0 
or run -in medication and albuterol/salbutamol inhalation aerosol provided at Visit 1).
DIAGNOSTIC ASSESSMENTS AND OTHER CRITERIA
4.Laboratory test abnormalities: Evidence of clinically  significant abnor mal 
laboratory  tests during screening or run -in which are still abnormal upon repeat 
analysis and are not believed to be due to disease(s) present.  Each Investigator will 
use his/her own discretion in determining the clinical significance of the abnormality .
6.3. Lifest yle Restrictions
No lifesty le restrictions are required for this study .
6.4. Pre-Screening/ Screening/Run -in/Randomization Failures
A participant will be assigned a participant number at the time the informed consent is 
signed at Visit 0.
The study  site will be responsible for reporting pre -screen failures. The following 
information will be collected in the eCRF for participants who are pre -screen failures:
Demographic information including race, age and gender
Participant number
Serious Adverse Event information only for any  SAE considered as related to 
study  participation
Investigator signature [CONTACT_633407] ,pre-screening failures, screening failures, run-in failures
and randomization failures
will be defined as follows:
Pre-screening failures: those participant s that sign the informed consent 
document but do not have a Visit 1 (Screening) procedure. 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
37Screening failures: those participant s that complete at least one Visit 1 
(Screening) procedure but do not enter the run -in period.
A participant who completes Visit [ADDRESS_845698] entered the run- in period.
Run-in failures: those participant s that enter the run -in period but do not have 
any Visit 2 (Ran domization) procedures .
Randomization failures: those participants that complete at least one Visit 2 
(Randomization) procedure but do not enter the double- blind study  treatment 
period.
Any participant who completes the run -in period and then meets the 
randomization criteria and is dispensed the double -blind study  treatment at Visit 
[ADDRESS_845699] entered the treatment period.
RAMOS NG will be contact[CONTACT_633384]. 
In order to ensure transparent reporting of screen /run-infailure participant s, meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements, and 
respond to queries from Regulatory  authorities, a minimal set of screen /run-
in/randomization failure information is required including demography , screen/run-
in/randomization failure details, eligibility  criteri a, and an y SAE s(see Section 9.2.4 and 
Appendix 4 ).Further details are provided in the study -specific eCRF completion 
guidelines document .
7. TREATMENTS
Study  treatment is defined as any  investigational treatment(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according 
to the study  protocol. 
The term ‘study  treatment’ within this trial is us ed to describe the 
combination of products received by [CONTACT_97246]. Study 
treatment may  also be used to only reference the randomized study  treatment when 
described together with the FF 100 mcg open -label treatment.
7.1. Treatments Administered
7.1.1. Description of FF 100 mcg and Double -Blind Study Treatment
The ELLIPTA device will be used during the run-in period and the treatment period .  The 
ELLIPTA dry  powder inhaler (DPI)is a molded plastic two- sided device with a dose 
counter that can hold two individual blister strips.  The ELLIPTA will deliver, when 
actuated, the contents of a single blister simultaneously  from each of the two strips. The 
ELLIPTA is individually sealed in a foil laminate overwrap that also contains a silica gel 
desiccant packet.
A description of the FF (GW685698) 100 mcg inhalation powder administered via the 
ELLIPTA is provided in Table 
1; descriptions of the double -blind study  treatments 
administered via the ELLIPTA are provided in Table 2. 2018N371775_00
2016N289466_01 CONFIDENTIA L
[ADDRESS_845700] Strip Second Strip
GW685698 blended w ith 
lactose monohydrateLactose monohydrate with magnesium 
stearate1
Dosage Form ELLIPTA DPI w ith 30 doses (2 strips w ith 30 blisters)
Unit Dose strengths 100 mcg per blister Not applicable
Physical description White pow der White pow der
Route of 
AdministrationInhaled
1. Magnesium stearate 1.0% w/w of total drug product.
Table 2 Description of Study  Treatment Inhalation Powder in ELLIPTA
7.1.2. Description of Albuterol/Salbutamol
Albuterol/salbutamol via metered -dose inhaler (MDI) will be issued for reversibility  
testing at Visit 1.  An albuterol/salbutamol MDI  for as 
needed (prn) use throughout the 
study  will be provided starting at Visit 1; at the I nvestigator’s discretion, more than one  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
39MDI  may  be provided at any  one time. Albuterol/salbutamol will be sourced from local 
commercial stock.  If not available locall y, GS K will source centrally .The contents of the 
label will be in accordance with all applicable regulatory  requirements.
7.1.3. Study Treatment and FF 100 mcg Return
ELLIPTAs containing FF 100 mcg and stud y treatment will be dispensed to a participant 
during their visit to the study  clinic (as applicable). The participant must return all 
dispensed ELLIPTAs at the subsequent clinic visit. The schedule for dispensing and 
collecting FF 100 mcg and study  treatment ELLIPTAs is provided in the Schedule of 
Activities table (Section 2).
All used and unused study  treatment, FF 100 mcg and albuterol/salbutamol 
will be 
returned to [COMPANY_004] at the end of the study  to be available for disposal.  In some instances 
for sites outside the US, study  supplies wil l be disposed of locall y either b y the site, the 
country  medical department or third -party vendor.  Detailed instructions for the return of 
the study  drug can be found in the Study  Reference Manual ( SRM ).
If any ELLIPTA fails to function properl y, the participant should return to the clinic as 
soon as possible to obtain a new inhaler.  The site will use the I WRS (RAMOS NG) to 
obtain a new treatment pack number for the participant and dispense a new study  
treatment kit from the site’s study  treatment supply  as instructed by  [CONTACT_941] I WRS.
In addition, any  metered dose inhaler (MDI ) that fails to function properl y must be 
identified and returned to [COMPANY_004] for testing.  Details of the failure will be documented in 
the eCRF.
7.2. Dose Modification
There were no dose modifica tions planned for this protocol.
7.3. Method of Treatment A ssignment
Participant s will be assigned to study  treatment in accordance with the randomization 
schedule. The randomization code will be generated by  [CONTACT_417506] a validated 
computerized sy stem . Participa nt s will be randomized using an interactive web response 
system (I WRS) RAMOS NG. The stud y will use central -based randomization to allocate 
treatments. Once a randomization number is assigned to a participant it cannot be 
reassigned to an y other participan tin the study .
Following the 2 -week run -inperiod and participant to satisfy ing all eligibility  criteria, 
participant s willbe randomized 1:1:1 to one of the followi ng three double -blind 
treatments for the duration of the treatment period : 
UMEC 62.5 mcg QD
UMEC 31.25 mcg QD
Placebo QD 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
40The duration of double -blind treatment for each participant is 24 weeks. O n the morning 
of each scheduled clinic study visit, participant s will refrain from taking their morning 
dose of study  treatment and FF 100 mcg 
until i nstructed to do so by  [CONTACT_6477]. 
Study  treatment will be taken at the clinic at approximately  the s ame time of day  as taken 
at the Randomization Visit (Visit 2 ). On the other day s during the treatment period (i.e. 
“non -clinic days”), participants wi ll be instructed to take their study  treatment each 
morning at approximately  the same time. Each Investigator will be provided with 
sufficient supplies to conduct the trial. Additional treatment packs will be supplied as 
needed to the sites. Details of how to use the I WRS sy stem (RAMOS NG) to randomize 
participant s and manage study  treatment supplies (including dispensing) is prov ided in 
the RAMOS NG I WRS manual and SR M.
7.4. Blinding
This will be a double
-blind study  and the following will appl y. 
The Investiga toror treating phy sician may  unblind a participant ’s treatment 
assignment only in the case of an emergency OR in the event of a serious 
medical condition when knowledge of the stud y treatment is essential for the 
appropriate clinical management or welfare of the participant as judged b y the 
Investigator . 
Investigator s have direct access to the participant ’s individual study  treatment. 
It is preferred (but not required) that the Investigator first contacts the Medical 
Monitor or appropriate [COMPANY_004] study  pers onnel to discuss options before unblinding 
the participant ’s treatment assignment. 
If [COMPANY_004] personnel are not contact[CONTACT_222201], the Investigator must 
notify [COMPANY_004] within 24 hours after unblinding, but without revealing the treatment 
assignment of the unblinded participant , unless that information is important for 
the safet y of participant s currentl y in the stud y. 
The date and event or condit ion which led to the unblinding (i.e. the primary 
reason) will be recorded in source documentation and in the eCRF. 
Should a participant’s treatment assignment be unblinded then the participant may  
continue the assigned study  treatment and be followed- up as per protocol until the 
completion of the Safet y Follow -up assessments .
[COMPANY_004]’s Global Clinical Safet y and Pharmacovigilance (GCSP) staff may  unblind the 
treatment assignment for any  participant with an SAE. If the SAE requires that an 
expedited regulatory  report be sent to one or more regulatory  agencies, a copy  of the 
report, identify ing the participant ’s treatment assignment, may  be sent to Investigator s in 
accordance with local regulations and/or [COMPANY_004] policy
.Participants will not be withdrawn 
from the study .
7.5. Packaging and Labeling
The contents of the label will be in accordance with all applicable regulato ry 
requirements. 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
417.6. Preparation/Handling/Storage/A ccountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  treatment received and any  discrepancies 
are reported and resolved b efore use of the stud y treatment.
2.Only  participants enrolled in the study  may  receive study  treatment and only  
authorized site staff may  supply  or administer study  treatment. All study  treatments 
must be stored in a secure, environmentall y controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized site staff.
3.The investigator, institution, or the head of the medical institution (where applicable) 
is responsibl e for stud y treatment accountability, reconciliation, and record 
maintenance (i .e., receipt, reconciliation, and final disposition records).
4.Further guidance and information for the final disposition of unused study  treatment 
are provided in the SRM.
Under normal conditions of handling and administration, study  treatment is not 
expected to pose significant safet
y risks to site staff .  Take adequate precautions to 
avoid direct ey e or skin contact [CONTACT_23968]. In the case of 
uninte ntional occupational exposure notify  the monitor, Medical Monitor and/or 
[COMPANY_004] study  contact.
A Material Safety  Data Sheet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investig ator, where this is required b y local laws, or is available upon request from 
[COMPANY_004].
7.7. Treatment Compliance
When participant sare dosed at the site, they  will receive FF 100 mcg and study  treatment 
under medical supervision.  The date and time of each dose adm inistered in the clinic will 
be recorded in the eCRF .  The dose of study  treatment and study  participant identification 
will be confirmed at the time of dosing b y a member of the stud y site staff.  
When participant s self
-administer study  treatment(s) at home , compliance with study  
treatment will be assessed through query ing the participant during the site visits and 
recording the number of doses remaining in the ELLIPTA in the eCRF (see the SRM for 
details) .  A record of the number of ELLIPTAs 
dispensed to each participant must be 
maintained and reconciled with study  treatment and compliance records. 
Participant compliance with FF 100 mcg and study  treatment will be assessed at 
scheduled clinic visits by [CONTACT_633397] c ounter on 
the returned inhaler (s) (see Section 7.1.3).  Participant s should be  80% to 120% 
compliant on taking both FF 100 mcg and study  treatment between each pair of 
scheduled and consecutive on- treatment clinic visits , as applicable . Participant s who fall 
outside this range should be re -educated on treatment compliance b y their site. This re -
education should be documented in the participant’s source document. If FF 100 mcg 
and/or study  treatment isprematurel y discontinued during the course of the study  or  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
42compliance repeatedly falls outside of acceptable ranges, the study  sponsor/site monitor 
must be contact[CONTACT_633398] .
7.8. Concomitant Therapy
All asthma medicat ions used within approximately 6 weeks prior to screening and during 
the study  (including the post -treatment period) should be recorded in the eCRF.
All non- asthma medications taken during the study (after randomization including post -
treatment) and an y changes to concomitant medications will be recorded in the eCRF. 
Note: Study provided FF 100 mcg and albuterol/salbutamol should not be recorded in 
the eCRF; however non -study supplied FF 100 mcg and albuterol/salbutamol will be 
recorded in the eCRF.
The mi nimum requirement is that the drug name, reason for use, dose (including unit e.g. 
mcg) and frequency , route and the dates of administration are to be recorded.
Medications initiated after completion of the assessments at Visit 5/EOS or the Earl y 
Withdrawa l Visit will not be recorded in the eCRF unless taken to treat an AE or asthma 
exacerbation. Detailed information of permitted and prohibited medications is included in 
the SRM for y our reference.   Participant s who have completed the Early Withdrawal 
Visit are allowed to use any  medications prescribed by  [CONTACT_633387].
7.8.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014]
[IP_ADDRESS]. Permitted A sthma Medications
In addition to FF 100 mcg and stud y treatment, t he following medications are permitted 
during this study :
Study -provided albuterol/salbutamol will be dispensed at Visit [ADDRESS_845701] be judged 
capable of withholding albuterol/salbutamol for at least 6 hours prior to stud y 
visits.
Temporary  changes in medications are permitted for the treatment of moderate asthma 
exacerbations, at the Investigator’s/treating ph ysician’s discretion. Asthma exacerbations 
should be treated in line with national and international recommendatio ns and local 
medical standards. Asthma medications permitted on a temporary  basis to treat a 
moderate asthma exacerbation include but are not limited to the following (the Medical 
Monitor may  be contact[CONTACT_245939]; see the SRM for contact [CONTACT_3031]
[refer to S ection [IP_ADDRESS] for guidance on moderate asthma exacerbation] ):
An increase in ICS dose.
Systemic corticosteroids (tablets, suspension or injection) for no more than 2 
days. 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
43An Investigator -advised change in SABA use (i.e., routinely  scheduled versus 
as needed use).
Leukotriene receptor antagonists (LTRAs) and leukotriene modifiers.
Oral theoph ylline.
[IP_ADDRESS]. Permitted Non-Asthma Medications
The following medications are permitted during this study :
Medications for rhinitis (e.g., intranasal corticosteroids, antihistamines [including 
ocular and intranasal], cromoly n, nedocromil, nasal decongestants)
Note: Use of these medications should be captured on the concomitant medication 
pages of the eCRF prior to ECG measurements.
Antibiotics for short term treatment of acute infections. L ong term treatment with 
topi[INVESTIGATOR_417436].
Decongestants :Participant s may  take decongestants during the study ,but these 
are disallowed for 24 h ours prior to ECG measurements.
Immunotherap y: Immunotherap y for the treatment of allergies is allowed during 
the study  provided it was initiated 4 weeks prior to Visit 1 and participant s remain 
in the maintenance phase for the duration of the study .
Topic al and ophthalmic corticosteroids .
Systemic and ophthalmic beta -blockers: Administer with caution as s ystemic 
beta-blockers block the pulmonary  effect of beta- agonists and may  produce severe 
bronchospasm in patients with reversible obstructive airway s dise ase. 
Cardioselective beta -blockers should be considered, although they  also should be 
administered with caution.
Localized corticosteroid injections (e.g. intra -articular and epi[INVESTIGATOR_13873]).
Tricy clic antidepressants and monoamine oxidase inhibitors (MAOI s). 
(Administer with extreme caution as they  may  potentiate the effects of beta -
agonists on the cardiovascular s ystem, including QTc prolongation)
Diuretics.  (Caution is advised in the co- administration of beta -agonists with non-
potassium sparing diuretics as this may  result in ECG changes and/or 
hypokalemia )
Cytochrome P450 3A4 ( CYP3A4) inhibitors (Caution should be exercised when 
considering the coadministration of long- term ketoconazole and other known 
strong CYP3A4 inhibitors (e.g., ritonavir, clarithromy cin, conivaptan, indinavir, 
itraconazole, lopi[INVESTIGATOR_054], nefazodone, nelfinavir, saquinavir, telithromy cin, 
troleandomycin, voriconazole) because increased sy stemic corticosteroid and 
increased cardiovascular adverse effects may  occur )
Vaccinations (Influenza va ccine, Pneumonia vaccine, Shingles vaccine, etc.) 
(Administration of influenza and pneumonia vaccines should be considered based 
on clinical discretion of the Investigator and local/national guidelines. Current  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
44influenza vaccines and pneumonia vaccines will be captured on the concomitant 
medication pages of the eCRF )
All medications for other disorders may  be continued throughout the study  provided their
use would not be expected to affect the participant s’ lung function or safety assessments
(e.g., cardiac measurements). However , no sy stemic corti costeroids will be permitted.
7.9. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_417438] 3 isnot permitted during the study .
Table 3 Conc omitant Medications
Medication No use during the study and/or within the 
following time interval before V isit 1
Inhaled short -acting anticholinergics 6 hours
Inhaled short -acting anticholinergics+ Short -
acting beta agonist combination6 hours
Inhaled lo ng-acting anticholinergics other than 
study treatment2days
Immunosuppressive medications
including immunomodulators12 weeks
Inhaled long -acting beta 2-agonists (e.g., 
salmeterol, formoterol) or combination products 
containing inhaled long -acting beta 2-agonists 
(e.g., Seretide, Symbicort)
Inhaled very long -acting beta2 -agonists, 
(Indacaterol, Olodaterol)
Oral long -acting beta 2-agonists (e.g., 
bambuterol) [ADDRESS_845702] (rescue 
albuterol/salbutamol will be provided and is 
permitted during the study)6hours (including all study visits)
Theophyllines, slow-release
bronchodilators, ketotifen, nedocromil sodium,
sodium cromoglycate, roflumilast48 hours Tempor ary use will be permitted 
during the study to treat moderate asthma 
exacerbations
Anti-leukotrienes 48 hours. Temporary use will be permitted 
during the study to treat moderate asthma 
exacerbations
Any other investigational drug 30 days or within 5 drug half-lives of the 
investigational drug (whichever is longer)
7.10. Treatment after the End of the Study
Participant s will not receive an y additional treatment from [COMPANY_004] after completion of the 
study  because other treatment options are available . 2018N371775_00
2016N289466_01 CONFIDENTIA L
[ADDRESS_845703]-
study  care of the participant ’s medical condition, whether or not [COMPANY_004] is providing 
specific post -study  treatment.
8. DISCONTINUA TION CRIT ERIA
8.1. Discontinuation of Study  Treatment
Partic ipants that permanently stop study treatment are encouraged to remain in the 
study .  Participant s have the right to discontinue study  treatment before the end of the 
study .  A participant may also be asked to discontinue study  treatment at the 
Investigator ’s discretion.
Participant s who withdraw from study  treatment prematurel y (for an y reason) should, 
where possible, continue to be followed -up as per protocol until the completion of the 
Safety  Follow -up assessments .If this is not possible, the Investigato r must encourage the 
participant to participate in as much of the study  as they  are willing (or able) to.
A participant may be withdrawn from study  treatment at any  time. A reason for 
premature discontinuation of study  treatment (e.g., AE, lack of efficacy [including 
moderate or severe asthma exacerbation] , protocol deviation, Investigator discretion, 
consent withdrawn etc.) must be captured in the eCRF.
A participant must be withdrawn from study  treatment if any  of the following stoppi[INVESTIGATOR_118048]: 
Liver Chemistry : Meets any  of the protocol- defined liver chemistry  stoppi[INVESTIGATOR_3418] 
QTc: Meets an y of the protocol -defined stoppi[INVESTIGATOR_3418] 
Pregnancy : Positive pregnancy  test
8.1.1. Liver Chemistry Stoppi[INVESTIGATOR_633361] (in alignment with the FDA 
premarketing clinical liver safety  guidance). These protocol guidelines are in alignment 
with FDA premarketing clinical liver safe ty guidance: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf.
Discontinuation of study  treatment for abnormal liver tests should be considered by  [CONTACT_32845] a participant meets one of the conditions outlined in the algorithm or if 
the investigator believes that it is in the best interest of the participant. 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
46Phase II Liver Chemistry Stoppi[INVESTIGATOR_288590] t 
Discontinue  Study  Treatmen t Plus
Bilirubin≥2x
ULN (>35% 
direct) 
or plus
INR>1.5 , if 
measur ed*
Possi ble
Hy’s LawALT≥3xULNALT≥5xULNALT≥3xULN
Plus
Sympt oms of 
liver injury
or 
hyper sensitivityALT≥3xULN
but able to 
monitor 
week ly for 
4 week sNo
Yes
YesYes YesNo No No
NoYes
ALT≥3xULN
persist for
4 week s or 
stoppi[INVESTIGATOR_278786]
*INR value not applicable to subjects on  anticoagu lantsYesIf subj ect to be moni tored weekl y must refer to Liver Safety Requi red  Actions and  Follow  up 
Assessme nts  section  in  the  Appendi x
Must refer to Liver Safety Requi red Actions and Follow  up Assess ments section in the Appendi x
Repor t as an SAE if possible Hy’s Law case:  ALT≥3xUL N and  Bilirubin≥2x ULN (>35% direct)  or 
INR>1.5 , if measured*
Liver Safet y Required Actions a nd Follow up Assessments can be found in Appendix 7
8.1.2. QTc Stoppi[INVESTIGATOR_633362] 9.4.3.
The same QT correction formula 
must be used for each individual participant to 
determine eligibilit y for and discontinuation from the study.  This formula may 
not be changed or substituted once the participant has been enrolled.
For example, if a participant is eligible for the protocol based on QTcB (QT 
interval corrected for heart rate b y Bazett’s for mula ), then QTcB must be used 
for discontinuation of this individual participant as well.
Once the QT correction formula has been chosen for a participant ’s eligibility , 
the same formula must continue to be used for that participant for all QTc data 
being 
collected for data analysis. Safety ECGs and other non- protocol specified 
ECGs are an exception.  
The QTc should be based on averaged QTc values of triplicate electrocardiograms 
obtained over a brief (e.g., 5- 10 minute) recording period.
For this study , the following QTc stoppi[INVESTIGATOR_31764] , lead to withdrawal 
from study  treatment :
QTc>500 msec or uncorrected QT>600 msec 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
47Change from baseline: QTc> 60 msec
For patients with underl ying bundle branch block, follow the discontinuation criteria 
listed below:
Baseline QTc with Bundle Branch Block <450 msec , Discontinuation QTc with 
Bundle Branch Block >500 msec
Baseline QTc with Bundle Branch Block <450 -480  msec , Discontinuation QTc 
with Bundle Branch Block ≥530 msec
8.1.3. Rechallenge
[IP_ADDRESS]. Study  Treatment Restart or Rechallenge
Study  treatment restart or rechallenge after liver chemistry  stoppi[INVESTIGATOR_496917].
8.2. Withdrawal from the Study
A participant may  withdraw from the study  at an y time at his/her own request, 
or may  be withdrawn at any  time at the discretion of the investigator for safety , 
behavioral, compliance or administrative reasons.
If the participant withdraws consent for disclosure of future information, the 
sponsor may
 retain and continue to use any  data collected before such a 
withdrawal of consent.
If a participant withdraws from the study , he/she may  request destruction of any  
samples taken and not tested, and the investigator must document this in the site 
study  records.
In the event of earl y withdra wal from the study , every  effort should be made to 
have the participant to return to the clinic for an Early  Withdrawal Visit and 
Safety  Follow -up,and to return all study  related materials. Assessments to be 
performed during the Early  Withdrawal Visit andthe Safet y Follow -up contact 
[CONTACT_633388] (Section 2).
8.3. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and 
is unable to be contact[INVESTIGATOR_530] b y the study  site. 
The following actions must be taken if a participant fails to return to the clinic for a 
required stud y visit:
The site must attempt to contact [CONTACT_43207]/or should continue in the study .
Before a participant is deemed lost to follow up, the investigator or des ignee 
must make every  effort to regain contact [CONTACT_6635] (where possible, 3  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
48telephone calls and, if necessary , a certified letter to the participant’s last known 
mailing address or local equivalent methods). These contact [CONTACT_633399]’s medical record.
Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study  with a primary  reason of lost to follow -up. 
9. STUDY A SSESSMENTS A ND PROCEDURES
Study  procedures and the ir timing are summarized in the Schedule of Activities ( SoA) 
(Section 2). There are no protocol waivers or exemptions allowed. Immediate safet y 
concerns should be discussed with the sponsor immediately  upon occurrence or 
awaren ess to determine if the participant should continue or discontinue study  treatment.
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study conduct.
No study related procedures may be performed until the informed consent form has 
been signed by [CONTACT_2299] .  A Pre- S creening visit (Visit 0) is required in order to 
administer the informed consent before an y changes are made to the participant ’s current 
medical regimen.  Selection and modificati on of the participant ’s medications prior to 
study  participation is based on the phy sician’s judgment according to sound medical 
practice, principles, and each participant ’s needs.  A participant ’s treatment must not be 
changed merel y for the purpose of en abling the participant’s participation in the stu dy.
During the P re-Screening visit (V isit 0) the following information will be captured in the 
eCRF for each participant : 
Demographic information including race, age and gender
Participant number
Serious Ad verse Event information only for any  SAE considered as related to 
study  participation
Investigator signature [CONTACT_633408] 
(Visit 1):
Weight and height
A
sthma diagnosis histor y including:
The age of the participant when they  were first provided with an inhaler for 
asthma
Completion of an asthma medical history  questionnaire: a cop y of this 
questionnaire and instructions for its use can be found in the SRM
Smoking history and status
Exacerbation history
Asthma and other concurrent medications 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
49Medical History  including previous and/or concurrent medical conditions, 
detailed cardiovascular risk factor history , pneumonia, and pneumonia vaccine 
status
Reason for screen failure (if applic able)
Vital signs
Questionnaires (ACQ;; E -RS)
Pre-and post -albuterol/salbutam ol lung function
Inclusion/Exclusion criteria assessment
Physical examination
12-lead ECG
Child bearing status assessment for all potential female participants
Clinical laboratory
tests (including hematology , chemistry , urinal ysis and serum 
pregnancy  test)
AE/ SAE assessment
Inaddition the following procedures must be completed at Screening ( Visit 1):
Electronic device training / dispense eDiary
Review/dispense Medical Problems/M
edication Taken worksheet
Dispense F F 100 mcg run-in medication
9.1. Efficacy  Assessments
The timings of all efficacy  assessments are specified in the Schedule of Activities ( SoA)
(Section 2).
9.1.1. Questionnaires
The questionnaires shoul d be completed before any  procedures are performed on the 
participant to avoid influencing the participant ’s response. To avoid biasing responses, 
the 
participant s should not be told the results of diagnostic tests prior to com pleting the 
questionnaires an d it is recommended that the questionnaires be administered at the same 
time of day  during each visit (as applicable) using the provided electronic device (unless 
otherwise specified) .  Adequate time must be allowed to complete all items on the 
questionnai res; the questionnaires must be reviewed for completeness and, if necessary , 
the participant must be encouraged to complete any  missing assessments or items.
Instructions for completing the questionnaires can be found in the SRM.
[IP_ADDRESS]. Global A ssessment of Sever ity and Response to Treatment
The participant will be asked to complete the G lobal Assessment of S everity  and 
Response to Treatment at the visits specified in the Schedule of Activities table (Section 
2). The Global Assessment of Severity  is a single item questionnaire; participant s are  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
50asked to rate their asthma sy mptoms at the study  visit using a five -point scale (none, 
mild, moderate, severe, very  severe).  The Response to Treatment is a single question of 
the patient’s overa ll evaluation of response to treatment, using a seven -point rating scale 
with the following definitions: 1 = significantl y improved; 2 = moderatel y improved; 3 = 
mildly  improved; 4 = no change; 5 = mildl y worse; 6 = moderatel y worse; and 7 = 
significantl y worse. Instructions for completing the questionnaires can be found in the 
SRM.
[IP_ADDRESS]. Asthma Control Questionnaire (A CQ)
The ACQ measures attributes of asthma control [ Juniper 1999], measured with questions 
designed to be self -completed by [CONTACT_2299].  Participants will complete the ACQ at 
specified stud y visits. The ACQ -5 includes five questions (concerning nocturnal 
awakening, waking in the morning, activity  limitation, shortness of breath and wheeze) 
which enquire about the frequenc y and/or severit y of sy mptoms over the previous week. 
The ACQ -[ADDRESS_845704] of a zero (no impairment/limitation) to six 
(total impairment/ limitation) scale. The recall period is the past week. A score of <0.75 
indicates well -controlled asthma and a score 1.5 indicates poorl y controlled asthma 
[Junipe r2006].  A change of  0.5 in score suggests a clinically  important change in sc ore 
[Juniper 2005].
[IP_ADDRESS]. St. George’s Respi[INVESTIGATOR_633346] (SGRQ)
The SGRQ is a well established instrument, comprising [ADDRESS_845705], and activity . The questions are designed to be self -completed by  [CONTACT_2299]
[Jones 1992] with a recall over the past 3 months .  A change of 4 points is considered a 
clinically  relevant change [ Jones 2005].
[IP_ADDRESS]. Asthma Quality  of Life Questionnaire (A QLQ)
The AQLQ was developed to measure the functional impairments related to asthma 
experienced by [CONTACT_67022] 17+ years old.  The AQLQ (+12), is a modified version of the 
original AQLQ and validated for use in asthma patients between the ages of 12 and 70 
[Junipe r2005]. The response scale ranges from 1 (totally  impaired) to 7 (not at all 
impaired).  The questions are designed to be self -completed by  [CONTACT_477022] a 
recall over the past 2 weeks.  A change of 0.5 is considered clinicall y important [ Juniper
1994].
9.1.2. Daily  Diaries
Participant s will be issued with a combination spi[INVESTIGATOR_417458] 1 for 
twice dail y use (in the morning upon waking and in the evening just before going to bed)
throughout the stud y. The eDiary  device will be provided by a third- party vendor . 
Information on the device and its use are documented in the SRM and the third- party 
vendor manual . Participants will be instructed on how to use the device in order to record 
results for the following in the eDiary  each day from Visit 1 onwards : 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
51Daily symptom assessment (E -RS and supplemental asthma items; night -time 
awakening, asthma sy mptom and phy sical activity quest ions)
The n umber of inhalations of rescue albutero l/salbutamol used during the day and 
night.
Morning and evening FEV 1
Morning and Evening PEF
Morning FF 100 mcg medication use
Morning double -blind study  medication use (during the treatment period only )
Section 9.1.2 describes the assessments and questionnaires recorded on the eDiary  
device, as well as the alerts that can be triggered based on recorded results. The data from 
the eDiary  device will be automatically  transmitted t o a centralised server. 
Participants will also be issued with a paper Medical Problems/Medications Taken
worksheet to record medical problems experienced and medications used during the 
study (please refer to the SRM for further details) . Participants mus t also use this paper 
worksheet to record all healthcare contacts that occur during their participation in the 
study . This paper worksheet will be used to assist participant recall in discussions with 
the Investigator , for site staff to then enter as appro priate in the eCRF.
[IP_ADDRESS]. eDiary  Questionnaires, Assessments and A lerts
For information on the eDiary  questions, please refer to Appendix 8 .
[IP_ADDRESS].1. E-RS
The Evaluating Respi[INVESTIGATOR_244774] (E -RS) in COPD consists of 11 items from the 14 
item Exac erbations of COPD ( EXACT -PRO )instrument.  E -RS is intended to cap ture 
information related to respi[INVESTIGATOR_23908], i.e. breathlessness, cough, sputum 
production, chest congestion and chest tightness. The E -RS was developed for use in 
patients with COPD but symptom experience of patients with asthma may  be 
appropriatel y measured with the E -RS. The daily recording of information allows an 
assessment of the underlying day  to day  variability  of a patient's s ymptoms. The 
instrument is to be completed dail y each night prior to going to bed .  The 11 -items are 
scored on a 5 -point scale of “not at all” to “extreme”.  The E -RS has a scoring range of 0 -
40.
[IP_ADDRESS].2. Supplemental Asthma Items
To ensure that asthma s ymptoms are completel y evaluated, two additional questions will
be asked.  A question on wheeze, a symptom of importance in asthma will also be asked 
within the context of the daily  diary . An item on breathlessness activities will evaluate 
shortness of breath associated with strenuous activities.  Subject s will be ask ed to respond 
to the question ‘Did y ou wheeze today ?’ with response options of: Not at all, Rarely , 
Occasionall y, Frequently, Almost constantly.  Subjects will be asked to respond to the 
question “Were you short of breath today when performing strenuous ac tivities such  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
52climbing stairs, running, or participating in sports activity  with a response scale of not at 
all, slightly , moderatel y, severel y, extremely  or too breathless to do these.
[IP_ADDRESS].3. Night -time Awakening, Asthma Symptom and Physical Activity 
Questions
Every morning upon waking (from the morning after Visit 1 onwards ), participant s will 
answer a question on the occurrence of night- time awakenings due to asthma sy mptoms. 
The participant ’s response to the question on the occurrence of night- time awakenings 
will be either ‘Yes’ (i.e. Did y ou wake up due to asthma sy mptoms ( i.e. wheezing, 
coughing, shortness of breath, or chest tightness ) or ‘No’ (i.e. they  did not experience at 
least one night -time awakening due to asthma s ymptoms ). If ‘Yes’ ,participants wil l be 
asked to respond either ‘Yes’ or ‘No’ to the question on rescue medication (i.e. when you 
woke up due to your asthma symptoms did you use an y rescue bronchodilator?) .
On the evening of Visit 1 (just before going to bed) and every  evening there- after, 
participant s will answer a question on day time asthma sy mptoms and day time phy sical 
activity  limitation. These questions will be answered on a 5- point scale (0 to 4) with ‘0’ 
representing no daytime asthma s ymptoms/phy sical activity  limitations and ‘4’ 
representing very  severe day time asthma sy mptoms or total day time activity  limitation.
(Please describe the severity  of your asthma s ymptoms (i.e. cough, wheeze, chest 
tightness, shortness of breath) today  [0=no asthma sy mptoms, 1=mild asthma sy mptoms, 
2= moderate asthma s ymptoms, 3=severe asthma sy mptoms, 4= very  severe asthma 
symptoms ]. How limited were you in your a ctivities today  because of your asthma [ 0=not 
at all limited, 1=a little limited, 2=moderatel y limited, 3=severely limited, 4=totally 
limited ]).
[IP_ADDRESS].4. Morning and Evening Home Spi[INVESTIGATOR_417459]/eDiary  device will be issued to participant s at Visit 1 for 
daily  monitoring of their lung function (i.e. FEV 1and PEF) . The home Spi[INVESTIGATOR_14007]/eDiary  
device will be provided by a third -party vendor . Information on the device and its use 
are 
documented in the SRM an d the third- party vendor manual .Participant s will conduct 
spi[INVESTIGATOR_417460] , prior to study  treatment and FF 100 mcg dosing ,
and each evening. Three measurements foreach session will be recorded by  [CONTACT_2416] s in the eDiary. Assessments will be performed:
After completing all other eDiary  assessments
Prior to albuterol/salbutamol use
Prior to study  treatment and FF [ADDRESS_845706] of the assigned double- blind study  treatment.
[IP_ADDRESS].5. Alerts
For safet y the following alerts, indicative of worsening asthma, will be programmed into 
the eDiary with instructions for the participant to conta ct the investigator (either by  
[CONTACT_18623]/or b y visiting the stud y clinic) if any  of the alert criteria are met: 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
53Nocturnal awakening(s) due to asthma requiring albuterol/salbutamol use for 2 
consecutive nights.
An increase from baseline of ≥ 4 puffs /da y of albuterol/salbutamol use on 2 
consecutive day s.
A ≥30% decrease in AM PEF from baseline on 2 consecutive mornings.
A ≥30% decrease in PM PEF from baseline on 2 consecutive evenings
A ≥30% decrease in AM FEV1 from baseline on 2 consecutive mornings.
A ≥30% decrease in PM FEV1 from baseline on [ADDRESS_845707] 3 
acceptable spi[INVESTIGATOR_417445] (from a maximum of 8 attempts) should be achiev ed 
on each occasion that spi[INVESTIGATOR_417446], in accordance with the 
American Thoracic S ociety / European Respi[INVESTIGATOR_21584] y (ATS/ERS )standards [ Miller
2005]. The highest of 3 technicall y acceptable measurements will be recorded at each 
visit:
Pre-dose Spi[INVESTIGATOR_038]: At Visits 1through 5/EOS (and the Early  Withdrawal 
Visit, if applicable), participant s should withhold short -acting beta -2-agonists 
(SABAs) for [ADDRESS_845708] be performed:
oBetween 6am and 11am on the day  of the visit.
oAt the same time of day  (1 hour) as the assessment performed at Visit 2
(the baseline assessment).
oAt least 24 hours after the participant ’s last morning  dose of study  
treatment on the day  prior to the visit.
oBefore the 
participant ’s morning  dose of study  treatment on the day  of the 
visit.
Post-dose Spi[INVESTIGATOR_038]: At Visits 2 and 5/EOS (and the Earl y Withdrawal Visit, if 
applicable), spi[INVESTIGATOR_417447] 3 hours after the 
participant ’s morning  dose of study  treatment; the assessment performed at Visit 
5/EOS should be performed at the same time of day  (1 hour) as the assessment 
performed at Visit 
2 (the baseline assessment). At each visit, participant s should 
withhold short -acting beta -2-agonists (SABAs) between receiving their morning 
dose of study  treatment and completing the spi[INVESTIGATOR_44022], if possible.
Spi[INVESTIGATOR_417448]  a third -party vendor; the s ame 
third
-party vendor will also centrall y analyse the spi[INVESTIGATOR_417449] . Details 
on performing the spi[INVESTIGATOR_44022], including information on the equipment 
provided and its use as well as specific instructions on performing the spi[INVESTIGATOR_633363], are documented in the SRM and the third- party vendor manual. 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
[IP_ADDRESS]. Reversibility  (Albuterol/Salbutamol)
All reversibility evaluations should follow the recommendations of the AT S/ERS Task 
force: Standardization of Lung Function Testing [ Miller 2005]. A pre-bronchodilator
spi[INVESTIGATOR_417451] a washout period of at least [ADDRESS_845709] s.
To perform the reversibility  assessment, 4 puffs of the provided albuterol /salbutamol is 
administered (aspace r device may  be used, if required). F ollowing completion of the pre-
bronchodilator assessment, a second spi[INVESTIGATOR_417452] 20 to 60
minutes after a dministration of the albuterol /salbutamol.
Percent r eversibility  will be calculated as follows:
(Post -bronchodilator FEV 1–Pre-bronchodilator FEV 1) x [ADDRESS_845710] 
demonstrate a  12% and 200 mL  incre ase in FEV 1to be eligible for the study .If these 
reversibility  criteria are not met at Visit 1 then the participant may  not enter the 2- week 
run-in period; however, the reversibility  assessment may  be repeated once within 7 day s 
of Visit 1 if either crit eria a) or b) are met:
a)≥9% increase in FEV 1between 20 and 60 minutes following 4 inhalations of 
albuterol/salbutamol aerosol at Visit 1.
b)Documented evidence of a reversibility  assessment within [ADDRESS_845711] -bronchodilator increase in FEV 1 of≥12% and ≥[ADDRESS_845712]  reversibility  (defined as ≥12% 
and ≥200 mL  increase in FEV 1between 20 and 60 minutes following 4 inhalations of 
albuterol/salbutamol aerosol) at the second attempt then, provided th at all other eligibility  
criteria assessed at Visit 1 are met, the participant may  enter the 2- week run -in period.
9.1.4. Asthma Exacerbations
Moderate and s evere asthma exacerbation data will be collected from the start of 
randomized double blinded treatment until Visit 5/EOS Visit or the Early  Withdrawal 
Visit for tho
separticipants that withdraw from participation in the study  (see Section 
8.2). For consistency ,exacerbations separated b y less than 7 day s will be treated as a 
contin uation of the same exacerbation.
Participants will
complete a paper Medical Problems/Medications Taken worksheet to
record medical problems experienced and medications used during the study, as well as 
all emergency  department visits and/or hospi[INVESTIGATOR_059] s that occur during their
participation in the study . This paper worksheet must be reviewed by  [CONTACT_737] (or
designee) at each visit to the study  site to assist the I nvestigator in the identification of
new asthma exacerbations. 2018N371775_00
2016N289466_01 CONFIDENTIA L
[ADDRESS_845713] igator (or 
designee).
[IP_ADDRESS]. Moderate A sthma Exacerbation
Guidance for identify ing moderate exacerbations includes the following [ Reddel 2009, 
Virchow 2015 ]
A moderate asthma exacerbation is considered to be a deterioration in asthma 
symptoms, deterioration in lung function, or increased rescue bronchodilator use 
lasting for at least 2 day s or more, but will not be severe enough to warrant 
systemic corticosteroid use for 3 day s or more and/ or hospi[INVESTIGATOR_059]. 
A moderate asthma exacerbation is an event that, when recognized, should result 
in a temporary  change in treatment, in an effort to prevent the exacerbation from 
becoming sever e.
At the I nvestigator’s discretion, a temporary  change in background asthma medication 
will be permitted in order to treat the s ymptoms of a moderate asthma exacerbation 
(Refer to S ection 7.8.1 above)
The Medical Monitor may b e contact[CONTACT_245939], see the
medical monitor/Sponsor I nformation Page .
[IP_ADDRESS]. Severe A sthma Exacerbation
A severe asthma exacerbation is defined as: 
The deterioration of asthma requiring the use of systemic corticosteroids (tablets,
suspens ion or injection) for at least 3 days.
OR
An inpatient hospi[INVESTIGATOR_633349], requiring
systemic corticosteroids.
9.2. Adverse Events
The definitions of an AE or SAE can be found in Appendix 4 .
The investigator and an y designees are responsible for detecting, documenting, and 
reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AEs that are serious, considered related to the study  treatment or the study , 
or that caused the participant to discontinue the study  treatment or withdraw from the 
study  (see Section 8).
9.2.1. Time Period and Frequency  for Collecting A E and SA E 
Information
Any SAEs assessed as related to study  participation (e.g ., protocol -mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] 
product will be recorded from the time a participant consents to participate in the 
study  up to and including any  follow -up contact.  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
56AEs will be collected from the start of Study  Screening until the follow -up contact 
(see Section 9.2.3) at the timepoints sp ecified in the Schedule of Activities (SoA) 
table (Section 2).
Medical occurrences that begin pr ior to the start of study  treatment but after 
obtaining informed consent may  be recorded on the Medical History /Current 
Medical Conditions section of the e
CRF.
All SAEs will be recorded and reported to [COMPANY_004] within 24 hours, as indicated in
Appendix 4 .The investigator will submit any  updated SAE data to the sponsor 
within 24 hours of it being available.
Investigator s are not obligated to activel y seek AEs or SAEs in former study 
participant s. However, if the Investigator learns of any  SAE, including a death, at 
any time after a participant has been discharged from the study , and he/she 
considers the event reasonably  related to the study treatment or study  
participation, the Investigator must promptl y notify [COMPANY_004].
NOTE: The method of reco rding, evaluating and assessing causality  of AEs and SAEs 
plus procedures for completing and transmitting SAE reports to 
[COMPANY_004] are provided in 
Appendix 4
9.2.2. Method of Detecting A Es and SA Es
Care will be taken not to introduce bias when d etecting AEs and/or SAEs. Open- ended 
and non- leading verbal questioning of the participant is the preferred method to inquire 
about AE occurrence.  Appropriate questions include:
“How are you feeling?” 
“Have you had an y (other) medical problems since y ourlast visit/contact?” 
“Have you taken an y new medicines, other than those provided in this study , since 
your last visit/contact?” 
Participant s will be issued with a paper Medical Problems/Medications Taken worksheet
to record an y medical problems experie nced and medications used during the study .This 
paper worksheet will be used to assist participant recall in discussions with the 
Investigator (or designee) , for site staff to then enter as appropriate in the eCRF.
9.2.3. Follow -up of A Es and SA Es
After the init ial AE/SAE report, the Investigator is required to proactivel y follow each 
participant at subsequent visits/contacts.  All SAEs, and non- serious AEs of special 
interest (as defined in Section 9.2.5), will be followed until the event is resolved, 
stabilized, otherwise explained, or the participant is lost to follow -up (as defined in 
Section 8.3). Further information on follow -up procedures is given in Appendix 4
9.2.4. Regulatory  Reporting Requirements for SA Es
Prompt notification by  [CONTACT_11012] a SAE is essential so 
that legal obligations and ethical responsibilities towards the safet y of  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
57participants and the safety  of a study  treatment under cli nical investigation are 
met. 
The sponsor has a legal responsibility  to notify  both the local regulatory  
authority  and other regulatory  agencies about the safet y of a stud y treatment 
under clinical investigation. The sponsor will comply  with country -specif ic 
regulatory  requirements relating to safet y reporting to the regulatory authority, 
Institutional Review Boards (IRB)/Independent Ethics Committees (I EC), and 
investigators.
Investigator safety reports must be prepared for suspected unexpected serious 
adverse reactions (S[LOCATION_003]R) according to local regulatory  requirements and 
sponsor policy and forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE or 
other specific safet y information eg, summary  or listing of SAE) from the 
sponsor will review and then file it along with the Investigator’s Brochure and 
will notify  the IRB/IEC, if appropriate according to local requirements.
9.2.5. Adverse Events of Special Interest (A ESIs)
AE groups of special interest hav e been defined as AEs which have specified areas of 
interest for one or more of class of drugs (ICS, L AMA). Some AE groups may  have 
subgroups defined.
The following table presents the current special interest AE groups and subgroups. These 
may be updated prior to conclusion of the study  reporting. The final list, including the 
preferred terms which contribute to each of the groups will be documented a priori in the 
study  Reporting and Analy sis Plan (RAP).
Special interest AE group
Special interest AE subgro up
Cardiovascular effects Cardiac arrh ythmia
Cardiac failure
Cardiac ischemia
Stroke
Anticholinergic s yndrome -
Urinary  retention -
Dry mouth / dry ing of 
airway  secretions-
Gastrointestinal obstruction -
Antimuscarinic ocular Glaucoma (antimuscarinic/corticosteroid) 2018N371775_00
2016N289466_01 CONFIDENTIA L
[ADDRESS_845714] AE subgro up
effects / Corticosteroids 
associated ey e disordersCataracts (corticosteroid)
Pneumonia and L RTI Pneumonia 
LRTI excluding pneumonia
Adrenal suppression -
Decreased bone mineral 
density  and associated 
fractures-
Effects on glucose -
Hypersensitivity -
Local steroid effects -
9.2.6. Cardiovascular and Death Events
For an y cardio vascular events detailed in Appendix 4 and all deaths, whether or not they 
are considered SAEs, specific Cardiovascular (CV) and De ath sections of the eCRF will 
be required to be completed. These sections include questions regarding cardiovascular 
(including sudden cardiac death) and non- cardiovascular death. 
The CV eCRFs are presented as queries in response to reporting of certain CV MedDRA 
terms. The CV information should be recorded in the specific cardiovascular section of 
the e CRF within one week of receipt of a CV Event data query prompting its completion. 
The Death eCRF is provided immediately  after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed within one 
week of when the death is reported.
9.2.7. Pneumonia
Medical history  will also be taken for pneumonia in previous [ADDRESS_845715] X- ray 
should be performed to confirm a diagnosis, whenever a participant has a suspected 
pneumonia.   Suspected pneumonias will require confirmation as defined by [CONTACT_417515](s) on chest x- ray AND at least 2 of the following signs and sy mptoms: 
Increased cough 
Increased sputum purulence (color) or production 
Auscultatory  findings of adventitious sounds ( e.g., egophon y, bronchial breath 
sounds, rales, etc.) 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
59Dyspnea or tachy pnea
Fever (ora l temperature >37.5 degrees centigrade [ °C])
Elevated white blood cells ( WBC )(>10,000/ millimetres cubed [ mm3]or >15% 
immature forms)
Hypoxemia ( Oxyhemoglobin ( HbO2 )saturation <88% or at least 2% lower than 
baseline value)
All pneumonias must be captured on the AE/SAE page of the eCRF and on the 
pneumonia page of the eCRF. 
For all suspected cases of pneumonia, investigator s are strongl y encouraged to confirm 
the diagnosis (this includes obtaining a chest x -ray) and to initiate appropriate therap y as 
prom ptly as possible. All diagnoses of pneumonia (radiographicall y confirmed or 
unconfirmed) must be reported as an AE or SAE (if applicable).
9.2.8. Radiography  (Chest X -Rays)
Confirmation by  [CONTACT_13190] x -ray (posteroanterior and lateral) should be performed as soon as 
possible and preferabl y within [ADDRESS_845716]/v isit.
If a pregnancy  is reported then the Investigator should inform [COMPANY_004] within 2 weeks of 
learning o
f the pregnancy  and should follow the procedures outlined in Appendix 5.
Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAE.
9.3. Treatment of Overdo
se
An overdose is defined as a dose greater than the total doses described above which 
results in clinical signs and sy mptoms.  These should be recorded by  [CONTACT_417509]/SAE eCRF pages.  I n the event of an overdose of study treatment, the Inve stigator 
should use clinical judgment in treating the overdose and contact [CONTACT_417510].
[COMPANY_004] is not recommending specific treatment guidelines for overdose and toxicity  
management. The Investigator is advised to refer to the relevant document(s) for detailed 
information regarding warnings, precautions, contraindications, adverse events, and other 
significant data pertaining to the stud y drug being used in this study . Such documents 
may include, but not be limited to, the IB or equivalent document provided by  [CONTACT_23983]. 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
609.4. Safet y Assessments
Planned time points for all safety  assessments are provided in the Schedule of Activities 
(SoA).
9.4.1. Physical Examinations
Physical exams will be performed at the time points specified in the Schedule of 
Activities (SoA) ta ble (Section 2).
A complete ph ysical examination will include, at a minimum, assessment of the 
Cardiovascular, Respi[INVESTIGATOR_696] , Gastrointes tinal and Neurological s ystems.
Height and weight wi ll be measured at Visit 1.
Investigators should pay  special attention to clinical signs related to previous 
serious illnesses.
9.4.2. Vital Signs
Vital signs will be performed at the time points specified in the Schedule of Activities 
(SoA) table ( Section 2) prior to conduc tingspi[INVESTIGATOR_633350] 100 mcg. Blood pressure (s ystolic and diastolic) and 
pulse rate will be measured in the sitting position after approximately  [ADDRESS_845717]. A 
single set of values will be colle cted and recorded in the source documentation and 
eCRF.
9.4.3. Electrocardiograms
All sites will use standardised ECG equipment provided by  a centralized external vendor. 
A single 12 -lead ECG and rhy thm strip will be recorded after measurement of vital signs 
and spi[INVESTIGATOR_038] . Recordings will be made at the time -
points defined in the Schedule of 
Activities (SoA) table ( Section 2). All ECG measurements will be made with the 
participant in a supi[INVESTIGATOR_633364] r approximately  5 minutes 
before each reading.
For participant s who meet the QTc, protocol defined stoppi[INVESTIGATOR_3418], triplicate ECGs 
(over a brief period of time) should be performed ( Section 8.1.2).
The Investigator, a design ated sub
-Investigator or other appropriatel y trained site 
personnel will be responsible for performing each 12- lead ECG. The Investigator must 
provide his/her dated signature [CONTACT_238540], attesting to the authenticit y 
of the ECG machine i nterpretation.
All ECGs will be electronically  transmitted to an independent cardiologist and evaluated. 
The independent cardiologist, blinded to treatment assignment, will be responsible for 
providing measurements of heart rate, QT intervals and an interp retation of all ECGs 
collected in this study . A hard cop y of these results will be sent to the I nvestigator. The  2018N371775_00
2016N289466_01 CONFIDENTIA L
[ADDRESS_845718] provide his/her dated signature [CONTACT_417535], attesting to 
his/her review of the independent cardiologist’s assess ment.
Details of the cardiac monitoring procedures will be provided b y the centralized 
cardiology  service provider.
9.4.4. Clinical Safety  Laboratory  Assessments
Refer to Appendix 2for the list of clinical laboratory  tests to be performed and 
to the Schedule of Activities ( SoA)for the timing and frequency . 
The investigator must review the laboratory  report, document this review, and 
record an y clinicall y relevant changes occurring during the stud y in the AE 
section of the CRF. The laboratory  reports must be filed with the source 
documents. Clinically  significant abnormal laboratory  findings are those which 
are not associated with the underl ying disease, unless judged b y the investigator 
to be more severe than expected for t he participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal 
during participation in the study  or within [ADDRESS_845719] dose of study  
treatment should be repeated until the values return to normal or base line or are 
no longer considered significantly  abnormal by  [CONTACT_43210]. 
If such values do not return to normal/baseline within a period of time judged 
reasonable b y the investigator, the etiology should be identified and the sponso r 
notified.
All protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory  manual and the Schedule of 
Activities ( SoA).
9.5. Pharmacokinetics
Pharmacokinetics i s not relevant for this protocol.
9.6. Pharmacody namics
Pharmacod ynamic parameters are not evaluated in this study .
9.7. Genetics
Information regarding genetic/ pharmacogenetic (PGx) research is included in Appendix 
6.The IEC/I RB and, where re quired, the applicable regulatory  agency  must approve the 
PGx and genetic assessments before these can be conducted at the site.  The approval(s) 
must be in writing and will clearly  specify  approval of the PGx and genetic assessments 
(i.e., approval of Appendix 6).
In some cases, approval of the PGx and genetic assessments can occur after approval is 
obtained for the rest of the study .  If so, then the written approval will clearly  indicate 
approval of the PGx and genetic assessments i s being deferred and the study , except for  2018N371775_00
2016N289466_01 CONFIDENTIA L
[ADDRESS_845720] of the study  will clearl y indicate this and 
therefore, PGx and genetic assessme nts will not be conducted.
9.8. Biomarkers
Biomarkers are not evaluated in this study .
9.9. Health Economics OR Medical Resource Utilization and 
Health Economics
Health Economics/Medical Resource Utilization and Health Economics parameters are 
not evaluated in this study .
10. STATISTICA L CONSIDER ATIONS
10.1. Hypotheses
The primary  objective of this study  is to evaluate the efficacy  of UMEC 62.[ADDRESS_845721] for the primary  efficacy  endpoint is such that the null hy pothesis is that there is 
no difference between treatment groups. 
H0: T1 – T 2 = 0
Thealternative hy pothesis is that there is a difference between treatment groups.
H1: T1 – T 2 ≠ 0
For the primary  endpoint (and other lung function related efficacy endpoints), the 
primary  treatment comparisons of interest are:  
UMEC 62.5mcg vs Placebo
UMEC 31.25mcg vs Placebo
For each comparison test on the primary  endpoint, the null hy pothesis is there is no 
difference between treatment groups.  The alternative hy pothesis is there is a difference 
between treatment groups.
Therefore T 1and T 2for these endpoints are the mean changes from baseline for the 
UMEC therap y and placebo , respectivel y, as listed above. 
Details on all pairwise treatment comparisons of interest are provided in S ection 10.5.2. 2018N371775_00
2016N289466_01 CONFIDENTIA L
[PHONE_13177].2. Sample Size Determination
Sample size calculation is based on the primary  efficacy  endpoint of mean change from 
baseline in trough FEV1 at the end of the 24 -week treatment period.
A total of 3 84 randomized participant s are required for this study , with 128 participant s 
in each of the three double- blind treatment groups: UMEC 62.5mcg, UMEC 31.25mcg or 
Placebo. Assuming 10% mi ssing data on spi[INVESTIGATOR_417468] 24- week treatment 
period, due to earl y withdrawal from study, approximately  [ADDRESS_845722] deviations in change from baseline trough FEV1 at Week 24 
ranged from 325 to 354m L;from this a SD estimate of 350 mL was chosen. This was 
estimated from a wide selection of studies , critically to minimise the risk of reduced 
power for the primary  endpoint. The range of observed treatment differences across the 
Tiotropi[INVESTIGATOR_633352] 133 – 185mL , which supports the expectation that the 
treatment effect seen in a moderate asthma population islarger than in the more severe 
asthma population in study  205715 treated on a background of FF/VI . This is in line with 
data from 
[COMPANY_004] study 200699 which showed UMEC 62.5 mcg to be an effective dose. An 
average increase in change from baseline trough FEV1 at Day  29 of 136 mL  was 
observed in an asthma subset of patients treated with FF/UMEC (100/62.5) compared 
with FF (100 mcg) alone. The [COMPANY_004] phase III closed triple asthma study  205715, which 
this study  supports, is in a more severe asthma population and conservatively  assumes a 
SD estimate of 400 mL.
Based on a true population difference of 130 mL, a sample size of 115 patients per 
treatment gro
up has an estimated 80% power to observe statistical significance at the two 
sided 5% level, for each of the two primary  comparisons of interest for each UMEC dose . 
Using the above assumptions the smallest observed effect predicted to result in a 
statistic ally significant difference between treatment groups is 90.5 mL (minimum 
detectable difference) .
No interim anal ysis is planned for this study .
10.3. Sample Size Sensitivity
To demonstrate the sensitivity  of the sample size calculation for this study , the follow ing 
table and graph show the power function for a fixed sample size of n= 115per arm in the 
intent to t reat(ITT)population for the primary  efficacy  anal ysis, vary ing the true
treatment difference and estimated standard deviation on the change from baseli ne in 
trough FEV 1at the end of the 24 -week treatment period. 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
64Treatment difference (mL)
Standard Deviation100 115 130 145 160
300 0.71 0.82 0.91 0.95 0.98
350 0.58 0.70 0.80 0.88 0.93
400 0.47 0.58 0.69 0.78 0.86
10.4. Sample site re -estimation or adjustment
No sample size re -estimation is planned.
10.5. Data Analysis
10.5.1. Analysis population
The following participant populations will be identified:
All Participant s Enrolled Population: This population will comprise all participant s for 
whom a record exists on the study  database, including pre- screened participant s that sign  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
65the informed consent document but do not complete a Visit 1 (screening) procedure (i.e., 
pre-screening failures), or participant s that complete at least one Visit 1 procedure but do 
not ente r the run- in period (i.e., screening failures). This population will be used for the 
summary  of participant disposition . 
All Participant s Screened Population: This population contains all participants that 
complete at least one Visit 1 (Screening) procedu re. This population will be used for the 
summary  of participant disposition (including reasons for screening failures and run-in 
failures) and for the listing of AEs and SAEs for non -randomized participant s. 
ITTPopulation: This population will comprise all randomized participants, excluding 
those who were randomized in error. A participant who is recorded as a screen failure or 
run-in failure, but is randomized and does not receive a dose of study  treatment, is 
considered to be randomized in error. Any other participant who receives a 
randomization number will be considered to have been randomized. This will constitute 
the primary  population for all efficacy  and safety  anal yses. 
10.5.2. Treatment Comparisons
To demonstrate the benefit of UMEC the primary  compari sons of interest for the primary  
efficacy  endpoint are :
UMEC 62.5 mcg vs Placebo
UMEC 31.[ADDRESS_845723] that aim to informally  estimate any  
potential benefit of increasing the UMEC dose are given below f or all efficacy  endpoints. 
UMEC 62.[ADDRESS_845724] in the 
hierarch y. 
A step
-down procedure with the following hierarchy  will be used for the primary  
comparisons in the primary  endpoint.  
The contrast between UMEC 62.5 mcg vs Placebo 
(two-sided, alpha = 0.05.  Null hy pothesis of no treatment difference)
The contrast between UMEC 31.[ADDRESS_845725] acebo 
(two-sided, alpha = 0.05.  Null hy pothesis of no treatment difference) 2018N371775_00
2016N289466_01 CONFIDENTIA L
[ADDRESS_845726] hypothesis has been 
rejected, thus maintaining the overall significance level at 5%.   
Specificall y, if t he defined treatment comparison for the primary  efficacy  endpoint at the 
highestdose of UMEC 62.[ADDRESS_845727] hypothesis is not rejected a nominal p -value for the 
second h ypothesis may be provided in the displays for descriptive purposes only  and will 
not alter the conclusion of the step -down procedure.
No multiplicity  adjustment will be made on these two treatment comparisons on the 
secondar y endpoint .
For all efficacy  endpoints (primary , secondary  and other), treatment comparisons 
between UMEC 62.5 vs UMEC 31.25 mcg informally  investigating the benefit of 
increasing UMEC dose will be made without adjusting for multiplicity .  Any  p -values ≤ 
0.[ADDRESS_845728] acceptable/borderline acceptable (pre -dose) FEV1 value obtained prior to 
randomization (either from Visit 2pre-dose or from Visit 1pre-bronchodilator ).
The primary  efficacy  analy sis will evaluate the “de facto” ty pe estimand in the I ntent- to-
Treat population, using a mixed -model repeated measures (MMRM) analysis, including 
all trough FEV 1recorded post randomization.  Analy ses will include the fixed, 
categorical effects of treatment, visit, treatment by [CONTACT_23259], sex,as well as the 
continuous, fixed covariates of age, baseline value, and baseline value by  [CONTACT_150133].  Point estimates and 95% confidence intervals will be calculated for the 
following primary  comparisons of interest. 
UMEC 62.5 mcg vs Placebo
UMEC 31.[ADDRESS_845729] as outlined in Section 10.5.2 will also 
be provided for t he primary  efficacy  endpoint.
10.6.2. Secondary Analyses
Full details of the analy ses to be performed on the secondary  efficacy  endpoint will be 
given in the RAP.
10.6.3. Other A nalyses
Full details of the analy ses to be performed on all efficacy  endpoints, as well as de tails of 
time points to be analy zed, will be given in the RAP.
10.6.4. Interim A nalyses
No interim anal ysis is planned for this study .
10.6.5. Exploratory  Analyses
The psy chometric properties of the E -RS and Supplemental asthma items will be 
evaluated to 
characterize theE-RS as an endpoint for asthma.  These exploratory  anal yses 
may be provided in a separate RAP. 2018N371775_00
2016N289466_01 CONFIDENTIA L
[PHONE_13178]. REFERENCES
Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 
National Asthma Education and Prevention Programme, National Heart, Lun g and Blood 
Institute, National Institutes of Health (NIH) 2007. Available from: 
http://www.nhlbi.nih.gov/health- pro/guidelines/current/asthma -guidelines
GlaxoSmithKline Document Number: 2011N123107_03 GW685698+[COMPANY_004]573719 
Investigator’s Brochure, dated 19 J un 2014 and 2016 Supplement
Global Strategy for Asthma Management and Prevention , Global Initiative for Asthma 
(GINA ) 2016. Available from: http://www.ginasthma.org/
Jones PW, Quirk FH, Bavey stock CM, Littlejohns P. A self -complete measure of health 
status for chronic airflow limitation. The St. George's Respi[INVESTIGATOR_21606]. Am Rev 
Respir Dis 1992;145:1321-1327.
Jones PW. St. George’s Respi[INVESTIGATOR_21606]: MCI D. Journal of Chronic 
Obstructive Pulmonary Disease 2005;2:75 -79.
Junipe r EF, Bousquet J , Abetz L , Bateman ED; GOAL Committee. I dentify ing 'well-
controlled' and 'not well -controlled' asthma using the Asthma Control Questionnaire. 
Respir Med 2006;100 :616- 621.
Juniper EF , Guy att GH, Willan A, Griffith L E. Determining a minimal important change 
in a disease -specific quality  of life instrument. J Clin Epi[INVESTIGATOR_5541] 1994;47: 81
-87.
Juniper EF, O'By [CONTACT_21143], Guy att GH, Ferrie PJ, King DR. Development and validation of 
a questionnaire to measure asthma control. Eur Respir J 1999;14:902 -
907.
Juniper EF, Sven sson K, Mörk AC, Ståhl E. Measurement properties and interpretation of 
three shortened versions of t he asthma control questionnaire. Respir Med 2005;99: 553-
558.
Junipe r EF, Svensson K, Mörk AC, Ståhl E. Modification of the Asthma Quality  of Life 
Questionna ire (standardised) in patients 12 y ears and older. 
Health and Quality of Life 
Outcomes 2005; 3:58.
Miller MR et al. Standardization of L ung Function Testing. Eur Resp J 2005; 26:153 -161.
Quanjer P, Stanojevic S, Cole T, Baur X., Hall G, Enright P, et al. on behalf of the ERS 
Global L ung Function Initiative. Multi- ethnic reference values for spi[INVESTIGATOR_105221] 3 -95 
year age range: the global lung function 2012 equations. Eur Respir J 2012;40:1324-
1343.
Reddel HK, Taylor DR, Bateman ED, Boulet L -P, Boushey  HA, Busse WW, et al. On
behalf of the American Thoracic Societ y/European Respi[INVESTIGATOR_21584] y task force on 
asthma control and exacerbations. An official American Thoracic Societ y/European 
Respi[INVESTIGATOR_21584] y statement: asthma control and exacerbations; standar dizing endpoints  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
69for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59 -
99. 
US Department of Health and Human Sciences; Food and Drug Administration (FDA).
Guidance for Industry ; Drug -Induced Liver Injury: Premarketing Cl inical Evaluation 
(July  2009). 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf (Accessed 16 July  2014).
Virchow JC, Backer V, de Blay  F, Kuna P, L jorring C, Prieto J L, et al. Defining 
moderate asthma exace rbations in clinical trials based on ATS/ERS joint statement. 
Respi[INVESTIGATOR_33593] 2015;109:547 -556
Wyrwich KW, Khan SA, Navaratnam P, Nolte H, Gates Jr DF. Validation and agreement 
across four versions of the asthma control questionnaire in patients with persistent 
asthma. Resp Med 2011;105:698 -712. 2018N371775_00
2016N289466_01 CONFIDENTIA L
[PHONE_13179]. APPENDICES
12.1. Appendix 1: A bbreviations and Trademarks
Abbrev iations
ACQ Asthma Control Questionnaire
ADR Adverse Drug Reaction
AE Adverse Event
AESI Adverse Event of Special Interest
ALT Alanine Transaminase
AM Morning
AQLQ Asthma Quality  of Life Questionnaire
AST Aspartate Transaminase
ATS American Thoracic Society
BMI Body Mass Index
BPM Beats Per Minute
BST Bioanal ytical Science and Toxicokinetics
BUN Blood Urea Nitrogen
CI Confidence Interval
CON SORT Consolidated Standards of Reporting Trials
COPD Chronic Obstructive Pulmonary  Disease
DNA Deox yribonucleic acid
DPI [INVESTIGATOR_417473]
(e)CRF (Electronic) Case Report Form
eDiary Electronic Diary
EOS End of study
E-RS Evaluating Respi[INVESTIGATOR_633354]1 Forced expi[INVESTIGATOR_4034] 1 second
FF Fluticasone Furoate
FP Fluticasone Propi[INVESTIGATOR_633365] d Vital Capacity
GCP Good clinical practice
GCSP Global Clinical Safety  and Pharmacovigilance
GINA Global I nitiative for Asthma
[COMPANY_004] GlaxoSmithKline
hCG Human Chorionic Gonadotropin
HIV Human Immunodeficiency  Virus
HPA Hypothalamic Pi[INVESTIGATOR_633355] y
IB Investigator ’s Brochure 2018N371775_00
2016N289466_01 CONFIDENTIA L
[ADDRESS_845730] Infection
MACE Major Adverse Cardiac Event
MAOI Monoamine Oxidase I nhibitors
MedDRA Medicinal Dictionary  for Regulatory  Activities
mcg ( g) Microgram
MDI Metered Dose Inhaler
mg Milligram
min Minute
mL Milliliter
MMRM Mixed -Model Repeated Measures
MSDS Material Safet y Data Sheet
msec Millisecond
NIH National Institutes of Health
NYHA [LOCATION_001] Heart Association
PEF Peak Expi[INVESTIGATOR_633356] y
QTc QT interval corrected f or heart rate
QTcB QT interval corrected for heart rate b y Bazett’s formula
QTcF QT interval corrected for heart rate b y Fridericia’s formula
RAP Reporting and Anal ysis Plan
RBC Red Blood Cell
RNA Ribonucleic acid
SABA Short -Acting Beta -2-Agonists
SAE Serious Adverse Event
SGRQ St. George’s Respi[INVESTIGATOR_633366] 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
72US [LOCATION_002]
VI Vilanterol
VT Ventricular Tach ycardia
WBC White Blood Cell
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_633391] 2018N371775_00
2016N289466_01 CONFIDENTIA L
[PHONE_13180].2. Appendix 2: Clinical Laboratory  Tests
All protocol required la boratory  assessments (haematology , clinical chemistry  
and urinal ysis) must be conducted in accordance with the L aboratory  Manual, 
and Protocol Schedule of Activities (Section 2)Laboratory  requisition forms 
must be completed and samples must be clearl ylabelled with the participant
number, protocol number, site/centre number, and visit date. Details for the 
preparation and shipment of samples will be provided by  [CONTACT_633392]. Reference for all safet y parameters will be 
provided to the site by  [CONTACT_90633].
All blood samples which will be taken pre -dose, will be sent to a central 
laboratory  for anal ysis (details provided in the Laboratory Manual). Standard 
reference ranges will be used. 
If additional non -protocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in participant management or 
are considered clinically  significant b y the Investigator (e.g., SAE or AE or dose 
modification) the results must be recorded in the eCRF. 
Refer to the Laboratory  Manual for appropriate processing and handling of 
samples to avoid duplicate and/or additional blood draws.
Protocol -specific require ments for inclusion or exclusion of participants are 
detailed in Section 6 of the protocol.
Additional tests may  beperformed at any  time during the study  as determined 
necessary  by [CONTACT_633400]. 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
74Protocol -Required Safety Laboratory Assessments
Laboratory 
AssessmentsParameters
HaematologyPlatelet Count RBC Indices: WBC count with Differential:
Red Blood Cell ( RBC )
CountMCV Neutrophils
Hemoglobin MCH Lymphocytes
Hematocrit Monocytes
Eosinophils
Basophils
Clinical 
Chemistry 1Blood Urea 
Nitrogen 
(BUN )Potassium AST (SGOT) Total and direct 
bilirubin
Creatinine Sodium ALT (SGPT) Total Protein
Glucose Calcium Alkaline phosphatise Albumin
Routine 
UrinalysisSpecific grav ity
pH, glucose, protein, blood and ketones by [CONTACT_5230]
Microscopic examination (if blood or protein is abnormal)
Other 
Screening 
TestsFollicle stimulating hormone (FSH) and estradiol (as needed in females 
of non -reproductive potential only)
Serum/urine hCG Pregnancy test (as specif ied in the Schedule of 
Activities table [Section 2])
NOTES :
5.Details of L iver Chemistry  Stoppi[INVESTIGATOR_131963] -Up 
Assessments after liver stoppi[INVESTIGATOR_633367] e given in Section 8.1.1 and 
Appendix 7 2018N371775_00
2016N289466_01 CONFIDENTIA L
[PHONE_13181].3. Appendix 3: Study  Governance Considerations
Regulatory  and Ethical Considerations
This study  will be conducted in accordance with the protocol and with:
Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Brochure, and other 
relevant documents (eg, advertisements) must be submitted to an I RB/IEC by  
[CONTACT_20003] b y the I RB/IEC before the study  is 
initiated. 
Any amendments to the protocol will require IEC/I RB approval before 
implementation of changes made to the stud y design, except for changes 
necessary  to eliminate an immediate hazard to study participants. 
The investigator will be responsible for the following:
Providing written summaries of the status of the study to the IRB/IEC 
annually  or more frequently  in accordance with the requirements, policies, 
and procedures established by  [CONTACT_1201]/EC
Notify ing the IRB/IEC of SAE or other significant safet y findings as 
required b y IRB/IEC procedures
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European 
regulation 536/2014 for clinical studies (if applicable), and all o ther 
applicable local regulations
Financial Disclosure
Investigators and sub -investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the stud y and for 1 y earafter completion of the study .
Informed Consent Process
The inves tigator or his/her representative will explain the nature of the study  to 
the participant or his/her legally  authorized representative and answer all 
questions regarding the study .  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
76Participants must be informed that their participation is voluntary . Parti cipants 
or their legall y authorized representative will be required to sign a statement of 
informed consent that meets the requirements of [ADDRESS_845731] (HI PAA) 
requirement s, where applicable, and the I RB/IEC or study  center. 
The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized per son obtaining the informed consent 
must also sign the I CF.
Participants must be re -consented to the most current version of the ICF(s) 
during their participation in the study . 
A cop y of the ICF(s) must be provided to the participant or the participant’s 
legally  authorized representative. 
Participants who are rescreened are required to sign a new ICF.
Data Protection
Participants will be assigned a unique identifier by  [CONTACT_456]. Any  participant 
records or datasets that are transferred to the sponsor wil l contain the identifier 
only; participant names or any  information which would make the participant 
identifiable will not be transferred. 
The participant must be informed that his/her personal study -related data will be 
used by  [CONTACT_10999]. The level of 
disclosure must also be explained to the participant. 
The participant must be informed that his/her medical records may  be examined 
by [CONTACT_17080] y Assurance auditors or other authorized personnel appointed
by [CONTACT_456], b y appropriate IRB/IEC members, and by  [CONTACT_43216].
Publication Policy
The results of this study  may  be published or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all ma nuscripts or abstracts to 
the sponsor before submission. This allows the sponsor to protect proprietary  
information and to provide comments.
The sponsor will comply  with the requirements for publication of study  results. 
In accordance with standard editor ial and ethical practice, the sponsor will 
generall y support publication of multicenter studies only in their entiret y and not 
as individual site data. In this case, a coordinating investigator [INVESTIGATOR_43192] b y mutual agreement.
Authorship will be det ermined by  [CONTACT_43217]. 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
77Dissemination of Clinical Study  Data
For this study  participant data will be entered into [COMPANY_004] defined eCRFs, 
transmitted electronically to [COMPANY_004] or designee and combined with data provided 
from other sources in a validated data s ystem.  
Data Quality  Assurance
Management of clinical data will be performed in accordance with applicable 
[COMPANY_004] standards and data cleaning procedures to ensure the integrit y of the data, 
e.g., removing errors and inconsistencies in the data.
Adverse events and concomitant medications terms will be coded using 
MedDRA (Medical Dictionary  for Regulatory  Activities) and an internal 
validated medication dictionary , [COMPANY_004]Dr ug.  
eCRFs (including queries and audit trails) will be retained b y [COMPANY_004], and copi[INVESTIGATOR_633358] I nvestigator to maintain as the Investigator copy.  Participant 
initials will not be collected or transmitted to [COMPANY_004] according to [COMPANY_004] policy.
All participant data relating to the stud y will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically  (eg, laboratory  
data). The investigator is responsible for verify ing that data entries are accurate 
and correct b y physicall y or electronically signing the CRF. 
The investigator must maintain accurate documentation (source data) that 
supports the information entered in the CRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulat ory agency  inspections and provide direct access to source data 
documents. 
The sponsor or designee is responsible for the data management of this study  
including qualit y checking of the data. 
Study  monitors will perform ongoing source data verification to confirm that 
data entered into the CRF b y authorized site personnel are accurate, complete, 
and verifiable from source documents; that the safety  and rights of participants 
are being protected; and that the study  is being conducted in accordance with the
currentl y approved protocol and an y other stud y agreements, ICH GCP, and all 
applicable regulatory  requirements. 
Records and documents, including signed ICF, pertaining to the conduct of this 
study  must be retained by [CONTACT_1732] 25years after study  completion 
unless local regulations or institutional policies require a longer retention period. 
No records may  be destroy ed during the retention period without the written 
approval of the sponsor. No records may  be transferred to another location or
party  without written notification to the sponsor.  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
78Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
Data r eported on the CRF or entered in the eCRF that are transcribed from 
source documents must be consistent with the source documents or the 
discrepancies must be explained. The investigator may  need to request previous 
medical records or transfer records, dep ending on the study . Also, current 
medical records must be available.
Study and Site Closure
[COMPANY_004] or its designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of [COMPANY_004]. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time, provided th ere is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include 
but are not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of participants by [CONTACT_093]
Discontinuation of further study  treatment development 2018N371775_00
2016N289466_01 CONFIDENTIA L
[PHONE_13182].4. Appendix 4: A dverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
Definition of A E
AE Definition
An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of a study  treatment, whether or not considered related to the 
study  treatment.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study  treatment.
Events Meeting the AE Definition 
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator (ie, not related to progression of 
underly ing disease).
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or inte nsity  of the condition.
New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such ove rdoses should be reported regardless of sequelae.
"Lack of efficacy " or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy  
assessments. However, the signs, s ymptoms, and/or clinical sequelae resulting from 
lack of efficacy  will be reported as AE or SAE if they  fulfill the definition of an AE 
or SAE. 
The signs, s ymptoms, and/or clinical sequelae resulting from lack of efficacy  will be 
reported as AE or SAE if they  fulfill the definition of an AE or SAE. Also, "lack of 
efficacy " or "failure of expected pharmacological action" constitutes an AE or SAE.
Events NOT Meeting the AE Definition 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
80assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
Definition of SA E
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study , 
death due to progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hy potheticall y might have caus ed death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_42244]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the AE 
should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza,  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
81and accidental trauma (eg, sprained ankle) which may  interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anoma ly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or h ospi[INVESTIGATOR_268678]. These events should usually  
be considered serious.
Examples of such events include invasi ve or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse.
Recording A E and SA E
AE and SA E Recording
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_004] in lieu of completion of the [COMPANY_004] /AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004]. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_31785].
The investigator will attempt to establish a diagnosis of the event base d on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal discomfort 
and not interfering with every day activities.
Moderate: An event that causes sufficiently  discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities. An AE that is assessed as  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
82severe should not be confused with an SAE. Severe is a category  utilized for rating 
the intensity  of an event; a nd both AE and SAE can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment and 
each occurrence of each AE/SAE.
A "reasonable possibility " of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  treatment 
administration will be considered and investigated.
The investigator will also consult the I nvestigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the m edical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to [COMPANY_004]. However, it is very 
important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to [COMPANY_004] .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow-up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of AE and SAE
The investigator is obligated to perform or arrange for the conduct of supple mental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_31859]/or causalit y of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathological examinations, 
or consultation with other health care professionals.
If a participant dies during participation in the study or during a recognized follow -
up period, the investigator will provide [COMPANY_004] with a cop y of an y post-mortem 
findings including histopathology .  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
83New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to  [COMPANY_004] within 24 hours of 
receipt of the information.
Reporting of SA E to [COMPANY_004]
SAE Reporting to [COMPANY_004] via Electronic Data Collec tion Tool
The primary  mechanism for reporting SAE to [COMPANY_004] will be the electronic data 
collection tool.
If the electronic s ystem is unavailable for more than 24 hours, then the site will use 
the paper SAE data collection tool (see next section).
The site wi ll enter the SAE data into the electronic sy stem as soon as it becomes 
available.
After the stud y is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
If a si te receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form or to the 
assigned SAE contact [CONTACT_107461].
Contacts for SAE reporting can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774].
SAE Reporting to [COMPANY_004] via Paper CRF
Facsimile transmission of the SAE paper CRF is the prefe rred method to transmit 
this information to the assigned SAE contact [CONTACT_107461].
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_9337] a cop y of the SAE data collection tool sent by [CONTACT_428224] o r courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found at the beginning of this protoc ol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774]. 2018N371775_00
2016N289466_01 CONFIDENTIA L
[PHONE_13183].5. Appendix 5: Contraceptive Guidance and Collection of 
Pregnancy  Information
Definitions
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post-menopausal 
unless permanentl y sterile (see below)
Women in the following categories are not considered WOCBP
6.Premenarchal
7.Premenopausal female with ONE of the following:
Documented h ysterectomy
Documented bilateral salpi[INVESTIGATOR_1656]
Documented bilateral oophorectom y
Note:  Documentation can come from the site personnel’s: review of participant’s 
medical records, medical examination, or medical history  interview.
8.Postmenopausal female
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. A high follicle stimulating hormone (FSH) level in 
the postmenopausal range may  be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormonal replacement therapy  
(HRT). However, in the absence of 12 months of amenorrhea, a single FSH 
measurement is insufficient. 
Females on HRT and whose menopausal status is in doubt will be required to 
use one of the non -hormonal highl y effective contraception methods if they wish 
to continue their HRT during the study . Otherwise, they  must discontinue HRT 
to allow confirmation of postmenopausal status before study  enrollment.
Contraception Guidance
Female participants
Female participants of childbearing potential are eligible to participate if they  agree to 
use a highly  effective method of contraception consistently  and correctly  as described in 
Table 4. 2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
85Table 4 Highly  Effective Contraceptive Methods
Highly Effective Contraceptive Methods That Are User Dependent a
Failure rate of <1%  per year when used consistently and correctly. 
Combined (estrogen -and progestogen -containing ) hormonal contraception associated with 
inhibition of ovulation 
oral
intravaginal 
transdermal 
Progestogen -only hormonal contraception associated with inhibition of ovulationb
injectable 
Highly Effective Methods That Are User Independent 
Implantable progestogen -only hormonal contraception associated with inhibition of 
ovulationb
Intrauterine device (IUD)
Intrauterine hormone -releasin g system (IUS)
bilateral tubal occlusion
Vasectomized partner 
(A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not, a n additional highly effective method of contraception should be used.)
Sexual abstinence 
(Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated w ith the study drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and 
the preferred and usual lifestyle of the participant.)
NOTES: 
a. Typi[INVESTIGATOR_633368]. Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants in clinical studies.
Pregnancy  Testing
WOCBP should only  be included after a confirmed menstrual period and a negative 
highl ysensitive urine or serum pregnancy test 
Pregnancy  testing will be performed whenever a menstrual cy cle is missed or when 
pregnancy  is otherwise suspected 
Pregnancy testing, with a sensitivity  of [5, 10, 25] mI U/mL will be performed [and 
assay ed in a cer tified laboratory  OR and assay ed in the central laboratory  OR using  2018N371775_00
2016N289466_01 CONFIDENTIA L
[ADDRESS_845732] kit provided by  [CONTACT_2237]  / provided by  [CONTACT_456] /approved by  
[CONTACT_633394]]  
Collection of Pregn ancy  Information
Female Participants who become pregnant
Investigator will collect pregnancy  information on any  female participant, who 
becomes pregnant while participating in this study. 
Information will be recorded on the appropriate form and submitted to [COMPANY_004] within 
24 hours of learning of a participant's pregnancy . 
Participant will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow up information on participant and neonate, which will 
be forwarded to [COMPANY_004] General ly, follow -up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date.  
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure. 
While pregnancy itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE or 
SAE. 
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post -study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  [CONTACT_093], will be reported to [COMPANY_004]
as described in Appendix 4 . While the investigator is not obligated to actively  seek 
this information in former study  participants, he or she may  learn of an SAE through 
spontaneous reporting. 
Any female participant who becomes pregnant while participating in the study will 
immediately discontinue study medication. 2018N371775_00
2016N289466_01 CONFIDENTIA L
[PHONE_13184].6. Appendix 6: Genetics
Genetic s –Background
Naturall y occurring genetic variation may  contribute to inter -individual variability in 
response to medicines, as well as an individual's risk of developi[INVESTIGATOR_42259]. 
Genetic factors associated with disease characteristics may  also be associated with 
response to therap y, and could help to explain some clinical study outcomes. For 
example, genetic variants associated with age- related macular degeneration (AMD) are 
reported to account for much of th e risk for the condition [ Gorin 2012] with certain 
variants reported to inf luence treatment response [ Chen2012]. Thus, knowledge of the 
genetic etiology  of disease may  better inform understanding of disease and the 
development of medicines. Additionally , genetic variability  may  impact the 
pharmacokinetics (absorption, distribution, metabolism, and elimination), or 
pharmacod ynamics (relationship between concentration and pharmacologic effects or the 
time course of pharmacologic effects) of a specific medicine and/or clinical outcomes 
(efficacy  and/or safet y) observed in a clinical study.
Genetic Research Objectives and A nalyses
The objectives of the genetic research are to investigate the relationship between genetic 
variants and: 
Response to medicine or any  concomitant medicines;
Asthma susceptibility , severity , and progression and related conditions
Genetic data may  be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include focused candidate gene approaches and/or 
examination of a large number of genetic variants throughout the genome (whole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives highlighted above.  Analy ses ma y be performed using data 
from multiple clinical studies to investigate these research objectives.
Appropriate descriptive and/or statistical analy sis methods will be used. A detailed 
description of an y planned anal yses will be documented in a Reporting an d Analy sis Plan 
(RAP) prior to initiation of the anal ysis. Planned analy ses and results of genetic 
investigations will be reported either as part of the clinical RAP and study  report, or in a 
separate genetics RAP and report, as appropriate.
Study Populati on
Any participant who is enrolled in the study  can participate in genetic research.  Any  
participant who has received an allogeneic bone marrow transplant must be excluded 
from the genetic research.
Study Assessments and Procedures
A key  component of succ essful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
88identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in disease and medi cine response.  
A 6ml blood sample will be taken for Deox yribonucleic acid (DNA) extraction. A 
blood sample is collected at the baseline visit, after the participant has been 
randomized and provided informed consent for genetic research. Instructions for 
collection and shippi[INVESTIGATOR_278799]. 
The DNA from the blood sample may  undergo quality  control anal yses to confirm 
the integrit y of the sample. If there are concerns regarding the quality of the sample, 
then the sample may  be destroy ed. The blood sample is taken on a single occasion 
unless a duplicate sample is required due to an inability  to utilize the original sample.  
The genetic sample is labelled (or “coded”) with the same stud y specific number used to
label other samples and data in the study.   This number can be traced or linked back to 
the participant by [CONTACT_42393]. Coded samples do not carry personal 
identifiers (such as name [CONTACT_42405]). 
Samples will be stored securel y and may be kept for up to [ADDRESS_845733] 
participant completes the study , or [COMPANY_004] may  destroy  the samples sooner.  [COMPANY_004] or those 
working with [COMPANY_004] (for example, other researchers) will only  use samples collected from 
the study  for the purpose stated in this protocol and in the informed consent form.  
Samples may  be used as part of the development of a companion diagnostic to support 
the [COMPANY_004] medicinal product.
Participant s can request their sample to be destro yed at an y time.
Informed Consent
Participant s who do not wish to participate in the genetic research may  still participate in 
the study .  Genetic informed consent must be obtained prior to an y blood being taken.
Participant Withdrawal from Study
If a participant who has consented to partic ipate in genetic research withdraws from the 
clinical study  for any  reason other than being lost to follow -up, the participant will be 
given a choice of one of the following options concerning the genetic sample, if alread y 
collected:
Continue to participate in the genetic research in which case the genetic DNA 
sample is retained
Discontinue participation in the genetic research and destroy  the genetic DNA 
sample 
If a participant withdraws consent for genetic research or requests sample destruction for 
anyreason, the Investigator must complete the appropriate documentation to request 
sample destruction within the timeframe specified by  [CONTACT_420264] .  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
89Genoty pe data may  be generated during the study  or after completion of the study  and 
may be anal yzed during the study  or stored for future anal ysis. 
If a participant withdraws consent for genetic research and genot ype data has not 
been analy zed, it will not be anal yzed or used for future research.  
Genetic data that has been anal yzed at the time of withdrawn consent will 
continue to be stored and used, as appropriate.
Screen and Baseline Failures
If a sample for genetic research has been collected and it is determined that the 
participant does not meet the entry criteria for participation in the study, then the 
Investigator should instruct the participant that their genetic sample will be destroy ed. No 
forms are required to complete this process as it will be completed as part of the consent 
and sample reconcilia tion process.  In this instance a sample destruction form will not be 
available to include in the site files.
Provision of Study Results and Confidentiality  of Participant ’s Genetic Data
[COMPANY_004] may  summarize the genetic research results in the clinical study  report, or 
separately  and may  publish the results in scientific journals. 
[COMPANY_004] may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. [COMPANY_004] does not inform the 
participant , famil y mem bers, insurers, or employ ers of individual genot ypi[INVESTIGATOR_42261] ’s medical care at the time of the study , 
unless required b y law. This is due to the fact that the information generated from genetic 
studies is generall y preliminary in nature, and therefore the significance and scientific 
validity  of the results are undetermined.  Further, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care.
References
Chen H, Yu KD, Xu GZ. Association between Variant Y402H in Age- Related Macular 
Degeneration (AMD) Susceptibility  Gene CFH and Treatment Response of AMD: A 
Meta -Anal ysis. PloS ONE 2012; 7: e42464
Gorin MB. Genetic insights into age- related macular degeneratio n: Controversies 
addressing risk, causality, and therapeutics. Mol. Asp. Med. 2012; 33: 467 -486. 2018N371775_00
2016N289466_01 CONFIDENTIA L
[PHONE_13185].7. Appendix 7: Liver Safety : Required A ctions and Follow -up 
Assessments
Phase II l iver chemistry stoppi[INVESTIGATOR_633359]  (in alignment with the FDA 
premarketing clinical liver safety  guidance [ Food and Drug Administration , 2009]).
Phase II liver chemistry stoppi[INVESTIGATOR_633369] – Liver Stoppi[INVESTIGATOR_53053]- absolute ALT  5xULN
ALT Increase ALT 3xULN persists for 4 weeks
Bilirubin1, 2ALT  3xULN andbilirubin 2xULN (>35% direct bilirubin)
INR2ALT  3xULN andINR>1.5, if INR measured
Cannot Monitor ALT 3xULN and cannot be monitored weekly for 4 weeks
Symptomatic3ALT   3xULN associated with symptoms (new or worsening) believed to be 
related to liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stoppi[INVESTIGATOR_90567]
Immediately discontinue  study treatment 
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF and complete an
SAE data collection tool if the event also meets 
the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the participant until liver chemistries
resolve, stabilize, or return to within baseline 
(see MONITORING below)
Do not restart/rechallenge participant with 
study treatm ent unless allowed per protocol and 
[COMPANY_004] Medical Governance approval is granted 
(refer to Section 8.1.3 )
If restart/rechallenge not allowed per protocol or 
not granted , permanently discontinue study 
treatment and may continue participant in the study 
for any protocol specified follow up assessments Viral hepatitis serology4
Blood sample for pharmacokinetic (PK) 
analysis, obtained [ADDRESS_845734] 
dose5
Serum creatine phosphokinase (CPK) 
and lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinica l symptoms of liver injury , or 
hypersensitivity, on the AE report form
Record use of concomitant medications 
on the concomitant medications report 
form including acetaminophen, herbal 
remedies, other over the counter  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
91MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin ) and perform 
liver event follow up assessments within  24 hrs
Monitor participant s twice weekly until liver 
chemistries resolve, stabilize or return to within 
baseline 
A specialist or hepatology consultation is 
recommended
For All other criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin) and perform 
liver event follow up assessments within  24-72 
hrs 
Monitor participant s weekly until liver 
chemistries resolve, stabilize or return to within 
baselinemedications .
Record alcohol use on the liver event 
alcohol intake case report form
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth 
muscle antibody, Type 1 anti- liver 
kidney microsomal antibodies, and 
quantitative total immunoglobulin G 
(IgG or gamma globulins).
Serum acetami nophen adduct HPLC 
assay (quantifies potential 
acetaminophen contribution to liver 
injury in participant s with definite or 
likely acetaminophen use in the 
preceding week (James 2009) Not 
Required in China
Liver imaging (ultrasound, m agnetic 
resonance, or computerised 
tomography) and /or liver biopsy to 
evaluate liver disease; complete Liver 
Imaging and/or Liver Biopsy CRF 
forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirub in fractionation is not 
immediately available, discontinue study treatment for that participant if ALT 3xULN andbilirubin 2xULN.. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2. Allevents of ALT  3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT  3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to participants receiving anticoagulants
3. New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)
4. Includes: Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatiti s E IgM antibody 
5. PK sample may not be required for participant s known to be receiving placebo or non -[COMPANY_004] comparator 
treatments.)  Record the date/time of the PK blood sample draw and the date/time of the last dose of study 
treatment prior to blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the 
participant ’s best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot 
be collected in the time period indicated above, do not obtain a PK sample. Instructions for sample handling and 
shippi[INVESTIGATOR_42253].    2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
92Phase II liver chemistry increased monitoring criteria with continued therapy
Liver Chemistry Increased Monitoring Criteria – Liver Monitoring Event
Criteria Actions
ALT  3xULN and<5xULN andbilirubin 
<2xULN , without symptoms believed to 
be related to liver injury or 
hypersensitivity , and who can be 
monitored weekly for 4 weeksNotify the [COMPANY_004] medical monitor within 24 hours of 
learning of the abnormality to discuss participant
safety. 
Participant can continue study treatment   
Participant must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline 
If at any time participant meets the live r chemistry 
stoppi[INVESTIGATOR_3418], proceed as described above
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor participant s twice monthly 
until liver chemistries normalize or return to within 
baseline.
References
James LP, Letzig L, S impson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784. 2018N371775_00
2016N289466_01 CONFIDENTIA L
[PHONE_13186].8. Appendix 8: Daily Diary  Questions
12.8.1. Morning Questions
The participant should complete the morning eDiary  questions upon wakening and prior 
to the administration of study  treatment.
Night -time Awakening
1. Did y ou wake up due to asthma 
symptoms (i.e. wheezing, coughing, 
shortness of breath, or ches t 
tightness).No
Yes
2.If Yes; when you woke up due to 
your asthma sy mptoms did you use 
any rescue inhaler?No
Yes
12.8.2. Evening Questions
The participant should complete the evening eDiary questions just before going to bed.
E-RS
1.Did your chest feel congested 
today?Not at all
Slightly
Moderately
Severely
Extremely
2.How often did you cough today? Not at all 
Rarely 
Occasionally 
Frequently 
Almost constantly 
3.How much mucus (phlegm) did 
you bring up when co ughing 
today?None at all 
A little 
Some 
A great deal 
A very great deal 
4.How difficult was it to bring up 
mucus (phlegm) today?Not at all 
Slightly 
Moderately 
Quite a bit 
Extremely  2018N371775_00
2016N289466_01 CONFIDENTIA L
[ADDRESS_845735] discomfort 
today?Not at all 
Slight 
Moderate 
Severe 
Extreme 
6. Did your chest feel tight today? Not at all
Slightly
Moderately
Severely
Extremely
7.    Were you breathless today? Not at all
Slightly
Moderately
Severely
Extremely
8. Describe how breathless you were 
today:Unaware of breathlessness
Breathless during strenuous activity
Breathless during light activity
Breathless when washing or dressing
Present when resting 
9. Were you short of breath today 
when performing your usual 
personal care activities like 
washing or dressing?Not at all 
Slightly 
Moderately 
Severely 
Extremely 
Too breathless to do these 
10. W ere y ou short of breath today 
when performing your usual indoor 
activities like cleaning or 
household work?Not at all 
Slightly 
Moderately 
Severely 
Extremely 
Too breathless to do these 
11. W ere y ou short of breath today 
when performing your usual 
activities outside the home such 
as yard work or errands?Not at all 
Slightly 
Moderately 
Severely 
Extremely 
Too breathless to do these  2018N371775_00
2016N289466_01 CONFIDENTIA L
205832
95Supplemental Asthma Items
1. Did you wheeze today?’ Not at all 
Rarely
Occasionally 
Frequently
Almost constantly
2. Were you short of breath today 
when performing stre nuous activities 
such climbing stairs, running, or 
participating in sports activity.  Not at all 
Slightly 
Moderately 
Severely 
Extremely
Asthma Symptom and Physical Activity Questions
1.Please describe the severity of 
your asthma sy mptoms today (i.e. 
cough, wheeze, chest tightness, 
shortness of breathNo asthma sy mptoms
Mild asthma sy mptoms
Moderate asthma sy mptoms
Severe asthma sy mptoms
Very severe asthma sy mptoms
2.How limited were you in your 
activities today because of your 
asthmaNot at all limited
A little limited
Moderately limited
Severely limited
Totally limited 2018N371775_00
2016N289466_01 CONFIDENTIA L
[PHONE_13187].9. Appendix 9: Country -specific requirements
There are currently  no country  specific requirements.  2018N371775_00
2016N28 9466_01 CONFIDENTIA L
[PHONE_13175].10. Appendix 10: Protocol A mendment History
The Protocol A mendment Summary  of Changes Table for the current amendment is 
located directly  before the Table of Contents (TOC). 2018N371775_00
2016N289466_00 CONFIDENTIA L
GlaxoSmithKline group of companies 205832
1TITLE PA GE
Protocol Title: A Phase IIb, 24 week, randomized, double -blind, 3 arm parallel group 
study , comparing the efficacy , safet y and tolerability  of two doses of umeclidinium 
bromide administered once- daily via a dry  powder inhaler, v ersus placebo, in participants
with asthma
Protocol Number : 205832
Short Title : A randomized, double- blind, parallel group stud y, comparing the efficacy , 
safet y and tolerability of two doses of umeclidinium bromide administered once- daily via 
a dry  powder inhaler, versus p lacebo , in participant s with asthma
Compound Number: GW685698+[COMPANY_004]573719
Sponsor Name [CONTACT_29560]: 
GlaxoSmithKline Research & Development Limited
[ADDRESS_845736] Inform ation can be found in the Study 
Reference Manual
Regulatory Agency Identifying Number(s): INDNo. 104479, EudraCT number 2016-
002843-40
Approval Date: 19-AUG - 2016
Copy right 2016 the GlaxoSmithKline group of companies. All rights reserved.  
Unauthor ised cop ying or use of this information is prohibited. 2018N371775_00
 2018N371775_00
[COMPANY_003]
[COMPANY_003]
2016N289466_00 CONFIDENTIA L
205832
3TABLE OF CONTENTS
PAGE
1.SYNOPSIS ............................................................................................................... 6
2.SCHEDULE OF ACTIVITI ES (SOA) ....................................................................... 10
3.INTRODUCTION ................................................................
.................................... 15
3.1. Study Rationale .......................................................................................... 15
3.2. Background ................................................................................................ 15
3.3. Benefit/Risk Assessment ............................................................................ 15
3.3.1. Risk Assessment ......................................................................... 16
3.3.2. Benefit Assessment ..................................................................... 22
3.3.3. Overall Benefit: Risk Co nclusion .................................................. 22
4.OBJECTIVES AND ENDPO INTS ........................................................................... 22
5.STUDY DESIGN .................................................................................................... 24
5.1. Overall Design ............................................................................................ 24
5.2. Number of Participants ............................................................................... 26
5.3. Participant and Study Completion ............................................................... 26
5.4. Scientific Rationale for Study Design .......................................................... 26
5.5. Dose Justification ........................................................................................ 27
6.STUDY POPULATION ........................................................................................... 27
6.1. Inclusion Criteria ......................................................................................... 27
6.2. Exclusion Criteria ........................................................................................ 29
6.2.1. Randomization Criteria ................................................................ 31
6.2.2. Inclusion Criteria for Randomization ............................................ 31
6.2.3. Exclusion Criteria for Randomization ........................................... 32
6.3. Lifestyle Restrictions ................................................................................... 32
6.4. Pre-Screening/Screening/Run -in/Randomization Failures .......................... 32
7.TREATMENTS ....................................................................................................... 33
7.1. Treatments Administered ............................................................................ 33
7.1.1. Description of FF 100 mcg and Double- Blind Study 
Treatment .................................................................................... 33
7.1.2. Description of Albuterol/Salbutamol ............................................. 34
7.1.3. Study Treatment and FF 100 mcg Return .................................... 35
7.2. Dose Modification ....................................................................................... 35
7.3. Method of Treatment Assignment ............................................................... 35
7.4. Blinding ....................................................................................................... 36
7.5. Packaging and Labeling .............................................................................. 36
7.6. Preparation/Handling/Storage/Accountability .............................................. 37
7.7. Treatment Compliance................................................................................ 37
7.8. Concomitant Therapy .................................................................................. 38
7.8.1. Permitted Medications and Non -Drug Therapi[INVESTIGATOR_014] .......................... 38
[IP_ADDRESS]. Permitted Asthma Medications ................................... 38
[IP_ADDRESS]. Permitted Non -Asthma Medications ........................... 39
7.9. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_014] ........................................ 40
7.10. Treatment after the End of the Study .......................................................... 40 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
48.DISCONTINUATION CRIT ERIA ............................................................................. 41
8.1. Discontinuation of Study Treatment ............................................................ 41
8.1.1. Liver Chemistry Stoppi[INVESTIGATOR_2121] ................................................ 41
8.1.2. QTc Stoppi[INVESTIGATOR_2121] .................................................................. 42
8.1.3. Rechallenge ................................................................................. 43
[IP_ADDRESS]. Study Treatment Restart or Rechalleng e.................... [ADDRESS_845737] to Follow Up ........................................................................................ 43
9.STUDY ASSESSMENTS AN D PROCEDURES ..................................................... 44
9.1. Efficacy Assessments ................................................................................. 45
9.1.1. Questionnaires ............................................................................ 45
[IP_ADDRESS]. Global Assessment of Severity and Response 
to Treatment ............................................................... 45
[IP_ADDRESS]. Asthma Control Questionnaire (ACQ) ......................... 46
[IP_ADDRESS]. St. George’s Respi[INVESTIGATOR_633329] 
(SGRQ) ...................................................................... 46
[IP_ADDRESS]. Asthma Quality of Life Questionnaire (AQLQ) ............ 46
9.1.2. Daily Diaries ................................................................................ 46
[IP_ADDRESS]. eDiary Questionnaires, Assessments and 
Alerts .......................................................................... 47
[IP_ADDRESS].1. E-RS....................................................... 47
[IP_ADDRESS].2. Supplemental Asthma Items ................... 47
[IP_ADDRESS].3. Night -time Awakening, Asthma 
Symptom and Physical Activit y 
Questions ............................................... 48
[IP_ADDRESS].4. Morning and Evening Home 
Spi[INVESTIGATOR_038] .............................................. 48
[IP_ADDRESS].5. Alerts ...................................................... [ADDRESS_845738] ............................................................. 49
[IP_ADDRESS]. Reversi bility (Albuterol/Salbutamol) ............................ 50
9.1.4. Asthma Exacerbations ................................................................ .50
[IP_ADDRESS]. Moderate Asthma Exacerbation .................................. 51
[IP_ADDRESS]. Severe Asthma Exacerbation ..................................... [ADDRESS_845739] (AESIs) ................................ .53
9.2.6. Cardiovascular and Death Events ................................................ 54
9.2.7. Pneumonia .................................................................................. 54
9.2.8. Radiography (Chest X -Rays) ....................................................... 55
9.2.9. Pregnancy ................................................................................... 55
9.3. Treatment of Overdose ............................................................................... 55
9.4. Safety Assessments ................................................................................... 56
9.4.1. Physical Examinations ................................................................ .56
9.4.2. Vital Signs .................................................................................... 56
9.4.3. Electrocardiograms ...................................................................... 56
9.4.4. Clinical Safety La boratory Assessments ...................................... 57
9.5. Pharmacokinetics ....................................................................................... 57 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
59.6. Pharmacodynamics .................................................................................... 57
9.7. Genetics ..................................................................................................... 57
9.8. Biomarkers ................................................................................................ .58
9.9. Health Economics OR Medical Resource Utilization and Health 
Economics .................................................................................................. 58
10.STATISTICAL CONSIDER ATIONS ........................................................................ 58
10.1. Hypotheses ................................................................................................ .58
10.2. Sample Size Determination ........................................................................ 59
10.3. Sample Size Sensitivity ............................................................................... 59
10.4. Sample site re -estimation or adjustment ..................................................... 60
10.5. Data Analysis .............................................................................................. 60
10.5.1. Analysis populatio n...................................................................... 60
10.5.2. Treatment Comparisons .............................................................. 61
10.5.3. Multiple Comparisons and Multiplicity .......................................... 61
10.6. Statistical Analysis ...................................................................................... 62
10.6.1. Primary Ana lyses ......................................................................... 62
10.6.2. Secondary Analyses .................................................................... 63
10.6.3. Other Analyses ............................................................................ 63
10.6.4. Interim Analyses .......................................................................... 63
10.6.5. Exploratory Analyses ................................................................... 63
11.REFERENCES ....................................................................................................... 64
12.APPENDICES ........................................................................................................ 66
12.1. Appendix 1: Abbreviations and Trademarks ................................................ 66
12.2. Appendix 2: Clinical Laboratory Tests ......................................................... 69
12.3. Appendix 3: Study Governance Considerations .......................................... 71
12.4. Appendix 4: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ....................................... 75
12.5. Appen dix 5: Contraceptive Guidance and Collection of Pregnancy 
Information .................................................................................................. 80
12.6. Appendix 6: Genetics .................................................................................. 83
12.7. Appendix 7: Liver Safety: Required Actions and Follow -up 
Assessments .............................................................................................. 86
12.8. Appendix 8: Daily Diary Questions .............................................................. 89
12.8.1. Morning Questions ....................................................................... 89
12.8.2. Evening Questions ....................................................................... 89
12.9. Appendix 9: Country -specific requirements ................................................. 92 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
61. SYNOPSIS
Protocol Title: A Phase IIb, 24 week, randomized, double -blind, 3 arm parallel group 
study , comparing the efficacy , safet y and tolerability  of two doses of umeclidinium 
bromide administered once- daily via a dry  pow der inhaler, v ersus placebo, in participants
with asthma
Short Title: A randomized, double- blind, parallel group stud y, comparing the efficacy , 
safet y and tolerability of two doses of umeclidinium bromide administered once- daily via 
a dry  powder inhaler, v ersus placebo, in participants with asthma
Rationale:
In the [LOCATION_002] (US) , the long-acting muscarinic antagonist (LAMA) tiotropi[INVESTIGATOR_633330] -term maintenance treatment of asthma in patients 12 y ears of 
age and older.
GlaxoSmithKl ine ([COMPANY_004]) is currentl y developi[INVESTIGATOR_007] a once -daily ‘closed’ triple therap y of a n
inhaled corticosteroid (ICS) /LAMA/ long-acting beta -2-agonist (LABA )combination 
[fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI)] in a single device, with 
the aim of 
providing a new treatment option for the management of asthma in adults. 
Through the evaluation of UMEC 62.5 micrograms ( mcg) and 31.25 mcg compared to 
placebo, this study  will provide important informa tion regarding the efficacy , safety and 
tolerability of UMEC when administered viaa separate inhaler to participant s on a 
background of FF without VI .
The primary  objective of this study  is to evaluate the effects of UMEC 62.5 mcg and 
UMEC 31.25 mcg on lung function compared with placebo after 24 weeks of tr eatment.
Objectives and Endpoints:
Objective Endpoint
Primary
Evaluate the effects of UMEC 62.5 mcg 
and UMEC 31.25 mcg on lung function 
(trough Forced Expi[INVESTIGATOR_1814] 1 
second [FEV 1]) vs placebo after 24 
weeks of treatment.Mean change from baselin e in clinic 
trough FEV 1at Week 24
Secondary
Evaluate the effects of UMEC 62.5 mcg 
and UMEC 31.25 mcg on lung function 
(3hours post dose FEV 1) vs placebo after 
24 weeks of treatment.Mean change from baseline in clinic FEV [ADDRESS_845740] dose at Week 2 4 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
7Objective Endpoint
Safety
 To evaluate the  safety and tolerability of 
UMEC 62.5 mcg and UMEC 31.25 mcg 
compared to placebo Incidence and type of adverse events
 Electrocardiogram (ECG) 
measurements
 Vital signs
Overall Design:
This is a Phase IIb, randomized, double -blind, placebo controlled, 3 -arm parallel group 
study , comparing the efficacy , safet y and tolerability  of UMEC (62.5 mcg and 
31.25 mcg) administered once- dailyin participants with asthma that is not well controlled
(i.e. participants with an Asthma Control Qu estionnaire -6 [ACQ -6]total score >0.75 at 
Visit 2 [the R andomization Visit ]) despi[INVESTIGATOR_633331].
Number of Participant s:
The total number of randomized participant s required is approximately  384, with 128
participant s randomized 1:1:1 to each of the 3 double -blind treatment arms .   2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
8Treatment Groups and Duration:
Eligible participant s will be requested to participa te in the study  for a maximum of 
approximat ely 31weeks ( Visit 0to the Follow -up contact , inclusive ) during which time, 
participants will complete the following 4 phases of the study :
Pre-screening: Details about the study  and procedures will be explained 
through the informed consent process. The Pre -screening Visit (Visit 0 ), 
including the informed consent process, must be c ompleted within 4 weeks prior 
to Visit 1 as well as prior to any protocol -required changes to a participant’ s 
usual as thma treatment and the initiation of any Visit 1 procedures.
Participant s that receive LABA (or LAMA) as a component of their regular (i.e. 
pre-study ) therap y must stop L ABA (or LAMA) treatment from 48 hours prior 
to Visit 1 (Screening) until after they have completed the study ; therefore, the 
investigator must use their clinical judgment to determine if the participant may 
stop L ABA (or LA MA) prior to study  entry  without incurring undue risk.
Screening / run- in: Participant s who meet all the eligibility  criteria at Visit 1 
(Screening), will enter the run -in period for approximately  2 weeks to continue 
assess ingthe participant ’s eligibility for the study . On the morning of Visit 1, 
participant s will refrain from taking themorning dose of their regular (i.e. pre -
study ) ICS asthma medication. Participant s satisfying all inclusion/exclusion 
criteria and who have successfully  completed all protocol procedures at 
screening will be provided with FF 100 mcg via the ELLIPTA dry -powder 
inhaler (DPI) to take once daily  (QD), in the morning, d uring the 2- week run -in 
period; the first dose of FF 100 mcg will be self -administered by  [CONTACT_633401] e leaving the clinic. Participants will refrain from using their own ICS 
asthma medication during the 2 -week run- in and treatment period. Participants 
will also be provided with rescue medication (albuterol/salbutamol) to use on an 
as-needed basis througho ut the stud y.
Randomization / treatment :At Visit 2 (the Randomization Visit), participants 
who meet all of the randomization criteria willbe randomized 1:1:1 to receive 
oneof the following three double -blind study  treatments via the ELLIPTA DPI  
[INVESTIGATOR_74964] t he 24 -week treatment period:
UMEC 62.5 mcg QD
UMEC 31.25 mcg QD
Placebo QD
Participants will continue to administer FF 100 mcg once dail y (QD), in the 
morning from a separate ELLIPTA DPI [INVESTIGATOR_633332]. On the 
morning of Visits 2, 3, 4, and 5, participant s will perform their electronic Diary  
(eDiary ) assessments at home but refrain from taking their morning dose of 
study  treatment andFF 100 mcg (as applicable) until instructed to do so by
[CONTACT_6477]. At Visits 2, 3, [ADDRESS_845741] dose of study  treatment and FF 100 mcg in the clinic on Day  
169(Visit 5). Participants are expected on non -clinic visit daysto take their  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
9study  treatment and FF 100 mcg at home in the morning at approximately  the 
same time each day,as directed b y the clinic. 
Safety 
follow -up: A safety  follow -up telephone contact [CONTACT_417494] 7 day s after the participant completes all of the 
protocol -defined procedures for V isit 5 /End of Study  (EOS )or, if applicable, the 
Early Withdrawal V isit. A participant will be considered to have completed the 
study  when they  have completed all phases of the study inc luding screening, 
run-in, the randomiz ed treatment phase, and safety  follow -up.
Key Elements of Analysis Plan
The primary  efficacy  analy sis will evaluate the “de facto ” type estimand in the I ntent- to-
Treat population, using a mixed -model repeated measures (MMRM) analy sis, including 
all clinic trough FEV 1recorded post randomization. Analy ses will include the fixed, 
categorical effects of treatment, visit, treatment by [CONTACT_23259], sex, aswell as the 
continuous, fixed covariates of age, baseline value , and baseline value b y visit 
interaction. Point estimates and 95% confidence intervals will be calculated for the 
primary  comparisons of interest:
UMEC 62.5 mcg v ersus Placebo
UMEC 31.[ADDRESS_845742] of missing data will be detailed in the reporting and anal ysis plan(RAP ).
The detail s of the statistical anal ysis methods for the secondary  efficacy  endpoint will be 
provided in the RAP .  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
102. SCHEDULE OF ACTIVITI ES(SOA)
Protocol Activit yPre-
ScreenScreen
Run-inTreatment Period Follow -up
Visit 0 12
Randomization3 45/End of Study  
(EOS)Early  Withdrawal 
(EW)Safety
Follow -up Contact
[CONTACT_633380]-42to -
14-14 1 29 85 169
Week -6 to -2 -2 0 4 12 241 week after Visit 
5/EOS or EW Visit
Window -7d -5/+2d -5/+2d -5/+2d -1/+4d
Informed consent
(ICF)a X
Genetic I CFbX
Inclusion and 
exclusion criter iaX
DemographycX X
Medical history X
Asthma historyd
X
Smoking History 
and status X
Concomitant 
medication reviewX X X X X X X X
Register visit in 
Interactive W eb 
Response System
(IWRS)(RAMOS 
NG)eX X X X X X X
Randomiz ationfX
Laboratory  
Assessments
Urinalysis X
Hematology and 
clinical chemistryg X
Hepatitis B and C Xm
Genetic sample Xn 
 
 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
11Protocol Activit yPre-
ScreenScreen
Run-inTreatment Period Follow -up
Visit 0 12
Randomization3 45/End of Study  
(EOS)Early  Withdrawal 
(EW)Safety
Follow -up Contact
[CONTACT_633380]-42to -
14-14 1 29 85 169
Week -6 to -2 -2 0 4 12 241 week after Visit 
5/EOS or EW Visit
Window -7d -5/+2d -5/+2d -5/+2d -1/+4d
Serum pregnancy 
testXoXoXo
Urine pregnancy 
testXoXoXo
Safety  
Assessments
Physical exam 
including height 
and weighthX X X
12-lead 
Electrocardiogram
(ECG )iX X X X
Vital signsjX X X X X X
Adverse Event (AE)
reviewX X X X X X X
Serious Adverse 
Event (SAE) 
reviewX X X X X X X X
Study Treatment
Dispense open 
label fluticasone 
furoate (FF) [ADDRESS_845743] open label 
FF 100 mcgX X X X X
Dispense double -
blind study 
treatmentX X X 
 
 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
12Protocol Activit yPre-
ScreenScreen
Run-inTreatment Period Follow -up
Visit 0 12
Randomization3 45/End of Study  
(EOS)Early  Withdrawal 
(EW)Safety
Follow -up Contact
[CONTACT_633380]-42to -
14-14 1 29 85 169
Week -6 to -2 -2 0 4 12 241 week after Visit 
5/EOS or EW Visit
Window -7d -5/+2d -5/+2d -5/+2d -1/+4d
Administer double -
blind study 
treatmentXpXpXpXp
Collect double -blind 
study treatmentX X X X
Assess FF 
100mcg run-in 
medication 
complianceX
Assess FF 
100mcg and 
double -blind study 
treatment 
complianceX X X X
Efficacy  
Assessments
Global Assessm ent 
of Severity k X X X X X
Global Assessment 
of Response to 
Treatment kX X X X
Asthma C ontrol 
Questionnaire 
(ACQ -6)kX Xq
Asthma C ontrol 
Questionnaire 
(ACQ -5)kX X X X
St. George’s 
Respi[INVESTIGATOR_6004] 
(SGRQ ) kX X X X X 
 
 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
13Protocol Activit yPre-
ScreenScreen
Run-inTreatment Period Follow -up
Visit 0 12
Randomization3 45/End of Study  
(EOS)Early  Withdrawal 
(EW)Safety
Follow -up Contact
[CONTACT_633380]-42to -
14-14 1 29 85 169
Week -6 to -2 -2 0 4 12 241 week after Visit 
5/EOS or EW Visit
Window -7d -5/+2d -5/+2d -5/+2d -1/+4d
Asthma Quality of 
Life Questionnaire 
(AQLQ )kX X X X X
Evaluating 
Respi[INVESTIGATOR_633333] (E -RS) 
+Asthma symptoms 
+ Peak Expi[INVESTIGATOR_396975] (PEF) + Home 
Forced Expi[INVESTIGATOR_568928] 1 second
(FEV)1k, lX
eDiary Dispense X
eDiary Collect X X
eDiary Review X X X X X
Dispense paper 
Medical 
Problems/Medicatio
ns Taken 
worksheetX X X X X
Review paper 
Medical 
Problems/Medicatio
ns Taken
worksheetX X X X X X
Reversibility Xr
Pre-dose 
spi[INVESTIGATOR_038] (clinic)XsXsXsXsXsXs
Post-dose 
spi[INVESTIGATOR_038] (clinic)XtXtXt 
 
 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
14Notes:
a)The ICF must be signed before any study procedures, including medication cessation.
b)Genetics research consent may be obtained at the same time as the study IC and must be obtained prior to obta ining a genetic blood sample.
c)Demography may be captured at either the Pre -screen Visit or Screening Visit (for participant s who do not have a Pre-screen Visit).
d)The assessment of asthma history will include: the age of the participant when they were first provided with an inhaler for asthma; completion of an asthma 
medical history questionnaire (a copy of this questionnaire and instructions for its use can be found in the SRM).
e)The IW RS will be used for randomization, emergency unblinding and study treatme nt supply management (Please refer to the RAMOS NG IW RS manual and 
SRM for more information).
f)Participant s must not be randomized prior to confirming their eligibility to participate in the study.
g)If test otherwise performed within [ADDRESS_845744] dose of study treatment, testing at screening is not required.
h)Physical Examination willinclude height andweight at Visit 1 only . 
i)ECG to be obtained 15 minutes to 45 minutes after the administration of study treatment.
j)The vital signs assessment will include the measurement of blood pressure, heart rate,
k)Assessment(s) to be completed prior to the administration of study treatment.
l)To be completed using the provided combined spi[INVESTIGATOR_14007]/eDiary device. Assessments should be completed in the morning upon wak ening and in the evening 
immediately prior to going to bed.
m)Hepatitis C RNA is optional however a confirmatory negative Hepatitis C RNA test must be obtained, to be able to enrol participants with positive Hepatitis C 
antibody due to prior resolved disease . Hep B/C: If test otherwise performed within [ADDRESS_845745] dose of study treatment, testing at screening is not 
required.
n)Pharmacogenetic sample may be drawn any time from Visit 2 onwards.
o)Assessments only to be conducted in females of reproduc tive potential.
p)Study treatment should be administered at approximately the same time of day at each applicable clinic visit.
q)Baseline ACQ -5 will be derived from items 1 -5 of the Randomization (Visit 2) ACQ -6.
r)Following completion of the pre -dose spi[INVESTIGATOR_23943] y assessments, the reversibility test will be conducted between 20 and 60 minutes following 4 inhalations of 
albuterol/salbutamol aerosol. If airway reversibility is not demonstrated at Visit 1 then the assessment may be repeated with in 7 days of Visit 1 (see Section 9.1.3 .
for details of the criteria to be met before a repeat of the reversibility assessment is permitted). If airway reversibility is successfu lly demonstrated at the second 
attempt and all other eligibility criter ia assessed at Visit 1 are met then the participant may enter the 2 -week run -in period.
s)Pre-dose s pi[INVESTIGATOR_633334] 6am and 11am after withholding rescue medication for at least 6 hours and prior to taking the morning do se of 
study trea tment and FF 10 0mcg. After V2 pre -dose spi[INVESTIGATOR_96610] 1 hour of the V2 spi[INVESTIGATOR_038].
t)Post-dose spi[INVESTIGATOR_417440] 3 hours ( 15 minutes) after taking the morning dose of study treatment. Rescue medication should be withheld for at 
least [ADDRESS_845746] -dose spi[INVESTIGATOR_633335] 1hour of the V2 spi[INVESTIGATOR_038] . 
 
 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
153. INTRODUCTION
3.1. Stud y Rationale
In the [LOCATION_002] (US) , the long-acting muscarinic antagonist (LAMA) tiotropi[INVESTIGATOR_633330] -term maintenance treatment of asthma in patients 12 y ears of 
age and older.
GlaxoSmithKline ([COMPANY_004]) is currentl y dev elopi[INVESTIGATOR_007] a once -daily ‘closed’ triple therap y of a 
ICS/LAMA/ long-acting beta -2-agonist ( LABA )combination [FF /umeclidinium 
(UMEC )
/vilanterol (VI)] in a single device, with the aim of providing a new treatment 
option for the management of asthma in adults. Through the evaluation of UMEC 
62.[ADDRESS_845747] effective anti- inflammatory  
treatments for all severities of persistent asthma [ National Institutes of Health ( NIH)
2007; Global I nitiative for Asthma (GINA ) 2016].  Treatment with ICS controls asthma 
symptoms, improves quality  of life and lung function, decreases airway  hyper -
responsiveness, controls airway  inflammation, and reduces the frequency  and severit y of 
asthma exacerbations, thereb y red ucing asthma morbidity .  
Despi[INVESTIGATOR_633336] y of treatments and published guidelines, patients may have asthma 
that is not well controlled.
This trial will, primarily , evaluate trough FEV 1to characterize the efficacyof two doses
of UMEC (62.5 mcg and 31.25 mcg) in the treatment of asthma when administered as an 
open combination with FF 100mcg. UMEC is currently  under development as a closed 
triple therap y in combination with FFand VIin a single inhaler .
3.3. Benefit/Risk A ssessment
More detailed inform ation about the known and expected benefits and risks and 
reaso nably expected adverse events related to FF and UMEC can be found in the 
Investigator ’s Brochure (s) (IB ). The table below provides a summary  of the key  risks in 
association with FF and UMEC. I t is noted that both FF and UMEC have also been 
developed in combi nation with VI , therefore relevant safet y experience is also provided 
by [CONTACT_633381]/VI and UMEC/VI  combinations.    2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
163.3.1. Risk Assessment
Potential Risk of Clinical 
SignificanceSummary of Data/Rationa le for Risk Mitigation Strategy
Investigational Product (IP) [e.g., GW685698+[COMPANY_004]573719 ] 
Cardiovascular effects of 
UMEC UMEC
Cardiovascular effects are a potential class effect associated with 
anti-muscarinic therapi[INVESTIGATOR_014]. In the UMEC/VI clinical development 
program in chronic obstructive pulmonary  disease (COPD ) patients, 
UMEC/VI  was generall y well tolerated. Overall, a low number of 
atrial arrh ythmias were reported based on [ADDRESS_845748] with the combination over individual components.  Few of 
these findings were reported as SAEs and none were fatal. In a 
narrow* Major Adverse Cardiac Event (MACE) analy sis , the
incidence of non -fatal my ocardial infarction (Medical Dictionary  for 
Regulatory  Activities (MedDRA) Preferred Terms (PTs) of 
myocardial infarction and acute m yocardial infarction) was low 
(<1%) across all treatment groups, although small imbalances in 
exposure adjusted frequency  were observed between UMEC -and VI 
containing treatment groups when compared with placebo and 
tiotropi[INVESTIGATOR_1890].  There was no obvious dose relationship or additive effect 
from the combination.  Whether this represents a true effect is 
difficult to determine due to the small numbers. During clinical 
studies in COPD (62.5 and 125mcg daily  dose of UMEC) and in 
Health y Volunteers (in the Thorough QT stud y, UMEC 500mcg dail y 
dose), no effect was observed on heart rate, blood pressure or QT.Mitigation strategy  for UMEC 
- Exclusion criteria as specified in 
Section 6.2 ofthe protocol
-Collection of cardiovascular risk 
factors and medical history  at 
baseline
-ECGs as per schedule in 
Section 2
-Vital sign assessments (heart rate
and blood pressure) as per schedule in 
Section 2
-
Cardiovascular AEs and SAEs will 
be captured on the electronic Case 
Report Form (eCRF) ( seeAppendix 4 )
-Protocol defined stoppi[INVESTIGATOR_633337] 8.1
-MACE anal ysis
-Instream review of blinded data 
 
 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
17Potential Risk of Clinical 
SignificanceSummary of Data/Rationa le for Risk Mitigation Strategy
Healthy  Volunteers (in the Thorough QT stud y, UMEC 500 mcg 
daily  dose), no effect was observed on heart rate, blood pressure or 
QT.
Data from Thorough QT (TQT) studies with FF, FF/VI and 
UMEC/VI  suggest that, at the doses to be used in phase III studies, 
the closed triple (FF/UMEC/VI ) is unlikel y to cause clinically 
relevant effects on QTc1. No difference in QTcF2was observed 
between UMEC/VI 125/25mcg or UMEC 500 mcg and placebo. 
UMEC/VI  500/100 mcg increased QTcF on average b y 8.2 msec 
(milliseconds) (90% Confidence Intervals (CI): 6.2, 10.2) at 30 
minutes (min) only . A lack of effect was demonstrated for QTcF with 
FF/V I 200/25mcg (for 7 days). At a supratherapeutic dose of FF/VI 
(800/100mcg for 7 day s), the largest mean time -matched difference 
from placebo was 9.6 msec (90% CI: 7.2, 12.0) at 30 min only .
1QT interval corrected for heart rate
2QT interval corrected for heart rate by [CONTACT_6550]’s formula
Anticholinergic effects 
(including constipation 
nausea, dry mouth, 
glaucoma, raised 
intraocular pressure and 
blurred vision, urinary  
retention) In clinical studies in COPD, few anticholinergic effects were 
associated with UMEC; those observed included dry  mouth, 
constipation and cough.  Based on post -marketing experience 
dysgeusia has been added as an Adverse Drug Reaction (ADR) for 
inhaled UMEC and UMEC/VI .  In addition, UMEC/VI  has had 
urinary  retention, dysuria, vision blurred, glaucoma and increased 
intraocular pressure and paradoxical bronchospasm added as ADRs.   
ICS has a similar class risk of glaucoma and elevated intraocular -Patients with known narrow -angle 
glaucoma, prostatic h yperplasia or 
bladder outflow obstruction that, in 
the opi[INVESTIGATOR_689], 
contraindicates stud y participa tion or 
use of an inhaled anticholinergic, will 
be excluded from participating in the 
study .
-Review AEs/SAEs 
 
 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
18Potential Risk of Clinical 
SignificanceSummary of Data/Rationa le for Risk Mitigation Strategy
pressure (IOP); however these effects occur b y a different mechanism 
that is not expected to be sy nergistic or additive when FF is used in
combination with UMEC.
Systemic ICS effects 
-Aderenal suppression
-Cataracts & glaucoma
-Reduced bone mineral 
density  and associated 
fracturesNo studies have shown a clinically  relevant effect of FF/VI or FF on 
the hy pothalamic pi[INVESTIGATOR_417483] (HPA). This includes a formal HPA 
study  (HZA106851), which assessed the effects of FF/VI 100/25 and 
200/25 on serum cortisol and 24 hour serum cortisol excretion, and 
multiple s tudies with COPD and asthma participant s which 
monitored urinary  cortisol.  
During clinical development of FF & FF/VI no events of Adrenal 
Suppression were reported.  There has been no evidence for adrenal 
suppression based on post- marketing experience to date.  
In stud y HZA106839 (FF/VI, FF and fluticasone propi[INVESTIGATOR_16847] (FP) in 
participant s with asthma), formal Ophthalmic assessments were 
conducted (including Lens Opacities Classification Sy stem III 
(LOCS III) evaluations for ocular opacities) throughout the study . 
This study  showed no apparent effects on lens opacification, 
compared to baseline assessment.  
During studies in both participant s with asthma and COPD, no 
associated affect on ocular disorders was observed.  Spontaneous 
data received to date does not alter the understanding of this risk.  
A decrease in bone mineral density  and the risk of fractures is a class 
concern for an y ICS-containing product for the treatment of COPD.
In two replicate 12 month studies in the FF/VI clinical program, in a -Review AEs/SAEs
-The occurrence of bone fractures 
will be recor ded in the eCRF. 
 
 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
19Potential Risk of Clinical 
SignificanceSummary of Data/Rationa le for Risk Mitigation Strategy
total of 3,255 patients with COPD, the incidence of bone fractures 
overall was low in all treatment groups, with a higher incidence in all 
FF/V I groups (2%) compared with the VI 25 mcg group (<1%).  
Although there were more fractures in the FF/VI groups compared 
with the VI 25mcg group, fractures t ypi[INVESTIGATOR_1306] y associated with 
corticosteroid use (e.g., spi[INVESTIGATOR_629921]/thoracolumbar vertebral 
fractures, hip and acetabular fractures) occurred in <1% of the FF/VI 
and VI treatment arms.  In an integrated anal ysis of 11 studies in 
asthma with FF/VI (7,034 patients) and 10 studies in asthma with FF 
(6,219), the incidence of fractures with FF/VI and FF was 1%, and 
usually  associated with trauma.   
Pneumonia While I CS use is a recognised risk for pne umonia in patients with 
COPD, a clear causal relationship between inhaled corticosteroid use 
and pneumonia in participant s with asthma has not been established.  
In an 18 study  integra tion in the FF/VI asthma program, the 
incidence of pneumonia (adjusted for exposure) observed with FF/VI 
100/25 and FF 100 mcg (8.5/1000 patient y ears and 9.6/1000 patient 
years, respectivel y) was similar to that seen with placebo (9.3/1000 
patient y ears). A higher incidence in the FF/VI 200/25 and FF 200 
arms were observed (18.3/1000 patient years and 23.6/1000 patient 
years, respectivel y). However, the 95% CIs were wide and 
overlapped across all treatment groups, including placebo. Few of the 
pneumonia ev ents led to hospi[INVESTIGATOR_633339], and 
there were no observed differences in the incidence of serious events 
between the two treatment strengths.  The risk of pneumonia in 
asthma patients is very  low and is consistent with the risk of other 
ICS.  Exclusion criteria:
-Immune suppression (e.g., Human 
Immunodeficiency  Virus [HI V], 
Lupus) or other risk factors for 
pneumonia (e.g.,neurological 
disorders affecting control of the 
upper airway , such as Parkinson’s 
Disease, M yasthenia Gravi s).
-Participant s at potentially  high risk 
(e.g., very  low body  mass index 
[BMI ] or severel y malnourished) will 
only be included at the discretion of 
the Investigator.
Medical history will also be taken for 
pneumonia in previous 12 months, 
including recor ding of any  epi[INVESTIGATOR_1841]  
 
 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
20Potential Risk of Clinical 
SignificanceSummary of Data/Rationa le for Risk Mitigation Strategy
Pneumonia experience with UMEC
In the All Clinical Studies groupi[INVESTIGATOR_007], the incidence of on -treatment 
AEs in the Pneumonia and lower respi[INVESTIGATOR_2826] (LRTI) 
adverse events of special interest (AESI) category  with UMEC 
62.5 mcg (1%; 34.6/10 00SY) was similar to placebo (1%; 
34.8/1000SY) and lower than the incidence reported in the UMEC 
125mcg (3%; 72.6/1000SY). A higher incidence of AEs in the 
Pneumonia AESI  category  was reported for UMEC 125 mcg (2%; 
37.4/1000SY) compared with UMEC 62.5 mcg (<1%; 19.8/1000SY) 
and placebo (<1%; 10.7/1000SY). The proportion of participant s 
with SAEs in the Pneumonia AESI  category  was similar between 
both U MEC treatment groups, UMEC 62.5 mcg (<1%; 4.9/1000SY) 
and UMEC 125 mcg (<1%; 17.6/1000SY) and placebo (<1% ; 
10.7/1000SY).resulting in hospi[INVESTIGATOR_11956].  
The occurrence of pneumonia will be 
recorded in the eCRF.
Where possible a chest X -ray should 
be performed to confirm a diagnosis, 
whenever a participant has a 
suspected pneumonia.
All reports of pneu monia 
(radiographicall y confirmed and 
unconfirmed) must be reported as an 
AE or SAE, if applicable 
Instream review of blinded data.
Review of AESI relevant for 
pneumonia using pre -specified 
MedDRA preferred terms. AE terms 
relating to other Lower Respi[INVESTIGATOR_633370] (excluding 
pneumonia) will also be reviewed.  
Hypersensitivity There have been post- marketing reports of h ypersensitivity  reactions 
with FF/VI and UMEC/VI, including anaph ylaxis, angioedema, rash, 
and urticaria.  The formulation als o contains lactose.Participant s with a history  of allergy  
or hy persensitivity  to an y 
corticosteroid, 
anticholinergic/muscarinic receptor 
antagonist, beta2 -agonist, 
lactose/milk protein or magnesium  
 
 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
21Potential Risk of Clinical 
SignificanceSummary of Data/Rationa le for Risk Mitigation Strategy
stearate are excluded from 
participation in this study  (Section 
6.2). 
-Review AEs/SAEs
Paradoxical 
bronchospasmRare reports of paradoxical bronchospasm (which may  be life 
threatening) with other inhalational products have been reported.  
There have been rare post- marketing reports of paradoxical 
bronchospasm with FF/VI and UMEC/VI.Patients will undergo regular medical 
assessments during clinical studies.  
-Review AEs/SAEs
Pregnancy  and lactation There has been limited pregnancy  exposure to FF and FF/VI in 
humans. Animal studies have shown reproductive toxicity  after 
administration of corticosteroids and beta2 -agonists. 
There is a limited amount of data from the use of UMEC in pregnant 
women. Animal studies do not indicate direct or indirect harmful 
effects with respect to reprod uctive toxicity . 
There is limited information on the excretion of FF or VI or their 
metabolites in human milk. However, other corticosteroids and 
beta2 -agonists are detected in human milk.I t is unknown whether 
umeclidinium is excreted in human milk. The e xcretion of 
FF/UMEC/VI in breast milk has not been evaluated. A risk to 
breastfed newborns/infants cannot be excluded.Females who are pregnant or breast-
feeding are not eligible for 
participating in the stud y.
Females of child -bearing potential 
will need to follow the contraceptive 
requirements that are specified in
Appendix 5.  
 
 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
22The risks for FF100mcg are recognised pharmacological class effects associated with 
ICS therap y, which are included in the table above . The experience with FF is provide d 
in the respective IB.  
3.3.2. Benefit A ssessment
The benefit of UMEC at two dosage strengths 62.5 and 31.25 mcg as compared to 
Placebo in patients with asthma on backgro und therapy  of FF 100 mcg is expected to 
improve lung function. The inclusion of two strengths of UMEC will allow comparison 
to placebo for the dose currentl y marketed in COPD, as well as a lower dose. This will 
help show the efficacy  and safet y of UMEC in asthma when administered as an open 
combination on a background of FF. AnotherLAMA, tiotropi[INVESTIGATOR_1890], is currently  approved 
for the maintenance treatment of asthma. 
3.3.3. Overall Benefit: Risk Conclusion
Taking into account the measures taken to minimize the risk to the participant s 
participating in the stud y, the potential risks identified in association with UMEC are 
justified by  [CONTACT_633402] s with asthma.  
The current experience and safet y profile with UMEC in previous Phase II asthma studies 
(alone and in combination with FF) and from clinical trial and marketing experience in 
the COPD population is supportive of evaluating this compound in asthma patients . The 
potential risks associated with the known pharmacology  of UMEC 
is offset by  [CONTACT_633383] I CS
therap y. Furthermore, t he approval of another LAMA (tiotropi[INVESTIGATOR_1890]) for the treatment of
asthma demonstrates the suitability  for the use of this class of drug in the asthma 
population.  
4. OBJECTIVES A ND ENDPO INTS
For a def inition of baseline for each of the endpoints listed below, please refer to Section 
10.6.
Objectives Endpoints
Primary
Evaluate the effects of UMEC 
62.5 mcg and UMEC 31.25 mcg 
on lung function (trough FEV1) 
versu s placebo afte r 24 weeks of 
treatment.Mean change from baseline in 
clinic 
trough FEV 1atWeek 24
Secondary
Evaluate the effects of UMEC 
62.5 mcg and UMEC 31.25 mcg on 
lung function (3hours post dose Mean change from baseline in clinic 
FEV 1at [ADDRESS_845749] dose at Week 24 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
23Objectives Endpoints
FEV1) versu s placebo after 24 
weeks of treatment.
Safety  
To evaluate the  safet y and 
tolerability  of UMEC 62.5 mcg and 
UMEC 31.25 mcg compared to 
placeboIncidence and t ype of adverse events
ECG measurements
Vital signs
Other
To evaluate other e fficacy  assessments 
of UMEC 62.5 mcg and UMEC 
31.25 mcg compared to placeboMean change from baseline in morning 
(AM) pre -dose Peak Expi[INVESTIGATOR_105177] 
(PEF) over the 24 week treatment 
period
Mean change from baseline in evening
(PM)PEF over the 24 week trea tment 
period
Mean change from baseline in daily  
home trough FEV1 over the 24 week 
treatment period
Mean change from baseline in daily  
rescue medication use over the 24 
week treatment period
Mean change from baseline in SGRQ
total score at Week 24
Percent of patients meeting a 
responder threshold of ≥ 4 points 
improvement (decrease) from baseline 
for the SGRQ total score at Week 24
Mean change from baseline in SGRQ 
domain scores at Week 24
Mean change from baseline in the 
AQLQ total score at Week 24
Percent of patients meeting a 
responder threshold of ≥ 0.5 points 
improvement from baseline for the 
AQLQ total score at Week 24
Mean change from base line in E -RS
total score over the 24 week treatment 
period
Mean change from baseline in  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
24Objectives Endpoints
ACQ -5 total score at Week 24
Percent of patients meeting a 
responder threshold of ≥0.5 in change 
from baseline for the ACQ -5 at Week 
24
Annualized rate of moderate/ severe 
asthma exacerbations
5. STUDY DESIGN
5.1. Overall Design
This is a Phase IIb, randomized, double -blind, placebo contro lled, 3- arm parallel group 
study , comparing the efficacy , safet y and tolerability  of UMEC (
62.5 mcg and 
31.25 mcg) administered once- dailyin participants with asthma that is not well controlled 
(i.e. participants with an ACQ -6 total score > 0.75 at Visit 2[the R andomization Visit ]) 
despi[INVESTIGATOR_633331].
Eligible participant s will be requested to participa te in the study  for a maximum of 
approximately  31weeks ( Visit 0to the Follow -up contact , inclusive ) during which time, 
participants will complete the following 4 phases of the study : 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
25Pre-screening: Details about the study  and procedures will be explained 
through the informed consent process. The Pre -screening Visit (Visit 0 ), 
including the informed consent process, must be completed within 4 weeks prior 
to Visit 1 as well as prior to any  protocol -required changes to a participant’s 
usual asthma treatment and the initiation of any Visit 1 procedures. Subjects will 
continue treatment with their regular (i.e. pre- study ) asthma medication(s ) 
during the pre -screening period; however, medications that are prohibited within 
a specified time interval prior to Visit 1 are defined in Section 7.9.
Participant s that 
receive LABA (or LAMA) as a component of their regular (i.e. 
pre-study ) therap y must stop L ABA (or LAMA) treatment from  48 hours prior 
to Visit 1 (Screening) until they have completed the study ; therefore, the 
investigator must use their clinical judgment to determine if the participant may 
stop L ABA (or LAMA ) prior to study  entry  without incurring undue risk.
Screening / run- in: Participant s who meet all the eligibility  criteria at Visit 1 
(Screening), will enter the run -in period for approximately  2 weeks to continue 
assess ingthe participant ’s eligibility  for the study . On the morning of Visit 1, 
participant s will refrain from taking the morning dose of their regular (i.e. pre-
study ) ICS asthma medication. Participant s satisfying all inclusion/exclusion 
criteria and who have successfully  completed all protoc ol procedures at 
screening will be provided with FF 100 mcg via the ELLIPTA dry -powder 
inhaler (DPI) to take once daily  (QD), in the morning, during the 2- week run -in 
period; the first dose of FF 100 mcg will be self -administered by  [CONTACT_633378]. Participants will refrain from using their own ICS 
asthma medication during the 2 -week run- in and treatment period. Participants 
will also be provided with rescue medication (albuterol/salbutamol) to use on an 
as-needed basis throughout the stud y.
Randomization / treatment: At Visit 2 (the Randomization Visit), participants 
who meet all of the randomization criteria will be randomized 1:1:1 to receive 
oneof the following three double -blind study  treatments via the ELLIPTA DPI  
[CONTACT_78482] 24-week treatment period:
UMEC 62.5 mcg QD
UMEC 31.25 mcg QD
Placebo QD
Participants will continue to administer FF 100 mcg once dail y (QD), in the 
morning from a separate ELLIPTA DPI [INVESTIGATOR_633332]. On the 
morning of Visits 2, 3, 4, and 5, participant s will perform their electronic Diary  
(eDiary ) assessments at home but refrain from taking their morning dose of 
study  treatment andFF 100 mcg (as applicable) until instructed to do so by
[CONTACT_6477]. At Visits 2, 3, [ADDRESS_845750] at the clinic (see Section 
7.2). Participant s will take their last dose of study  treatment and FF 100 mcg in 
the clinic on Day  169 (Visit 5). Participants are expected on non -clinic visit day s
to take their study  treatment and FF 100 mcg at home in the morning at 
approximately  the same time each day,as directed by  [CONTACT_3652]. 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
26Safety f ollow -up: A safety  follow -up telephone contact [CONTACT_238244] w ill be 
conducted approximately 7 day s after the participant completes all of the 
protocol -defined procedures for V isit 5 /End of Study  (EOS )or, if applicable, the 
Early Withdrawal V isit. A participant will be considered to have completed the 
study  when the y have completed all phases of the study  including screening, 
run-in, the randomi zed treatment phase, and safety  follow -up.
To demonstrate the benefit of UMEC the primary  comparisons of interest for the primary  
efficacy  endpoint are:
UMEC 62.5 mcg versus ( vs
)Placebo
UMEC 31.[ADDRESS_845751] that aim to informally  estimate any  
potential benefit of increasing the UMEC dose are given below for all efficacy  endpoints. 
UMEC 62.[ADDRESS_845752] not withdrawn consent are encouraged to continue in the study  and 
complete all remaining protocol specified clinic visits (see Section 8.1)
5.2. Number of Participants
The total number of randomi zed participant s required is 
approximately  384, with 128
participant s randomized 1:1:1 to each of the 3 double -blind treatment arms (seeSection 
10).  
5.3. Participant and Study  Completion
A participant will be considered to have c ompleted the study  when they  have completed 
allphases of the stud y including pre-screening, screening, run
-in, the randomi zed 
treatment phase, and safety  follow -up.
The end of the stud y is defined as the date of the last scheduled procedure shown in the 
Schedule of Activities table (see Section 2) for the last participant in the trial globall y.
5.4. Scientific Rationale for Study  Design
This study  will use a multicenter, randomized, double -blind, 3 arm parallel
-group design.  
This i s a well -established design to evaluate the efficacy , safety , and tolerability  of the 
UMEC 
drug.  A placebo arm is included . All participant s will be placed on open -label FF 
100mcg when they  enter the 2 week run -in period and continue it through the 24 we ek 
treatment period. The primary  objective of this study  is to evaluate the effects of UMEC 
62.5 mcg and UMEC 31.25 mcg on lung function compared with placebo after 24 weeks 
of treatment. 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
27GlaxoSmithKline ([COMPANY_004]) is currentl y developi[INVESTIGATOR_007] a once -daily ‘closed’ triple therapy  of a 
ICS/LAMA/LABA combination [FF /UMEC/ VI)] in a single device, with the aim of 
providing a new treatment option for the management of asthma in adults. Through the 
evaluation of UMEC 62.5 mcg and 31.25 mcg compared to placebo this study  will 
provide important informa tion regarding the efficacy , safety and tolerability of UMEC in 
asthma when administered via a separate inhaler to participant s on a background of FF
without VI .
5.5. Dose Justification
The 200699 (IB Supplement, GlaxoSmithKline Document 2011N123107_03) data 
showed UMEC 62.5 mcg to be an effective dose; after 4 weeks of treatment in the 
subset of patients with a primary  diagnosis of asthma, an average increase in change 
from baseline trough FEV 1at Day  29 of 136 m L was observed in those participant s
treated with FF/UMEC (100/62.5 mcg) compared to those participant s treated with 
FF(100 mcg) alone. However, stud y 200699 did not assess the UMEC 31.25 mcg 
dose, therefore, the efficacy  and safet y profile of both 31.25 and 62.5 mcg doseswill 
be assessed in this study when administered via a separate inhaler to participant s 
treated on a background of FF 100 mcg. No safety signal was identified with any  of 
the UMEC doses (15.6, 62.5, 125 and 250 mcg) evaluated in the 200699 study .
6. STUDY POPULA TION
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
6.1. Inclusion Criteria
Participants are eligible to be included in the stud y only if all of the following criteria 
apply :
AGE
1.Age: 18 years of age or older at the time of signing the informed consent.
TYPE OF PARTICI PANT AND DISEASE CHARACTERI STICS
2.Diagnosis: Participant s with a diagnosis of asthma as defined b y the National 
Institutes of Health [ NIH, 2007] at least 6 months prior to Visit 0.
3.Asthma Control :ACQ -6total score of >0.75 at Visit 1 .
4.Current Asthma Maintenance Therapy : Participant s are eligible if they  have 
required daily  ICS therapy  100mg/day fluticasone propi[INVESTIGATOR_16847] (FP, or 
equivalent) with or without L ABA or LAMA for at least [ADDRESS_845753] been no changes in maintenance asthma medications d uring the 4 
weeks imm ediatel y prior to Visit 0 .
Examples of acceptable dose s of commonly  prescribed I CS medication will be 
provided in the Study  Reference Manual (SRM) .  Dosing regimen (once or twice 
daily  to equal the total daily  dose) should be restricted to the current local product  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
28labels.
5.Spi[INVESTIGATOR_038]: Both of the following:
a.A best pre -bronchodilator morning (AM) FEV1 ≤85% of the predicted 
normal value. Predicted values will be based upon the ERS Global L ung 
Function Initiative [ Quanjer , 2012].
b. A best post- bronchodilator FEV1/ forced vital c apacity (FVC ) ≥0.7 at 
Visit 1.
6.Reversibility of Disease: Airway  reversibility  is defined as ≥12% and ≥200 mL  
increase in FEV1 between 20 and 60 minutes following 4 inhalations of 
albuterol/salbutamol aerosol at Visit 1.
Note: If the participant does not meet the above reversibility criteria at Visit 1 
then the reversibility assessment may be repeated once within 7 days of Visit 1 if 
either criteria a) or b) are met:
a) ≥9% increase in FEV1 betwee n 20 and 60 minutes following 4 
inhalations of albuterol/salbutamol aerosol at Visit 1.
b) Documented evidence of a reversibility assessment within [ADDRESS_845754] -
bronchodilator increase in FEV1 of 
≥12% and ≥[ADDRESS_845755] reversibility (defined as 
≥12% and ≥200 mL increase in FEV1 betwee n 20 and 60 minutes following 4 
inhalations of albuterol/salbutamol aerosol) at the second attempt then, provided 
that all other eligibility criteria assessed at Visit 1 are met, the participant may 
enter the 2- week run- inperiod (seeSection 9.1.3 ).
7.Short -Acting β2 Agonists (SABAs): All subjects must be able to replace their 
current SABA inhaler with albuterol/salbutamol aerosol inhaler at Visit [ADDRESS_845756] be judged capable of 
withholding albuterol/salbuta mol for at least 6 hours prior to study  visits.
SEX
8.Gender:
a.Male participants
b.Female participants: 
A female participant is eligible to participate if she is not pregnant (see Appendix 5),
not breastfeeding, and at least one of t he following conditions applies:
Not a woman of childbearing potential (WOCBP) as defined in Appendix 5
OR
A WOCBP who agrees to follow the contraceptive guidance in Appendix [ADDRESS_845757] dose of study   2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
29treatment.
INFORMED CONSENT
9.Informed Consent: Able to give written informed consent prior to participation 
in the study , which will include the ability  to comply  with the requirements and 
restricti ons list ed in the consent form and in this protocol.  Participant s must be 
able to read, comprehend, and write at a level sufficient to complete study  related 
materials.
6.2. Exclusion Criteria
Participant s are excluded from the study  if any  of the following criteria apply :
MEDICAL CONDITIONS
1.Pneumonia :Chest X -ray documented pne umonia in the 12 weeks prior to Visit 1.
2.Asthma Exacerbation: Any severe asthma exacerbation, defined as deterioration of 
asthma requiring the use of systemic corticosteroids (oral, parentera l or depot) within 
12 weeks of Visit 1, or an inpatient hospi[INVESTIGATOR_633371] 12 weeks of Visit 1.
3.Concurrent Respi[INVESTIGATOR_31753]: Current evidence of pneumonia, pneumothor ax, 
atelectasis, pulmonary  fibrotic disease, bronchopulmonary  dysplasia, chronic 
bronchitis, emphy sema, chronic obstructive pulmonary  disease, lung cancer, or other 
respi[INVESTIGATOR_633342].
4.Pregnancy: Women who are pregnant or lactating or are planning on becoming 
pregnant during the study.
5. Risk Factors for Pneumonia : Immune suppression (e.g., HIV, Lupus) or other 
risk factors for pneumonia (e.g., neurological disorders affecting control of the upper 
airway , such as Parkinson’s Disease, Myasthenia Gravis) . Patients at potentially  high 
risk (e.g., very low BMI, severel y malnourished, or very  low FEV 1) will only  be 
included at the discretion of the Investigator .
6.Other diseases/abnormalities : Participant s with historical or current evidence of 
clinically  significant cardiovascular, neurological, psy chiatric, renal, hepatic, 
immunological, gastrointestinal, urogenital, nervous sy stem, musculoskeletal, skin, 
sensory , endocrine (including uncontrolled diabetes or thy
roid disease) or 
hematologica l abnormalities that are uncontrolled .  Significant is defined as any  
disease that, in the opi[INVESTIGATOR_689], would put the safet y of the participant
at risk through participation, or which would affect the efficacy  or safet y analysis if 
the dise ase/condition exacerbated during the stud y.
7.Unstable liver disease as defined b y the presence of ascites, encephalopathy, 
coagulopath y, hypoalbuminaemia, esophageal or gastric varices or persistent 
jaundice, cirrhosis, known biliary  abnormalities (with the exception of Gilbert’s 
syndrome or as ymptomatic gallstones).  Note: Chronic stable hepatitis B and C are 
acceptable if the participant otherwise meets entry criteria 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
308.Clinically significant ECG abnormality: Evidence of a clinicall y significant 
abnormality  in the 12-lead ECG performed during screening or run- in. The PI  [INVESTIGATOR_633343] ’s medical history  and exclude participant
s who would be at undue risk by  
[CONTACT_7624] t he trial. An abnormal and clinically  significant finding is defined as a 
12-lead tracing that is interpreted as, but not limited to, any of the following:
AF with r apid ventricular rate >120 beats per m inute ( BPM )
sustained or nonsustained ventricular tach ycardia (VT)
Second degree heart block Mobitz ty pe II and third degree heart block (unless 
pacemaker or defibrillator had been inserted)
QTcF ≥500 msec in patients with QRS <120 msec and QTcF ≥530 msec in 
patients with QRS 
≥120 msec
9.Unstable or life threatening cardiac disease: participant s with any  of the following 
at Screening (Visit 1) would be excluded:
Myocardial infarction or unstable angina in the last 6 months 
Unstable or life threatening cardiac arrh ythmia requiring intervention in the last 
3 months
[LOCATION_001] Heart Association ( NYHA )Class IV Heart failure
10.Antimuscarinic effects: Participant s with a medical condition such as narrow -angle 
glaucoma, urinary  retention, prostatic hy pertrophy or bladder neck obstruction should 
only be included if in the opi[INVESTIGATOR_2511] I nvestigator the benefit outweighs the risk 
and that the condition would not contraindicate study  participation.
11.Cancer : Participant s with carcinoma that has not been in complete remission for at 
least [ADDRESS_845758] had carcinoma in situ of the cervix, squamous 
cell carcinoma and basal cell carcinoma of the skin would not be excluded based on 
the 5 year waiting period if the participant has been considered cured b y treatment.
12.Questionable validity of consent : Participant s with a history  of ps ychiatric disease, 
intellectual deficiency , poor motivation or other conditions that will limit the validity  
of informed consent to participate in the study .
PRIOR/CONCOMITANT THERAPY
13.Medication prior to spi[INVESTIGATOR_038] : Participant s who are medically  unable to withhold 
their albuterol/salbutamol for the 6- hour period required prior to spi[INVESTIGATOR_417426] y visit.
PRIOR/CONCURRENT CLI NICAL STUDY EXPERIEN CE/RELEVANT 
HABITS
14.Tobacco Use: Current smoker or a smoking history  of ≥10 pack years (e.g., 
20cigarettes/day  for 10 years).  A participant may not have used inhaled tobacco 
products within the past 12 months (i.e., cigarettes, cigars or pi[INVESTIGATOR_28303]). 2018N371775_00
2016N289466_00 CONFIDENTIA L
[PHONE_13188].Drug/alcohol abuse : Participant s with a known or suspected history  of alcohol or 
drug abuse within the last 2 y ears.
Diagnostic assessments
16.Allergy or Hypersensitivity : A history  of allergy or hy persensitivity  to any  
corticosteroid, anticholinergic/muscarinic receptor antagonist, beta2 -agonist, 
lactose/milk protein or magnesium stearate.
Other Exclusions
17.Non-compliance : Participant s at risk of non- compliance, or unable to comply  with 
the study  procedures.  Any  infirmit y, disability, or geographic location that would 
limit compliance fo r scheduled visits.
18.Affiliation with investigator site : Study  investigators, sub- investigators, study  
coordinators, emplo yees of a participating investigator or study  site, or immediate 
family  members of the aforementioned that is involved with this study .
19. Inability to read: In the opi[INVESTIGATOR_2511] I nvestigator, any  participant who is unable to 
read and/or would not be able to complete stud y related materials.
6.2.1. Randomization Criteria
At the end of the run -inperiod (Visit 2) , study  participants must fulfil the following 
additional criteria in order to be randomized into the study  and enter the treatment period :
6.2.2. Inclusion Criteria for Randomization
TYPE OF PARTICI PANT AND DIAGNOSIS INCL UDING DI SEASE SEVERI TY
1.Asthma Control : ACQ -6total score of >0.75 at Visit 2.
2.Percent -predicted FEV 1: Spi[INVESTIGATOR_038] : A best pre -bronchodilator morning (AM) 
FEV1 ≤85% of the predicted normal value at Visit 2.Predicted values will be based 
upon the ERS Global L ung Function Initiative [ Quanjer ,2012].
CONCURRENT CONDITIONS/MEDICAL HISTORY
3. Liver function tests at Visit 1:
alanine aminotransferase (ALT) ≤ 2 x upper limit of normal (ULN)
alkaline phosphatase  ≤1.[ADDRESS_845759]
bilirubin ≤1.5 x UL N (isolated bilirubin >1.[ADDRESS_845760] bilirubin <35%)
eDIARY
4.Compliance with completion of the Dail y eDiary reporting defined as completion of 
all questions/assessments on [ADDRESS_845761] 7 day s during the run- in period. 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
326.2.3. Exclusion Criteria for Randomization
CONCURRENT CONDITIONS/MEDI CAL  HISTORY
1.Respi[INVESTIGATOR_60623]: Occurrence of a culture -documented or suspe cted bacterial or 
viral infection of the upper or lower respi[INVESTIGATOR_53121], sinus or middle ear during the 
run-in period that led to a change in asthma management or, in the opi[INVESTIGATOR_684] , is expected to affect the participant ’s asthma status or the participant ’s 
ability  to participate in the study .
2. A sthma exacerbation: Evidence of a moderate asthma exacerbation leading to a 
change in therap yor severe exacerbation during screening or the run-inperiod , 
defined as deterioration of asthma requir ing the use of s ystemic corticosteroids 
(tablets, suspension, or injection) or an in -patient hospi[INVESTIGATOR_633344] s ystemic corticosteroids.
CONCOMITANT MEDICATIONS/TREATMENTS
3.Asthma medication: Changes in asthma medication (excluding changes after Visit 0 
or run -in medication and albuterol/salbutamol inhalation aerosol provided at Visit 1).
DIAGNOSTIC ASSESSMENTS AND OTHER CRITERIA
4.Laboratory test abnormalities: Evidence of clinically  significant abnormal 
laboratory  tests during screening or run -in which are still abnormal upon repeat 
analysis and are not believed to be due to disease(s) present.  Each Investigator will 
use his/her own discretion in determining the clinical significance of the abnormal ity.
6.3. Lifest yle Restrictions
No lifesty le restrictions are required for this study .
6.4. Pre-Screening/ Screening/Run -in/Randomization Failures
A participant will be assigned a participant number at the time the informed consent is 
signed at Visit 0 .
The study  site will be responsible for reporting pre-screen failures. The following 
information will be collected in the eCRF for participant s who are pre -screen failures:
Demographic information including race, age and gender
Participant number
Serious Adverse Event information only for any  SAE considered as related to 
study  participation
Investigator signature [CONTACT_633407] ,pre-screening failures, screening failures, run-in failures
and randomization failures
will be defined as follows:
Pre-screening failures: those participant s that sign the informed consent 
document but do not have a Visit 1 (Screening) procedure. 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
33Screening failures: those participant s that complete at least one Visit 1 
(Screening) procedure but do not enter the run -in period . 
A participant who completes Visit [ADDRESS_845762] entered the run- in period.
Run-in failures: those participant s that enter the run -in period but do not have 
any Visit 2 (Ra ndomization) procedures.
Randomization failures: those participant s that complete at least one Visit 2 
(Randomization) procedure but do not enter the double- blind study  treatment 
period.
Any participant who completes the run -in period and then meets the 
randomization criteria and is dispensed the double -blind study  treatment at Visit 
[ADDRESS_845763] entered the treatment period.
RAMOS NG will be contact[CONTACT_633403].
In order to ensure transparent reporting of screen /run-infailure participant s, meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements, and 
respond to queries from Regulatory  authorities, a minimal set of screen /run-
in/randomization failure information is required including demography , screen /run-
in/randomization failure details, eligibility  criteri a, and an y SAE s(see Section 9.2.4 and
Appendix 4 )
. Further details are provided in the study -specific eCRF completion 
guidelines document .
7. TREATMENTS
Study  treatment is defined as any  investigational treatment(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according 
to the study  protocol. The term ‘study  treatment’ within this trial is u sed to describe the 
combination of products received by [CONTACT_97246]. Study 
treatment may  also be used to only reference the randomized study  treatment when 
described together with the FF 100 mcg open -label treatment.
7.1. Treatments Administered
7.1.1. Description of FF 100 mcg and Double -Blind Study  
Treatment
The ELLIPTA device will be used during the run-in period and the treatment period .  The 
ELLIPTA dry powder i nhaler (DPI)is a molded plastic two- sided device with a dose 
counter that can hold two individual blister strips.  The ELLIPTA will deliver, when 
actuated, the contents of a single blister simultaneously  from each of the two strips. The 
ELLIPTA is individually sealed in a foil laminate overwrap that also contains a silica gel
desiccant packet.
A description of the FF (GW685698) 100mcg inhalation powder administered via the 
ELLIPTA is provided in Table 
1; descriptions of the double -blind study  treatments 
administered via the ELLIPTA are provided in Table 2. 2018N371775_00
2016N289466_00 CONFIDENTIA L
[ADDRESS_845764] Strip Second Strip
GW685698 blended w ith 
lactose monohydrateLactose monohydrate with magnesium 
stearate1
Dosage Form ELLIPTA DPI w ith 30 doses (2 strips w ith 30 blisters)
Unit Dose strengths 100 mcg per blister Not applicable
Physical description White pow der White pow der
Route of 
AdministrationInhaled
1. Magnesium stearate 1.0% w/w of total drug product.
Table 2 Description of Study  Treatment Inhalation Powder in ELLIPTA
7.1.2. Description of A lbuterol/Salbutamol
Albuterol/salbutamol via metered -dose inhaler (MDI) will be issued for reversibility  
testing at Visit 1.  An albuterol/salbutamol MDI  for as needed (prn) use throughout the 
study  will be provided starting at Visit 1; at the I nvestigator’s discretion, more than one  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
35MDI  may  be provided at any  one time. Albuterol/salbutamol will be sourced from local 
commercial stock.  If not available locall y, [COMPANY_004] will source centrally .The contents of the 
label will be in accordance with all applicable regulatory  requirements.
7.1.3. Stud y Treatment and FF 100mcg Return
ELLIPTA s contai ning FF 100 mcg and study  treatment will be dispensed to a participant 
during their visit to the study  clinic (as applicable) . The participant must return all 
dispensed ELLIPTAs at the subsequent clinic visit. The schedule for dispensing and 
collecting FF 100 mcg and study  treatment ELLIPTA s is provided in the Schedule of 
Activities table (Section 2).
All used and unused study  treatment, FF 100 mcg and albuterol/salbutamol 
will be 
returned to [COMPANY_004] at the end of the study  to be available for disposal.  In some instances 
for sites outside the US, study  supplies wi ll be disposed of locall y either b y the site, the 
country  medical department or third -party vendor.  Detailed instructions for the return of 
the study  drug can be found in the Study  Reference Manual ( SRM ).
If any ELLIPTA fails to function properl y, the participant should return to the clinic as 
soon as possible to obtain a new inhaler.  The site will use the I WRS (RAMOS NG) to 
obtain a new treatment pack number for the participant and dispense a new study  
treatment kit from the site’s study  treatment supply as instructed by  [CONTACT_941] I WRS.
In addition, any  metered dose inhaler (MDI ) that fails to function properl y must be 
identified and returned to [COMPANY_004] for testing.  Details of the failure will be documented in 
the eCRF.
7.2. Dose Modification
There were no dose modific ations planned for this protocol.
7.3. Method of Treatment A ssignment
Participant s will be assigned to study  treatment in accordance with the randomization 
schedule. The randomization code will be generated by  [CONTACT_417506] a validated 
computerized sy stem . Particip ants will be randomized using an interactive web response
system (IWRS) RAMOS NG. The stud y will use central -based randomization to allocate 
treatments. Once a randomization number is assigned to a participant it cannot be 
reassigned to an y other participa ntin the study .
Following the 2 -week run -inperiod and participant to satisfy ing all eligibility  criteria, 
participant s willbe randomized 1:1:1 to one of the followi ng three double -blind 
treatments for the duration of the treatment period : 
UMEC 62.5 mcg QD
UMEC 31.25 mcg QD
Placebo QD 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
36The duration of double -blind treatment for each participant is 24 weeks . On the morning 
of each scheduled clinic study visit, participant s will refrain from taking their morning 
dose of study  treatment and FF
100mcg until instructed to do so by  [CONTACT_6477]. 
Study  treatment will be taken at the clinic at approximately  the s ame time of day  as taken 
at the Randomization Visit (Visit 2 ). On the other day s during the treatment period (i.e. 
“non -clinic days”), participants w ill be instructed to take their study  treatment each 
morning at approximately  the same time. Each Investigator will be provided with 
sufficient supplies to conduct the trial. Additional treatment packs will be supplied as 
needed to the sites. Details of ho w to use the I WRS sy stem (RAMOS NG) to randomize 
participant s and manage study  treatment supplies (including dispensing) is prov ided in 
the RAMOS NG I WRS manual and SR M.
7.4. Blinding
This will be a double
-blind study  and the following will appl y. 
The Investig atoror treating phy sician may  unblind a participant ’s treatment 
assignment only in the case of an emergency OR in the event of a serious 
medical condition when knowledge of the stud y treatment is essential for the 
appropriate clinical management or welfar e of the participant as judged b y the 
Investigator . 
Investigator s have direct access to the participant ’s individual study  treatment. 
It is preferred (but not required) that the Investigator first contacts the Medical 
Monitor or appropriate [COMPANY_004] study  personnel to discuss options before unblinding 
the participant ’s treatment assignment. 
If [COMPANY_004] personnel are not contact[CONTACT_222201], the Investigator must 
notify [COMPANY_004] within 24 hours after unblinding, but without revealing the treatment 
assignment of the unblinded participant , unless that information is important for 
the safet y of participant s currentl y in the stud y. 
The date and event or condit ion which led to the unblinding (i.e. the primary 
reason) will be recorded in source documentation and i n the eCRF.
Should a participant’s treatment assignment be unblinded then the participant may  
continue the assigned study  treatment and be followed
-up as per protocol until the 
completion of the Safet y Follow -up assessments .
[COMPANY_004]’s Global Clinical Safet y and Pharmacovigilance (GCSP) staff may  unblind the 
treatment assignment for any  participant with an SAE. If the SAE requires that an 
expedited regulatory  report be sent to one or more regulatory  agencies, a copy  of the 
report, identify ing the participant ’s treatment assignment, may  be sent to Investigator s in 
accordance with local regulations and/or [COMPANY_004] policy
.Participant s will not be withdrawn 
from the study .
7.5. Packaging and Labeling
The contents of the label will be in accordance with all applicable regulat ory 
requirements. 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
377.6. Preparation/Handling/Storage/A ccountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  treatment received and any  discrepancies 
are reported and resolved before use of the stud y treatment.
2.Only  participants enrolled in the study  may  receive study  treatment and only  
authorized site staff may  supply  or administer study  treatment. All study  treatments 
must be stored in a secure, environmentall y controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions with access 
limited to the investigator and authorized site staff.
3.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for study treatment accountability, reconciliation, and record 
maintenance (i .e., receipt, reconciliation, and final disposition records).
4.Further guidance and information for the final disposition of unused study  treatment 
are provided in the SRM.
Unde r normal conditions of handling and administration, study  treatment is not 
expected to pose significant safet
y risks to site staff .  Take adequate precautions to 
avoid direct ey e or skin contact [CONTACT_23968]. In the case of 
unint entional occupational exposure notify the monitor, Medical Monitor and/or 
[COMPANY_004] study  contact.
A Material Safety  Data Sheet (MSDS)/equivalent document describing occupational 
hazards and recommended handling precautions either will be provided to the 
investi gator, where this is required b y local laws, or is available upon request from 
[COMPANY_004].
7.7. Treatment Compliance
When participant sare dosed at the site, they  will receive FF 100 mcg and study  treatment 
under medical supervision.  The date and time of each dose ad ministered in the clinic will 
be recorded in the eCRF .  The dose of study  treatment and study  participant identification 
will be confirmed at the time of dosing b y a member of the stud y site staff.  
When participant s self
-administer study  treatment(s) at home , compliance with study  
treatment will be assessed through query ing the participant during the site visits and 
recording the number of doses remaining in the ELLIPTA in the eCRF (see the SRM for 
details) .  A record of the number of ELLIPTAs 
dispensed t o each participant must be 
maintained and reconciled with study  treatment and compliance records. 
Participant compliance with FF 100 mcg and study  treatment will be assessed at 
scheduled clinic visits by [CONTACT_633404] (s)(see Section 7.1.3).  Participant s should be  80% to 120% 
compliant on taking both FF 100 mcg and study  treatment between each pair of 
scheduled and consecutive on- treatment clinic visits , asapplicable . Participant s who fall 
outside this range should be re -educated on treatment compliance b y their site. This re -
education should be documented in the participant ’s source document. If FF 100 mcg 
and/or study  treatment isprematurel y discontinued during the course of the study  or  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
38compliance repeatedly falls outside of acceptable ranges, the study  sponsor/site monitor 
must be contact[CONTACT_633398] .
7.8. Concomitant Therapy
All asthma medica tions used within approximately 6 weeks prior to screening and during 
the study  (including the post -treatment period) should be recorded in the eCRF.
All non- asthma medications taken during the study (after randomization including post -
treatment) and an y changes to concomitant medications will be recorded in the eCRF. 
Note: Study provided FF100mcg and albuterol/salbutamol should not be recorded in 
the eCRF; however non -
study supplied FF 100 mcg and albuterol/salbutamol will be 
recorded in the eCRF.
The m inimum requirement is that the drug name, reason for use, dose (including unit e.g. 
mcg) and frequency , route and the dates of administration are to be recorded.
Medications initiated after completion of the assessments at Visit 5/EOS or the Earl y 
Withdraw al Visit will not be recorded in the eCRF unless taken to treat an AE or asthma 
exacerbation. Detailed information of permitted and prohibited medications is included in 
the SRM for y our reference.   Participant s who have completed the Early Withdrawal 
Visitare allowed to use any  medications prescribed by  [CONTACT_633387].
7.8.1. Permitted Medications and Non -
Drug Therapi[INVESTIGATOR_014]
[IP_ADDRESS]. Permitted A sthma Medications
In addition to FF 100 mcg and stud y treatment, t he following medications are permitted 
during this study :
Study -provided albuterol/salbutamol will be dispensed at Visit [ADDRESS_845765] be judged 
capable of withholding albuterol/salbutamol for at least 6 hours prior to stu dy 
visits.
Temporary  changes in medications are permitted for the treatment of moderate asthma 
exacerbation s,at the Investigator’s/treating ph ysician’s discretion. Asthma exacerbations 
should be treated in line with national and international recommendati ons and local 
medical standards. Asthma medications permitted on a temporary  basis to treat a 
moderate asthma exacerbation include but are not limited to the following (the Medical 
Monitor may  be co ntacted for additional guidance; see the SRM for contact i nformation
[refer to S ection [IP_ADDRESS] forguidance onmoderate asthma exacerbation] ):
An increase in ICS dose .
Systemic corticosteroids (tablets, suspension or injection) fo r no more than 2 
days. 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
39An Investigator -advised change in SABA use (i.e., routinely  scheduled versus 
as needed use).
Leukotriene receptor antagonists (LTRAs) and leukotriene modifiers.
Oral theoph ylline.
[IP_ADDRESS]. Permitted Non-Asthma Medications
The following medications are permitted during this study :
Medications for rhinitis (e.g., intranasal corticosteroids, antihistamines [including 
ocular and intranasal], cromoly n, nedocromil, nasal decongestants)
Note: Use of these medications should be captured on the concomitant medication 
pages of the eCRF prior to ECG measurements.
Antibiotics for short term treatment of acute infections. L ong term treatment with 
topi[INVESTIGATOR_417436].
Decongestants :Participant s may  take decongestants during the study ,but these 
are disallowed for 24 hours prior to ECG measurements .
Immunotherap y: Immunotherap y for the treatment of allergies is allowed during 
the study  provided it was initiated 4 weeks prior to Visit 1 and participant s remain 
in the maintenance phase for the duration of the study .
Topi [INVESTIGATOR_238426] .
Systemic and ophthalmic beta -blockers: Administer with caution as s ystemic 
beta-blockers block the pulmonary  effect of beta- agonists and may  produce severe 
bronchospasm in patients with reversible obstructive airway s disease. 
Cardioselective beta -blockers should be considered, although they  also should be 
administered with caution.
Localized corticosteroid injections (e.g. intra -articular and epi[INVESTIGATOR_13873]).
Tricy clic antidepressants and monoamine oxidase inhibitors (MAOI s). 
(Administer with extreme caution as they  may  potentiate the effects of beta -
agonists on the cardiovascular s ystem, including QTc prolongation)
Diuretics.  (Caution is advised in the co- administration of beta -agonists with non-
potassium sparing diuretics as this may  result in ECG changes and/or 
hypokalemia )
Cytochrome P450 3A4 ( CYP3A4) inhibitors (Caution should be exercised when 
considering the coadministration of long- term ketoconazole and other known 
strong CYP3A4 inhibitors (e.g., ritonavir, clarithromy cin, conivaptan, indinavir, 
itraconazole, lopi[INVESTIGATOR_054], nefazodone, nelfinavir, saquinavir, telithromy cin, 
troleandomycin, voriconazole) because increased sy stemic corticosteroid and 
increased cardiovascular adverse effects may  occur )
Vaccinations (Influenza vaccine, Pneumonia vaccine, Shingles vaccine, etc.) 
(Administration of influenza and pneumonia vaccines should be considered based 
on clinical discretion of the Investigator and local/national guidelines. Current  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
40influenza vaccines and pneumonia vaccines wi ll be captured on the concomitant 
medication pages of the eCRF )
All medications for other disorders may  be continued throughout the study  provided their
use would not be expected to affect the participant s’ lung function or safety assessments
(e.g., cardia c measurements). However , no sy stemic corti costeroids will be permitted.
7.9. Prohibited Medications and Non -Drug Therapi[INVESTIGATOR_417438] 3 isnot permitted during the study .
Table 3 Concomitant Medications
Medication No use during the study and/or within the 
following time interval before V isit 1
Inhaled short -acting anticholinergics 6 hours
Inhaled short -acting anticholinergics+ Short -
acting beta agonist combination6 hours
Inhaled l ong-acting anticholinergics other than 
study treatment2days
Immunosuppressive medications
including immunomodulators12 weeks
Inhaled long -acting beta 2-agonists (e.g., 
salmeterol, formoterol) or combination products 
containing inhaled long -acting beta 2-agonists 
(e.g., Seretide, Symbicort)
Inhaled very long -acting beta2 -agonists, 
(Indacaterol, Olodaterol)
Oral long -acting beta 2-agonists (e.g., 
bambuterol) [ADDRESS_845766] (rescue 
albuterol/salbutamol will be provided and is 
permitted during the study)6hours (including all study visits)
Theophyllines, slow-release
bronchodilators, ketotifen, nedocromil sodium,
sodium cromoglycate, roflumilast48 hours Tempo rary use will be permitted 
during the study to treat moderate asthma 
exacerbations
Anti-leukotrienes 48 hours. Temporary use will be permitted 
during the study to treat moderate asthma 
exacerbations
Any other investigational drug 30 days or within 5 drug half-lives of the 
investigational drug (whichever is longer)
7.10. Treatment after the End of the Study
Participant s will not receive an y additional treatment from [COMPANY_004] after completion of the 
study  because other treatment options are available . 2018N371775_00
2016N289466_00 CONFIDENTIA L
[ADDRESS_845767]-
study  care of the participant ’s medical condition, whether or not [COMPANY_004] is providing 
specific post -study  treatment.
8. DISCONTINUA TION CRIT ERIA
8.1. Discontinuation of Study  Treatment
Parti cipants that permanently stop study treatment are encouraged to remain in the 
study .  Participant s have the right to discontinue study  treatment before the end of the 
study .  A participant may also be asked to discontinue study  treatment at the 
Investigator’s discretion.
Participant s who withdraw from study  treatment prematurel y (for an y reason) should, 
where possible, continue to be followed -up as per protocol until the completion of the 
Safety  Follow -up assessments .If this is not possible, the Investigat or must encourage the 
participant to participate in as much of the study  as they  are willing (or able) to.
A participant may be withdrawn from study  treatment at any  time. A reason for 
premature discontinuation of study  treatment (e.g., AE, lack of efficacy [including 
moderate or severe asthma exacerbation] , protocol deviation, Investigator discretion, 
consent withdrawn etc.) must be captured in the eCRF.
A participant must be withdrawn from study  treatment if any  of the following stoppi[INVESTIGATOR_118048]:
Liver Chemistry : Meets any  of the protocol- defined liver chemistry  stoppi[INVESTIGATOR_3418] 
QTc: Meets an y of the protocol -defined stoppi[INVESTIGATOR_3418] 
Pregnancy : Positive pregnancy  test
8.1.1. Liver Chemistry  Stoppi[INVESTIGATOR_633372] (in alignment with the FDA 
premarketing clinical liver safety  guidance). These protocol guidelines are in alignment 
with FDA premarketing clinical liver saf ety guidance: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf.
Discontinuation of study  treatment for abnormal liver tests should be considered by  [CONTACT_32845] a participant meets one of the conditions outlined in the algorithm or if 
the investigator believes that it is in the best interest of the participant. 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
42Phase II Liver Chemistry Stoppi[INVESTIGATOR_288590] t 
Discontinue  Study  Treatmen t Plus
Bilirubin≥2x
ULN (>35% 
direct) 
or plus
INR>1.5 , if 
measur ed*
Possi ble
Hy’s LawALT≥3xULNALT≥5xULNALT≥3xULN
Plus
Sympt oms of 
liver injury
or 
hyper sensitivityALT≥3xULN
but able to 
monitor 
week ly for 
4 week sNo
Yes
YesYes YesNo No No
NoYes
ALT≥3xULN
persist for
4 week s or 
stoppi[INVESTIGATOR_278786]
*INR value not applicable to subjects on  anticoagu lantsYesIf subj ect to be moni tored weekl y must refer to Liver Safety Requi red  Actions and  Follow  up 
Assessme nts  section  in  the  Appendi x
Must refer to Liver Safety Requi red Actions and Follow  up Assess ments section in the Appendi x
Repor t as an SAE if possible Hy’s Law case:  ALT≥3xUL N and  Bilirubin≥2x ULN (>35% direct)  or 
INR>1.5 , if measured*
Liver Safet y Required Actions a nd Follow up Assessments can be found inAppendix 7
8.1.2. QTc Stoppi[INVESTIGATOR_633362] 9.4.3.
The same QT correction formula 
must be used for each individual participant to 
determine eligibili ty for and discontinuation from the study .  This formula may  
not be changed or substituted once the participant has been enrolled.
For example, if a participant is eligible for the protocol based on QTcB (QT 
interval corrected for heart rate b y Bazett’s formula ), then QTcB must be used 
for discontinuation of this individual participant as well.
Once the QT correction formula has been chosen for a participant ’s eligibility , 
the same formula must continue to be used for that participant for all QTc data 
being collected for data analysis
. Safety ECGs and other non- protocol specified 
ECGs are an exception.  
The QTc should be based on averaged QTc values of triplicate electrocardiograms 
obtained over a brief (e.g., 5- 10 minute) recording period.
For this study , the following QTc stoppi[INVESTIGATOR_31764] , lead to withdrawal 
from study  treatment :
QTc>500 msec or uncorrected QT>600 msec 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
43Change from baseline: QTc> 60 msec
For patients with underl ying bundle branch block, follow the discontinuation criteria 
listed below:
Baseline QTc with Bundle Branch Block <450 msec , Discontinuation QTc with 
Bundle Branch Block >500 msec
Baseline QTc with Bundle Branch Block <450 -480  msec , Discontinuation QTc 
with Bundle Branch Block ≥530 msec
8.1.3. Rechallenge
[IP_ADDRESS]. Study  Treatment Restart or Rechallenge
Study  treatment restart or rechallenge after liver chemistry  stoppi[INVESTIGATOR_496917].
8.2. Withdrawal from the Study
A participant may  withdraw from the study  at an y time at his/her own request, 
or may  be withdrawn at any  time at the discretion of the investigator for safety , 
behavioral, compliance or administrative reasons.
If the participant withdraws consent for disclosure of future information, the 
sponsor may
 retain and continue to use any  data collected before such a 
withdrawal of consent.
If a participant withdraws from the study , he/she may  request destruction of any  
samples taken and not tested, and the investigator must document this in the site 
study  records.
In the event of earl y withdr awal from the study , every  effort should be made to 
have the participant to return to the clinic for an Early  Withdrawal Visit and 
Safety  Follow -up,and to return all study  related materials. Assessments to be 
performed during the Early  Withdrawal Visit and the Safet y Follow -up contact 
[CONTACT_633388] (Section 2).
8.3. Lost to Follow Up
A participant will be considered lost to follow -up if he or she repeatedl y fails to return for 
scheduled visits and
is unable to be contact[INVESTIGATOR_530] b y the study  site. 
The following actions must be taken if a participant fails to return to the clinic for a 
required stud y visit:
The site must attempt to contact [CONTACT_43207]/or should continue in the study .
Before a participant is deemed lost to follow up, the investigator or de signee 
must make every  effort to regain contact [CONTACT_6635] (where possible, 3  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
44telephone calls and, if necessary , a certified letter to the participant’s last known 
mailing address or local equivalent methods). These contact [CONTACT_19425]’s medical record.
Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study  with a primary  reason of lost to follow -up. 
9. STUDY A SSESSMENTS A ND PROCEDURES
Study  procedures and th eir timing are summarized in the Schedule of Activities ( SoA)
(Section 2). There are no protocol waivers or exemptions allowed. Immediate safet y 
concerns should be discussed with the sponsor immediately  upon occurrence or 
aware ness to determine if the participant should continue or discontinue study  treatment.
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study conduct.
No study related procedures may be performed until the informed consent form has 
been signed by [CONTACT_2299] .  A Pre- S creening visit (Visit 0) is required in order to 
administer the informed consent before an y changes are made to the participant ’s current 
medical regimen.  Selection and modificat ion of the participant ’s medications prior to 
study  participation is based on the phy sician’s judgment according to sound medical 
practice, principles, and each participant ’s needs.  A participant ’s treatment must not be 
changed merel y for the purpose of e nabling the participant’s participation in the stu dy.
During the P re-Screening visit (V isit 0) the following information will be captured in the 
eCRF for each participant: 
Demographic information including race, age and gender
Participant number
Serious A dverse Event information only for any  SAE considered as related to 
study  participation
Investigator signature [CONTACT_633408] 
(Visit 1):
Weight and height
A
sthma diagnosis histor y including:
The age of the participant when they  were first provided with an inhaler for 
asthma
Completion of an asthma medical history  questionnaire: a cop y of this 
questionnaire and instructions for its use can be found in the SRM
Smoking history and statu s
Exacerbation history
Asthma and other concurrent medications 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
45Medical History  including previous and/or concurrent medical conditions, 
detailed cardiovascular risk factor history , pneumonia, and pneumonia vaccine 
status
Reason for screen failure (if appli cable)
Vital signs
Questionnaires (ACQ; SGRQ; AQLQ ; E-RS)
Healthcare Resource Utilization
Pre-and post -albuterol/salbutam ol lung function
Inclusion/Exclusion criteria assessment
Physical examination
12-lead ECG
Child bearing status assessment for all poten tial female participant s
Clinical laboratory
 tests (including hematology , chemistry , urinal ysis and serum 
pregnancy  test)
SAE assessment
Inaddition the following procedures must be completed at Screening ( Visit 1):
Electronic device training / dispense eD iary
Review/dispense Medical Problems/Medication Taken worksheet
Dispense F F
100mcg run-in medication
9.1. Efficacy  Assessments
The timings of all efficacy  assessments are specified in the Schedule of Activities ( SoA)
(Section 2).
9.1.1. Questionnaires
The questionnaires should be completed before any  procedures are performed on the 
participant to avoid influencing the participant ’s response. To avoid biasing responses, 
the 
participant s should not be told the results of diagnostic tests pr ior to completing the 
questionnaires and i t is recommended that the questionnaires be administered at the same 
time of day  during each visit (as applicable) using the provided electronic device (unless 
otherwise specified) .  Adequate time must be allowed t o complete all items on the 
questionnaires; the questionnaires must be reviewed for completeness and, if necessary , 
the participant must be encouraged to complete any  missing assessments or items.
Instructions for completing the questionnaires can be found in the SRM.
[IP_ADDRESS]. Global A ssessment of Severity  and Response to Treatment
The participant will be asked to complete the G lobal Assessment of S everity  and 
Response to Treatment at the visits specified in the Schedule of Activities table (Section 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
462). The Global Assessment of Severity  is a single item questionnaire; participant s are 
asked to rate their asthma sy mptoms at the study  visit using a five -
point scale (none, 
mild, moderate, severe, very  severe).  The Response to T reatment is a single question of 
the patient’s overall evaluation of response to treatment, using a seven- point rating scale 
with the following definitions: 1 = significantl y improved; 2 = moderatel y improved; 3 = 
mildly  improved; 4 = no change; 5 = mildl y worse; 6 = moderatel y worse; and 7 = 
significantl y worse. Instructions for completing the questionnaires can be found in the 
SRM.
[IP_ADDRESS]. Asthma Control Questionnaire (ACQ)
The ACQ measures attributes of asthma control [ Juniper 1999], measured with que stions 
designed to be self -completed by  [CONTACT_2299] .  Participant s will complete the ACQ at 
specified stud y visits. The ACQ -5 includes five questions (concerning nocturnal 
awakening, waking in the morning, activity  limitation, shortness of br eath and w heeze )
which enquire about the frequency  and/or severit y of sy mptoms over the previous week.
The ACQ -[ADDRESS_845768] of a zero (no impairment/limitation) to six 
(total impairment/ limitation) scale. The recall period is the past week. Ascore of <0.75 
indicates well -controlled asthma and a score 1.5 indicates poorl y controlled asthma 
[Junipe r2006].  A change of  0.5 in score sugge sts a clinically  important change in score 
[Juniper 2005].
[IP_ADDRESS]. St. George’s Respi[INVESTIGATOR_633346] (SGRQ)
The SGRQ is a well established instrument, comprising [ADDRESS_845769], and activity . The questions are designed to be self -completed by  [CONTACT_2299]
[Jones1992] with a recall over the past 3 months .  A change of 4 points is considered a 
clinically  relevant change [ Jones
2005].
[IP_ADDRESS]. Asthma Quality  of Life Questionnaire ( AQLQ)
The AQLQ was developed to measure the functional impairments related to asthma 
experienced by [CONTACT_67022] 17+ years old.  The AQLQ (+12), is a modified version of the 
original AQLQ and validated for use in asthma patients between the ages of 12 and 70 
[Junipe r2005]. The response scale ranges from 1 (totally  impaired) to 7 (not at all 
impaired).  The questions are designed to be self -completed by  [CONTACT_477022] a 
recall over the past 2 weeks.  A change of 0.5 is considered clinicall y important [ Juniper
1994].
9.1.2. Daily Diaries
Participant s will be issued with a combination spi[INVESTIGATOR_417458] 1 for 
twice dail y use (in the morning upon waking and in the evening just before going to bed)
throughout the stud y. The eDiary  device will be provided by a third- party vendor . 
Information on the device and its use are documented in the SRM and the third- party 
vendor manual . Participants will be instructed on how to use the device in order to record 
results for the following in the eDiary  each day from Visit 1 onwards : 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
47Daily symptom assessment (E -RS and supplemental asthma items; night -time 
awakening, ast hma sy mptom and phy sical activity questions)
The n umber of inhalations of rescue albutero l/salbutamol used during the day and 
night.
Morning and evening FEV 1
Morning an d Evening PEF
Morning FF 100 mcg medication use
Morning double -blind study  medication u se (during the treatment period only )
Section 9.1.2 describes the assessments and questionnaires recorded on the eDiary  
device, as well as the alerts that can be triggered based on recorded results. The data from 
the eDiary  device will be automatically  transmitted to a centralised server . 
Participant s will also be issued with a paper Medical Problems/Medications Taken
worksheet to record medical problems experienced and medications used during the 
study (please refer to the SRM for further details) .Participant s must also use this paper 
worksheet to record all healthcare contacts that occur during their participation in the 
study . This paper worksheet will be used to assist participant recall in discussions with 
the Investigator , for site staff to then enter as appropriate in the eCRF.
[IP_ADDRESS]. eDiary  Questionnaires, Assessments and A lerts
For information on the eDiary  questions, please refer to Appendix 8 .
[IP_ADDRESS].1. E-RS
The Evaluating Respi[INVESTIGATOR_244774] (E -RS) in COPD con sists of 11 items from the 14 
item Exacerbations of COPD ( EXACT -PRO )instrument.  E -RS is intended to cap ture 
information related to respi[INVESTIGATOR_23908], i.e. breathlessness, cough, sputum 
production, chest congestion and chest tightness. The E -RS was developed for use in 
patients with COPD but symptom experience of patients with asthma may  be 
appropriatel y measured with the E -RS. The daily recording of information allows an 
assessment of the underlying day  to day  variability  of a patient's s ymptoms. The 
instrument is to be completed dail y each night prior to going to bed .  The 11 -items are 
scored on a 5 -point scale of “not at all” to “extreme”.  The E -RS has a scoring range of 0 -
40.
[IP_ADDRESS].2. Supplemental Asthma Items
To ensure that asthma s ymptoms are completel y evaluated, two additional questions will 
be asked.  A question on wheeze, a symptom of importance in asthma will also be asked 
within the context of the daily  diary . An item on breathlessness activities will evaluate 
shortness of breath associated with stre nuous activities.  Subject s will be asked to respond 
to the question ‘Did y ou wheeze today ?’ with response options of: Not at all, Rarely , 
Occasionall y, Frequently, Almost constantly.  Subjects will be asked to respond to the 
question “Were you short of br eath today  when performing strenuous activities such  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
48climbing stairs, running, or participating in sports activity  with a response scale of not at 
all, slightly , moderatel y, severel y, extremely  or too breathless to do these.
[IP_ADDRESS].3. Night -time Awakening, Asthma Sy mptom and Physical Activity 
Questions
Every  morning upon waking (from the morning after Visit 1 onwards ), participant s will 
answer a question on the occurrence of night- time awakenings due to asthma sy mptoms. 
The participant ’s response to the question on t he occurrence of night- time awakenings 
will be either ‘Yes’ (i.e. Did y ou wake up due to asthma sy mptoms ( i.e. wheezing, 
coughing, shortness of breath, or chest tightness ) or ‘No’ (i.e. they  did not experience at 
least one night -time awakening due to asthm a symptoms ). If ‘Yes’ ,participants will be 
asked to respond either ‘Yes’ or ‘No’ to the question on rescue medication (i.e. when you 
woke up due to your asthma symptoms did you use an y rescue bronchodilator?) .
On the evening of Visit 1 (just before going to bed) and every  evening there- after, 
participant s will answer a question on day time asthma sy mptoms and day time phy sical 
activity  limitation. These questions will be answered on a 5- point scale (0 to 4) with ‘0’ 
representing no daytime asthma s ymptoms/ph ysical activity  limitations and ‘4’ 
representing very  severe day time asthma sy mptoms or total day time activity  limitation.
(Please describe the severity  of your asthma s ymptoms (i.e. cough, wheeze, chest 
tightness, shortness of breath) today  [0=no asthma s ymptoms, 1=mild asthma sy mptoms, 
2= moderate asthma s ymptoms, 3=severe asthma sy mptoms, 4= very  severe asthma 
symptoms ]. How limited were you in your a ctivities today  because of your asthma [ 0=not 
at all limited, 1=a little limited, 2=moderatel y limited, 3=severely limited, 4=totally 
limited ]).
[IP_ADDRESS].4. Morning and Evening Home Spi[INVESTIGATOR_417459]/eDiary  device will be issued to participant s at Visit 1 for 
daily  monitoring of their lung function (i.e. FEV 1and PEF) . The home Spi[INVESTIGATOR_14007]/eDiary  
device will be provided by a third -party vendor . Information on the device and its use 
are 
documented in the SRM an d the third- party vendor manual .Participant s will conduct 
spi[INVESTIGATOR_417460] ,prior to study  treatment and FF 100 mcg dosing ,
and each evening. Three measurements for each session will be recorded by  [CONTACT_2416] s in the eDiary. Assessments will be performed:
After completing all other eDiary  assessments
Prior to albuterol/salbutamol use
Prior to study  treatment and FF [ADDRESS_845770] of the assigned double- blind study  treatment.
[IP_ADDRESS].5. Alerts
For safet y the following alerts, indicative of worsening asthma, will be programmed into 
the eDiary  with in structions for the participant to contact [CONTACT_093] (either by  
[CONTACT_18623]/or b y visiting the stud y clinic) if any  of the alert criteria are met: 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
49Nocturnal awakening(s) due to asthma requiring albuterol/salbutamol use for 2 
consecutive nights.
An increase from base line of ≥ 4 puffs /day  of albuterol/salbutamol use on 2 
consecutive day s.
A ≥30% decrease in AM PEF from baseline on 2 consecutive mornings.
A ≥
30% decrease in PM PEF from baseline on 2 consecutive evenings
A ≥
30% decrease in AM FEV1 from baseline on 2 con secutive mornings.
A ≥
30% decrease in PM FEV1 from baseline on [ADDRESS_845771] 3 
acceptable spi[INVESTIGATOR_417445] (from a maximum of 8 attem pts) should be achieved 
on each occasion that spi[INVESTIGATOR_417446], in accordance with the 
American 
Thoracic Society / European Respi[INVESTIGATOR_21584] y (ATS/ERS )standards 
[Miller , 2005]. The highest of 3 technicall y acceptable measurements will be recorded at 
each visit:
Pre-dose Spi[INVESTIGATOR_038]: At Visits 1through 5/EOS (and the Early  Withdrawal 
Visit, if applicable), participant s should withhold short -acting beta -
2-agonists 
(SABAs) for [ADDRESS_845772] be performed:
oBetween 6am and 11am on the day  of the visit.
oAt the same time of day  (1 hour) as the assessment performed at Visit 2
(the baseline assessment).
oAt least 24 hours after the participant ’s last morning dose of study  
treatment on the day  prior to the visit.
oBefore the participant ’s morning dose of study  treatment on the day  of the 
visit.
Post-dose Spi[INVESTIGATOR_038]: At Visits 2 and 5/EOS (and the Earl y Withdrawal Visit, if 
applicable), spi[INVESTIGATOR_633373] 3 hours after the 
participant ’s morning dose of study  treatment; the assessment performed at Visit 
5/EOS should be performed at the same time of day  (1 hour) as the assessment 
performed at Visit 
2(the baseline assessment). At each visit, participant s should 
withhold short -acting beta -2-agonists (SABAs) between receiving their morning 
dose of study  treatment and completing the spi[INVESTIGATOR_44022], if possible.
Spi[INVESTIGATOR_417448]  a thi rd-party vendor; the same 
third- party vendor will also centrall y analyse the spi[INVESTIGATOR_417449] . Details 
on performing the spi[INVESTIGATOR_44022], including information on the equipment 
provided and its use as well as specific instructions on performing the spi[INVESTIGATOR_417450], are documented in the SRM and the third- party vendor manual. 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
[IP_ADDRESS]. Reversibility (Albuterol/Salbutamol)
All reversibility evaluations should follow the recommendations of the AT S/ERS Task 
force: Standardization of Lung Funct ion Testing [ Miller ,2005]. A pre-bronchodilator
spi[INVESTIGATOR_417451] a washout period of at least [ADDRESS_845773] s.
To perform the reversibility  assessment, 4 puffs of t he provided albuterol /salbutamol is 
administered (aspace r device may  be used, if required). F ollowing completion of the pre-
bronchodilator assessment, a second spi[INVESTIGATOR_417452] 20 to 60
minutes after a dministration of the albuterol /salbutamol.
Percent reversibility  will be calculated as follows:
(Post -bronchodilator FEV 1–Pre-bronchodilator FEV 1) x [ADDRESS_845774] 
demonstrate a 12% and 200 mL  increase in FEV 1to be eligible for the study .If these 
reversibility  criteria are not met at Visit 1 then the participant may not enter the 2- week 
run-in period; however, the reversibility  assessment may  be repeated once within 7 day s 
ofVisit 1 if either criteria a) or b) are met:
a)≥9% increase in FEV 1between 20 and 60 minutes following 4 inhalations of 
albuterol/salbutamol aerosol at Visit 1.
b)Documented evidence of a reversibility  assessment within [ADDRESS_845775] -bronchodilator increase in FEV 1 of≥12% and ≥[ADDRESS_845776]  reversibility  (defined as ≥12% 
and ≥200 mL  increase in FEV 1between 20 and 60 minutes following 4 inhalations of 
albuterol/salbutamol aerosol) at the second attempt then, provided th at all other eligibility  
criteria assessed at Visit 1 are met, the participant may enter the 2- week run -in period.
9.1.4. Asthma Exacerbations
Moderate and s evere asthma exacerbation data will be collected from the start of 
randomized double blinded treatment until Visit 5/EOS Visit or the Early  Withdrawal 
Visit for tho
separticipants that withdraw from participation in the study  (see Section
8.2). For consistency ,exacerbations separated b y less than 7 day s will be treated as a 
contin uation of the same exacerbation.
Participant s will complete a paper Medical Problems/Medications Taken worksheet to
record medical problems experienced and 
medications used during the study, as well as 
all emergency  department visits and/or hospi[INVESTIGATOR_059] s that occur during their
participation in the study . This paper worksheet must be reviewed by  [CONTACT_737] (or
designee) at each visit to the study  site to assist the I nvestigator in the identification of
new asthma exacerbations. 2018N371775_00
2016N289466_00 CONFIDENTIA L
[ADDRESS_845777] igator (or 
designee).
[IP_ADDRESS]. Moderate A sthma Exacerbation
Guidance for identify ing moderate exacerbations includes the following [ Reddel 2009, 
Virchow 2015 ]
A moderate asthma exacerbation is considered to be a deterioration in asthma 
symptoms, deterioration in lung function, or increased rescue bronchodilator use
lasting for at least 2 day s or more, but will not be severe enough to warrant 
systemic corticosteroid use for 3 day s or more and/ or hospi[INVESTIGATOR_1838]. 
A moderate asthma exacerbation is an event that, when recognized, should result 
in a temporary  change in treatment, in an effort to prevent the exacerbation from 
becoming sever e.
At the I nvestigator’s discretion, a temporary  change in background asthma medication 
will be permitted in order to treat the s ymptoms of a moderate asthma exacerbation 
(Refer to S ection 7.8.1 above)
The Medical Monitor may b e contact[CONTACT_245939], see the
medical monitor/Sponsor I nformation Page .
[IP_ADDRESS]. Severe A sthma Exacerbation
A severe asthma exacerbation is defined as: 
The deterioration of asthma requiring the use of systemic corticosteroids (tablets,
suspens ion or injection) for at least 3 days.
OR
An inpatient hospi[INVESTIGATOR_633349], requiring
systemic corticosteroids.
9.2. Adverse Events
The definitions of an AE or SAE can be found in Appendix 4 .
The investigator and an y designees are responsible for detecting, documenting, and 
reporting events that meet the definition of an AE or SAE and remain responsible for 
following up AEs that are serious, considered related to the study  treatment or the study , 
or that caused the participant to discontinue the study  treatment or withdraw from the 
study  (see Section 8).
9.2.1. Time Period and Frequency  for Collecting A E and SA E 
Information
Any SAEs assessed as related to study  participation (e.g ., protocol -mandated 
procedures, invasive tests, or change in existing therap y) or related to a [COMPANY_004] 
product will be recorded from the time a participant consents to participate in the 
study  up to and including any  follow -up contact.  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
52AEs will be collected from the start of Study  Treatment until the follow -up 
contact (see Section 9.2.3 )at the timepoints sp ecified in the Schedule of Activities 
(SoA) t able (Section 2).
Medical occurrences that begin pr ior to the start of study  treatment but after 
obtaining informed consent may  be recorded on the Medical History /Current 
Medical Conditions section of the eCRF.
All SAEs will be recorded and reported to [COMPANY_004] within 24 hours, as indicated in
Appendix 4 .The investigator will submit any  updated SAE data to the sponsor 
within 24 hours of it being available.
Investigator s are not obligated to activel y seek AEs or SAEs in former study 
participant s. However, if the Investigator learns of any  SAE, including a death, at 
any time after a participant has been discharged from the study , and he/she 
considers the event reasonably  related to the study treatment or study  
participation, the Investigator must promptl y notify [COMPANY_004].
NOTE: The method of reco rding, evaluating and assessing causality  of AEs and SAEs 
plus procedures for completing and transmitting SAE reports to 
[COMPANY_004] are provided in 
Appendix 4
9.2.2. Method of Detecting A Es and SA Es
Care will be taken not to introduce bias when d etecting AEs and/or SAEs. Open- ended 
and non- leading verbal questioning of the participant is the preferred method to inquire 
about AE occurrence.  Appropriate questions include:
“How are you feeling?” 
“Have you had an y (other) medical problems since y ourlast visit/contact?” 
“Have you taken an y new medicines, other than those provided in this study , since 
your last visit/contact?” 
Participant s will be issued with a paper Medical Problems/Medications Taken worksheet
to record an y medical problems experie nced and medications used during the study .This 
paper worksheet will be used to assist participant recall in discussions with the 
Investigator (or designee) , for site staff to then enter as appropriate in the eCRF.
9.2.3. Follow -up of A Es and SA Es
After the init ial AE/SAE report, the Investigator is required to proactivel y follow each 
participant at subsequent visits/contacts.  All SAEs, and non- serious AEs of special 
interest (as defined in Section 9.2.5), will be followed until the event is resolved, 
stabilized, otherwise explained, or the participant is lost to follow -up (as defined in 
Section 8.3). Further information on follow -up procedures is given in Appendix 4
9.2.4. Regulatory  Reporting Requirements for SA Es
Prompt notification by  [CONTACT_11012] a SAE is essential so 
that legal obligations and ethical responsibilities towards the safet y of  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
53participants and the safety  of a study  treatment under cli nical investigation are 
met. 
The sponsor has a legal responsibility  to notify  both the local regulatory  
authority  and other regulatory  agencies about the safet y of a stud y treatment 
under clinical investigation. The sponsor will comply  with country -specif ic 
regulatory  requirements relating to safet y reporting to the regulatory authority, 
Institutional Review Boards (IRB)/Independent Ethics Committees (I EC), and 
investigators.
Investigator safety reports must be prepared for suspected unexpected serious 
adverse reactions (S[LOCATION_003]R) according to local regulatory  requirements and 
sponsor policy and forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing a SAE or 
other specific safet y information eg, summary  or listing of SAE) from the 
sponsor will review and then file it along with the Investigator’s Brochure and 
will notify  the IRB/IEC, if appropriate according to local requirements.
9.2.5. Adverse Events of Special Interest (A ESIs)
AEgroups of special interest hav e been defined as AEs which have specified areas of 
interest for one or more of class of drugs (ICS, L AMA ). Some AE groups may  have 
subgroups defined.
The following table presents the current special interest AE groups and subgroups. These 
may be updated prior to conclusion of the study  reporting. The final list, including the 
preferred terms which contribute to each of the groups will be documented a priori in the 
study  Reporting and Analy sis Plan (RAP).
Special interest AE group
Special interest AE subgro up
Cardiovascular effects Cardiac arrh ythmia
Cardiac failure
Cardiac ischemia
Stroke
Anticholinergic s yndrome -
Urinary  retention -
Dry mouth / dry ing of 
airway  secretions-
Gastrointestinal obstruction -
Antimuscarinic ocular Glaucoma (antimuscarinic/corticosteroid) 2018N371775_00
2016N289466_00 CONFIDENTIA L
[ADDRESS_845778] AE subgro up
effects / Corticosteroids 
associated ey e disordersCataracts (corticosteroid)
Pneumonia and L RTI Pneumonia 
LRTI excluding pneumonia
Adrenal suppression -
Decreased bone mineral 
density  and associated 
fractures-
Effects on glucose -
Hypersensitivity -
Local steroid effects -
9.2.6. Cardiovascular and Death Events
For an y cardio vascular events detailed in Appendix 4 and all deaths, whether or not they 
are considered SAEs, specific Cardiovascular (CV) and De ath sections of the eCRF will 
be required to be completed. These sections include questions regarding cardiovascular 
(including sudden cardiac death) and non- cardiovascular death. 
The CV eCRFs are presented as queries in response to reporting of certain CV MedDRA 
terms. The CV information should be recorded in the specific cardiovascular section of 
the e CRF within one week of receipt of a CV Event data query prompting its completion. 
The Death eCRF is provided immediately  after the occurrence or outcome of death is 
reported. Initial and follow -up reports regarding death must be completed within one 
week of when the death is reported.
9.2.7. Pneumonia
Medical history  will also be taken for pneumonia in previous [ADDRESS_845779] X- ray 
should be performed to confirm a diagnosis, whenever a participant has a suspected 
pneumonia.   Suspected pneumonias will require confirmation as defined by [CONTACT_417515](s) on chest x- ray AND at least 2 of the following signs and sy mptoms: 
Increased cough 
Increased sputum purulence (color) or production 
Auscultatory  findings of adventitious sounds ( e.g., egophon y, bronchial breath 
sounds, rales, etc.) 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
55Dyspnea or tachy pnea
Fever (ora l temperature >37.5 degrees centigrade [ °C])
Elevated white blood cells ( WBC )(>10,000/ millimetres cubed [ mm3]or >15% 
immature forms)
Hypoxemia ( Oxyhemoglobin ( HbO2 )saturation <88% or at least 2% lower than 
baseline value)
All pneumonias must be captured on the AE/SAE page of the eCRF and on the 
pneumonia page of the eCRF. 
For all suspected cases of pneumonia, investigator s are strongl y encouraged to confirm 
the diagnosis (this includes obtaining a chest x -ray) and to initiate appropriate therap y as 
prom ptly as possible. All diagnoses of pneumonia (radiographicall y confirmed or 
unconfirmed) must be reported as an AE or SAE (if applicable).
9.2.8. Radiography  (Chest X -Ray s)
Confirmation by  [CONTACT_13190] x -ray (posteroanterior and lateral) should be performed as soon as 
possible and preferabl y within [ADDRESS_845780]/v isit.
If a pregnancy  is reported then the Investigator should inform [COMPANY_004] within 2 weeks of 
learning o
f the pregnancy  and should follow the procedures outlined in Appendix 5.
Abnormal pregnancy  outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAE.
9.3. Treatment of Overdo
se
An overdose is defined as a dose greater than the total doses described above which 
results in clinical signs and sy mptoms.  These should be recorded by  [CONTACT_417509]/SAE eCRF pages.  I n the event of an overdose of study treatment, the Inve stigator 
should use clinical judgment in treating the overdose and contact [CONTACT_417510].
[COMPANY_004] is not recommending specific treatment guidelines for overdose and toxicity  
management. The Investigator is advised to refer to the relevant document(s) for detailed 
information regarding warnings, precautions, contraindications, adverse events, and other 
significant data pertaining to the stud y drug being used in this study . Such documents 
may include, but not be limited to, the IB or equivalent document provided by  [CONTACT_23983]. 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
569.4. Safet y Assessments
Planned time points for all safety  assessments are provided in the Schedule of Activities 
(SoA).
9.4.1. Physical Examinations
Physical exams will be performed at the time points specified in the Schedule of 
Activities (SoA) ta ble (Section 2).
A complete ph ysical examination will include, at a minimum, assessment of the 
Cardiovascular, Respi[INVESTIGATOR_696] , Gastrointes tinal and Neurological s ystems.
Height and weight wi ll be measured at Visit 1.
Investigators should pay  special attention to clinical signs related to previous 
serious illnesses.
9.4.2. Vital Signs
Vital signs will be performed at the time points specified in the Schedule of Activities 
(SoA) table ( Section 2) prior to conduc tingspi[INVESTIGATOR_633350] 100 mcg. Blood pressure (s ystolic and diastolic) and 
pulse rate will be measured in the sitting position after approximately  [ADDRESS_845781]. A 
single set of values will be colle cted and recorded in the source documentation and 
eCRF.
9.4.3. Electrocardiograms
All sites will use standardised ECG equipment provided by  a centralized external vendor. 
A single 12 -lead ECG and rhy thm strip will be recorded after measurement of vital signs 
and spi[INVESTIGATOR_038] . Recordings will be made at the time -
points defined in the Schedule of 
Activities (SoA) table ( Section 2). All ECG measurements will be made with the 
participant in a supi[INVESTIGATOR_633364] r approximately  5 minutes 
before each reading.
For participant s who meet the QTc, protocol defined stoppi[INVESTIGATOR_3418], triplicate ECGs 
(over a brief period of time) should be performed ( Section 8.1.2).
The Investigator, a design ated sub
-Investigator or other appropriatel y trained site 
personnel will be responsible for performing each 12- lead ECG. The Investigator must 
provide his/her dated signature [CONTACT_238540], attesting to the authenticit y 
of the ECG machine i nterpretation.
All ECGs will be electronically  transmitted to an independent cardiologist and evaluated. 
The independent cardiologist, blinded to treatment assignment, will be responsible for 
providing measurements of heart rate, QT intervals and an interp retation of all ECGs 
collected in this study . A hard cop y of these results will be sent to the I nvestigator. The  2018N371775_00
2016N289466_00 CONFIDENTIA L
[ADDRESS_845782] provide his/her dated signature [CONTACT_417535], attesting to 
his/her review of the independent cardiologist’s assess ment.
Details of the cardiac monitoring procedures will be provided b y the centralized 
cardiology  service provider.
9.4.4. Clinical Safet y Laboratory  Assessments
Refer to Appendix 2for the list of clinical laboratory  tests to be performed and 
to the Schedule of Activities ( SoA)for the timing and frequency . 
The investigator must review the laboratory  report, document this review, and 
record an y clinicall y relevant changes occurring during the stud y in the AE 
section of the CRF. The laboratory  reports must be filed with the source 
documents. Clinically  significant abnormal laboratory  findings are those which 
are not associated with the underl ying disease, unless judged b y the investigator 
to be more severe than expected for t he participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal 
during participation in the study  or within [ADDRESS_845783] dose of study  
treatment should be repeated until the values return to normal or base line or are 
no longer considered significantly  abnormal by  [CONTACT_43210]. 
If such values do not return to normal/baseline within a period of time judged 
reasonable b y the investigator, the etiology should be identified and the sponso r 
notified.
All protocol -required laboratory  assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory  manual and the Schedule of 
Activities ( SoA)
.
9.5. Pharmacokinetics
Pharmacokinetics i s not relevant for this protocol.
9.6. Pharmacody namics
Pharmacod ynamic parameters are not evaluated in this study .
9.7. Genetics
Information regarding genetic/ pharmacogenetic (PGx) research is included in Appendix 
6.The IEC/I RB and, where re quired, the applicable regulatory  agency  must approve the 
PGx and genetic assessments before these can be conducted at the site.  The approval(s) 
must be in writing and will clearly  specify  approval of the PGx and genetic assessments 
(i.e., approval of Appendix 6).
In some cases, approval of the PGx and genetic assessments can occur after approval is 
obtained for the rest of the study .  If so, then the written approval will clearly  indicate 
approval of the PGx and genetic assessments i s being deferred and the study , except for  2018N371775_00
2016N289466_00 CONFIDENTIA L
[ADDRESS_845784] of the study  will clearl y indicate this and 
therefore, PGx and genetic assessme nts will not be conducted.
9.8. Biomarkers
Biomarkers are not evaluated in this study .
9.9. Health Economics OR Medical Resource Utilization and 
Health Economics
Health Economics/Medical Resource Utilization and Health Economics parameters are 
not evaluated in this study .
10. STATISTICA L CONSIDER ATIONS
10.1. Hypotheses
The primary  objective of this study  is to evaluate the efficacy  of UMEC 62.[ADDRESS_845785] for the primary  efficacy  endpoint is such that the null hy pothesis is that there is 
no difference between treatment groups. 
H0: T1 – T 2 = 0
Thealternative hy pothesis is that there is a difference between treatment groups.
H1: T1 – T 2 ≠ 0
For the primary  endpoint (and other lung function related efficacy endpoints), the 
primary  treatment comparisons of interest are:  
UMEC 62.5mcg vs Placebo
UMEC 31.25mcg vs Placebo
For each comparison test on the primary  endpoint, the null hy pothesis is there is no 
difference between treatment groups.  The alternative hy pothesis is there is a difference 
between treatment groups.
Therefore T 1and T 2for these endpoints are the mean changes from baseline for the 
UMEC therap y and placebo , respectivel y, as listed above. 
Details on all pairwise treatment comparisons of interest are provided in S ection 10.5.2. 2018N371775_00
2016N289466_00 CONFIDENTIA L
[PHONE_13189].2. Sample Size Determination
Sample size calculation is based on the primary  efficacy  endpoint of mean change from 
baseline in trough FEV1 at the end of the 24 -week treatment period.
A total of 3 84 randomized participant s are required for this study , with 128 participant s 
in each of the three double- blind treatment groups: UMEC 62.5mcg, UMEC 31.25mcg or 
Placebo. Assuming 10% mi ssing data on spi[INVESTIGATOR_417468] 24- week treatment 
period, due to earl y withdrawal from study, approximately  [ADDRESS_845786] deviations in change from baseline trough FEV1 at W eek 24 
ranged from 325 to 354m L;from this a SD estimate of 350 mL was chosen. This was 
estimated from a wide selection of studies , critically to minimise the risk of reduced 
power for the primary  endpoint. The range of observed treatment differences across the 
Tiotropi[INVESTIGATOR_633352] 133 – 185mL , which supports the expectation that the 
treatment effect seen in a moderate asthma population islarger than in the more severe 
asthma population in study  205715 treated on a background of FF/VI . This is in line with 
data from 
[COMPANY_004] study 200699 which showed UMEC 62.5 mcg to be an effective dose. An 
average increase in change from baseline trough FEV1 at Day  29 of 136 mL  was 
observed in an asthma subset of patients treated with FF/UMEC (100/62.5) compared 
with FF (100 mcg) alone. The [COMPANY_004] phase III closed triple asthma study  205715, which 
this study  supports, is in a more severe asthma population and conservatively  assumes a 
SD estimate of 400 mL.
Based on a true population difference of 130 mL, a sample size of 115 patients per 
treatment gro
up has an estimated 80% power to observe statistical significance at the two 
sided 5% level, for each of the two primary  comparisons of interest for each UMEC dose . 
Using the above assumptions the smallest observed effect predicted to result in a 
statistic ally significant difference between treatment groups is 90.5 mL (minimum 
detectable difference) .
No interim anal ysis is planned for this study .
10.3. Sample Size Sensitivity
To demonstrate the sensitivity  of the sample size calculation for this study , the follow ing 
table and graph show the power function for a fixed sample size of n= 115per arm in the 
intent to t reat(ITT)population for the primary  efficacy  anal ysis, vary ing the true
treatment difference and estimated standard deviation on the change from baseli ne in 
trough FEV 1at the end of the 24 -week treatment period. 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
60Treatment difference (mL)
Standard Deviation100 115 130 145 160
300 0.71 0.82 0.91 0.95 0.98
350 0.58 0.70 0.80 0.88 0.93
400 0.47 0.58 0.69 0.78 0.86
10.4. Sample site re -estimation or adjustment
No sample size re -estimation is planned.
10.5. Data Analysis
10.5.1. Analysis population
The following participant populations will be identified:
All Participant s Enrolled Population: This population will comprise all participant s for 
whom a record exists on the study  database, including pre- screened participant s that sign  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
61the informed consent document but do not complete a Visit 1 (screening) procedure (i.e., 
pre-screening failures), or participant s that complete at least one Visit 1 procedure but do 
not ente r the run- in period (i.e., screening failures). This population will be used for the 
summary  of participant disposition . 
All Participant s Screened Population: This population contains all participants that 
complete at least one Visit 1 (Screening) procedu re. This population will be used for the 
summary  of participant disposition (including reasons for screening failures and run-in 
failures) and for the listing of AEs and SAEs for non -randomized participant s. 
ITTPopulation: This population will comprise all randomized participant s, excluding 
those who were randomized in error. A participant who is recorded as a screen failure or 
run-in failure, but is randomized and does not receive a dose of study  treatment, is 
considered to be randomized in error. Any other participant who receives a 
randomization number will be considered to have been randomized. This will constitute 
the primary  population for all efficacy  and safety  anal yses. 
10.5.2. Treatment Comparisons
To demonstrate the benefit of UMEC the primary  compari sons of interest for the primary  
efficacy  endpoint are :
UMEC 62.5 mcg vs Placebo
UMEC 31.[ADDRESS_845787] that aim to informally  estimate any 
potential benefit of increasing the UMEC dose are given below f or all efficacy  endpoints. 
UMEC 62.[ADDRESS_845788] in the 
hierarch y. 
A step
-down procedure with the following hierarchy  will be used for the primary  
comparisons in the primary  endpoint.  
The contrast between UMEC 62.5 mcg vs Placebo 
(two-sided, alpha = 0.05.  Null hy pothesis of no treatment difference)
The contrast between UMEC 31.[ADDRESS_845789] acebo 
(two-sided, alpha = 0.05.  Null hy pothesis of no treatment difference) 2018N371775_00
2016N289466_00 CONFIDENTIA L
[ADDRESS_845790] hypothesis has been 
rejected, thus maintaining the overall significance level at 5%.   
Specificall y, if t he defined treatment comparison for the primary  efficacy  endpoint at the 
highestdose of UMEC 62.[ADDRESS_845791] hypothesis is not rejected a nominal p -value for the 
second h ypothesis may be provided in the displays for descriptive purposes only  and will 
not alter the conclusion of the step -down procedure .
No multiplicity  adjustment will be made on these two treatment comparisons on the 
secondar y endpoint .
For all efficacy  endpoints (primary , secondary  and other), treatment comparisons 
between UMEC 62.5 vs UMEC 31.25 mcg informally  investigating the benefit of 
increasing UMEC dose will be made without adjusting for multiplicity .  Any  p -values ≤ 
0.[ADDRESS_845792] acceptable/borderline acceptable (pre -dose) FEV1 value obtained prior to 
randomization (either from Visit 2pre-dose or from Visit 1pre-bronchodilator ).
The primary  efficacy  analy sis will evaluate the “de facto” ty pe estimand in the I ntent- to-
Treat population, using a mixed -model repeated measures (MMRM) analysis, including 
all trough FEV 1recorded post randomization.  Analy ses will include the fixed, 
categorical effects of treatment, visit, treatment by [CONTACT_23259], sex,as well as the 
continuous, fixed covariates of age, baseline value, and baseline value by  [CONTACT_150133].  Point estimates and 95% confidence intervals will be calculated for the 
following primary  comparisons of interest. 
UMEC 62.5 mcg vs Placebo
UMEC 31.[ADDRESS_845793] as outlined in Section 10.5.2 will also 
be provided for t he primary  efficacy  endpoint.
10.6.2. Secondary Analyses
Full details of the analy ses to be performed on the secondary  efficacy  endpoint will be 
given in the RAP.
10.6.3. Other A nalyses
Full details of the analy ses to be performed on all efficacy  endpoints, as well as de tails of 
time points to be analy zed, will be given in the RAP.
10.6.4. Interim Analyses
No interim anal ysis is planned for this study .
10.6.5. Exploratory  Analyses
The psy chometric properties of the E -RS and Supplemental asthma items will be 
evaluated to characterize theE-RS as an endpoint for asthma.  These exploratory  anal yses 
may be provided in a separate RAP. 2018N371775_00
2016N289466_00 CONFIDENTIA L
[PHONE_13190]. REFERENCES
Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 
National Asthma Education and Prevention Programme, National Heart, Lun g and Blood 
Institute, National Institutes of Health (NIH) 2007. Available from: 
http://www.nhlbi.nih.gov/health- pro/guidelines/current/asthma -guidelines
Global Strategy for Asthma Management and Prevention , Global Initiative for Asthma 
(GINA ) 2016. Availa ble from: http://www.ginasthma.org/
GlaxoSmithKline Document Number: 2011N123107_03 GW685698+[COMPANY_004]573719 
Investigator’s Brochure, dated [ADDRESS_845794]. George's Respi[INVESTIGATOR_21606]. Am Rev 
Respir Dis 1992;145:1321-1327.
Jones PW. St. George’s Respi[INVESTIGATOR_21606]: MCI D. Journal of Chronic 
Obstructive Pulmonary Disease 2005;2:75 -79.
Junipe r EF, Bousquet J, Abetz L , Bateman ED; GOAL Committee. I dentify ing 'well-
controlled' and 'not well -controlled' asthma using the Asthma Control Questionnaire. 
Respir Med 2006;100 :616- 621.
Juniper EF , Guy att GH, Willan A, Griffith L E. Determining a minimal important change
in a disease -specific quality  of life instrument. J Clin Epi[INVESTIGATOR_5541] 1994;47: 81
-87.
Juniper EF, O'By [CONTACT_21143], Guy att GH, Ferrie PJ, King DR. Development and validation of 
a questionnaire to measure asthma control. Eur Respir J 1999;14:902 -
907.
Juniper EF, Sve nsson K, Mörk AC, Ståhl E. Measurement properties and interpretation of 
three shortened versions of t he asthma control questionnaire. Respir Med 2005;99: 553-
558.
Junipe r EF, Svensson K, Mörk AC, Ståhl E. Modification of the Asthma Quality  of Life 
Questionn
aire (standardised) in patients 12 y ears and older. Health and Quality of Life 
Outcomes 2005; 3:58.
Miller MR et al. Standardization of L ung Function Testing. Eur Resp J 2005; 26:153 -161.
Quanjer P, Stanojevic S, Cole T, Baur X., Hall G, Enright P, et al. on behalf of the ERS 
Global L ung Function Initiative. Multi- ethnic reference values for spi[INVESTIGATOR_105221] 3 -95 
year age range: the global lung function 2012 equations. Eur Respir J 2012;40:1324-
1343.
Reddel HK, Taylor DR, Bateman ED, Boulet L -P, Boushey  HA, Busse WW, et al. On
behalf of the American Thoracic Societ y/European Respi[INVESTIGATOR_21584] y task force on 
asthma control and exacerbations. An official American Thoracic Societ y/European 
Respi[INVESTIGATOR_633374]: asthma control and exacerbations; standa rdizing endpoints  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
65for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59 -
99. 
US Department of Health and Human Sciences; Food and Drug Administration (FDA).
Guidance for Industry ; Drug -Induced Liver Injury: Premarketing C linical Evaluation 
(July  2009). 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf (Accessed 16 July  2014).
Virchow JC, Backer V, de Blay  F, Kuna P, L jorring C, Prieto J L, et al. Defining 
moderate asthma exacerbations in clinical trials based on ATS/ERS joint statement. 
Respi[INVESTIGATOR_33593] 2015;109:547 -556
Wyrwich KW, Khan SA, Navaratnam P, Nolte H, Gates Jr DF. Validation and agreement 
across four versions of the asthma control questionnaire in patients with persistent 
asthma. Resp Med 2011;105:698 -712. 2018N371775_00
2016N289466_00 CONFIDENTIA L
[PHONE_13191]. APPENDICES
12.1. Appendix 1: A bbreviations and Trademarks
Abbrev iations
ACQ Asthma Control Questionnaire
ADR Adverse Drug Reaction
AE Adverse Event
AESI Adverse Event of Special Interest
ALT Alanine Transaminase
AM Morning
AQLQ Asthma Quality  of Life Questionnaire
AST Aspartate Transaminase
ATS American Thoracic Society
BMI Body Mass Index
BPM Beats Per Minute
BST Bioanal ytical Science and Toxicokinetics
BUN Blood Urea Nitrogen
CI Confidence Interval
CONSORT Consolidated Standards of Reporting Trials
COPD Chronic Obstructive Pulmonary  Disease
DNA Deox yribonucleic acid
DPI [INVESTIGATOR_417473]
(e)CRF (Electronic) Case Report Form
eDiary Electronic Diary
EOS End of study
E-RS Evaluating Respi[INVESTIGATOR_633354]1 Forced expi[INVESTIGATOR_4034] 1 second
FF Fluticasone Furoate
FP Fluticasone Propi[INVESTIGATOR_633375] I nitiative for Asthma
[COMPANY_004] GlaxoSmithKline
hCG Human Chorionic Gonadotropin
HIV Human Immunodeficiency  Virus
HPA Hypothalamic Pi[INVESTIGATOR_633355] y
IB Investigator ’s Brochure 2018N371775_00
2016N289466_00 CONFIDENTIA L
[ADDRESS_845795] Infection
MACE Major Adverse Cardiac Event
MAOI Monoamine Oxidase I nhibitors
MedDRA Medicinal Dictionary  for Regulatory  Activities
mcg ( g) Microgram
MDI Metered Dose Inhaler
mg Milligram
min Minute
mL Milliliter
MMRM Mixed -Model Repeated Measures
MSDS Material Safet y Data Sheet
msec Millisecond
NIH National Institutes of Health
NYHA [LOCATION_001] Heart Association
PEF Peak Expi[INVESTIGATOR_633356] y
QTc QT interval corrected for heart rate
QTcB QT interval corrected for heart rate b y Bazett’s formula
QTcF QT interval corrected for heart rate b y Fridericia’s formula
RAP Reporting and Anal ysis Plan
RBC Red Blood Cell
RNA Ribonucleic acid
SABA Short -Acting Beta -2-Agonists
SAE Serious Adverse Event
SGRQ St. George’s Respi[INVESTIGATOR_633366] 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
68US [LOCATION_002]
VI Vilanterol
VT Ventricular Tach ycardia
WBC White Blood Cell
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks not owned by [CONTACT_633391] 2018N371775_00
2016N289466_00 CONFIDENTIA L
[PHONE_13192].2. Appendix 2: Clinical Laboratory  Tests
All protocol required laboratory  assessments (haematology , clinical chemistry  
and urinal ysis) must be conducted in accordance with the L aboratory  Manual, 
and Protocol Schedule of Activities (Section 2)Laboratory  requisition forms 
mus
t be completed and samples must be clearl ylabelled with the participant
number, protocol number, site/centre number, and visit date. Details for the 
preparation and shipment of samples will be provided by  [CONTACT_633392]. Reference for all safet y parameters will be 
provided to the site by  [CONTACT_90633].
All blood samples which will be taken pre -dose, will be sent to a central 
laboratory  for anal ysis (details provided in the Laborator y Manual). Standard 
reference ranges will be used. 
If additional non -protocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in participant management or 
are considered clinically  significant b ythe Investigator (e.g., SAE or AE or dose 
modification) the results must be recorded in the eCRF. 
Refer to the Laboratory  Manual for appropriate processing and handling of 
samples to avoid duplicate and/or additional blood draws.
Protocol -specific requir ements for inclusion or exclusion of participants are 
detailed in Section 6 of the protocol.
Additional tests may  beperformed at any  time during the study  as determined 
necessary  by [CONTACT_633405]. 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
70Protocol -Required Safety Laboratory Assessments
Laboratory 
AssessmentsParameters
HaematologyPlatelet Count RBC Indices: WBC count with Differential:
Red Blood Cell ( RBC )
CountMCV Neutrophils
Hemoglobin MCH Lymphocytes
Hematocrit Monocytes
Eosinophils
Basophils
Clinical 
Chemistry 1Blood Urea 
Nitrogen 
(BUN )Potassium AST (SGOT) Total and direct 
bilirubin
Creatinine Sodium ALT (SGPT) Total Protein
Glucose Calcium Alkaline phosphatise Albumin
Routine 
UrinalysisSpecific gra vity
pH, glucose, protein, blood and ketones by [CONTACT_5230]
Microscopic examination (if blood or protein is abnormal)
Other 
Screening 
TestsFollicle stimulating hormone (FSH) and estradiol (as needed in females 
of non -reproductive potential only)
Serum/urin e hCG Pregnancy test (as specif ied in the Schedule of 
Activities table [Section 2])
NOTES :
1.Details of L iver Chemistry  Stoppi[INVESTIGATOR_131963] -Up 
Assessments after liver stoppi[INVESTIGATOR_633376] a re given in Section 8.1.1 and 
Appendix 7 2018N371775_00
2016N289466_00 CONFIDENTIA L
[PHONE_13167].3. Appendix 3: Study  Governance Considerations
Regulatory  and Ethical Considerations
This study  will be conducted in accordance with the protocol and with:
Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Brochure, and other 
relevant documents (eg, advertisements) must be submitted to an I RB/IEC by  
[CONTACT_20003] b y the I RB/IEC before the study  is 
initiated. 
Any amendments to the protocol will require IEC/I RB approval before 
implementation of changes made to the stud y design, except for changes 
necessary  to eliminate an immediate hazard to study participants. 
The investigator will be responsibl e for the following:
Providing written summaries of the status of the study to the IRB/IEC 
annually  or more frequently  in accordance with the requirements, policies, 
and procedures established by  [CONTACT_1201]/EC
Notify ing the IRB/IEC of SAE or other significant safet y findings as 
required b y IRB/IEC procedures
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European 
regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations
Financial Disclosure
Investigators and sub -investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification o r disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the stud y and for 1 y earafter completion of the study .
Informed Consent Process
The inve stigator or his/her representative will explain the nature of the study  to 
the participant or his/her legally  authorized representative and answer all 
questions regarding the study .  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
72Participants must be informed that their participation is voluntary . Part icipants 
or their legall y authorized representative will be required to sign a statement of 
informed consent that meets the requirements of [ADDRESS_845796] (HI PAA) 
requirements, where applicable, and the I RB/IEC or study  center. 
The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized pe rson obtaining the informed consent 
must also sign the I CF.
Participants must be re -consented to the most current version of the ICF(s) 
during their participation in the study . 
A cop y of the ICF(s) must be provided to the participant or the participant’s 
legally  authorized representative. 
Participants who are rescreened are required to sign a new ICF.
Data Protection
Participants will be assigned a unique identifier by  [CONTACT_456]. Any  participant 
records or datasets that are transferred to the sponsor will contain the identifier 
only; participant names or any  information which would make the participant 
identifiable will not be transferred. 
The participant must be informed that his/her personal study -related data will be 
used by  [CONTACT_10999]. The level of 
disclosure must also be explained to the participant. 
The participant must be informed that his/her medical records may  be examined 
by [CONTACT_17080] y Assurance auditors or other authorized personnel appointed 
by [CONTACT_456], b y appropriate IRB/IEC members, and by  [CONTACT_43216].
Publication Policy
The results of this study  may  be published or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all m anuscripts or abstracts to 
the sponsor before submission. This allows the sponsor to protect proprietary  
information and to provide comments.
The sponsor will comply  with the requirements for publication of study  results. 
In accordance with standard edito rial and ethical practice, the sponsor will 
generall y support publication of multicenter studies only in their entiret y and not 
as individual site data. In this case, a coordinating investigator [INVESTIGATOR_43192] b y mutual agreement.
Authorship will be de termined by  [CONTACT_43217]. 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
73Dissemination of Clinical Study  Data
For this study  participant data will be entered into [COMPANY_004] defined eCRFs, 
transmitted electronicall y to [COMPANY_004] or designee and combined with data provided 
from other sources in a validated data s ystem.  
Data Quality  Assurance
Management of clinical data will be performed in accordance with applicable 
[COMPANY_004] standards and data cleaning procedures to ensure th e integrit y of the data, 
e.g., removing errors and inconsistencies in the data.
Adverse events and concomitant medications terms will be coded using 
MedDRA (Medical Dictionary  for Regulatory  Activities) and an internal 
validated medication dictionary , [COMPANY_004]D rug.  
eCRFs (including queries and audit trails) will be retained b y [COMPANY_004], and copi[INVESTIGATOR_633358] I nvestigator to maintain as the Investigator copy.  Participant 
initials will not be collected or transmitted to [COMPANY_004] according to [COMPANY_004] policy.
All part icipant data relating to the stud y will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically  (eg, laboratory  
data). The investigator is responsible for verify ing that data entries are accurate 
and correct b yphysicall y or electronically signing the CRF. 
The investigator must maintain accurate documentation (source data) that 
supports the information entered in the CRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regula tory agency  inspections and provide direct access to source data 
documents. 
The sponsor or designee is responsible for the data management of this study  
including qualit y checking of the data. 
Study  monitors will perform ongoing source data verification to confirm that 
data entered into the CRF b y authorized site personnel are accurate, complete, 
and verifiable from source documents; that the safety  and rights of participants 
are being protected; and that the study  is being conducted in accordance with the 
currentl y approved protocol and an y other stud y agreements, ICH GCP, and all 
applicable regulatory  requirements. 
Records and documents, including signed ICF, pertaining to the conduct of this 
study  must be retained by [CONTACT_1732] 25years after study  completion 
unless local regulations or institutional policies require a longer retention period. 
No records may  be destroy ed during the retention period without the written 
approval of the sponsor. No records may  be transferred to another location or 
party  without written notification to the sponsor.  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
74Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from 
source documents must be consistent with the source documents or the 
discrepancies must be explained. The investigator may  need to request previous 
medical records or transfer records, de pending on the study . Also, current 
medical records must be available.
Study and Site Closure
[COMPANY_004] or its designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of [COMPANY_004]. Study  sites will b e closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time, provided t here is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud y site b y the sponsor or investigator may include 
but are not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of participants b y
the investigator
Discontinuation of further study  treatment development 2018N371775_00
2016N289466_00 CONFIDENTIA L
[PHONE_13181].4. Appendix 4: A dverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting
Definition of A E
AE Definition
An AE is an y untoward medical occurrence in a clinical study participant, temporally 
associated with the use of a study treatment, whether or no t considered related to the 
study  treatment.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of a study  treatment.
Events Meeting the AE Definition 
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator (ie, not related to progression of 
underly ing disease).
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or int ensity  of the condition.
New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such ov erdoses should be reported regardless of sequelae.
"Lack of efficacy " or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy  
assessments. However, the signs, s ymptoms, and/or clinical sequelae resulting from 
lack of efficacy  will be reported as AE or SAE if they  fulfill the definition of an AE 
or SAE. 
The signs, s ymptoms, and/or clinical sequelae resulting from lack of efficacy  will be 
reported as AE or SAE if they  fulfil l the definition of an AE or SAE. Also, "lack of 
efficacy " or "failure of expected pharmacological action" constitutes anAE or SAE.
Events NOT Meeting the AE Definition 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
76assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/di sorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
Definition of SA E
If an event is not an AE pe r definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study , 
death due to progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hy potheticall y might have cau sed death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_22770], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_42244]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the AE 
should be considered serious.
Hospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen from 
baseline is n ot considered an AE.
d.Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza,  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
77and accidental trauma (eg, sprained ankle) which may  interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e.Is a congenital anom aly/birth defect
f.Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately  life-threatening or result in death or hospi[INVESTIGATOR_268678]. These events should usually  
be considered serious.
Examples of such events include invas ive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse.
Recording A E and SA E
AE and S AE Recording
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
related to the event.
The investigator will then record all relevant AE/SAE inf ormation in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_004] in lieu of completion of the [COMPANY_004] /AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y [COMPANY_004] . In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copi[INVESTIGATOR_31785] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal discomfort 
and not interfering with every day activities.
Moderate: An event that causes sufficiently discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities. An AE that is assessed as  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
78severe should not be confused with an SAE. Severe is a category  utilized for rating 
the intensity  of an event; and both AE and SAE can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y treatment and 
each occurrence of each AE/SAE.
A "reasonable possibility " of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  treatment 
administration will be considered and investigated.
The investigator will also consult the I nvestigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to [COMPANY_004] .However, it is very 
important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to [COMPANY_004] .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow-up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of AE and SAE
The investigator is obligated to perform or arrange for the conduct of suppl emental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_31859]/or causalit y of the AE or SAE as fully as possible. This may 
include additional laboratory  tests or investigations, histopathological examinat ions, 
or consultation with other health care professionals.
If a participant dies during participation in the study or during a recognized follow -
up period, the investigator will provide [COMPANY_004] with a cop y of an y post-mortem 
findings including histopathology . 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
79New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to t [COMPANY_004] within 24 hours of 
receipt of the information.
Reporting of SA E to [COMPANY_004]
SAE Reporting to [COMPANY_004] via Electronic Data Coll ection Tool
The primary  mechanism for reporting SAE to [COMPANY_004] will be the electronic data 
collection tool.
If the electronic s ystem is unavailable for more than 24 hours, then the site will use 
the paper SAE data collection tool (see next section).
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
After the stud y is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form or to the 
assigned SAE contact [CONTACT_107461].
Contacts for SAE reporting can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774].
SAE Reporting to [COMPANY_004] via Paper CRF
Facsimile transmission of the SAE paper CRF is the pre ferred method to transmit 
this information to the assigned SAE contact [CONTACT_107461].
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_9337] a cop y of the SAE data collection tool sent by [CONTACT_19515].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found at the beginning of this protocol on the 
Sponsor/Medical Monitor Contact [CONTACT_23774]. 2018N371775_00
2016N289466_00 CONFIDENTIA L
[PHONE_13170].5. Appendix 5: Contraceptive Guidance and Collection of 
Pregnancy  Information
Definitions
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becomi ng post -menopausal 
unless permanentl y sterile (see below)
Women in the following categories are not considered WOCBP
1.Premenarchal
2. P remenopausal female with ONE of the following:
Documented h ysterectomy
Documented bilateral salpi[INVESTIGATOR_1656]
Documented bilatera l oophorectom y
Note:  Documentation can come from the site personnel’s: review of participant’s 
medical records, medical examination, or medical history  interview.
3. P ostmenopausal female
A postmenopausal state is defined as no menses for 12 months without a n 
alternative medical cause. A high follicle stimulating hormone (FSH) level in 
the postmenopausal range may  be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormonal replacement therapy  
(HRT). However, in the absence of 12 months of amenorrhea, a single FSH 
measurement is insufficient. 
Females on HRT and whose menopausal status is in doubt will be required to 
use one of the non -hormonal highl y effective contraception methods if they wish 
to continue their HRT during t he stud y. Otherwise, they must discontinue HRT 
to allow confirmation of postmenopausal status before study  enrollment.
Contraception Guidance
Female participants
Female participants of childbearing potential are eligible to participate if they  agree to 
usea highly  effective method of contraception consistently  and correctly  as described in 
Table 4. 2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
81Table 4 Highly  Effective Contraceptive Methods
Highly Effective Contraceptive Methods That Are User Dependenta
Failure rate of <1%  per year when used consistently and correctly. 
Combined (estrogen -and progestogen -containing ) hormonal contraception associated with 
inhibition of ovulation 
oral
intravaginal 
transdermal 
Progestogen -only hormonal contraceptio n associated with inhibition of ovulationb
injectable 
Highly Effective Methods That Are User Independent 
Implantable progestogen -only hormonal contraception associated with inhibition of 
ovulationb
Intrauterine device (IUD)
Intrauterine hormone -releas ing system (IUS)
bilateral tubal occlusion
Vasectomized partner 
(A vasectomized partner is a highly effective contraception method provided that the partner is 
the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. If 
not,an additional highly effective method of contraception should be used. )
Sexual abstinence 
(Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and 
the preferred and usual lifestyle of the participant.)
NOTES: 
a. Typi[INVESTIGATOR_633377]. Use should be consistent 
with local regulations regarding the use of contraceptive methods for participants inclinical studies.
Pregnancy  Testing
WOCBP should only  be included after a confirmed menstrual period and a negative 
highly sensitive urine or serum pregnancy test 
Pregnancy  testing will be performed whenever a menstrual cy cle is missed or when 
pregnancy  is otherwise suspected 
Pregnancy
 testing, with a sensitivity  of [5, 10, 25] mI U/mL will be performed [and 
assay ed in a c ertified laboratory  OR and assay ed in the central laboratory  OR using  2018N371775_00
2016N289466_00 CONFIDENTIA L
[ADDRESS_845797] kit provided by  [CONTACT_2237]  / provided by  [CONTACT_456] /approved by  
[CONTACT_633394]]  
Collection of Pre gnancy  Information
Female Participants who become pregnant
Investigator will collect pregnancy  information on any  female participant, who 
becomes pregnant while participating in this study. 
Information will be recorded on the appropriate form and submitte d to [COMPANY_004] within 
24 hours of learning of a participant's pregnancy . 
Participant will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow up information on participant and neonate, which will 
be forwarded to [COMPANY_004] Gener ally, follow- up will not be required for longer than 6 to 8 
weeks bey ond the estimated delivery  date.  
Any termination of pregnancy  will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure. 
While pregnan cy itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be reported as an AE or 
SAE. 
A spontaneous abortion is alway s considered to be an SAE and will be reported as 
such.  
Any SAE occurring as a result of a post
-study  pregnancy  which is considered 
reasonabl y related to the study  treatment by  [CONTACT_093], will be reported to [COMPANY_004]
as described in Appendix 4 . While the investigator is not obligated to actively  seek 
this information in former study  participants, he or she may  learn of an SAE through 
spontaneous reporting. 
Any female participant who becomes pregnant while participating in the study will 
immediately discontinue study medication. 2018N371775_00
2016N289466_00 CONFIDENTIA L
[PHONE_13193].6. Appendix 6: Genetics
Genet ics – Background
Naturall y occurring genetic variation may  contribute to inter -individual variability in 
response to medicines, as well as an individual's risk of developi[INVESTIGATOR_42259]. 
Genetic factors associated with disease characteristics may  also be associated with 
response to therap y, and could help to explain some clinical study outcomes. For 
example, genetic variants associated with age- related macular degeneration (AMD) are 
reported to account for much of th e risk for the condition [ Gorin 2012] with certain 
variants reported to inf luence treatment response [ Chen 2012]. Thus, knowledge of the 
genetic etiology  of disease may  better inform understanding of disease and the 
development of medicines. Additionally , genetic variability  may  impact the 
pharmacokinetics (absorption, distribution, metabolism, and elimination), or 
pharmacod ynamics (relationship between concentration and pharmacologic effects or the 
time course of pharmacologic effects) of a specifi c medicine and/or clinical outcomes 
(efficacy  and/or safet y) observed in a clinical study.
Genetic Research Objectives and A nalyses
The objectives of the genetic research are to investigate the relationship between genetic 
variants and: 
Response to medici ne or any  concomitant medicines;
Asthma susceptibility , severity , and progression and related conditions
Genetic data may  be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include focused candidate gene approaches and/or 
examination of a large number of genetic variants throughout the genome (whole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives highlighted above.  Analy ses may be performed using data 
from multiple clinical studies to investigate these research objectives.
Appropriate descriptive and/or statistical analy sis methods will be used. A detailed 
description of an y planned anal yses will be documented in a Reporting and Analy sis Plan 
(RAP) prior to initiation of the anal ysis. Planned analy ses and results of genetic 
investigations will be reported either as part of the clinical RAP and study  report, or in a 
separate genetics RAP and report, as appropriate.
Study Popula tion
Any participant who is enrolled in the study  can participate in genetic research.  Any  
participant who has received an allogeneic bone marrow transplant must be excluded 
from the genetic research.
Study Assessments and Procedures
A key  component of su ccessful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
84identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in disease and me dicine response.  
A 6ml blood sample will be taken for Deox yribonucleic acid (DNA) extraction. A 
blood sample is collected at the baseline visit, after the participant has been 
randomized and provided informed consent for genetic research. Instructions for 
collection and shippi[INVESTIGATOR_278799]. 
The DNA from the blood sample may  undergo quality  control anal yses to confirm 
the integrit y of the sample. If there are concerns regarding the quality of the sample, 
then the sample may  be destroy ed. The blood sample is taken on a single occasion 
unless a duplicate sample is required due to an inability  to utilize the original sample.  
The genetic sample is labelled (or “coded”) with the same stud y specific number used to 
label other samples and data in the study.   This number can be traced or linked back to 
the participant by [CONTACT_42393]. Coded samples do not carry personal 
identifiers (such as name [CONTACT_42405]). 
Samples will be stored securel y and may be kept for up to [ADDRESS_845798] 
participant completes the study , or [COMPANY_004] may  destroy  the samples sooner.  [COMPANY_004] or those 
working with [COMPANY_004] (for example, other researchers) will only  use samples collected from 
the study  for the purpose stated in this protocol and in the informed consent form.  
Samples may  be used as part of the development of a companion diagnostic to support 
the [COMPANY_004] medicinal product.
Participant s can request their sample to be destro yed at an y time.
Informed Consent
Participant s who do not wish to participate in the genetic research may  still participate in 
the study .  Genetic informed consent must be obtained prior to an y blood being taken.
Participant Withdrawal from Study
If a participant who has consented to participate in genetic research withdraws from the 
clinical study  for any  reason other than being lost to follow -up, the participant will be 
given a choice of one of the following options concerning the genetic sample, if alread y 
collected:
Continue to participate in the genetic research in which case the genetic DNA 
sample is retained
Discontinue participation in the genetic research and destroy  the genetic DNA 
sample 
If a participant withdraws consent for genetic research or requests sample destruction for 
any reason, the Investigator must complete the appropriate documentation to request 
sample destruction within the timeframe specified by  [CONTACT_420264] .  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
85Genoty pe data may  be generated during the study  or after completion of the study  and 
may be anal yzed during the study  or stored for future anal ysis. 
If a participant withdraws consent for genetic research and genot ype data has not 
been analy zed, it will not be anal yzed or used for future research.  
Genetic dat a that has been anal yzed at the time of withdrawn consent will 
continue to be stored and used, as appropriate.
Screen and Baseline Failures
If a sample for genetic research has been collected and it is determined that the 
participant does not meet the ent ry criteria for participation in the study , then the 
Investigator should instruct the participant that their genetic sample will be destroy ed. No 
forms are required to complete this process as it will be completed as part of the consent 
and sample reconciliation process.  In this instance a sample destruction form will not be 
available to include in the site files.
Provision of Study Results and Confidentiality  of Participant ’s Genetic Data
[COMPANY_004] may  summarize the genetic research results in the clinical stud y report, or 
separately  and may  publish the results in scientific journals. 
[COMPANY_004] may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. [COMPANY_004] does not inform the 
participant , famil y members, insurers, or employ ers of individual genot ypi[INVESTIGATOR_42261] ’s medical care at the time of the study , 
unless required b y law. This is due to the fact that the information generated from genetic 
studie s is generall y preliminary in nature, and therefore the significance and scientific 
validity  of the results are undetermined.  Further, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care.
References
Chen H, Yu KD, Xu GZ. Association between Variant Y402H in Age- Related Macular 
Degeneration (AMD) Susceptibility  Gene CFH and Treatment Response of AMD: A 
Meta -Anal ysis. PloS ONE 2012; 7: e42464
Gorin MB. Genetic insights into age- related macular degenerat ion: Controversies 
addressing risk, causality, and therapeutics. Mol. Asp. Med. 2012; 33: 467 -486. 2018N371775_00
2016N289466_00 CONFIDENTIA L
[PHONE_13194].7. Appendix 7: Liver Safety : Required A ctions and Follow -up 
Assessments
Phase II l iver chemistry stoppi[INVESTIGATOR_633359]  (in alignment with the FDA 
premarketing clinical liver safety  guidance [ Food and Drug Administration , 2009]).
Phase II liver chemistry stoppi[INVESTIGATOR_90566] – Liver Stoppi[INVESTIGATOR_53053]- absolute ALT  5xULN
ALT Increase ALT 3xULN persists for 4 weeks
Bilirubin1, 2ALT  3xULN andbilirubin 2xULN (>35% direct bilirubin)
INR2ALT  3xULN andINR>1.5, if INR measured
Cannot Monitor ALT 3xULN and cannot be monitored weekly for 4 weeks
Symptomatic3ALT   3xULN associated with symptoms (new or worsening) believed to be 
related to liver injury or hypersensitivity
Required Actions and Follow up Assessments following ANY Liver Stoppi[INVESTIGATOR_90567]
Immediately discontinue  study treatment 
Report the event to [COMPANY_004] within 24 hours
Complete the liver event CRF and complete an
SAE data collection tool if the even t also meets 
the criteria for an SAE2
Perform liver event follow up assessments 
Monitor the participant until liver chemistries
resolve, stabilize, or return to within baseline 
(see MONITORING below)
Do not restart/rechallenge participant with 
study trea tment unless allowed per protocol and 
[COMPANY_004] Medical Governance approval is granted 
(refer to Section 8.1.3 )
If restart/rechallenge not allowed per protocol or 
not granted , permanently discontinue study 
treatment and may continue participant in the study 
for any protocol specified follow up assessments Viral hepatitis serology4
Blood sample for pharmacokinetic (PK) 
analysis, obtaine d [ADDRESS_845799] 
dose5
Serum creatine phosphokinase (CPK) 
and lactate dehydrogenase (LDH).
Fractionate bilirubin, if total 
bilirubin 2xULN
Obtain complete blood count with 
differential to assess eosinophilia
Record the appearance or worsening of 
clinical symptoms of liver injury , or 
hypersensitivity, on the AE report form
Record use of concomitant medications 
on the concomitant medications report 
form including acetaminophen, herbal 
remedies, other over the counter  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
87MONITORING:
For bilirubin or INR criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin ) and perform 
liver event follow up assessments within  24 hr s
Monitor participant s twice weekly until liver 
chemistries resolve, stabilize or return to within 
baseline 
A specialist or hepatology consultation is 
recommended
For All other criteria:
Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, b ilirubin) and perform 
liver event follow up assessments within  24-72 
hrs 
Monitor participant s weekly until liver 
chemistries resolve, stabilize or return to within 
baselinemedications .
Record alcohol use on th e liver event 
alcohol intake case report form
For bilirubin or INR criteria:
Anti-nuclear antibody, anti -smooth 
muscle antibody, Type 1 anti- liver 
kidney microsomal antibodies, and 
quantitative total immunoglobulin G 
(IgG or gamma globulins).
Serum aceta minophen adduct HPLC 
assay (quantifies potential 
acetaminophen contribution to liver 
injury in participant s with definite or 
likely acetaminophen use in the 
preceding week (James 2009) Not 
Required in China
Liver imaging (ultrasound, magnetic 
resonance, or computerised 
tomography) and /or liver biopsy to 
evaluate liver disease; complete Liver 
Imaging and/or Liver Biopsy CRF 
forms.
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study treatment for that participant if ALT 3xULN andbilirubin 2xULN.. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of det ectable urinary 
bilirubin on dipstick , indicating direct bilirubin elevations and suggesting liver injury. 
2. Allevents of ALT  3xULN andbilirubin  2xULN (>35% direct bilirubin) or ALT  3xULN andINR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the threshold value stated 
will not apply to participants receiving anticoagulants
3. New or worsening symptom s believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)
4. Includes: Hepatitis A IgM antibody; Hepat itis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C 
RNA; Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);  Hepatitis E IgM antibody 
5. PK s ample may not be required for participant s known to be receiving placebo or non -[COMPANY_004] comparator 
treatments.)  Record the date/time of the PK blood sample draw and the date/time of the last dose of study 
treatment prior to blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the 
participant ’s best approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot 
be collected in the time period indicated above, do not obtain a PK sample. Instruction s for sample handling and 
shippi[INVESTIGATOR_42253].    2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
88Phase II liver chemistry increased monitoring criteria with continued therapy
Liver Chemistry Increased Monitoring Criteria – Liver Monitoring Event
Criteria Actions
ALT  3xULN and<5xULN andbilirubi n 
<2xULN , without symptoms believed to 
be related to liver injury or 
hypersensitivity , and who can be 
monitored weekly for 4 weeksNotify the [COMPANY_004] medical monitor within 24 hours of 
learning of the abnormality to discuss participant
safety. 
Participant cancontinue study treatment   
Participant must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline 
If at any time participant meets the liver chemistry 
stoppi[INVESTIGATOR_007] c riteria, proceed as described above
If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor participant s twice monthly 
until liver chemistries normalize or return to within 
baseline.
References
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784. 2018N371775_00
2016N289466_00 CONFIDENTIA L
[PHONE_13195].8. Appendix 8: Daily Diary  Questions
12.8.1. Morning Questions
The participant should complete the morning eDiary  questions upon wakening and prior 
to the administration of study  treatment.
Night -time Awakening
1. Did y ou wake up due to asthma 
symptoms (i.e. wheezing, coughing, 
shortness of breath, or chest 
tightness).No
Yes
2.If Yes; when you woke up due to 
your asthma sy mptoms did you use 
any rescue inhaler?No
Yes
12.8.2. Evening Questions
The participant should complete the evening eDiary  questions just before going to bed.
E-RS
1.Did your chest feel congested
today?Not at all
Slightly
Moderately
Severely
Extremely
2.How often did you cough today? Not at all 
Rarely 
Occasionally 
Frequently 
Almost constantly 
3.How much mucus (phlegm) did 
you bring up when coughing 
today?None at all 
A little 
Some 
A great deal 
A very great deal 
4.How difficult was it to bring up 
mucus (phlegm) today?Not at all 
Slightly 
Moderately 
Quite a bit 
Extremely  2018N371775_00
2016N289466_00 CONFIDENTIA L
[ADDRESS_845800] discomfort 
today?Not at all 
Slight 
Moderate 
Severe 
Extreme 
6. Did your chest feel tight today? Not at all
Slightly
Moderately
Severely
Extremely
7.    Were you breathless today? Not at all
Slightly
Moderately
Severely
Extremely
8. Describe how breathless you were 
today:Unaware of breathlessness
Breathless during strenuous activity
Breathless during light activity
Breathless when washing or dressing
Present when resting 
9. Were you short of breath today 
when performing your usual 
personal ca re activities like 
washing or dressing?Not at all 
Slightly 
Moderately 
Severely 
Extremely 
Too breathless to do these 
10. W ere y ou short of breath today 
when performing your usual indoor 
activities like cleaning or 
household work?Not at all 
Slightly 
Moderately 
Severely 
Extremely 
Too breathless to do these 
11. W ere y ou short of breath today 
when performing your usual 
activities outside the home such 
as yard work or errands?Not at all 
Slightly 
Moderately 
Sever ely 
Extremely 
Too breathless to do these  2018N371775_00
2016N289466_00 CONFIDENTIA L
205832
91Supplemental Asthma Items
1. Did you wheeze today?’ Not at all 
Rarely
Occasionally 
Frequently
Almost constantly
2. Were you short of breath today 
when performing strenuous activities 
such climbing stairs, running, or 
participating in sports activity.  Not at all 
Slightly 
Moderately 
Severely 
Extremely
Asthma Symptom and Physical Activity Questions
1.Please describe the severity of 
your asthma sy mptoms today (i.e. 
cough, whe eze, chest tightness, 
shortness of breathNo asthma sy mptoms
Mild asthma sy mptoms
Moderate asthma sy mptoms
Severe asthma sy mptoms
Very severe asthma sy mptoms
2.How limited were you in your 
activities today because of your 
asthmaNot at all limit ed
A little limited
Moderately limited
Severely limited
Totally limited 2018N371775_00
2016N289466_00 CONFIDENTIA L
[PHONE_13196].9. Appendix 9: Country -specific requirements
There are currently  no country  specific requirements.  2018N371775_00